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The history of our antibiotics is inseparably connected to microorganisms as producers.
In particular, microorganisms with large genomes (often more than 8 MB) like many Actinobacteria
and the Myxococcales show the highest potential for secondary metabolite formation. In addition,
an important factor seems to be the differentiation process which is also found in both of these bacterial
groups. Many of the clinically used antibiotics like the cephalosporins, anthrycylines, macrolides,
glycopeptides, lipopetides and aminoglycosides are originally products of Actinobacteria [1].
The producers belong to a number of different genera like Streptomyces, Amycolatopsis, Micromonospora
and Actinoplanes. The phylum Actinobacteria belongs to the Gram-positive bacteria with a high GC
content. They can be mainly found in soil but there are also pathogenic and saprophytic species.
In particular, the mycelium-forming genera show characteristic differentiation by forming endospores
that can be arranged in spore chains or sporangia.
Besides, the Actinobacteria members of the Myxococcales were first reported to show bacteriolytic
effects in 1946 [2] but it took until the 1980s for the first antibiotic with high potential for market
development, Sorangicin, to be isolated [3]. Like Actinobacteria, most of the members of the
Myxococcales live in soil, they belong to the Gram-negative bacteria and form fruiting bodies during
their differentiation process. With the knowledge of the genome information, it is now clear that they
also harbor a large potential for the production of secondary metabolites [4,5].
The isolation of novel Actinobacteria and Myxobacteria still leads to new genetic potential for
the identification and isolation of bioactive compounds, especially antibiotics. With more and more
understanding of this genetic information, we also see a huge number of genes for which we do not
know the resulting product and the induction of these silent genes is one of the challenges [6].
This issue gathers 16 papers including 11 articles, 4 reviews and 1 communication. Six of them
describe novel species or isolates and their characterization by the use of a polyphasic approach [7–12]
as well as their secondary metabolites. Two of the articles describe Actinobacteria from uncommon
habitats like the Western Ghats region in India [13] and endophytic ones [14]. The study of the induction
of secondary metabolites by use of the OSMAC approach is the subject of one other article [15]. The other
two articles include the identification and heterologous expression of an antibiotic gene cluster [16] and
the biological activity of some volatile secondary metabolites [17]. In the communication, the authors
report the unexplored biosynthetic potential in Myxobacteria [18]. In the review section, we find
reports on polyketide biosynthesis in Streptomyces [19], the role of elicitors in antibiotic biosynthesis [20],
antiviral compounds from Myxobacteria [21] and an overview on the role of Myxobacteria as secondary
metabolite producers [22]. Altogether, in my view, this is a balanced snapshot of this impressive
research field.
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Abstract: In view of the fast depleting armamentarium of drugs against significant pathogens, like
methicillin-resistant Staphylococcus aureus (MRSA) and others due to rapidly emerging drug-resistance,
the discovery and development of new drugs need urgent action. In this endeavor, a new strain of
endophytic actinobacterium was isolated from the plant Datura metel, which produced secondary
metabolites with potent anti-infective activities. The isolate was identified as Streptomyces californicus
strain ADR1 based on 16S rRNA gene sequence analysis. Metabolites produced by the isolate had
been investigated for their antibacterial attributes against important pathogens: S. aureus, MRSA,
S. epidermis, Enterococcus faecium and E. faecalis. Minimum inhibitory concentration (MIC90) values
against these pathogens varied from 0.23 ± 0.01 to 5.68 ± 0.20 μg/mL. The metabolites inhibited
biofilm formation by the strains of S. aureus and MRSA (Biofilm inhibitory concentration [BIC90]
values: 0.74 ± 0.08–4.92 ± 0.49 μg/mL). The BIC90 values increased in the case of pre-formed biofilms.
Additionally, the metabolites possessed good antioxidant properties, with an inhibitory concentration
(IC90) value of 217.24 ± 6.77 μg/mL for 1, 1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging.
An insight into different classes of compounds produced by the strain ADR1 was obtained by chemical
profiling and GC-MS analysis, wherein several therapeutic classes, for example, alkaloids, phenolics,
terpenes, terpenoids and glycosides, were discovered.
Keywords: endophytic actinobacteria; Streptomyces sp., anti-S. aureus; anti-MRSA; anti-biofilm
1. Introduction
The emergence of drug resistance among pathogens has assumed alarming proportions in recent
times, causing rapid depletion in the current armamentarium of drugs to fight such infections [1].
This has posed a serious threat to human health globally and required the rapid development of new
and effective drugs at a pace faster than resistance to achieve desirable outcomes in the treatment of
infectious diseases. Some of these pathogens have gained exceptional notoriety due to their tremendous
ability to adapt, to evade the host immune response and to develop drug resistance. This has led
World Health Organization to enlist significant human pathogens under critical, high and medium
priority categories [2]. Enterococcus faecium (vancomycin resistant) and Staphylococcus aureus (methicillin
resistant) are considered as high priority pathogens for whom new antibiotics are required the most
urgently. Infections involving such pathogens are often associated with biofilms, which are responsible
for multi-fold increase in drug-resistance of the pathogens [3,4]. Therefore, it is highly desirable that
the new antibiotics possess anti-biofilm activities: disruption of pre-formed biofilms and inhibition of
biofilms formation.
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Some of the recent studies have reported that the reactive oxygen species were causing antibiotic
tolerance in S. aureus during systemic infections [5]. Further, oxidative immune response of the host
appeared to be switched on during bacterial infections, resulting in increased oxidative stress to the
host [6]. Additionally, the antibiotics used to treat infections might also cause an increase in the level
of oxidative stress [7,8]. It was reported that antioxidants might prevent oxidative stress-induced
pathology [9]. Biofilm formation in S. aureus is also enhanced in the presence of oxidative stress [10].
Therefore, providing antioxidants may help in the inhibition of biofilms formation and thus in the
prevention of concomitant resistance to antibiotics among the pathogens.
In view of the facts mentioned above, our research endeavors have focused on the discovery of novel
anti-infective therapeutics for the treatment and cure of drug resistant infections. Characterization of
antioxidant properties of metabolites was also part of our study design due to its foreseeable application
in therapy of infectious diseases. There are several approaches to develop drugs, for example, rational
drug design (structure-based design of inhibitors against target), synthetic and combinatorial chemistry,
high throughput screen of chemical libraries and mining of natural products [11,12]. However, from
the stand point of discovery of novel pharmacophore or new classes of drug working on as yet
unknown targets, mining of natural products is the obvious choice. Therefore, we chose natural
products in the search for new antibiotics. Furthermore, we have considered actinobacteria from vast
pool of natural product resources due to their versatility, ubiquity and ability to produce therapeutic
compounds with extensive chemical diversity [13,14]. The genus Streptomyces of actinobacteria has been
regarded as containing the most prolific producers of therapeutic compounds [15,16]. However, repeat
discovery of known molecules remains a challenge while hunting the actinobacteria for drugs [17,18].
One of the possible approaches to avoid the repeat discovery of the drugs could be the sourcing of
actinobacteria from niche habitats instead of common sources like soil. Accordingly, we have explored
endophytic actinobacteria in an effort to enhance the chances of finding new compounds as potential
drug candidates. Endophytic actinobacteria are the microorganisms that reside within the plant tissues
without causing any adverse effect to plants [19]. Further, for increasing the prospect of strain novelty,
we have selected a medicinally important plant, Datura metel, which had largely remained unexplored
for endophytic population of actinobacteria.
In the present communication, identification of a novel strain, Streptomyces californicus strain
ADR1 is reported from the plant D. metel. Secondary metabolites produced by the isolate ADR1 were
characterized for their antibacterial, antibiofilm and antioxidant properties. Further, the metabolite
preparations were analyzed for different class of therapeutically significant compounds produced by
the isolate.
2. Materials and Methods
2.1. Isolation of Endophytic Actinobacteria
The endophytic actinobacteria were isolated from the plant, Datura metel. The ex-plants were
surface sterilized by following the method reported elsewhere [20]. The sterilized plant parts were
aseptically grinded by using autoclaved mortar pestle in phosphate-buffered saline (PBS) pH 7.0. The
ground paste was spread over the following isolation media: nutrient agar, asparagine glycerol (AGS)
agar) [21], humic acid—vitamin agar [22] and starch casein nitrate (SCN) agar [23]. The media were
supplemented with cycloheximide (50 μg/mL). The plates were incubated at 28 ◦C for up to four weeks
with regular observations for potential actinobacterial colonies.
The putative actinobacterial colonies were transferred and maintained on AGS medium.
Purification of the isolates was achieved by repeated cycles of streaking on fresh plate. The purified
cultures were screened for anti-bacterial against S. aureus ATCC 29213 by well diffusion method [24].
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2.2. Molecular Identification and Characterization of the Isolate ADR1
Molecular identification of the strain ADR1 was based on 16S rRNA gene sequence
analysis. The genomic DNA of the strain ADR1 was isolated using the method developed
for Gram-positive bacteria [20] with a few modifications. Briefly, amplification of 16S rRNA
gene was carried out using universal primers: V1f (50-AGAGTTTGATCMTGGCTCAG-30), V9r
(50-AAGGAGGTGATCCANCCRCA-30), V3f (50-CCAGACTCCTACGGGAGGCAG-30) and V6r
(50-ACGAGCTGACGACARCCATG-30) in a PCR machine (Mastercycler® nexus, Eppendorf
International, Germany) by using the programme described elsewhere [25]. The amplified product
was sequenced by Sanger’s method using a 3130XL sequencer (Applied Biosystems, California, USA)
for the 16S rRNA gene using universal primers as described above. The sequences were aligned in
MEGA 6.0 to generate single consensus sequence. Homology search was performed using the standard
Basic Local Alignment Search Tool (BLAST) sequence similarity search tool of the NCBI database to
establish the identity of the isolate ADR1. Nucleotide sequences producing significant alignments
after BLAST analysis with the 16S rRNA gene sequence of ADR1 were retrieved in FASTA format.
These sequences were used to generate phylogenetic relationship of ADR1 with them by using the
software, Phylogeny.fr [26,27]. The analysis was done by using advanced mode of this tool, which is an
automated programme that performs step-by-step analysis starting from the multiple alignment of the
sequences (MUSCLE 3.8.31) [28], alignment curation (Gblocks 0.91b), construction of phylogenetic tree
(PhyML 3.1/3.0 aLRT) [29,30] to the visualization of phylogenetic tree (TreeDyn 198.3) [31]. The culture
was characterized for its morphological features on different international Streptomyces protocol (ISP)
media [32]. Isolate ADR1 was streaked on ISP1, ISP2, ISP3, ISP4, ISP5, ISP6 and ISP7 media plates
and was incubated for 7 days at 28 ◦C for phenotypic and morphological observations. Single colony
morphology of the culture was observed under Nikon stereo zoom microscope SMZ1270 at zooming
ratio of 12.7:1 and resolution of 8×. Mycelial structure was observed under Nikon E600 microscope
(Nikon, Tokyo, Japan) at a resolution of 100×.
2.3. Production of Secondary Metabolites
A single colony from freshly grown culture plate (72 h) was inoculated in 50 mL SCN broth
(pH 7.4), which was incubated at 28 ◦C for 72 h to develop the pre-seed culture. The production medium
(SCN broth, pH 7.2) was inoculated with the pre-seed culture (1%; v/v) to commence production of the
secondary metabolites, which was carried out for 7 days at 28 ◦C in an incubator shaker (Adolf Kuhner
AG, Birsfelden, Basel, Switzerland) run at 200 rpm. The cell-free broth was recovered by centrifugation
at 5000× g for 20 min in Sorvall RC 5C plus centrifuge (Kendro Laboratory Products, Newtown,
Connecticut, USA). The metabolites were recovered from the supernatant by using liquid-liquid
extraction with equal volume of ethyl acetate. The extracted metabolites were dried by using rotary
evaporator (50 ◦C) and vacuum oven (35 ◦C). The dried metabolite preparations were stored at
25 ◦C ± 2 ◦C till further use.
2.4. Antimicrobial Susceptibility Testing
The reference strains of bacterial pathogens used in this study were: S. aureus ATCC 29213,
S. aureus ATCC 25923, S. aureus ATCC 13709, MRSA ATCC 43300, MRSA 562, S. epidermis ATCC
12228, Enterococcus faecalis ATCC 29212, E. faecium ATCC 49224 and E. faecium AIIMS. In-vitro
antibacterial activity of the metabolite extract was determined on cation adjusted Muller Hinton agar
(MHA) (Himedia, Mumbai, India) plates using well diffusion method [24]. The minimum inhibitory
concentration (MIC90) values were measured in a 96-well microtiter plates by the broth microdilution
method as per the guidelines of Clinical and Laboratory Standards Institute (CLSI) [33]. Briefly, a
stock solution of the metabolite extract (1mg/mL) was prepared in 0.2% DMSO and cation adjusted
Muller Hinton broth. Bacterial pathogens (100 μL; 2 × 108 CFU/mL) and metabolite extract (100 μL) at
concentrations varying from 125 to 0.122 μg/mL were added to the individual well in the microtitre
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plate. A sample control (ADR1 extract alone) and blank (media only) were included in each assay. After
incubation for 24 h at 37 ◦C, iodonitrotetrazolium chloride (INT) (Sisco Research Laboratories, Mumbai,
India) was added to the wells and the plates were incubated further for 30 min. The absorbance was
measured on a multimode reader (Biotek Instruments, Winooski, Vermont, USA) at 490 nm. The
value of MIC90 was considered to be the minimum concentration at which no visible growth could be
observed. The following equation was used to compute the percent inhibition [34].
Growth inhibition of pathogen (%) = [(control OD490 nm − test OD490 nm)/control OD490 nm] × 100 (1)
2.5. Antibiofilm Assay
Biofilms of S. aureus ATCC 25923, S. aureus ATCC 29213, MRSA ATCC 43300 and MRSA 562 were
produced by using the method published elsewhere [35] in accordance with the CLSI guidelines [33].
Briefly, overnight grown reference cultures were suspended in tryptic soy broth (Himedia, Mumbai,
India) supplemented with 2% glucose to attain turbidity equivalent to 0.5 McFarland standard (2 ×
108 CFU/mL). A total of 100 μL of the cell suspension was transferred to the wells on the microtiter
plate and was incubated at 37 ◦C for 24 h under static condition. Non-adherent cells were aspired out
along with the medium. The wells were rinsed with 100 μL of phosphate-buffered-saline (PBS). Fresh
medium containing desired concentrations of ADR1 metabolites (from 250 to 0.49 μg/mL) were added
to the wells on the microtiter plate, which was then incubated for the next 24 h at 37 ◦C under static
condition. Viability of the biofilms was quantified by INT-calorimetric assay as described above. The
following equation was used to find % inhibition of biofilm [35].
Biofilm inhibition (%) = [(control OD 490 nm − test OD 490 nm)/control OD 490 nm] × 100 (2)
2.6. Antioxidant Activity
The antioxidant potential of ADR1 metabolites was assessed by measuring reduction of DPPH
(1, 1-diphenyl-2-picrylhydrazyl) free radicals as reported earlier [36]. Briefly, DPPH solution (0.1
mM) was prepared in methanol; 100 μL of this solution was added to 100 μL of the ADR1 metabolite
preparations at different concentrations varying from 1000 to 7.81 μg/mL in 96-well microtitre plate.
The plate was then incubated at 25 ◦C for 20 min in dark and the absorbance was measured at 517 nm.
The scavenging strength was calculated using the following formula [36].
% scavenging activity = [(absorbance of DPPH control − absorbance of DPPH in 
the presence of metabolite)/absorbance of DPPH control] × 100 
(3) 
2.7. Hemolytic Activities
Hemolytic activity was determined by disc diffusion assay using sheep blood agar (SBA) plates
(Himedia, Mumbai, India). A total of 10 μL solution containing varying concentrations of the ADR1
metabolites (1000 to 7.8125 μg/mL) were dispensed on discs placed aseptically on the SBA plates and
were incubated for 24 h at 37 ◦C. The type of hemolysis was observed as alpha, beta and gamma [37].
2.8. Secondary Metabolite Profiling and GC-MS Analysis
The ADR1 metabolite extract was used at a concentration of 5 mg/mL for chemical profiling of the
classes of metabolites present in the extract. The tests for the different class of metabolites, for example,
anthraquinones, glycosides, terpenoids, flavonoids, tannins, alkaloids, saponins, sterols, anthocyanins,
coumarins, tannins, lactones, terpenes, fatty acids, proteins/amino acids and carbohydrates were
carried out by using standard methods reported earlier [38–40].
Further analysis of the metabolites was carried out by employing GC-MS (GC-MS-QP2010 plus;
Shimadzu, Kyoto, Japan) as outlined below. A constant column flow rate of 1.21 mL/min with helium
gas was maintained in RESTEK capillary column (30 m × 0.25 mm I.D. × 0.25 μm film thickness).
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Initial oven temperature was 100 ◦C for 3 min, which was increased to 250 ◦C for a hold time of 5 min,
was further increased gradually to 280 ◦C where it was kept constant for 15 min. A total of 3 μL of
sample (3 mg/mL) was injected in split mode (split ratio of 10.0) and linear velocity of the column was
maintained at 40.9 cm/s. The mass fragmentation patterns (spectra) of the metabolites were obtained at
electron ionization (EI) of 70 eV scanned over a m/z range of 40–650. The compounds detected were
identified on the basis of comparison of the mass spectra with those available in the NIST14 and Wiley8
spectral library. The spectra having a match limit value lower than 700 were not considered.
2.9. Statistical Analysis
All the experiments were performed in triplicates. The data were expressed as mean ± standard
deviation. The statistical analysis and significance of the test was performed by analysis of variance
(ANOVA), using the software, graph pad prism 5.01. The graphs were also generated using grouped
analysis in the graph pad prism and represented with SEM in the form of error bar.
3. Results and Discussion
Eight putative actinobacterial endophytes, designated as ADR1 to ADR8, were isolated from
the plant, Datura metel. While no isolate could be found from the stem part of the plant, six were
obtained from the root tissues and two were from the leaves. The antibacterial potency of these
isolates was examined against the reference strain, S. aureus ATCC 25923. Based on the size of
the zone of inhibition, the isolate ADR1 was chosen for further studies as it produced largest zone
(22.5 ± 0.58 mm). Production of the metabolites by ADR1 was carried out under the conditions as
described under Section 2.3. The metabolite extract was recovered as red colour hygroscopic sticky
mass (approximately 120 mg/L).
3.1. Identification and Characterization of the Isolate ADR1
Amplification of the 16S rRNA gene from the genome of ADR1 produced a sequence of
1452 nucleotides. Blast analysis revealed 99.17% sequence identity of the ADR1 sequence with
S. californicus strains with a query coverage of 99%. The phylogenetic relationship of the strain ADR1
can be seen in Figure 1, where it showed closest relationship with S. californicus strains. The 16S rRNA
gene sequence obtained in this study was submitted as ‘Streptomyces californicus strain ADR1’ to NCBI
GenBank with accession no. KU299789.1.
A few strains of S. californicus had been reported earlier from the soil [41–44]. However, there are
no reports of any endophytic strain of S. californicus till date to the best of our knowledge, making the
present isolate as a new endophytic actinobacterial strain, designated as S. californicus strain ADR1.
The strain ADR1 was characterized for its cultural attributes on ISP media 1 to 7. The results
(Table 1) suggested that the extent of growth of the culture varied from scanty to abundant on
different ISP media. Further, differences with respect to the colour of substrate and aerial mycelia, and
production of diffusible pigments were also noted as described in the Table 1. When compared with
the cultural characteristics of non-endophytic S. californicus strains JCM 6910, MNM-1400 and G16, it
was observed that ADR1 shared a few similarities, for example, colour of aerial mycelium on ISP 2, 3
and diffusible pigments on 4, with S. californicus strain JCM 6910, a soil isolate from Japan [41,44,45].
However, the growth of ADR1 was abundant on ISP3, while that of JCM 6910 was poor. No diffusible
pigment was produced by ADR1 in ISP5, while violet pigment was produced by JCM 6910. Other soil
isolates of S. californicus, strain MNM-1400 and strain G16, were morphologically very different from
the strain ADR1 [44,45] Thus, the endophytic S. californicus strain ADR1 was evidently distinct from
the soil isolates.
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Figure 1. Phylogenetic analysis of isolate ADR1. Neighbour-joining phylogenetic tree showed
maximum likelihood model showing the phylogenetic relationship of selected isolate (highlighted
in blue) based on 16S rRNA gene sequence alignments. The numbers at the branching points are
the percentages of occurrence in 500 bootstrapped trees. Bar indicated 0.0008 substitutions per
nucleotide position.
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A detailed view of the morphology was obtained through the study of single colonies (Figure 2;
Panel A and B). Growth on different ISP media produced differences in colour and appearance of
the colonies, which appeared as dense, depressed and rocky on ISP1, while on ISP2, 3 and 5 the
aerial mycelia appeared to be fluffy and dusty. Clear exudates can be seen over the colony on ISP6.
The colonies on ISP7 appeared scantly grown lacking distinct structures that were observed on other
media. Prominent differences in the extent of growth, structure and pigmentation of the colonies on
different ISP media were consistent with the earlier reports [46]. Such media-dependent phenotypic
variations suggested that the primary and secondary metabolism of the culture varied significantly
with changes in composition of the medium, which is in agreement with the current understanding
of the physiology of the genus Streptomyces [47,48]. The microscopic observations showed highly
branched flexuous mycelium and the arrangement of spores in a chain inside mycelium as shown in
(Figure 2, panel C and D). These are some explicit features of Streptomyces species [32].
 
Figure 2. Morphological characterization of S. californicus ADR1. Colony observations were made on
different ISP media. Panel (A) represented the magnified view showing exterior structures of the single
colony while panel (B) showed interior view of the colony as observed under a Nikon Stereo Zoom
Microscope SMZ1270; the mycelial network of branched hyphae could be observed in panel (C) and
arrangement of spores in chains were viewed in panel (D).
3.2. Antibacterial Spectrum of ADR1 Metabolites Against Significant Gram-Positive Pathogens
The spectrum of activity of the ADR1 metabolites against different Gram-positive pathogens was
determined as described under Section 2. The results presented in Table 2 showed that the metabolite
extract possessed broad spectrum activity against Gram-positive pathogens as it effectively inhibited
growth of all the reference strains. It may be noted that the activities of metabolite extract against
MRSA strains were similar to those against S. aureus strains.
However, the above data provided more of a qualitative rather than quantitative estimate of
the antibacterial activity. An accurate view of the potency of the metabolites was achieved by
assessment of MIC90 values against the pathogenic strains used in this study. As presented in
Figure 3a, the MIC90 values of the ADR1 metabolites against different strains of S. aureus were
between 0.44 ± 0.07 − 0.84 ± 0.03 μg/mL, while against S. epidermis ATCC1222 it was even lower
(0.23 ± 0.01 μg/mL). It may be noted that the potency against MRSA strains (Figure 3b) was as good as
it was against S. aureus strains. These results can be considered as significant since the MIC90 values of
the ADR1 metabolites stood better than the standard drug vancomycin (0.5 to 2 μg/mL) for MRSA
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strains [49]. Other than S. aureus strains, the MIC90 values of 1.92 ± 0.03 and 3.35 ± 0.18 μg/mL were
observed against E. faecium strains AIIMS and ATCC 49214, respectively, which demonstrated good
sensitivity of these strains to ADR1 metabolites. E. faecalis ATCC 29212 was the least sensitive to ADR1
metabolites among the reference pathogens since its MIC90 value (5.68 ± 0.20 μg/mL) stood at the
maximum, but it was still better than some of the previously reported activities [50,51]. The MIC90
values of the metabolites from some of the recently reported Streptomyces spp. against the strains of
S. aureus and MRSA were in the ranges of 2–125 μg/mL [52–54], which indicated wide variation in the
anti-bacterial potency of the metabolites. The results of the present study clearly demonstrated that
the anti-bacterial potency of ADR1 metabolites appeared at the bottom of the range or even lower,





Figure 3. Potency of ADR1 metabolites for Gram-positive pathogens. Minimum inhibitory concentration
(MIC90) values of the metabolites against the target pathogens were corelated with its antibacterial
potency. Percent inhibition in growth at different concentration of the metabolites was measured
against the reference strains as shown in (a) and in (b). The data represented mean ± SEM values of
experiments done in triplicate (p value < 0.0001).
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Zone of Inhibition (mm)
1 Staphylococcus aureus ATCC 29213 22.5 ± 0.58
2 S. aureus ATCC 25923 19 ± 0.42
3 S. aureus ATCC 13709 20 ± 0.5
4 S. epidermis ATCC 12228 18 ± 0.45
5 Methicillin-resistant S. aureus(MRSA) ATCC 43300 21.3 ± 0.27
6 MRSA 562 (clinical strain) 19 ± 0.25
7 Enterococcus faecium ATCC 49224 16.5 ± 0.4
8 E. faecium AIIMS 19.4 ± 0.47
9 E. faecalis ATCC 29212 17 ± 0.52
3.3. Anti-Biofilm Activity of ADR1 Metabolites Against S. aureus and MRSA
Biofilm-associated infections posed a greater challenge in treatment of infectious diseases as it
is one of the major contributing factors in enhancing antibiotic-resistance among S. aureus and its
methicillin-resistant strains [3]. Therefore, the discovery of drugs with potent anti-biofilm activity is
needed more than ever before to combat the ever-growing global challenge of antibiotic resistance
against the notorious pathogens like S. aureus and MRSA. In view of this, the biofilm inhibitory
potential of the ADR1 metabolites was investigated. The results (Figure 4a) suggested that the ADR1
metabolites were able to effectively inhibit formation of biofilm by the S. aureus and the MRSA strains.
Up to 90% reduction in the formation of biofilm could be achieved at significantly lower concentration
of the metabolites; the BIC90 values were noted to be in the range of 0.74 ± 0.08 to 4.59 ± 0.71 μg/mL.
The effectiveness of the ADR1 metabolites in the inhibition of the biofilm was found to be better than
the previously reported activity of biofilm inhibition by actinobacterial metabolites where maximum
inhibition of 83% was recorded at 265 μg/mL [35]. However, when the activity against pre-formed
biofilms (24 h) was examined, the BIC90 values for S. aureus strains increased by many folds, for
example, up to 45.69 ± 3.32 and 89.54 ± 0.40 μg/mL for S. aureus ATCC 25923 and S. aureus ATCC 29213,
respectively. The biofilms produced by MRSA proved even more resistant (Figure 4b). It was reported
that some of the well-known antibiotics like pyrrolomycin and related compounds could inhibit the
biofilm only up to 67%–87% [55]. Similarly, in a study on the effect of antibiotics like rifampicin,
polymyxin B, kanamycin and doxycyclin on reduction of S. aureus biofilm formation, only rifampicin
was found to inhibit the biofilm by about 50% [56]. The effect of ADR1 metabolites on inhibition of
biofilm formation as well as on the preformed biofilms was better than some previously reported
metabolite extracts [57–59]. Inhibition of biofilm formation strongly suggested that the metabolites
prevented adherence of S. aureus and MRSA cell to the polystyrene surface. Further, their ability to
disrupt pre-formed biofilms might limit the biofilm-associated drug resistance among the pathogens.
3.4. Antioxidant Activity of the ADR1 Metabolites
Antioxidants assume significance for therapeutic applications in view of their role in neutralizing
reactive oxygen species in patients fighting diseases involving infectious agents or metabolic
disorders [60–62]. Hence, it was prudent to examine if the ADR1 metabolites possessed any such activity.
The standard assay, which measured the reduction of DPPH free radical, revealed the antioxidant
properties of ADR1 metabolites (Figure 5). The free radical scavenging activity of the metabolite
extract and of ascorbic acid (a well-known antioxidant agent), followed a different pattern, where a
sharp increase in DPPH scavenging activity (from 40% to 80%) was observed when concentration
of the metabolite was increased from 62.5 to 125 μg/mL. However, in the case of ascorbic acid, there
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was no significant change in the activity over the above concentration range. The IC90 value for
DPPH scavenging by ADR1 metabolite was achieved at the concentration of 217.24 ± 6.77 μg/mL,
while that for the ascorbic acid it was 904.32 ± 12.93 μg/mL (Figure 5), which was approximately
4-fold higher compared to ADR1 metabolites. However, interestingly IC50 of the ascorbic acid
was 4.617 ± 0.89 μg/mL while that of ADR1 extract was 77.41 ± 1.02 μg/mL (not plotted). It was
recently reported that the endophytic actinobacterial strains BPSAC77, 101, 121 and 147 showed DPPH
scavenging, with an IC50 value of 43.2 μg/mL, but the IC90 value was not reported in this study [63].
In another study, Streptomyces sp. had been found to scavenge DPPH free radicals at a much higher
concentration, with an IC50 value at 435.31 ± 1.79 μg/mL [64]. In one of the recent studies, it was
reported that IC50 values for DPPH scavenging activities of several isolates of actinobacteria varied
from 12 ± 1.8 to 65 ± 3.2 μg/mL [65]. Such variations were also noted by others [54]. These reports
indicated that there was a wide variation in the antioxidant activities of the metabolites produced by
different actinobacterial strains. An in-depth characterization of relevant compounds in pure form
may offer further insight into such differences in the activities.
(a) 
(b) 
Figure 4. Anti-biofilm activity of ADR1 metabolites. (a). Inhibition of biofilm formation and
(b) inhibition of pre-formed biofilm of S. aureus ATCC 29213, 25923, MRSA 562 and ATCC 43300 are
shown at various concentration of the ADR1 metabolites. The data represented mean ± SEM values of
experiments done in triplicate (p value < 0.0001).
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Figure 5. DPPH (1, 1-diphenyl-2-picrylhydrazyl) radical scavenging by ADR1 metabolites. Oxidation
of DPPH free radicals were measured at the different concentrations of the metabolite. The data
represented mean ± SEM values of the experiments done in triplicate (p value < 0.0001).
3.5. Haemolytic Activity
Drug-induced haemolytic anaemia (DIHA) and thrombocytopenia (DIT) are common adverse
effects associated with antibiotics [66]. Reports suggested that the haemolytic effects of antimicrobial
peptides tyrocidine A and gramicidin S, limited their use as topical agents [67,68]. Ceftriaxone, a
third-generation cephalosporin was also reported to cause haemolysis, attracting advise for restricted
administration of the drug [69]. So, it is very important for a potential drug to be tested for its haemolytic
activity to secure critical information on its clinical suitability. In this context, the haemolytic effect of
the ADR1 metabolites was tested. It was noted that the ADR1 metabolites did not show any sign of
haemolysis in the concentration range from 7.8125 to 1000 μg/mL (Figure 6), which was far greater
than the MIC90 values against test pathogens.
 
Figure 6. Haemolytic activity of the ADR1 metabolites. Spot No. 1 to 8 showed metabolite dilutions
from higher (1000 μg/mL) to lower concentration (7.8125 μg/mL). ‘PC’ was positive control with 0. 1%
SDS. SC represented solvent control.
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In some previous studies, the extracts with low or no haemolytic activity were considered suitable
for further characterization of their antimicrobial properties [70]. This implied that the metabolite
extract of strain ADR1 could be safe for further investigation into specific metabolites as probable
drug candidates.
3.6. Secondary Metabolite Profiling and GC-MS Analysis of Metabolite Extract
Characterization of bioactivities of the metabolites had demonstrated that the present endophytic
strain, S. californicus ADR1 was an unexplored source of antimicrobial, antibiofilm and antioxidant
agents, which might have potential clinical applications. It was therefore prudent to analyze the
composition of the metabolite extract to unravel the class of compounds produced. Therefore, the
ADR1 metabolite extract was subjected to chemical profiling using specific reagents. The tests revealed
the classes of compounds present in the extract of metabolites produced by the strain ADR1, which
included anthraquinones, anthocyanins, terpenoids, terpenes, flavonoids, phenols, alkaloids and
glycosides (Table 3). Various compounds, which belonged to these classes have therapeutic significance
and are routinely reported from phytochemical screening of plant extracts. But recent literature
suggested that actinobacteria too are proving to be excellent sources of such class of compounds [14,71].




Testes/Reagents Used Observations Results
Terpenoids Salkowski Test Reddish brown coloration at the interface +
Phenols Folin–Ciocalteu Test Blue coloration was appeared +
Flavonoids
Ferric chloride Test Formation of greenish colour
+
NaOH, HCl Intense yellow coloration after adding HCl
Terpenes Salkowski Regent Appearance of golden colour in thechloroform layer +
Alkaloids Wagner’s Test Formation of reddish-brown precipitate +
Anthocyanins HCl, Ammonia Appearance of pink-red, turns blue +
Anthraquinones H2SO4, Chloroform,Ammonia Light pink coloured layer of ammonia +
Glycosides Keller–Killiani Test A reddish-brown colour ring at the junctionof the two layers +
Tannins Lead Acetate Test No precipitation was observed −
Saponins Foam Test No frothing was observed −
Lactones Pyridine, sodiumnitroprusside, NaOH No change in coloration was observed −
Coumarins Alcoholic NaOH Yellow fluorescence was not appeared onthe paper soaked in NaOH −
Sterols Salkowski Test No red colour was appeared in the lowerlayer (two layers formed) −
Lignins Gallic acid No appearance of Olive-green coloration −
Carbohydrates Fehling’s Test No reddish violet ring appeared −
Fatty acids Ether No appearance of transparence on filterpaper −
Proteins Biuret Test No violet coloration was observed −
Note: ‘+’: Present; ‘−’: Absent.
While the results of chemical profiling were primarily qualitative in nature suggesting the presence
or the absence of a specific chemical class, it did not offer any clue about the identity of the compounds.
But it is important to have a deeper insight into the chemical class and identity of the specific compounds
produced by the culture if these are to be considered for drug development. In pursuit of this goal,
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GC-MS analysis of the ADR1 metabolites was undertaken to probe the identity of metabolites based
on their mass spectrum.
The GC-MS analysis revealed the presence of alkaloids, terpene, terpenoids and glycosides in the
ADR1 metabolite extract, thus confirming the findings of chemical profiling. The compounds were
assigned probable identities based on similarity index (SI) value, generated from the mass spectral
analyses of the test compounds and their comparison with the reference compounds listed in the NIST
and Wiley library. An SI of more than 85 was considered for assignment of probable identity to the
compounds [72]. Out of the total 30 peaks detected in the chromatogram, 20 peaks were specific to the
culture S. californicus ADR1 while rest of the peaks were related to the production media and the solvent
control (Figure S1). Only six of ADR1 metabolite peaks were found to have SI value greater than 85.
Thus, identities could be assigned to only these compounds (Table 4). Majority of the compounds
detected in the GC-MS chromatogram showed lower degree of similarity with SI values between 60–80
(Table S1), suggesting a high probability of occurrence of novel compounds among the secondary
metabolites produced by S. californicus strain ADR1.
The first compound, detected at RT 11.945 min, showed SI of 88 with Methanoazulen-9-ol,
decahydro-2, 2, 4, 8-tetramethyl-stereoisomer, which belonged to the class sesquiterpene and possessed
antibacterial as well as antioxidant properties [73]. This compound was earlier reported as a major
component of plant essential oils [74,75] but there are no reports on this from microbial sources
as yet. Another compound in ADR1 metabolite extract was detected at RT 14.519 min, which
showed SI of 90 with 5-z-methyl-2-z-hydroxycarbonyl-5-e-ethenyl-4-z-propen-2-ylcyclohexanone,
was a terpenoid having structure similar to Asperaculane B, a known GABA-transaminase inhibitor
having significance in epilepsy treatment [76]. Terpenes and terpenoids have wide therapeutic
potential like antimalarial, antibacterial, antiinflammatory, antioxidant as well as wound healing
properties [77]. A flavonoid that was found most abundant among the ADR1 metabolites, showed SI of
85 with 4′-Methoxy-2′-(trimethylsiloxy) acetophenone. Flavonoids are well regarded molecules with
broad-spectrum biological activities as well as applications in nutraceuticals and cosmetic industry [78].
However, there are no reports on the activity of this molecule till date. An alkaloid with SI of 88
in comparison to pyridineethanamine, n-methyl-n-[2-(4-pyridinyl) ethyl] was detected among the
ADR1 metabolites at RT 16.068 min. The compound is known for its importance in the treatment of
vertigo [79]. Alkaloids are well regarded for their wide spectrum of therapeutic activities including
antibacterial, antioxidant, anti-inflammatory, anti-diabetic, antimalarial and anticancer properties [80].
The presence of therapeutically important chemical classes of compounds in ADR1 metabolite extract
underscored its importance in the discovery of novel compounds with prominent therapeutic potential.
Table 4. Similarity Index-based analysis of the compounds in the secondary metabolite extract of S.
californicus ADR1. The data were obtained from GC-MS chromatogram. The reference compounds
were from NIST and Wiley Library.
S. No. RT (min)
Similarity
Index (SI)
Reference Compounds Chemical Class Therapeutic Properties






2 13.089 96 Naphtho[2,3-g]-1,6,2,5-dioxasilaborocin Organoboranic acid No activity reported
3 13.231 85 2-[(trimethylsilyl)oxy]-4-methoxyacetophenone Flavonoid No activity reported







5 15.102 92 1,2-benzenedicarboxylic acid Diisobutyl phthalate No activity reported
6 16.068 88 2-pyridineethanamine,n-methyl-n-[2-(4-pyridinyl)ethyl]
Alkaloid (betahistine
types)
Vasodilation and reduction of
endolymphatic pressure [79]
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4. Conclusions
The metabolites produced by S. californicus ADR1 had shown very low MIC90 values against a
range of Gram-positive pathogens including those notified by the WHO as high priority pathogens.
This suggested that it could be an excellent source for effective anti-infective compounds against
some of the most challenging pathogens like S. aureus, MRSA, S. epidermis, E. faecalis and E. faecium.
The ADR1 metabolites came across as potent inhibitors of biofilms of both methicillin-sensitive and
methicillin-resistant strains of S. aureus. Along with the antimicrobial activity, the metabolites exhibited
good antioxidant activity. Antioxidant property with no haemolytic activity indicated the potential
of ADR1 metabolites for use as antioxidants. The above bioactivities could be attributed to the
presence of several therapeutically significant class of compounds as revealed by the biochemical
profiling and the GC-MS analysis. These constituents, individually or in combination, may account for
the pharmacological actions of the extract. Low SI for several compounds in the ADR1 metabolite
preparations was noteworthy as it indicated greater possibility of finding novel molecules.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/6/929/s1,
Figure S1: GC-MS Chromatogram of ADR1 metabolites; Table S1: Compounds detected in the ADR1 metabolites
extract by GC-MS analysis using NIST & Wiley library as reference.
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Abstract: Cancer is a serious threat to human health. With the increasing resistance to known drugs,
it is still urgent to find new drugs or pro-drugs with anti-tumor effects. Natural products produced
by microorganisms have played an important role in the history of drug discovery, particularly in the
anticancer and anti-infective areas. The plant rhizosphere ecosystem is a rich resource for the discovery
of actinomycetes with potential applications in pharmaceutical science, especially Streptomyces. We
screened Streptomyces-like strains from the rhizosphere soil of wheat (Triticum aestivum L.) in Hebei
province, China, and thirty-nine strains were obtained. Among them, the extracts of 14 isolates
inhibited the growth of colon tumor cell line HCT-116. Strain NEAU-wh-3-1 exhibited better inhibitory
activity, and its active ingredients were further studied. Then, 16S rRNA gene sequence similarity
studies showed that strain NEAU-wh3-1 with high sequence similarities to Embleya scabrispora DSM
41855T (99.65%), Embleya hyalina MB891-A1T (99.45%), and Streptomyces lasii 5H-CA11T (98.62%).
Moreover, multilocus sequence analysis based on the five other house-keeping genes (atpD, gyrB,
rpoB, recA, and trpB) and polyphasic taxonomic approach comprising chemotaxonomic, phylogenetic,
morphological, and physiological characterization indicated that the isolate should be assigned to
the genus Embleya and was different from its closely related strains, therefore, it is proposed that
strain NEAU-wh3-1 may be classified as representatives of a novel species of the genus Embleya.
Furthermore, active substances in the fermentation broth of strain NEAU-wh-3-1 were isolated by
bioassay-guided analysis and identified by nuclear magnetic resonance (NMR) and mass spectrometry
(MS) analyses. Consequently, one new Zincophorin analogue together with seven known compounds
was detected. The new compound showed highest antitumor activity against three human cell lines
with the 50% inhibition (IC50) values of 8.8–11.6 μg/mL and good antibacterial activity against four
pathogenic bacteria, the other known compounds also exhibit certain biological activity.
Keywords: Rhizosphere soil; Embleya; NEAU-wh-3-1; compound; antitumor activity;
antibacterial activity
1. Introduction
Tumor, especially malignant tumor, has become one of the major diseases, which is a serious threat
to the health of people around the world [1,2]. According to records of the World Health Organization
Microorganisms 2020, 8, 441; doi:10.3390/microorganisms8030441 www.mdpi.com/journal/microorganisms23
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(WHO) in 2018, more than 9 million people died of cancer, which was the second leading cause of
death worldwide [3]. This figure will further rise because of aging, intensification of industrialization
and urbanization, lifestyle modifications, etc. [2]. Thus, the burden of cancer cannot be ignored
and the search for effective anticancer drugs is urgent [4]. On the other hand, the severe cancer
incidence is also an invisible spur to the development of anti-tumor drugs throughout the world. So
far, chemotherapy is still an important method for cancer treatment. Among the chemotherapeutics
used, antitumor antibiotics derived from natural products account for a large proportion [5–7]. Natural
product antibiotics were derived from various source materials including terrestrial plants, terrestrial
microorganisms, marine organisms, and some invertebrates [8].
Microbial natural products have, in fact, been an excellent resource for drug discovery, particularly
in the anticancer and anti-infective areas [9–11]. The phylum Actinobacteria accounts for a high
proportion of soil microbial biomass and contains the most economically significant prokaryotes,
producing more than half of the bioactive compounds in a literature survey, including antibiotics,
antitumor agents, and enzymes [8,12–14]. Many famous antibiotics, such as bleomycin (BLM),
mitomycin, anthracyclines [15], actinomycin D (ActD), polyether ionophore antibiotics, tetracyclines,
quinolones, and so on, are derived from actinomycetes, which played an important role in the drug
market [16]. Zincophorin, also referred to as M144255 or griseochellin, is a polyoxygenated ionophoric
antibiotic [17], and has been reported to possess strong activity against Gram-positive bacteria and
have strong cytotoxicity against human lung carcinoma cells A549 and Madin-Darby canine kidney
cells MDCK [17,18], which was also isolated from actinomycetes. As the main genus of Actinobacteria,
Streptomyces is the largest antibiotic producer. More than 70% of nearly 10,000 microbial origin
compounds are produced by Streptomyces while some rare actinobacterial genera only accounted for
less than 30% [19–22]. As abundant resources of larger number and wider variety of new antibiotics,
Streptomyces strains have been continuously noted rather than any other actinomycete genera [19,23].
Streptomyces are widely distributed in terrestrial ecosystems, especially in the soil [24,25]. However,
as time goes on, the possibility of finding novel compounds from Streptomyces in conventional soil
has decreased and the rediscovery rate is high [22,26]. In recent years, studies on actinomycetes
from diverse habitats have suggested new chemical structures and bioactive compounds [27,28].
Rhizosphere soil, the thin layer of soil around the roots of plants, has been a potential region for the
discovery of functional microbes due to its special ecological environment. As early as the beginning
of the last century, Hiltner proposed that there are more microorganisms in rhizosphere soil than
surrounding soil [29–31]. There is a close relationship between rhizosphere microorganisms and
plants. Plants can release organic compounds and signal molecules through root secretions to recruit
microbial flora that are beneficial to their own growth. Microbes can control plant pathogens and pests
by synthesizing multiple antibiotics, thereby indirectly promoting plant growth [32–34]. In recent
years, many biologically active microorganisms and active substances produced by their secondary
metabolism have been isolated from plant rhizosphere soil [35–38].
The genus Embleya, was very recently transferred from genus Streptomyces and established by
Nouioui et al [39] and is a new member of the family Streptomycetaceae in the order Streptomycetales [39,40].
Embleya forms well-branched substrate mycelia with long aerial hyphae in open spirals and contains
LL-diaminopimelic acid in the cell wall peptidoglycan, MK-9(H4) or MK-9(H6) as the major isoprenoid
quinone and phosphatidylethanolamine (PE) as the predominant phospholipid [41], which is very
similar to that of Streptomyces [42]. At present, the genus comprises only two species: Embleya
scabrispora and Embleya hyaline. Embleya scabrispora was originally proposed as Streptomyces scabrisporus
sp. nov. [43], and it has been reclassified to the genus Embleya as the type species [39,40], it could
produce hitachimycin with antitumor, antibacterial, and antiprotozoal activities [44–46]; and Embleya
hyaline was first described as Streptomyces hyalinum [41,47], and it has been reported to produce
nybomycin which is an effective agent against antibiotic-resistant Staphylococcus aureus and it was
called a reverse antibiotic [48].
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In this study, an Embleya strain, NEAU-wh-3-1, with better antitumor activity was isolated from
the wheat rhizosphere soil. The taxonomic identity of strain NEAU-wh3-1 was determined by a
combination of 16S rRNA gene sequence and five other house-keeping genes (atpD, gyrB, rpoB, recA,
and trpB) analysis with morphological and physiological characteristics. The active substances of
strain NEAU-wh-3-1 were also isolated, identified, and determined. Furthermore, the cytotoxicity and
antimicrobial activity of the isolated compounds were tested.
2. Materials and Methods
2.1. Isolation of Streptomyces-Like Strains
Rhizosphere soil of wheat (Triticum aestivum L.) was collected from Langfang, Hebei Province,
Central China (39◦32′ N, 116◦40′ E). The soil sample should be protected from light and air-dried
at room temperature for 14 days before isolation for Streptomyces-like strains. After drying, the
soil sample was ground into powder and then suspended in sterile distilled water followed by a
standard serial dilution technique. The diluted soil suspension was spread on humic acid-vitamin
agar (HV) [49] supplemented with cycloheximide (50 mg L−1) and nalidixic acid (20 mg L−1). After
28 days of aerobic incubation at 28 ◦C, colonies were transferred and purified on the International
Streptomyces Project (ISP) medium 3 [50], and maintained as glycerol suspensions (20%, v/v) at −80 ◦C
for long-period preservation.
2.2. Screening of Strains with Antitumor Activity
All the isolated were cultured on ISP medium 2 (yeast extract-malt extract agar) and incubated at
28 ◦C for 7 days. The spores of the strains were transferred into 250 mL Erlenmeyer flasks containing
30 mL of the production broth containing maltodextrin 4%, lactose 4%, yeast extract 0.5%, and MOPS
2%, at pH 7.2–7.4. on a rotary shaker at 250 r.p.m at 28 ◦C. After seven days, the production broth
was extracted with an equal volume of methanol for approximately 24 h. After filtration, the filtrate
substances were evaporated under reduced pressure at 50 ◦C to yield the crude extract and then
dissolved in DMSO (dimethyl sulfoxide) at concentrations of 20 μg/mL and 100 μg/mL. The HCT-116
(human colorectal carcinoma) cell lines were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% (w/v) fetal bovine serum in a humidified incubator at 37 ◦C of 5% CO2
incubator. The antitumor activities of extracts with two concentrations were investigated by the SRB
(Sulforhodamine B) colorimetric method. Briefly, treated cells were harvested and seeded at a density
of 5 × 104 cells/well into a sterile flat bottom 96-well plate for 24 h, the cells were treated with different
concentrations of the extracts for 48 h and growth inhibition was measured by determining the optical
density at 510 nm, and the assay was performed basing on an established method [51].
2.3. Morphological and Physiological and Biochemical Characteristics of NEAU-wh3-1
Gram staining was carried out by using the standard method and morphological characteristics
were observed by light microscopy (Nikon ECLIPSE E200, Nikon Corporation, Tokyo, Japan) and
scanning electron microscopy (Hitachi SU8010, Hitachi Co., Tokyo, Japan) using cultures grown on ISP
3 agar at 28 ◦C for 2 weeks. Samples for scanning electron microscopy were prepared as described
by Jin et al. [52]. Growth at different temperatures (4, 10, 15, 20, 25, 28, 32, 37, 40, and 45 ◦C) was
determined on ISP 3 medium after incubation for 14 days. Growth tests for pH range (pH 4.0–12.0, at
intervals of 1.0 pH unit) using the buffer system described by Zhao et al. [53] and tolerance of various
NaCl concentrations (0–10%, with an interval of 1%, w/v) were tested in GY (Glucose-yeast extract
powder) medium (glucose 1%, yeast extract 1%, K2HPO4 3H2O 0.05%, MgSO4 7H2O 0.05%, w/v, pH
7.2) at 28 ◦C for 14 days on a rotary shaker. Hydrolysis of Tweens (20, 40, and 80) and production of
urease were tested as described by Smibert and Krieg [54]. The utilization of sole carbon and nitrogen
sources, decomposition of cellulose, hydrolysis of starch and aesculin, reduction of nitrate, coagulation
25
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and peptonization of milk, liquefaction of gelatin, and production of H2S were examined as described
previously [55,56].
2.4. Chemotaxonomic Analysis of NEAU-wh3-1
Biomass for chemotaxonomic characterization was prepared by growing strain NEAU-wh3-1 in
ISP 2 broth in shake flasks at 28 ◦C for 7 days. Cells were harvested by centrifugation, washed twice
with distilled water, and freeze-dried. The whole-cell sugars were analyzed according to the procedures
developed by Lechevalier and Lechevalier [57]. The polar lipids were examined by two-dimensional
TLC (thin layer chromatography) and identified using the method of Minnikin et al. [58]. Menaquinones
were extracted from freeze-dried biomass and purified according to Collins [59]. Streptomyces lutosisoli
DSM 42165T [60] was used as the reference strain for identification of menaquinones. Extracts were
analyzed by a HPLC-UV method [61] using an Agilent Extend-C18 Column (150 × 4.6 mm, i.d. 5 μm)
(Agilent Corp., Santa Clara, CA, USA) at 270 nm.
2.5. Phylogenetic Analysis of NEAU-wh3-1
Extraction of genomic DNA, PCR amplification of the 16S rRNA gene sequence and sequencing
of PCR products were carried out using a standard procedure [62]. The PCR product was purified
and cloned into the vector pMD19-T (Takara Bio Inc., Dalian, China) and sequenced using an Applied
Biosystems DNA sequencer (model 3730XL, Applied Biosystems Inc., Foster City, California, USA). The
almost complete 16S rRNA gene sequence of strain NEAU-wh3-1, comprising 1487 bp, was obtained
and compared with type strains available in the EzBioCloud server [63] and retrieved using NCBI
BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi;), and then submitted to the GenBank database. The
phylogenetic tree was constructed based on the 16S rRNA gene sequences of strain NEAU-wh3-1
and related reference species. Sequences were multiply aligned in Molecular Evolutionary Genetics
Analysis (MEGA) using the Clustal W algorithm and trimmed manually where necessary. Phylogenetic
trees were generated with the neighbor-joining [64] and maximum-likelihood [65] algorithms using
MEGA software version MEGA 7.0 [66]. The stability of the topology of the phylogenetic tree was
assessed using the bootstrap method with 1000 replicates [67]. A distance matrix was generated using
Kimura’s two-parameter model [68]. All positions containing gaps and missing data were eliminated
from the dataset (complete deletion option). The gyrB gene was amplified with primers PF-1 and
PR-2 [69] under the PCR program for 16S rRNA gene. PCR of the atpD, recA, rpoB, and trpB genes
were performed using primers and amplification conditions described by Guo et al. [70]. The sequence
data were exported as single gene alignments or a concatenated five-gene alignment for subsequent
analysis as described above. Trimmed sequences of the five housekeeping genes were concatenated
head-to-tail in-frame in the order atpD (430 bp)-gyrB (354 bp)-recA (431 bp)-rpoB (208 bp)-trpB (556 bp).
Phylogenetic analysis was performed as described above.
2.6. Production
The strain Embleya sp. NEAU-wh3-1 was grown on the ISP medium 2 (yeast extract-malt extract
agar) and incubated for 6–7 days at 28 ◦C. The spores of the strain were transferred into two 1.0 L
Erlenmeyer flasks containing 250 mL of the seed medium and incubated at 28 ◦C for 48 h on a rotary
shaker at 250 r.p.m. All of the media were sterilized at 121 ◦C for 30 min. The seed culture (8%) was
transferred into 60 flasks (1.0 L) containing 250 mL of production broth. The production broth was
composed of maltodextrin 4%, lactose 4%, yeast extract 0.5%, MOPS 2%, at pH 7.2–7.4. The flasks were
incubated at 28 ◦C for 7 days, shaken at 250 r.p.m.
2.7. Extraction and Isolation
The final 15.0 L production broth was filtered to separate supernatant and mycelial cake. The
supernatant was subjected to a Diaion HP-20 resin column and eluted with 95% EtOH. The mycelial
cake was washed with water (3 L) and subsequently extracted with MeOH (3 L) to obtain soluble
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material. The MeOH extract and the EtOH eluents were evaporated under reduced pressure at 50 ◦C
to yield the crude extract (24 g). The crude extract was chromatographed on a silica gel column and
eluted with a stepwise gradient of CH2Cl2/MeOH (95:5/90:10/85:15/80:20/70:30/65:35, v/v) and giving
three fractions (Fr.1–Fr.3) based on the TLC profiles, which was performed on silica-gel plates with
solvent system of CHCl3/MeOH (9:1, v/v). The Fr.1 was subjected to a Sephadex LH-20 column eluted
with CH2Cl2/MeOH (1:1, v/v) and detected by TLC to give two subfractions (Fr.1-1-Fr.1-2). The Fr.1-1
was further isolated by semi-preparative HPLC (Agilent 1100, Zorbax SB-C18, 5 μm, 250 × 9.4 mm
inner diameter; 1.5 mL min−1; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH3CN/H2O (90:10,
v/v) to give compound 1 (tR 25.06 min, 10.5 mg), the Fr.1-2 was further isolated by preparative HPLC
(Shimadzu LC-8 A, Shimadzu-C18, 5 μm, 250 × 20 mm inner diameter; 20 mL min−1; 220 /254 nm;
Shimadzu, Kyoto, Japan) eluting with a stepwise gradient MeOH/H2O (30–80%, v/v 30 min), and giving
compound 2 (tR 12.7 min, 7.5 mg), compound 3 (tR 17.5 min, 12.7 mg) and compound 4 (tR 22.6 min,
16.3 mg). The Fr.2 was subjected to another silica gel column eluted with n-hexane/acetone (95:5-60:40,
v/v) and further purified by semi-preparative HPLC (Agilent 1100, Zorbax SB-C18, 5 μm, 250 × 9.4
mm inner diameter; 1.5 mLmin−1; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH3CN/H2O
(75:25, v/v) to give compound 5 (tR 15.1 min, 13.5 mg) and compound 6 (tR 24.3 min, 18.5 mg). Fr.3
was treated by an another silica gel column and eluted with a stepwise gradient of n-hexane/acetone
(100:0-40:60, v/v) to give three fractions Fr.3-1–Fr.3-3 according to their TLC profiles, which was observed
on silica-gel plates with solvent system of n-hexane/acetone (1:3, v/v). The Fr.3-3 was further purified
by semi-preparative HPLC (Agilent 1260, Zorbax SB-C18, 5 μm, 250 × 9.4 mm inner diameter; 1.5 mL
min−1; 220nm; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH3CN/H2O (45:55, v/v) to obtain
compounds 7 (tR 25.1 min, 13.0 mg) and 8 (tR 30.1 min, 7.5 mg).
2.8. General Experimental Procedures
IR spectra were recorded on a Thermo Nicolet Avatar FT-IR-750 spectrophotometer (Thermo,
Tokyo, Japan) using KBr disks. Optical rotations were measured on a Perkin-Elmer 341 polarimeter
(PerkinElmer, Inc. Suzhou, China). UV spectra were recorded on a Varian CARY 300 BIO
spectrophotometer (Varian, Cary, NC, USA). The HR-ESI-MS and ESI-MS were taken on a Q-TOF Micro
LC-MS-MS mass spectrometer (Waters Co, Milford, MA, U.S.A.). Nuclear magnetic resonance (NMR)
spectra (400 MHz for 1H and 100 MHz for 13C) were measured with a Bruker DRX-400 spectrometer
(Bruker, Rheinstetten, Germany). HPLC analysis was performed on a preparative HPLC (Shimadzu
LC-8 A, Shimadzu-C18, 5 μm, 250 × 20 mm inner diameter; 20 mL min−1; 220/254 nm; Shimadzu,
Kyoto, Japan) as well as a semipreparative HPLC (Agilent 1100, Zorbax SB-C18, 5 μm, 250 × 9.4 mm
inner diameter; 1.5 mL/min; 220/254 nm; Agilent, Palo Alto, CA, USA). Column chromatography were
consisted of silica gel (100–200 mesh, Qingdao Haiyang Chemical Group Co., Qingdao, China) as well
as Sephadex LH-20 gel (GE Healthcare, Glies, UK), which were analyzed by thin-layer chromatography
(TLC). TLC was performed on silica-gel plates (HSGF254, Yantai Chemical Industry Research Institute,
Yantai, China) and the developed plates were observed under a UV lamp at 254 nm or by heating after
spraying with sulfuric acid-ethanol, 5:95 (v/v).
2.9. Biological Assays
The cytotoxicity of the eight compounds was assayed by cell counting kit-8 (CCK-8) colorimetric
method [71] in vitro against the human leukemia cells K562, hepatocellular liver carcinoma cell line
HepG2, and the human colon tumor cell line HCT-116. The cell lines were routinely in Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 10% calf serum at 37 ◦C for 4 h in a humidified
atmosphere of 5% CO2 incubator. The adherent cells at logarithmic phase were digested by pancreatic
enzymes and inoculated onto 96-well culture plate at a density of 1.0 × 104 cells per/well. Test samples
and control were dissolved in DMSO (dimethyl sulfoxide) and then added to the medium, incubated
for 72 h. Then, the cell counting kit-8 (CCK-8, Dojindo, Kumamoto, Japan) reagent was added to the
medium followed by further incubation for 3 h. Absorbance at 450 nm with a 600 nm reference was
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measured thereafter using a SpectraMax M5 microplate reader (Molecular Devices Inc., Sunnyvale,
CA, USA). The inhibitory rate of cell proliferation was expressed as IC50 values and calculated by the
following formula:
Growth inhibition (%) = [ODcontrol-ODtreated]/ODcontrol×100
Doxorubicin was tested as a positive control, and cell solutions containing 0.5% DMSO were
tested as a negative control.
The antibacterial activities of the isolated compounds were tested against Gram-positive bacteria
Staphylococcus aureus, Bacillus subtilis, and Sarcina lutea and Gram-negative bacteria Klebsiella pneumoniae
and Escherichia coli with the minimum inhibitory concentration (MIC) method recommended by the
Clinical and Laboratory Standards Institute [72].
3. Results
3.1. Isolation and Screening of an Antitumor Compound Producing Strains
Thirty-nine strains belonging to actinomycetes were isolated from the soil samples. The crude
extracts of these isolates were examined for their cytotoxic activity at dilution concentrations of 100
μg/mL and 20 μg/mL. As a result of primary screening, fourteen strains showed cytotoxic activity
to human colon tumor cell line HCT-116 (Figure 1). Due to the superior cytotoxic activity of strain
NEAU-wh3-1, which inhibition rate was greater than 80% at both concentrations, further chemical
investigations were performed on this strain.
Figure 1. Antitumor activities of extracts obtained from fourteen isolates against human colon tumor
cell line HCT-116.
3.2. Polyphasic Taxonomic Characterization of NEAU-wh3-1
Morphological observation of 2-week-old cultures of strain NEAU-wh3-1 grown on ISP 3 medium
revealed that the strain has the typical characteristics of genus Embleya and formed well-developed,
branched substrate hyphae and aerial mycelium that differentiated into spiral spore chains consisted of
cylindrical spores (0.6–0.8μm × 0.9–1.3μm), the spores were rough-surfaced and non-motile (Figure 2).
Strain NEAU-wh3-1 was found to grow at a temperature range of 4 to 37 ◦C (optimum temperature
28 ◦C), pH 5 to 12 (optimum pH 7), and NaCl tolerance of 0% to 3% (optimum NaCl of 1%). The
physiological and biochemical properties of strain NEAU-wh3-1, Embleya scabrispora DSM 41855T,
Embleya hyalina MB891-A1T, and Streptomyces lasii 5H-CA11T are given in Table 1.
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Figure 2. Scanning electron micrograph of spore chains of strain NEAU-wh3-1 grown on ISP 3 agar for
2 weeks at 28 ◦C.
Table 1. The physiological and biochemical properties of strain NEAU-wh3-1, Embleya scabrispora DSM
41855T, Embleya hyalina MB891-A1T, Streptomyces lasii 5H-CA11T.
Characteristic 1 2a,c 3b 4c
Decomposition of
Cellulose − − ND +
Tween 20 − + ND +
Tween 40 + + ND +
Tween 80 − + ND +
Liquefaction of gelatin − − + +
Growth temperature (◦C) 4–37 18–36 10–28 15–38
pH range for growth 5–12 4–10 6–11 5–11
NaCl tolerance range (w/v, %) 0–3 0–3 0–1 0–2.5
Milk coagulation − w − +
Nitrate reduction − + − −
Starch hydrolysis − w − −
Carbon source utilization
l-arabinose + ± − −
Dulcitol + w − W
d-Fructose + − + −
d-Galactose + − + −
d-Glucose + + + +
Inositol − + + −
Lactose + + − +
d-Maltose + − ± −
d-Mannitol + − − −
d-Mannose + − + −
d-Raffinose + − − +
d-Ribose − + ND −
d-Sorbitol + − − −
d-Sucrose + ± W +
d-Xylose + + − −
l-Rhamnose − + + −
Nitrogen source utilization
l-Alanine + W ND +
l-Arginine + W ND +
l-Asparagine + W ND −
l-Aspartic acid + + ND +
Creatine + w ND −
l-Glutamic acid + w ND +
l-Glutamine + w ND +
Glycine + w ND +
l-Proline − + ND +
l-Serine + − ND −
l-Threonine + w ND +
l-Tyrosine + + ND +
















Whole cell-wall sugars Arabinose, glucose, ribose Arabinose Arabinose, glucose Glucose, ribose
Strains: 1, NEAU-wh3-1; 2, Embleya scabrispora DSM 41855T; 3, Embleya hyalina MB891-A1T; 4, Streptomyces
lasii 5H-CA11T. Abbreviation: +, positive; –, negative; ±, ambiguous; ND, not determined; w, weak;
DPG, diphosphatidylglycerol; PME, phosphatidylmonomethylethanolamine; PE, phosphatidylethanolamine;
PI, phosphatidylinositol; PIM, phosphatidylinositolmannoside; UL, unidentified lipid; GL, glucosamine-containing
lipid; PGL, phospholipid containing glucosamine. All data are from this study except where marked. a Data from
Ping et al. [43]; b Data from Komaki et al. [41]; c Data from Liu et al. [73].
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Chemotaxonomic analyses revealed that strain NEAU-wh3-1 contained LL-diaminopimelic acid
as cell wall diamino acid. The whole-cell sugar was found to contain arabinose, glucose, and ribose.
The phospholipid profile consisted of diphosphatidylglycerol (DPG), phosphatidylethanolamine
(PE), phosphatidylinositol (PI), and two unidentified lipids (ULs) (Supplementary Figure S1). The
menaquinones detected were MK-9(H4) (46.5%), MK-9(H6) (45.8%), and MK-9(H8) (7.7%).
The almost complete 16S rRNA gene sequence of strain NEAU-wh3-1 (1487 bp) was determined
and deposited with the accession number MN928616 in the GenBank/EMBL (European Molecular
Biology Laboratory)/DDBJ (DNA Data Bank of Japan) databases. EzBioCloud analysis suggests
that strain NEAU-wh3-1 shared the highest 16S rRNA gene sequence similarities with Embleya
scabrispora DSM 41855T (99.65%), Embleya hyalina MB891-A1T (99.45%), and Streptomyces lasii 5H-CA11T
(98.62%). Phylogenetic analysis based on the 16S rRNA gene sequences indicated that the strain
formed a stable cluster with E. scabrispora DSM 41855T, E. hyalina MB891-A1T, and S. lasii 5H-CA11T
based on neighbor-joining algorithm (Figure 3) and also supported by the maximum-likelihood
algorithm (Supplementary Figure S2). To further clarify the affiliation of strain NEAU-wh3-1 to its
closely related strains, partial sequences of housekeeping genes including atpD, gyrB, recA, rpoB, and
trpB were obtained. GenBank accession numbers of the sequences are displayed in Table S1. The
phylogenetic tree based on the neighbor-joining tree constructed from the concatenated sequence
alignment (1979 bp) of five housekeeping genes (Figure 4) suggested that the isolate clustered with E.
scabrispora DSM 41855T and E. hyalina MB891-A1T, and also supported by the maximum-likelihood
algorithm (Streptomyces lasii 5H-CA11T lacks housekeeping genes; Supplementary Figure S3). Moreover,
pairwise distances calculated for NEAU-wh3-1 and the related species using concatenated sequences of
atpD-gyrB-recA-rpoB-trpB were well above 0.007 (Table S2) for the related species, which was considered
to be the threshold for species determination [74].
Figure 3. Neighbor-joining tree showing the phylogenetic position of strain NEAU-wh3-1 (1487 bp) and
related taxa based on 16S rRNA gene sequences. Bootstrap values > 50% (based on 1000 replications)
are shown at branch points. Arthrobacter globiformis DSM 20124T (M23411) was used as an outgroup.
Asterisks indicate branches also recovered in the maximum-likelihood tree; Bar, 0.01 substitutions per
nucleotide position.
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Figure 4. Neighbor-joining tree based on multilocus sequence analysis (MLSA) analysis of the
concatenated partial sequences (1979 bp) from five housekeeping genes (atpD, gyrB, recA, rpoB, and trpB)
of strain NEAU-wh3-1 (in bold) with related taxa. Only bootstrap values above 50% (percentages of
1000 replications) are indicated. Asterisks indicate branches also recovered in the maximum-likelihood
tree; Bar, 0.05 substitutions per nucleotide position.
3.3. Structural Elucidation
The strain NEAU-wh3-1 was grown preparative scale in 15.0 L of production broth for 7
days. Bioassay-guided isolation of the active components of the strain yielded eight main bioactive
compounds. Compounds 2–8 are known compounds, which structures were elucidated as conglobatin
(2) [75], piericidin C1 (3) [76], piericidin C5 (4) [77], piericidin A1 (5) [78], piericidin A3 (6) [76], Mer-A
2026 A (7) [79], and BE-52211 D (8) [80] by analysis of their spectroscopic data and comparison with
literature values (Figure 5, Figures S12–S27). Compound 1 is a new zincophorin analogue (Figure 6,
Figures S4–S11) [17].
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Figure 5. The structures of compounds 1–8. Compound 1 was isolated as white solid with [α]25D + 15
(c 0.043, EtOH) and UV (EtOH) λmax nm (log ε): 202 (4.53). Its molecular formula was established
as C31H56O7 by HR-ESI-MS at m/z 539.3942 [M-H]- (calcd 539.3953 as C31H55O7). The IR spectrum
revealed hydroxyl absorption at 3320 cm−1 and carbonyl absorption at 1735 cm−1, as well as methyl
and methylene absorptions at 2953 cm−1 and 2924 cm−1.
Figure 6. 2D nuclear magnetic resonance (NMR) correlations of compound 1.
Analysis of 1H NMR spectrum of 1 revealed the presence of three olefinic protons at δH 5.52 (1H,
m), 5.36 (1H, m), 5.20 (1H, d, J = 8.9 Hz), seven aliphatic methine protons at δH 4.07 (1H, m), 4.06 (1H,
m), 3.77 (1H, d, J = 8.9 Hz), 3.72 (1H, dd, J = 9.6, 2.1 Hz), 3.58 (1H, d, J = 9.2 Hz), 3.49 (1H, m), 3.28 (1H,
m), seven methylene protons at δH 2.18 (1H, m), 2.13 (1H, m), 1.77 (1H, m), 1.67 (2H, m), 1.40 (1H, m),
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1.35 (1H, m), 1.28 (1H, m), one singlet methyl at δH 1.63 s, in addition to eight doublet methyl protons at
δH 1.18 (3H, d, J = 7.1 Hz), 1.15 (3H, d, J = 7.2 Hz), 1.11 (3H, d, J = 7.0 Hz), 0.98 (3H, d, J = 6.5 Hz), 0.97
(3H, d, J = 6.6 Hz), 0.86 (3H, d, J = 6.7 Hz), 0.81 (3H, d, J = 6.5 Hz), 0.70 (3H, d, J = 6.7 Hz). The 13C NMR
and DEPT135 spectra (Table 2) of 1 showed 31 resonances attributable to a carbonyl carbon at δC 175.6,
one sp2 quaternary carbon at δC 132.3, three sp2 methines at δC 136.6, 134.5, 132.4. In the sp3-carbon
region, the spectrum showed six oxygenated methines at δC 84.3, 83.3, 81.7, 76.1, 74.0, 69.4, six methines
at δC 42.2, 37.1, 36.5, 36.0, 33.0, 26.1, four methylenes at δC 34.2, 28.6, 27.1, 24.9 and nine methyl
carbons at δC 22.9, 22.9, 17.1, 16.7, 15.4, 12.3, 11.3, 10.8, 10.1. The 1H–1H COSY correlations (Figure 6)
of H-2/H-3/H2-4/H2-5/H-6/H-7/H-8/H-9/H-10/H-11/H-12/H-13/H2-14/H2-15/H-16/H-17/H-18/H-19
established connectivity from H-2 atom along the chain through to C-19 atom. The correlations between
H-21/H-22/H3-23/H3-24, H-12/H3-27, H-10/H3-28, H-18/H3-26, H-8/H3-29 protons in the 1H–1H COSY
spectrum (Figure 6) indicated the five structural units of C-21–C-24, C-18–C-26, C-12–C-27, C-10-C-28,
C-8-C-29. The observed HMBC (heteronuclear multiple bond correlation) correlations (Figure 6) from
H3-23, H3-24 to C-21, C-22, from H3-25 to C-19, C-21, from H3-26 to C-17, C-18, and C-19, from H3-27
to C-11, C-12, and C-13, from H3-28 to C-9, C-10, C-11, from H3-29 to C-7, C-8, C-9, from H3-30 to C-5,
C-6, C-7, from H3-31 to C-2 and C-3, from H-21 to C-19, H-20 to C-18, from H-19 to C-17, from H3-23 to
C-21 established the linkage of C-2–C-22. The carbonyl group was connected with C-2 by the HMBC
corrections from H-2 and H3-31 to C-1 (δC 175.6). The correlations from H-7 (δH 3.77 d, J = 8.9 Hz) to
C-3 (δC 74.0) indicated the linkage of C-3 and C-7 through an oxygen atom to form a tetrahydropyran
ring. Taking the molecular formula of C31H56O7 into account, four hydroxyl groups were situated at
C-9, C-11, C-13, C-19, respectively, and a carboxyl group was situated at C-1. Comparison the NMR
data of 1 with Zincophorin [17], a mocarboxylic acid ionophore contains one single tetrahydropyran
ring, which was isolated from a strain of Streptomyces griseus, implied that 1 was identified to be an
analogue of Zincophorin, the difference between two compounds was that the terminal ethyl group in
Zincophorin was replaced by a H proton in compound 1. On the basis of the above spectroscopic data,
a gross structure of 1 was established and named Zincophorin B, and the 1H and 13C resonances in 1
were assigned (Table 2).
Table 2. 1H and 13C NMR data of compound 1 in CDCl3.
No. δH (J in Hz) δC (p.p.m) No. δH (J in Hz) δC (p.p.m)
1 175.6 16 5.52 m 132.4
2 3.28 m 37.1
17 5.36 m 134.53 4.07 m 74.0
4 1.67 m 24.9
18 2.27 m 42.2
19 3.58 d (9.2) 81.7
5a 1.28 m 27.1 20 132.3
5b 1.40 m 21 5.20 d (8.9) 136.6
6 1.52 m 26.1 22 2.59 m 26.1
7 3.77 d (8.9) 76.1 23 0.97 d (6.6) 22.9
8 2.04 m 33.0 24 0.98 d (6.5) 22.9
9
3.72 dd
84.3 25 1.63 s 10.1(9.6, 2.1)
10 2.01 m 36.5 26 0.86 d (6.7) 16.7
11 3.49 m 83.3 27 1.15 d (7.2) 10.8
12 1.75 m 36.0
28 0.70 d (6.7) 12.3
29 1.11 d (7.0) 11.3
13 4.06 m 69.4 30 0.81 d (6.5) 17.1
14a 1.35 m 34.2 31 1.18 d (7.1) 15.4
14b 1.77 m
15a 2.13 m 28.6
15b 2.18 m
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3.4. Biological Activity
The cytotoxic activities of compounds 1–8 against K562, HCT-116, and HepG2 cancer cell lines
are showed in Table 3. Eight compounds restrained proliferation of the tested cells and compound 1
showed the highest cytotoxic activity, and the average IC50 values were lower than 10.0 μg/mL.





























8 11.42 ± 3.05 15.13 ± 1.76 10.83 ± 3.47
Doxorubicin 1.1 ± 0.1 0.9 ± 0.3 2.1 ± 0.2
The result of minimum inhibitory concentrations (MICs) showed that compound 1 showed
good activities against Gram-positive bacteria Staphylococcus aureus, Sarcina lutea, and Bacillus subtilis,
and the Gram-negative bacteria Klebsiella pneumoniae in vitro (Table 4). Compound 8 showed weak
antibacterial activity against two Gram-positive bacterium and the minimum inhibitory concentrations
(MICs) of compounds 2–7 were determined to be >10 mg/mL, so they had no activity against these
tested pathogens.
Table 4. The antibacterial activity of compounds 1-8.
Compounds
MIC (μg/mL)









1 31.0 ± 2.5 44.0 ± 5.8 3.5 ± 0.5 25.0 ± 1.5 —
2–7 — — — — —
8 210.0 ± 20.0 190.0 ± 15.0 — — —
4. Discussion
In this research, the results of morphological, physiological, and biochemical tests showed
that strain NEAU-wh3-1 has typical characteristics of the genus Embleya [41]. Such as containing
LL-diaminopimelic acid as the cell wall peptidoglycan, MK-9(H4), and MK-9(H6) as the major
menaquinones, phosphatidylethanolamine (PE) as the predominant phospholipid and arabinose in
the whole sugars. Moreover, strain NEAU-wh3-1 formed spiral spore chains and the spore surface
was rough, which are consistent with E. scabrispora DSM 41855T and E. hyalina MB891-A1T [39,41]. In
addition, the phylogenetic trees constructed from the 16S rRNA gene sequences and the concatenated
sequences alignment (1979 bp) of five housekeeping genes all suggested that the isolate should be
assigned to the genus Embleya.
However, some obvious differences could also be found between strain NEAU-wh3-1 and its
closely related strains regarding several phenotypic and chemotaxonomic characteristics (Table 1).
The isolate was able to grow at 4 ◦C, in contrast to its closely related strains, which were not. The
composition of phospholipids and menaquinones of strain NEAU-wh3-1 was also different from its
related species, E. scabrispora DSM 41855T, E. hyalina MB891-A1T and S. lasii 5H-CA11T. Most notably,
the whole-cell sugars of strain NEAU-wh3-1 was found to contain arabinose, glucose, and ribose,
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while E. scabrispora DSM 41855T only contains arabinose, E. hyalina MB891-A1T contains arabinose and
glucose and S. lasii 5H-CA11T contains glucose and ribose, which also could distinguish the strain
from its closely related strains. Other phenotypic differences include the temperature and pH range of
growth, patterns of carbon and nitrogen utilization, hydrolysis of cellulose, starch, and Tweens (20, 40,
and 80), liquefaction of gelatin, peptonization of milk, production of H2S, and urease and reduction of
nitrate. Therefore, it is evident from the phenotypic, genotypic, and chemotaxonomic data that strain
NEAU-wh3-1 may represent a novel species of the genus Embleya.
The genus Embleya, recently transferred from genus Streptomyces, is a new member of the
family Streptomycetaceae [39,40]. At present, it contains only two species: Embleya scabrispora, could
produce hitachimycin with antitumor, antibacterial, and antiprotozoal activities [44–46]; and Embleya
hyaline, could produce nybomycin which is an effective agent against antibiotic-resistant Staphylococcus
aureus and is called a reverse antibiotic [48]. During the study of the chemical properties of the
active ingredients of strain NEAU-wh3-1, eight active compounds were obtained, including one
macrolide dilactone, five piericidins, one β-hydroxy acetamides, an analogue of monocarboxylic acid
ionophore, which were observed to fit into at least three types based on their molecular skeletons.
This shows to some extent that this strain has the ability to produce metabolites with a wide variety
of different skeletal structures. Out of these compounds, Piericidins (3-7) were a class of polyene
alpha-pyridone heterocyclic antibiotics, among them, Piericidin A1(5) was first reported [81], which
was isolated from Streptomyces mobaraensis. Piericidins exhibit interesting biological activities, in
particular antitrypanosomal [82]. In our research, compounds 3-7 exhibited different degrees of
cytotoxicity on three types of tumor cells, but they did not show any antibacterial activity, which was
consistent with previous reports [78,81]. As a Piericidins-producing strain, NEAU-wh3-1 has certain
application potential in pest control. Conglobatin (2) is an unusual 16-membered macrocyclic diolide
originally isolated from a polyether-producing strain of Streptomyces conglobatus ATCC 31005T and was
reported to be essentially devoid of antifungal, antibacterial, antitumor, and antiprotozoal activity at
that time [75]. However, in recent research, FW-04-806 is identical in structure to conglobatin, and it
has been reported to inhibit the growth of a human chronic myelocytic leukemia K562 cell line with
an IC50 of 6.66 μg/mL, further study also investigated the effects of FW-04-806 on SKBR3 and MCF-7,
respectively [83]. Its mechanism of action appears to be novel, via direct binding to the N-terminal
domain of Hsp90 and disruption of its interaction with co-chaperone Cdc37 [84]. In our antitumor
activity test, Conglobatin (2) showed good bioactivity against two tumor cell lines, supporting it at least
partially accounted for the cytotoxic activity of the strain NEAU-wh3-1 extract. BE-52211 D (8) was a
cytotoxic metabolite from a strain of Streptomyces and had been reported to have moderate cytotoxicity
against human hepatocellular liver carcinoma cells HepG2, human leukemia cells K562, and human
colon carcinoma cells HCT-116 with the IC50 values of >10 μg/mL [80], which is consistent with the
result in the present study. Compound 1 structurally related to zincophorin, which was also referred to
as M144255 or griseochellin and is a polyoxygenated ionophoric antibiotic isolating from Streptomyces
griseus in 1984 [17]. It has been reported to possess strong in vivo activity against Gram-positive
bacteria and have strong cytotoxicity against human lung carcinoma cells A549 and Madin-Darby
canine kidney cells MDCK [18]. No biological activity has been reported against Gram-negative
bacteria, yeasts, and fungi [85]. The second member in the zincophorin family named CP-78545, was
found in the culture broth of Streptomyces sp. N731-45. The structural difference between them is that
CP-78545 has an extra terminal double bond; but they have similar spectrum and potency on biological
properties except for the antitumor activity (no reports) [86]. In our antitumor and antimicrobial
assays, compound 1 showed the highest antitumor activity against three human cell lines and good
antibacterial activity against Gram-negative bacteria. To our knowledge, this is the first report of this
kind of compound with antibacterial activity against Gram-negative bacteria. This study has enriched
the activity spectrum of Zincophorins.
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5. Conclusions
Strain producing a new compound with strong antitumor activity, isolated from the rhizosphere
soil of wheat (Triticum aestivum L.) in HeBei province, China. Morphological and chemotaxonomic
features together with phylogenetic analysis suggested that strain NEAU-wh3-1 belonged to the genus
Embleya. Cultural and biochemical characteristics combined with multilocus sequence analysis clearly
revealed that strain NEAU-wh3-1 may represent a novel species of the genus Embleya. Moreover, eight
compounds, including one new compound with higher antitumor activities against three human cell
lines, were isolated from the strain.
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Abstract: Ralstonia solanacearum is an important soil-borne bacterial plant pathogen. In this study, an
actinomycete strain named NEAU-HV9 that showed strong antibacterial activity against Ralstonia
solanacearum was isolated from soil using an in vitro screening technique. Based on physiological and
morphological characteristics and 98.90% of 16S rRNA gene sequence similarity with Streptomyces
panaciradicis 1MR-8T, the strain was identified as a member of the genus Streptomyces. Tomato
seedling and pot culture experiments showed that after pre-inoculation with the strain NEAU-HV9,
the disease occurrence of tomato seedlings was effectively prevented for R. solanacearum. Then,
a bioactivity-guided approach was employed to isolate and determine the chemical identity of
bioactive constituents with antibacterial activity from strain NEAU-HV9. The structure of the
antibacterial metabolite was determined as actinomycin D on the basis of extensive spectroscopic
analysis. To our knowledge, this is the first report that actinomycin D has strong antibacterial
activity against R. solanacearum with a MIC (minimum inhibitory concentration) of 0.6 mg L−1
(0.48 μmol L−1). The in vivo antibacterial activity experiment showed that actinomycin D possessed
significant preventive efficacy against R. solanacearum in tomato seedlings. Thus, strain NEAU-HV9
could be used as BCA (biological control agent) against R. solanacearum, and actinomycin D might be
a promising candidate for a new antibacterial agent against R. solanacearum.
Keywords: antibacterial activity; Ralstonia solanacearum; Streptomyces sp. NEAU-HV9; actinomycin D
1. Introduction
Tomato is one of the world’s most important vegetable crops, with a global annual yield of
approximately 160 million tons [1,2]. In China, long term continuous cropping is the main planting
practice for tomato, which has led to serious soilborne diseases [3]. Ralstonia solanacearum [4] is an
important soilborne bacterial plant pathogen [5]. Bacterial wilt caused by R. solanacearum is a serious and
common disease, which reduces the yield of tomato and many other crops in tropical, subtropical, and
warm-temperature regions of the world [6]. Because of worldwide distribution and a large host range
of more than 200 plant species in 50 families, including pepper, tomato, tobacco, potato, peanut, and
banana, this soil bacterium has been recognized as one of the causative agents of bacterial wilt disease
and is one of the leading models in pathogenicity [5]. In the absence of host plants, this bacterium can
Microorganisms 2020, 8, 351; doi:10.3390/microorganisms8030351 www.mdpi.com/journal/microorganisms4
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be free-living as a saprophyte in the soil or in water [7]. Plant breeding, field sanitation, crop rotation,
and use of bactericides have met with only limited success for R. solanacearum [8]. Furthermore,
pathogenic microbial multi-drug resistance is also increasing. Therefore, new natural resources and
antibiotics for suppressing this soilborne disease are needed.
Various recent studies have showed that biological control of bacterial wilt disease could be
achieved using antagonistic bacteria [8,9]. The suppressive effect of some antagonistic bacteria on
R. solanacearum was reported by Toyota and Kimura [10]. Moreover, the use of antagonistic bacteria to be
effective in control of R. solanacearum has been proved by Ciampi-Panno et al. under field conditions [8].
Streptomycetes are gaining interest in agriculture as plant growth promoting (PGP) bacteria and/or
biological control agents (BCAs) [11,12]. The Streptomyces genus comprises Gram-positive bacteria
which show a filamentous form; they can grow in various environments. Several Streptomyces
species such as S. aureofaciens, S. avermitilis, S. lividans, S. humidus, S. hygroscopicus, S. lydicus, S. plicatus,
S. olivaceoviridis, S. roseoflavus, S. scabies and S. violaceusniger have been used to control soilborne diseases
due to their greatly antagonistic activities by production of various antimicrobial substances [13–15].
Actinobacteria are famous for producing a variety of natural bioactive metabolites. Streptomyces is
an important source of bioactive compounds among all members of antibiotic production, accounting
for two-thirds of commercially available antibiotics [16]. Actinomycins belonging to a family of
chromopeptide lactones are produced by various Streptomyces. Among several antibiotics produced
by this genus, actinomycins are prominent. More than 20 naturally-occurring actinomycins were
isolated and observed to have commonality of two pentapeptidolactone moieties with an actnoyl
chromophore [17]; however, they differ in functional and/or positional group. Among actinomycins,
actinomycin D has been widely studied and used clinically as an anticancer drug, especially in the
treatment of childhood rhabdomyosarcoma, infantile kidney tumors and several other malignant
tumors [18,19]. However, no reports have been published on actinomycin D against phytopathogen
R. solanacearum.
In the existing protocol for virulence assays, one-month old tomato plantlets are soil-inoculated
with the bacterium and wilting symptoms, if any, are observed and recorded. In usual ground work,
tomato seeds are sown to obtain seedlings that take 5–6 days to sprout. Seedlings are then transferred
to pots containing soil and grown in a greenhouse for about one month. Following this, plants are
shifted to a growth chamber where plants are inoculated with the pathogen by soil drench or the stem
inoculation method [20,21]. Using this approach, it usually takes 40 days to perform a single virulence
assay. The infection achieved in this way is generally not axenic as the soil conditions used are not
devoid of other bacterial communities that can colonize the plant during its growth prior to the infection
study. Singh et al. [22] described a simple assay to study the pathogenicity of R. solanacearum on freshly
grown tomato seedlings instead of fully-grown tomato plants. From seed germination to completion of
the infection process, the study takes around 15 to 20 days. Pathogenicity due to R. solanacearum was
also demonstrated when there is no significant plant growth since no mineral/growth inducing factors
have been added into the water [23]. Under this same condition, there are reports of the bacterium’s
survivability without any growth [24]. The death of tomato seedlings was actually occurring due to
the presence of R. solanacearum in the water. On the basis of the previous study, we have discussed an
approach to study biological assays in tomato seedlings.
In this study, a Streptomyces sp., NEAU-HV9, was isolated and showed strong antimicrobial
activity against R. solanacearum. The taxonomic identity of NEAU-HV9 was determined by a
combination of 16S rRNA gene sequence analysis with morphological and physiological characteristics.
The potential control of actinomycin D produced by the strain NEAU-HV9 against R. solanacearum was
also investigated.
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2. Materials and Methods
2.1. Sample Collection
Soil samples were collected from a field situated in Bama yao Autonomous County, Hechi City,
Guangxi zhuang Autonomous Region (24◦15′ N, 107◦26′ E). The collected soil samples were brought to
the laboratory in sterile bags and kept at 4 ◦C until further analysis. Before isolation of actinomycetes,
the soil samples were air-dried at room temperature.
2.2. Screening and Isolation of Actinomycetes
The soil sample (5 g) was mixed with 45 mL distilled water and followed by an ultrasonic treatment
(160 W) for 3 min. The soil suspension was incubated at 28 ◦C and 250 rpm on a rotary shaker for
30 min. Subsequently, the supernatant was collected and subjected to serial dilutions from 10−2 to 10−5.
Each dilution (200 μL) was spread on a plate of humic acid-vitamin (HV) agar [25] supplemented with
cycloheximide (50 mg L−1) and nalidixic acid (20 mg L−1). Colonies were transferred and purified on
International Streptomyces Project (ISP) medium 3 [26] and stored for a long time in glycerol suspensions
(20%, v/v) at −80 ◦C after 14 days of aerobic incubation at 28 ◦C.
2.3. Screening of Antagonistic Actinobacteria Strains
The isolates were screened using the agar well diffusion method, and R. solanacearum was used
as the indicator bacterium [27]. To further investigate the antibacterial components produced by the
isolated cultures, these strains were cultured in ISP 2 medium [26] and the inhibitory activities of
the supernatant and cell precipitate were tested. Initially, the isolated cultures were grown in ISP
2 medium and incubated at 28 ◦C on a rotary shaker. After 7 days of incubation, the supernatants
were obtained by centrifugation at 8000 rpm and 4 ◦C for 10 min and subsequently filtrated with a
0.2 μm membrane filter. The cell precipitates were extracted with an equal volume of methanol for
approximately 24 h [28]. A cell suspension (1 mL at 1 × 108 cfu mL−1) of R. solanacearum was aseptically
plated onto Bactoagar-glucose (BG) media supplemented with 0.5% glucose [22]. Supernatant and
methanol extracts were collected from each isolate and tested initially for antimicrobial activity against
R. solanacearum; each well contained 200 μL of supernatant or methanol extract. The plates were
incubated at 37 ◦C for 12 h to test antibacterial activity. The diameters of inhibition zones were
measured by using vernier calipers [29]. The experiments were conducted twice. The isolates that
showed activities against tested organisms were collected and maintained. Among the collected
isolates, the potential isolate designated as NEAU-HV9 was selected for further studies.
2.4. Morphological and Biochemical Characteristics of NEAU-HV9
Morphological characteristics, using cultures grown on ISP 3 medium at 28 ◦C for 2 weeks, were
observed by light microscopy (Nikon ECLIPSE E200, Nikon Corporation, Tokyo, Japan) and scanning
electron microscopy (Hitachi SU8010, Hitachi Co., Tokyo, Japan). Scanning electron microscopy
samples were prepared as described by Jin et al. [30]. Cultural characteristics were determined using
2-week cultures grown at 28 ◦C on Czapek’s agar [31], Bennett’s agar [32], Nutrient agar [33], ISP 1 agar
and ISP 2-7 media [26]. The color designation of substrate mycelium and aerial mycelium was done
with ISCC–NBS (Inter-Society Color Council-National Bureau of Standards) Color Charts Standard
Sample No. 2106 [34]. Growth at different temperatures (10 ◦C, 15 ◦C, 18 ◦C, 20 ◦C, 25 ◦C, 28 ◦C,
32 ◦C, 35 ◦C, 37 ◦C and 40 ◦C) was determined on ISP 3 medium after incubation for 14 days. Growth
tests for pH range (pH 4.0–10.0, at intervals of 1.0 pH unit) using the buffer system described by
Zhao et al. [35] and NaCl tolerance (0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% and 10%, w/v) were
tested in ISP 2 broth at 28 ◦C for 14 days on a rotary shaker. Biochemical testing (decomposition of
adenine, casein, hypoxanthine, tyrosine, xanthine and cellulose, hydrolysis of starch, aesculin and
gelatin, milk peptonization and coagulation, nitrate reduction and H2S production), the utilization of
sole carbon and nitrogen sources were examined as described previously [36,37].
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2.5. Phylogenetic Analysis of NEAU-HV9
Strain NEAU-HV9 was cultured in ISP 2 medium for 3 days at 28 ◦C to harvest cells. The genomic
DNA was isolated using a Bacteria DNA Kit (TIANGEN Biotech, Co. Ltd., Beijing, China).
The universal bacterial primers 27F and 1541R were used to carry out PCR amplification of the
16S rRNA gene sequence [38,39]. The purified PCR product cloned into the vector pMD19-T
(Takara) and sequenced by using an Applied Biosystems DNA sequencer (model 3730XL, Applied
Biosystems Inc., Foster City, California, USA). The almost complete 16S rRNA gene sequence (1510 bp)
was uploaded to the EzBioCloud server (Available online: https://www.ezbiocloud.net/) [40] to
calculate pairwise 16S rRNA gene sequence similarity between strain NEAU-HV9 and related similar
species. The phylogenetic tree was reconstructed with neighbor-joining trees [41] using MEGA 7.0
software [42]. The confidence value of branches of the neighbor-joining tree was assessed using
bootstrap resampling with 1000 replication [43]. A distance matrix was calculated using Kimura’s
two-parameter model [44]. All positions containing gaps and missing data were eliminated from the
dataset (complete deletion option).
2.6. Fermentation
Strain NEAU-HV9 was grown and maintained for 7 days at 28 ◦C on ISP 3 medium agar plates.
Fermentation involved the generation of a seed culture. The stock culture was transferred into two
250 mL Erlenmeyer flasks containing 50 mL of the ISP2 medium and incubated at 28 ◦C for 72 h on a
rotary shaker at 250 rpm. All of the media were sterilized at 121 ◦C for 20 min. The seed culture (5%)
was transferred into 75 flasks (250 mL) containing 100 mL of production medium. The production
medium was composed of maltodextrin 4%, lactose 4%, yeast extract 0.5%, Mops 2% at pH 7.2–7.4.
The flasks were incubated at 28 ◦C for 7 days, shaken at 250 rpm. The final 7.5 L fermentation broth
was filtered to separate the supernatant and the mycelial cake. The supernatant was extracted with
ethyl acetate three times (3 × 2 L), and the mycelial cake was extracted with MeOH (3 L). The organic
phase was evaporated under reduced pressure at 55 ◦C to yield the red crude extract (5.2 g).
2.7. Isolation and Purification of Antibacterial Compounds
Crude extract from the mycelium and supernatant was combined and subjected to silica gel column
chromatography (Qingdao Haiyang Chemical Group, Qingdao, China; 100–200 mesh; 100 × 3 cm
column) using a gradient of ethyl acetate−MeOH (100:0−90:10) to yield three fractions (Fr.1-Fr.3) based
on the TLC (thin layer chromatography) profiles. TLC was performed on silica-gel plates with solvent
of ethyl acetate/MeoH (4:1). All fractions (Fr.) were screened against R. solanacearum. The most active,
Fr.1 and Fr.2, were applied to a Sephadex LH-20 column eluted with CH2Cl2/MeOH (1:1, v/v) and
then further purified by semipreparative HPLC (Agilent 1260, Zorbax SB-C18, 5 μm, 250 × 9.4 mm
inner diameter; 1.5 mL/min; 220 nm; 254 nm; Agilent, Palo Alto, CA, USA) MeOH/H2O (90:10, v/v) to
obtain Compound 1 (tR 10.928 min, 9.3 mg) and Compound 2 (tR 12.367 min, 60.4 mg). We chose the
main product, Compound 2, for further research. NMR spectra (1H and 13C) were measured with a
Bruker DRX-400 (400 MHz for 1H and 100 MHz for 13C) spectrometer (Bruker, Rheinstetten, Germany).
The ESI-MS (electrospray ionization mass spectra) spectra were taken on a Q-TOF Micro LC-MS-MS
mass spectrometer (Waters Co, Milford, MA, USA).
2.8. Determination of Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentration (MIC) of the antibacterial compounds was determined
as described by Rathod et al. [45]. R. solanacearum was grown in BG medium with 0.5% glucose in
shake flasks at 28 ◦C for 24 h. Cells were harvested by centrifugation, washed with 0.85% saline twice,
then the supernatant was discarded and 0.85% saline was added to the washed cells. The suspensions
were standardized to an optical density (OD) of 0.2 at 540 nm. Antibacterial compounds were two-fold
serially diluted to obtain concentrations ranging from 0.2 to 12.8 mg L−1 and one tube without drug
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served as a control. All of the tubes were inoculated with 1 mL of suspension of R. solanacearum above
and incubated at 37 ◦C for 12 to 16 h. The turbidity of each tube with respect to the control tube was
measured. The MIC value was defined as the lowest concentration of a compound that completely
inhibits growth.
2.9. Biological Assays in Tomato Seedlings
Germination of tomato seedlings and preparation of bacterial inoculum were prepared as described
by Singh et al. [22]. Freshly grown R. solanacearum was inoculated into 50 mL BG media broth with
0.5% glucose and incubated at 28 ◦C and 150 rpm for 24 h. The bacterial cultures were obtained by
centrifugation at 4000 rpm and 4 ◦C for 15 min and were then resuspended in an equal volume of
sterile distilled water to obtain a concentration of approximately 109 cfu mL−1. Strain NEAU-HV9 was
cultured in ISP 2 broth on rotary shaker for 3 days at 28 ◦C and centrifuged at 10,000 rpm. Subsequently,
cell pellets were diluted in 0.85% (w/v) NaCl solution and adjusted to 107, 108 or 109 cfu mL−1. Root
inoculation of R. solanacearum in tomato seedlings was carried out as described by Singh et al. [22].
About 15 to 20 mL of R. solancearum inoculum was taken in a sterile container. Tomato seedlings
(6 to 7 days old) were picked one at a time from the germinated seedling tray and then the roots of
each seedling were dipped in the bacterial inoculum (up to the root-shoot junction). Four treatments
were established as follows: TR 1 (tomato seedlings were pre-inoculated with suspension (107, 108 or
109 cfu mL−1) of strain NEAU-HV9 and then inoculated with R. solanacearum); TR 2 (tomato seedlings
were pre-inoculated with R. solanacearum and then transferred to microfuge tubes with the addition of
1 to 1.5 mL of sterile water and active fraction, where the final treatment concentrations were 1 ×MIC
and 2 × MIC, respectively); CK 1 (tomato seedlings were inoculated with sterile water); and CK 2
(tomato seedlings only were inoculated with R. solanacearum). For all of the treatments, the root-dip
inoculated seedlings were transferred to an empty 1.5 mL sterile microfuge tube. After approximately
5 minutes, 1 to 1.5 mL of sterile water was added to the tube. All the inoculated seedlings, along with
the controls, were transferred to a growth chamber maintained at 28 ◦C with 75% relative humidity
(RH) and a 12-h photoperiod. Seedlings were analyzed for disease progression after 7 days. Sets of
4 seedlings were recruited in each dilution inoculation, and each assay was performed in triplicate.
2.10. Pot Culture Experiments
Prior to use, seed surfaces were disinfected with 2% sodium hypochlorite for 2 min [46].
Both germination and plant growth conditions followed 75–90% RH and a 12-h photoperiod at
28 ◦C. Four treatments were established as follows: TR 1 (one day before transplanting the test
plants, strain NEAU-HV9 was added into the sterilized soil so that each gram of soil received about
1 × 109 cfu g−1 bacterial cells. Seven day old tomato seedlings were transferred to the soil; after three
weeks, plants were inoculated with a suspension (OD600 = 0.3) of R. solanacearum); TR 2 (seven day old
tomato seedlings were transferred to sterilized soil; after three weeks, tomato seedlings were irrigated
with a solution of actinomycin D (0.6 mg L−1). After one day, tomato plants were inoculated with a
suspension (OD600 = 0.3) of R. solanacearum by pouring it onto the soil of unwounded plants at a final
concentration of 1 × 107 cfu g−1 of soil [47]); CK 1 (seven day old tomato seedlings were transferred
to sterilized soil; after three weeks, tomato seedlings were irrigated with sterilized water as positive
control); and CK 2 (seven day old tomato seedlings were transferred to sterilized soil; after three weeks,
tomato seedlings were inoculated with a suspension (OD600 = 0.3) of R. solanacearum as a negative
control). All plants were kept in the greenhouse at 24–28 ◦C and 75–90% RH with a 12-h photoperiod.
Treatments were replicated three times with five plants per replication. The disease incidence was
rated using the 0–4 scale [48].
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3. Results
3.1. Isolation and Identification of an Antimicrobial Compound Producing Strain
More than 20 isolates from the soil samples were isolated, purified, and screened for bioactivity
against R. solanacearum. Among them, only four isolates showed bioactivity against R. solanacearum.
Since the methanol extract of the the cell pellet and supernatant of one isolate, designated as NEAU-HV9,
revealed a higher activity (30.5 mm and 32.8 mm) against the tested bacterial strain (Table 1, Figure S2),
this strain was selected for further studies.
Table 1. Bioactivities of the supernatant and cell pellet of NEAU-HV9 against R. solanacearum.
Methanol Extract of Cell Pellet Supernatant
Inhibitory zone diameters (mm) 30.5 32.8
Data shown are the mean of two replications.
Strain NEAU-HV9 was aerobic, Gram-stain positive and formed well-developed, branched
substrate hyphae and aerial mycelium that differentiated into spiral spore chains with oval spores
(Figure 1). The spore surface was wrinkled. It had good growth on ISP 1, ISP 2, ISP 3, ISP 4, ISP 5,
ISP 6, ISP 7, Bennett’s agar and Nutrient agar, and poor growth on Czapek’s agar (Figure S1). The data
on the growth characteristics of NEAU-HV9 in different media are given in Table S1.
Figure 1. Scanning electron micrograph of strain NEAU-HV9 grown on International Streptomyces
Project (ISP) 3 agar for 2 weeks at 28 ◦C.
Further characterization of NEAU-HV9 was performed by evaluating various biochemical tests
(Table S2). Growth at 15 ◦C to 37 ◦C (optimum: 28 ◦C) and in the range of pH 5 to 9 (optimum:
pH 7.0). Tolerate up to 7% (w/v) NaCl in the culture medium. Positive for hydrolysis of starch,
production of H2S, hydrolysis of aesculin and decomposition of adenine, hypoxanthine, tyrosine
and xanthine, negative for reduction of nitrate, coagulation and peptonization of milk, liquefaction
of gelatin and decomposition of casein. D-Glucose, D-maltose, D-mannitol, D-galactose, inositol,
D-mannose, L-rhamnose and D-sucrose are utilized as sole carbon sources, but not L-arabinose, dulcitol,
D-fructose, lactose, D-ribose, D-sorbitol or D-xylose. L-Alanine, D-arginine, L-asparagine, L-aspartic
acid, L-glutamic acid, L-glutamine, glycine, L-proline, L-serine, L-threonine and L-tyrosine are utilized
as sole nitrogen sources, but not creatine. The above growth data of isolate NEAU-HV9 denote that the
isolate has the typical characteristics of the genus Streptomyces.
Recently, it has been suggested that the 16S rRNA gene can be used as a reliable molecular clock
due to 16S rRNA sequences from distantly related bacterial lineages having similar functionalities [49].
Basically, the 16S rRNA gene sequence, comprising of about 1500 bp with hyper variable and conserved
regions, is universal in all bacteria. According to Woese’s report [50], comparing a stable part of the
genetic code could determine phylogenetic relationships of bacteria. The hyper variable regions of
the 16S rRNA gene sequences provide species-specific signature sequences, so it is widely used in
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bacterial identification all over the world. Therefore, the almost-complete 16S rRNA gene sequence
(1510 bp) of strain NEAU-HV9 was obtained and has been deposited as MN578143 in the GenBank,
EMBL (European Molecular Biology Laboratory) and DDBJ (DNA Data Bank of Japan) databases.
BLAST sequence analysis of the 16S rRNA gene sequence indicated that strain NEAU-HV9 was related
to members of the genus Streptomyces. The EzBioCloud analysis showed that strain NEAU-HV9 was
most closely related to Streptomyces panaciradicis 1MR-8T and Streptomyces sasae JR-39T with a gene
sequence similarity of 98.90% and 98.89%, respectively. In conclusion, based on the 16S rRNA gene
sequence and the genetic identity of isolate NEAU-HV9, the isolated strain was further identified by
neighbor-joining tree (Figure 2), and was also found to belong to the genus Streptomyces.
Figure 2. Neighbor-joining phylogenetic tree based on 16S rRNA gene sequences showing the
relationships among strain NEAU-HV9 (bold) and members of the genus Streptomyces. Bootstrap
percentages (≥50%) based on 1000 resamplings are listed at the nodes. Actinospica robiniae DSM 44927T
was used as the out-group. Scale bar represents 0.01 nucleotide substitutions per site.
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3.2. Structural Characterization of Compound
The active component was isolated from fermentation medium (7.5 L) and one bioactive compound
was obtained as red, amorphous powder. The compound had UV visible spectra at 215 nm, 440 nm
in methanol. The compound showed absorptions at 220 nm and 254 nm with a retention time of
12.367 min (Figure S3), similar to that of actinomycin class of compounds [51,52]. The structure of the
compound was further elucidated by 1H NMR, 13C NMR, and MS analysis as well as comparison
with previously reported data. The ESI-MS of the isolated compound revealed molecular ion peaks
at m/z 1277.6 [M+Na]+ (Figure S4), which was identical to that of actinomycin D [53]; 1H and 13C
spectra of the isolated compound in CD4O also showed great similarities to that of actinomycin
D [52,53] (Figures S5 and S6). In addition, the retention time of commercial actinomycin D (Biotopped,
purity: ≥98%) was 12.328 min (Figure S7), and the retention time of compound 2 was 12.367 min
(Figure S3). Compound 2 and commercial actinomycin D have similar activity against R. solanacearum
(Figure S8). The above results showed that the structure of the main active compound was confirmed
to be actinomycin D (Figure 3).
Figure 3. Chemical structure of actinomycin D.
3.3. Bioactivity of Isolated Compound
3.3.1. Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentration (MIC) of the antibacterial compound was determined
as described by Rathod et al. [45]. The minimum inhibitory concentration of actinomycin D was
determined as 0.6 mg L−1 (0.48 μmol L−1) against R. solanacearum (Table 2).
Table 2. Minimum inhibitory concentration (MIC) values of actinomycin D against R. solanacearum.
Pathogen MIC (mg/L)
R. solanacearum 0.6 ± 0.2
Data shown are the mean of three replications.
3.3.2. Biological Assays in Tomato Seedlings
The efficacy of the selected antagonist for the control of R. solanacearum was evaluated on tomato
seedlings (Figure 4 and Figure S9, Table 3). The disease assessment was carried out using the method
described in Kumar [23]. For the plants in the TR 1 group, the 109 cfu mL−1 suspension of NEAU-HV9
was effective against R. solanacearum when compared with the control (CK 2); all seedlings were
as healthy as the CK 1 group. The 108 cfu mL−1 suspension of NEAU-HV9 showed very weak
bioactivity against R. solanacearum compared with the control (CK 2); only one seedling was healthy
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and others were wilted. The 107 cfu mL−1 suspension of NEAU-HV9 exhibited no bioactivity against
R. solanacearum; all seedlings were wilted, the same as the seedlings that were dried.
Figure 4. Control efficiency of strain NEAU-HV9 against R. solanacearum. A, tomato seedlings were
inoculated with sterile water (CK 1); B, tomato seedlings only were inoculated with R. solanacearum
(CK 2); C, tomato seedlings were pre-inoculated with suspension (107 cfu mL−1) of NEAU-HV9 and
then inoculated with R. solanacearum (TR 1); D, tomato seedlings were pre-inoculated with suspension
(108 cfu mL−1) of NEAU-HV9 and then inoculated with R. solanacearum (TR 1); E, tomato seedlings were
pre-inoculated with suspension (109 cfu mL−1) of NEAU-HV9 and then inoculated with R. solanacearum
(TR 1); F, actinomycin D at the concentration 1 ×MIC (TR 2); G, actinomycin D at the concentration
2 ×MIC (TR 2).
Table 3. Effect of the strain NEAU-HV9 and actinomycin D on the incidence and control of tomato
bacterial wilt in tomato seedlings.
Treatment Wilt Incidence (%) Control Efficacy (%)
NEAU-HV9 (107 cfu mL−1) 100 ± 0 a 0 ± 0 a
NEAU-HV9 (108 cfu mL−1) 93 ± 11.6 b 6.6 ± 11.5 b
NEAU-HV9 (109 cfu mL−1) 0 ± 0 c 100 ± 0 c
Actinomycin D (1 ×MIC) 0 ± 0 c 100 ± 0 c
Actinomycin D (2 ×MIC) 0 ± 0 c 100 ± 0 c
Control 100 ± 0 a . . .
Data shown are the mean of three replications. Means within the same column followed by the same letter are not
significantly different (p = 0.05) according to Fisher’s least significant difference test.
Actinomycin D was highly effective against R. solanacearum in tomato seedlings (Figure 4 and
Figure S9, Table 3). It was notable that all seedlings of the control (CK 2) were wilted, however
after treatment with actinomycin D at the concentration 1 ×MIC and 2 ×MIC, none of the seedlings
exhibited disease symptoms; the control efficacy of the formulation was 100%.
3.4. Pot Culture Experiments
In the pot culture experiments, NEAU-HV9 and actinomycin D effectively suppressed the
development of bacterial wilt caused by R. solanacearum (Table 4, Figure S10). The negative control
treatment had 73.9% relative disease incidence. For strain NEAU-HV9 and actinomycin D, the control
efficacies of the formulations were 82% and 100%, respectively.
Table 4. Effect of the strain NEAU-HV9 and actinomycin D on the incidence and control of tomato
bacterial wilt in pot culture experiments.
Treatment Wilt Incidence (%) Control Efficacy (%)
NEAU-HV9 13.3 ± 5.8 b 82 ± 6 a
Actinomycin D 0 ± 0 b 100 ± 0 a
Control 73.9 ± 6.6 a
Wilt incidence (WI) was calculated as the percentage of leaves that were completely wilted. Control efficacy was
calculated using the following formula: control efficacy (%) = 100 × (WI of control −WI of treatment)/WI of control.
Data shown are the mean of three replications. Means within the same column followed by the same letter are not
significantly different (p = 0.05) according to Fisher’s least significant difference test.
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4. Discussion
Soil-borne diseases have caused a significant decline in yield in the monoculture tomato field [3].
Ralstonia solanacearum is an important soil-borne bacterial plant pathogen which is distributed all over
the world [5]. Recently, the biological control of soil-borne diseases has attracted more attention due to
its environmental friendliness and high efficiency [54]. Therefore, isolation, screening and application
of highly efficient antagonistic microorganisms is a key factor in biological control. With this outlook,
a Streptomyces sp. strain NEAU-HV9 was isolated and found to exhibit antibacterial activities against
R. solanacearum in the present study. By using 16S rRNA gene sequence analysis, combined with
morphological, cultural and physiological characteristics, the results showed that strain NEAU-HV9
belongs to members of the genus Streptomyces and was most closely related to Streptomyces panaciradicis
1MR-8T and Streptomyces sasae JR-39T with gene sequence similarities of 98.90% and 98.89%, respectively.
Actinobacteria, particularly Streptomyces, are ubiquitous in the rhizosphere soil and can protect
plant from pathogenic fungi/bacteria [55], so they have always been used in agriculture [56]. For instance,
several Streptomyces species such as strains CAI-24, CAI-121, CAI-127, KAI-32 and KAI-90 have been
used as BCAs against Fusarium wilt in chickpea plants [57]. The Streptomyces sp. CB-75, selected from
banana rhizosphere soil, showed antifungal activity against 11 plant pathogenic fungi [54]. In this
study, the Streptomyces sp. NEAU-HV9 exhibited strong antagonistic activity against R. solanacearum.
According to the study of Singh et al., susceptibility of early stages of tomato seedlings toward the
pathogen was confirmed by root-inoculation of R. solanacearum in early stages of tomato seedlings [22].
The antagonistic strains should reach a certain amount to demonstrate a significant biocontrol
effect [58,59]. In this study, we inoculated very high numbers of R. solanacearum and very high levels
of Streptomyces sp. NEAU-HV9 (109 cfu mL−1) in small tubes in the TR 1 group. After culturing
for seven days, all tomato seedlings were as healthy as the CK 1 control group (Table 3). There are
only R. solanacearum and Streptomyces sp. NEAU-HV9 in this artificial system, which can better prove
that a single NEAU-HV9 was able to be effective against R. solanacearum. On the seventh day, more
than 90% of seedlings inoculated with R. solanacearum were found to be killed, but water-inoculated
control seedlings were not wilted/dried [23]. Freshly grown tomato seedlings are too small to carry
out detailed disease assessment, and can only be described as healthy, healthy wilted or dried. In the
tests of this study, tomato seedlings inoculated with suspension (107 or 108 cfu mL−1) of NEAU-HV9
and R. solanacearum showed healthy wilted and dried disease phenotypes at different levels, while
all tomato seedlings inoculated with suspension (109 cfu mL−1) of NEAU-HV9 and R. solanacearum
were healthy (Figure 4). The results indicated that there are only R. solanacearum and Streptomyces sp.
NEAU-HV9 in this artificial system, which can better prove that a single NEAU-HV9 was able to be
effective against R. solanacearum. In addition, strain NEAU-HV9 effectively controlled R. solanacearum
on larger plants in pot culture experiments (Table 4). Thus, the test presented in this study is viable
for a preliminary screening of antagonistic actinobacterial strains against R. solanacearum and has
important aspects with respect to reduced time, space consumption and economics. Meanwhile, the
results showed the possibility of using Streptomyces sp. NEAU-HV9 as bioinoculant for R. solanacearum.
A wide range of bioactive secondary metabolites with anti-inflammatory, antibacterial, antifungal,
antialgal, antimalarial and anticancer activities were produced by actinomycetes. Actinomycetes
have produced about two-thirds of available antibiotics that have great practical value [60,61].
For example, Streptomyces TP-A0595 produced an antagonist that was determined as 6-prenylindole
and effective against Alternaria brassicicola by inhibiting the formation of infection hyphae [62].
Streptomyces griseus H7602 produced a monomer compound that has suppressive effect on infection
by Phytophthora capsici [63]. Some well-known antibiotics have been isolated from Streptomyces and
used as fungicides. Many types of antibiotics with high antibacterial activity were produced from
Streptomyces spectabilis, including streptovaricin [64], desertomycin [65] and spectinomycin [66], and
they have high application value in the pharmaceutical industry [67]. Actinomycin D (or Dactinomycin)
is a proverbial antitumor-antibiotic drug, which belongs to the actinomycin family and was isolated
from Streptomyces. Actinomycin D has been demonstrated to have various biological activities.
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Gram-negative bacteria were largely inhibited by using 10–100 mg per liter concentrations [68].
Actinomycin D produced by the bacterium Streptomyces hydrogenans IB310 was effective against both
bacterial and fungal phytopathogens [51], and the authors proposed that actinomycin D might be
developed as an antibacterial agent used in agriculture. However, there are no reports on antibacterial
activities against R. solanacearum and it is not currently used in agriculture. In this study, Streptomyces sp.
NEAU-HV9, which showed strong antibacterial activity against R. solanacearum, was isolated and
identified. To learn more about the chemical nature of the antibacterial activity of the culture
filtrate, the active compound actinomycin D was finally obtained. In this paper, we tested the
in vitro antibacterial activity of actinomycin D against R. solanacearum and obtained a MIC value of
0.6 mg L−1 (0.48 μmol L−1), which was many fold lower than other reported new natural antibacterial
agents [69], synthesized antibacterial agents and those of commercial fungicides including gentamicin
and streptomycin [70]. The antibacterial activity of actinomycin D against R. solanacearum tomato
seedlings treated with 1 ×MIC and 2 ×MIC were determined. None of the seedlings inoculated with
actinomycin D exhibited disease symptoms and the phytotoxic rating of actinomycin D was similar
to that of a water control. Thus, actinomycin D was not phytotoxic at a concentration of 0.6 mg L−1
(0.48 μmol L−1). The results suggest that actinomycin D might be useful as a candidate pesticide for
the treatment of Ralstonia solanacearum in tomato.
5. Conclusions
In summary, this study found that Streptomyces sp. NEAU-HV9 exerted significant antibacterial
activity against R. solanacearum, and actinomycin D, which was produced by Streptomyces sp.
NEAU-HV9, exhibited a minimum inhibitory concentration (MIC) against R. solanacearum of 0.6 mg L−1
(0.48 μmol L−1). In addition, Streptomyces sp. NEAU-HV9 and actinomycin D can effectively inhibit
the occurrence of R. solanacearum. From the results, it is obvious that Streptomyces sp. NEAU-HV9 is an
important microbial resource as a biological control against R. solanacearum and actinomycin D is a
promising candidate for the development of potential antibacterial biocontrol agents.
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Abstract: Basal stem rot (BSR), or Ganoderma rot disease, is the most serious disease associated with the
oil palm plant of Southeast Asian countries. A basidiomycetous fungus, Ganoderma boninense, is the
causative microbe of this disease. To control BSR in oil palm plantations, biological control agents
are gaining attention as a major alternative to chemical fungicides. In the course of searching
for effective actinomycetes as potential biological control agents for BSR, Streptomyces palmae
CMU-AB204T was isolated from oil palm rhizosphere soil collected on the campus of Chiang
Mai University. The culture broth of this strain showed significant antimicrobial activities against
several bacteria and phytopathogenic fungi including G. boninense. Antifungal and antibacterial
compounds were isolated by antimicrobial activity-guided purification using chromatographic
methods. Their structures were elucidated by spectroscopic techniques, including Nuclear Magnetic
Resonance (NMR), Mass Spectrometry (MS), Ultraviolet (UV), and Infrared (IR) analyses. The current
study isolated new phenyl alkenoic acids 1–6 and three known compounds, anguinomycin A (7),
leptomycin A (8), and actinopyrone A (9) as antimicrobial agents. Compounds 1 and 2 displayed broad
antifungal activity, though they did not show antibacterial activity. Compounds 3 and 4 revealed a
strong antibacterial activity against both Gram-positive and Gram-negative bacteria including the
phytopathogenic strain Xanthomonas campestris pv. oryzae. Compounds 7–9 displayed antifungal
activity against Ganoderma. Thus, the antifungal compounds obtained in this study may play a role in
protecting oil palm plants from Ganoderma infection with the strain S. palmae CMU-AB204T.
Keywords: actinomycetes; antimicrobial; phenyl alkenoic acid; rhizosphere; Streptomyces palmae
1. Introduction
Oil palm (Elaeis guineensis Jacq.) is an important economic crop in many tropical areas. In particular,
Indonesia, Malaysia, and Thailand are the leading palm oil producing countries of this region. The oil
palm plant typically has a productive life of 20 or more years, and oil can be harvested several times
each year. Consequently, it holds an advantage over all other oil-producing crops [1]. However,
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the plant is often damaged by fungal infections, and these can cause a decrease of crop yields and
result in the death of oil palm trees.
Fungal pathogens mainly infect the stems and leaves of oil palm trees during all stages of growth,
from seedlings to the mature stage, and consequently can affect both the quality and quantity of palm oil.
Basal stem rot (BSR), or Ganoderma rot disease, is the most severe disease of oil palm trees in Southeast Asian
countries, especially Malaysia and Indonesia [2]. In addition to these countries, BSR has also destroyed
oil palm plantations in Africa, Colombia [3], Papua New Guinea [4], and Thailand [5]. The causative
fungus Ganoderma boninense is a basidiomycetous fungus and belongs to the order Polyporales and the
family of Ganodermataceae. Fruiting bodies of Ganoderma typically form on the exterior of the oil palm
trunk and then release and spread the spores to the soil. The usual method of controlling BSR in oil
palm plantations is the use of chemical fungicides. Many fungicides, such as azoxystrobin, benomyl,
carbendazim, carboxin, cycloheximide, cyproconazole, drazoxolone, hexaconazole, methfuroxam,
nystatin, penconazole, thiram, triadimefon, triadimenol, tridemorph, and quintozene, could inhibit the
growth of Ganoderma [6–10]. However, the fungicides cannot actually cure infected palm trees; they can
only delay the spreading of the disease [9]. Furthermore, the applications of these chemical treatments
have some worrying effects on human health and ecosystems. Examples of this would be toxicity to
organisms and the suppression of beneficial microbes [9,11–13]. Nowadays, raising concerns about the
high cost of chemicals, and the environmental problems they are associated with, have encouraged
researchers to seek alternative strategies for BSR suppression.
The use of biological control agents represents a major alternative approach in the management of
oil palm diseases. Fungal species, such as Trichoderma harzianum, Trichoderma viride, and Gliocladium
viride, have been studied for their anti-Ganoderma activity, and their effectiveness against Ganoderma in
a glasshouse and in a field trial [2,14–16]. Certain Trichoderma species are known as mycoparasites
and have been utilized to control fungal pathogens. One of the biocontrol mechanisms of Trichoderma
spp. is the release of glucanase and chitinase enzymes that are involved in the cell-wall degradation of
G. boninense, and these can be elicitors in inducing a plant defense response [17,18]. Several strains
of bacteria, especially Pseudomonas aeruginosa, Pseudomonas syringae, and Burkholderia cepacia, have
also been studied for their potential to be applied as biological control agents [19–22]. Their potential
abilities to inhibit the spread of G. boninense and to reduce the incidence of the disease have been
documented [19–22]. Although the control mechanisms of these bacteria have not yet been clarified,
they may control Ganoderma by producing antifungal secondary metabolites. In addition, several
actinomycetes were screened for their antagonistic activity against G. boninense. Actinomycetes,
especially the genus Streptomyces, are well known for their ability to produce a wide variety of bioactive
metabolites [23–26]. Many Streptomyces species, such as Streptomyces hygroscopicus, Streptomyces
ahygroscopicus, Streptomyces abikoensis, and Streptomyces angustmyceticus, were found to be promising
biocontrol agents for BSR disease [27,28]. Streptomyces violaceorubidus released not only secondary
metabolites towards G. boninense but also released cell-wall degrading enzymes involved in the control
of this pathogen [29,30].
Actinomycetes associated with the oil palm rhizosphere may have an important role in protecting
plants from Ganoderma infection by releasing antibiotics and enzymes. Thus, we isolated actinomycetes
from the rhizosphere of healthy oil palm plants and screened the antifungal activities of their culture
broth against G. boninense. One actinomycete strain, CMU-AB204T, showed significant antimicrobial
activities against, not only G. boninense but also phytopathogenic fungi and several bacteria. We had
previously identified this strain and proposed that it could serve as a novel species, namely Streptomyces
palmae CMU-AB204T [31]. This actinomycete was selected to investigate antimicrobial secondary
metabolites. This report describes the results of the isolation, structural elucidation, and antimicrobial
activities of six new compounds, AB204-A–F (1–6), and three known compounds, anguinomycin A (7),
leptomycin A (8), and actinopyrone A (9), that were produced by S. palmae CMU-AB204T.
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2. Materials and Methods
2.1. Microbial Material
Streptomyces palmae CMU-AB204T was previously isolated from the rhizosphere of an oil palm
tree collected from the oil palm plantation at Chiang Mai University, Chiang Mai Province, Thailand,
in October 2012. This strain has been characterized using a polyphasic approach and was previously
proposed as S. palmae (type strain CMU-AB204T = JCM 31289T = TBRC 1999T) [31].
2.2. Culture Conditions
S. palmae CMU-AB204T was grown in the International Streptomyces Project medium 2 (ISP2)
agar [32] at 28 ◦C. For seed culture, 100 mL of ISP2 medium, consisting of 0.4% yeast extract (Becton,
Dickinson and Company, Sparks, MD, USA), 1.0% malt extract (Becton, Dickinson and Company,
Sparks, MD, USA), and 0.4% glucose, was prepared in an Erlenmeyer flask and the pH was adjusted
to 7.0 before sterilization. The slant culture of S. palmae was scraped by an inoculating loop and
inoculated into ISP2 medium. The inoculated flask was incubated at 30 ◦C for three days on a rotary
shaker at 150 rpm. Two mL portions of this seed culture were transferred into 500 mL Erlenmeyer
flasks containing 150 mL of ISP2 medium, which was followed by fermentation using a rotary shaker
at 150 rpm, 30 ◦C for seven days.
2.3. Compound Extraction and Isolation Procedure
The mycelia were separated from fermentation broth (40.0 L) by filtration. The culture filtrate and
mycelium were separately extracted twice with an equal volume of EtOAc. The organic layer was
evaporated using a rotary evaporator. Extracts from culture filtrate and mycelium were combined
and concentrated to dryness in vacuo to obtain a crude extract as a brown oil. The active secondary
metabolites were isolated by biological activity-guided purification. The crude extract (4.9 g) was
separated using an open column with silica gel (silica gel 60, 0.063–0.200 mm, Merck, Darmstadt,
Germany, 150 g of silica gel, Ø40 mm × 240 mm) and eluted with a stepwise gradient of CHCl3/MeOH:
100:0, 99:1, 98:2, 95:5, 90:10, 80:20, 50:50 and 0:100 (v/v), with 1.0 L each. Each eluent was collected in
two 500 mL Erlenmeyer flasks (S1–S16) and concentrated in vacuo. The components of each fraction
were analyzed using thin-layer chromatography (TLC, silica gel F254, Merck, Darmstadt, Germany)
plates with a thickness of 0.25 mm, developed with the CHCl3/MeOH solvent system. Compounds
were detected by UV light and phosphomolybdic acid reagent and followed by heating. The active
fractions S3 (580.4 mg) and S4 (608.8 mg) eluted with 99:1 (v/v) of CHCl3/MeOH were dissolved in a
small amount of MeOH and then separately subjected to Sephadex LH-20 column chromatography
(GE Healthcare Bio-Sciences, USA, Ø20 mm × 650 mm) with MeOH as the eluent. The eluate was
automatically fractionated into 100 fractions (L1–L100) by a fraction collector (CHF100AA, Advantec,
Tokyo, Japan). The active materials were detected from fractions L52–L64. From fractions S3 and S4,
59.6 mg of yellow semi-solid substance was obtained as an active material. Analytical and preparative
HPLC of these fractions were carried out on a JASCO HPLC system (JASCO, Tokyo, Japan); pump,
PU-2080 Plus; solvent mixer, LG-2808-04; UV detector, MD-1510. The HPLC columns included an
analytical column (Pegasil ODS SP100, Ø4.6 mm × 250 mm; Senshu Scientific, Tokyo, Japan) and a
preparative column (Pegasil ODS SP100, Ø20 mm × 250 mm; Senshu Scientific). This dried material
(59.6 mg) was subjected to preparative HPLC developed with a gradient system of CH3CN aqueous
solution containing 0.1% trifluoroacetic acid (60–90% CH3CN for 20 min, 90% CH3CN for 20 min) at
flow rate of 7.0 mL/min, and detection was achieved at 254 nm. The eluates at retention times of 16, 21,
32, 33, and 34 min were collected and concentrated in vacuo to dryness in order to afford AB204-A (1),
AB204-B (2), AB204-E (5), AB204-F (6), and a mixture of AB204-C (3) and D (4), respectively. Compound
9 was obtained from side fractions (L36–L49) of LH-20 column chromatography of S3. The combined
fractions (L36–L49 of S3) were purified by preparative TLC (silica gel, Merck, Darmstadt, Germany)
with a developing solvent of CHCl3/MeOH (20:1) to obtain 9. Compounds 7 and 8 were isolated from
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the active fraction that was eluted with 98:2 (v/v) of CHCl3/MeOH. The fraction was subjected to silica
gel column chromatography with the CHCl3/MeOH solvent system, and active compounds were
obtained from the 95:5 (v/v) fraction. This fraction was purified by preparative HPLC with a linear
gradient system of 60–90% CH3CN–H2O containing 0.1% trifluoroacetic acid for 30 min at a flow rate
of 7 mL/min and at room temperature. Detection was achieved at 254 nm. Compounds 7 and 8 were
eluted at 24 min and 27 min, respectively.
2.4. Analyses of the Chemical Structure and Physicochemical Properties
The purified compounds were prepared at a concentration of 1 mg/mL in MeOH for the measurement
of optical rotation, UV spectra, and IR spectra. An optical rotation [α]D of the compound suspension
was measured using a P-2200 polarimeter (JASCO, Tokyo, Japan). UV spectra of each compound were
recorded with a U-2810 spectrophotometer (Hitachi High-Tech Science Co., Tokyo, Japan), and IR
spectra (ATR) were measured using a FT–IR 4600 (JASCO, Tokyo, Japan). The isolated compounds were
dissolved in chloroform-d (CDCl3) or methanol-d4 (CD3OD) for NMR analyses. NMR spectra of each
compound were obtained on a JNM ECP500 NMR spectrometer (JEOL, Tokyo, Japan) with 500 MHz
for 1H NMR and 125 MHz for 13C NMR. Chemical shifts (ppm) of CDCl3 (δH 7.26, δC 77.0) and CD3OD
(δH 3.30, δC 49.0) were used as references. The accurate mass and molecular formulas of the isolated
compounds were established by liquid chromatography–mass spectrometry (LC–MS) analyses. Spectra
of electron ionization mass spectrometry (EI–MS) were analyzed using a JMS-AX505 HA spectrometer
(JEOL, Tokyo, Japan), while the spectra of electrospray ionization mass spectrometry (ESI–MS) were
obtained by a JMS-T100LP spectrometer (JEOL, Tokyo, Japan) equipped with an Agilent1100 HPLC
system (Agilent, CA, USA).
2.5. Measurement of Antimicrobial Activity
In the purification process of antimicrobial compounds, every fraction obtained from each
fractionation step was tested with representative microbes, Xanthomonas campestris pv. oryzae KB88,
Kocuria rhizophila ATCC 9341, Mucor racemosus IFO 4581, and G. boninense BCC 21330, by paper
disk diffusion assay. The antimicrobial activity of the purified compounds was analyzed using the
paper disk diffusion method (Ø8 mm disk, Advantec, Co., Ltd., Tokyo, Japan) against fourteen
microorganisms. Cell suspensions of Bacillus subtilis ATCC 6633 (5 × 105 cfu/mL), Escherichia coli
NIHJ (5 × 105 cfu/mL), K. rhizophila ATCC 9341 (2 × 105 cfu/mL), Mycobacterium smegmatis ATCC
607 (5 × 105 cfu/mL), Staphylococcus aureus ATCC 6538p (5 × 105 cfu/mL), Klebsiella pneumonia ATCC
10031 (5 × 105 cfu/mL), Proteus vulgaris NBRC 3167 (5 × 105 cfu/mL), Pseudomonas aeruginosa IFO
3080 (1 × 106 cfu/mL), and X. campestris pv. oryzae KB88 (1 × 106 cfu/mL) were individually mixed
into the medium containing 0.5% peptone, 0.5% meat extract, and 0.8% agar, while Aspergillus niger
ATCC 6275 (1 × 106 spores/mL), Candida albicans ATCC 64548 (2 × 105 cfu/mL), G. boninense BCC 21330
(2 × 105 cfu/mL), Mu. racemosus IFO 4581 (2 × 105 spores/mL), and Saccharomyces cerevisiae ATCC
9763 (1 × 106 cfu/mL) were individually mixed into the medium containing 1.0% glucose, 0.5% yeast
extract, and 0.8% agar, and poured into Petri dishes. After that, paper disks containing the purified
compounds at 50 μg/disk were put onto agar plates of each microorganism with three replicates.
All bacterial plates, except M. smegmatis ATCC 607 and X. campestris pv. oryzae KB 88, were incubated
at 37 ◦C for 24 h. M. smegmatis ATCC 607 was incubated at the same temperature for 48–72 h., whereas
X. campestris, yeasts, and fungi were incubated at 27 ◦C for 24–48 h. The diameter of the inhibition
zone was measured in mm units.
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3. Results
3.1. Biological Activity-Guided Purification of Active Components from Culture Broth of S. palmae
CMU-AB204T and Structure Determination of Active Components
S. palmae CMU-AB204T was cultured in 40 L of ISP2 medium at 28 ◦C for seven days, and the
broth and mycelia were extracted with EtOAc. The active components in culture broth extract
of strain CMU-AB204T were isolated by biological activities-guided purification using paper disk
assay. The extract was purified by silica gel column chromatography, Sephadex LH-20 column
chromatography, preparative TLC, and preparative HPLC. The eluates were concentrated in vacuo
to yield nine compounds, AB204-A (1, 10.2 mg), AB204-B (2, 8.2 mg), AB204-E (5, 14.2 mg), AB204-F
(6, 9.9 mg), a mixture (6.5 mg) of AB204-C (3) and AB204-D (4), 7 (7.0 mg), 8 (1.7 mg), and 9 (17.0 mg)
as depicted in Scheme 1.
AB204-A (1) was obtained as a pale yellow amorphous solid. It was found to be readily soluble in
acetonitrile, MeOH, CHCl3, and was observed to be less soluble in water. As the HREIMS analysis
showed m/z 190.1000 [M]+, the molecular formula of 1 was elucidated as C12H14O2 (calculated value
of 190.0994, Figure S1). The intense band at 1706 cm−1 of the IR spectrum in MeOH solution was
assigned as C=O stretching frequency of dimeric carboxylic acid moiety (Figure S2). Based on 1H
NMR analysis, 1 revealed four aromatic protons stacked at 7.14–7.18 ppm and a pair of olefinic protons
stacked at 5.70 ppm and 6.51 ppm (Figure S3). Coupling constants (J = 11.5 Hz) of the two olefinic
protons showed Z-configuration of the olefin moiety. Compound 1 had four additional methylene
protons at 2.41–2.51 ppm and one methyl singlet signal at 2.24 ppm (Table 1). The 13C NMR spectrum
showed 12 carbon signals: one carbonyl carbon at 177.2 ppm that indicated a carboxylic acid, eight
aromatic or olefinic carbons, two methylene carbons at 23.5 and 33.7 ppm, and one methyl carbon at
19.8 ppm (Table 1, Figure S4).
Table 1. NMR spectroscopic data of AB204-A (1) and B (2) (δH, 500 MHz; δC, 125 MHz).
Carbon No.
1 (in CDCl3) 2 (in CDCl3)
δC, Type δH, Mult (J in Hz) HMBC δC, type δH, Mult (J in Hz) HMBC
1 177.2, C 177.6, C
2 33.7, CH2 2.41–2.44, m C1, C3, C4 33.4, CH2 2.30, t (7.5) C1, C3, C4
3 23.5, CH2 2.46–2.51, m C1, C2, C5 24.2, CH2 1.63, tt (7.5, 7.5) C1, C2, C5
4 129.7 or129.8, CH 5.70, dt (11.5, 7.0) C1
′ 29.1, CH2 1.45, tt (7.5, 7.5) C2, C5, C6
5 129.7 or129.8, CH 6.51, d (11.5) C3, C2
′, C6′ 27.8, CH2 2.17, dtd (7.5, 7.5, 1.5) C3, C4, C6, C7
6 132.0, CH 5.69, dt (11.5, 7.5) C1′
7 128.5, CH 6.45, br.d (11.5) C5, C6′
1′ 136.2, C 136.7, C
2′ 136.2, C 136.2, C
3′ 129.8, CH 7.14–7.18 *, m 129.8, CH 7.13–7.18 *, m -
4′ 125.4 or127.1, CH 7.14–7.18 *, m
125.3 or
126.8, CH 7.13–7.18 *, m C2
′
5′ 125.4 or127.1, CH 7.14–7.18 *, m C3
′ 125.3 or
126.8, CH 7.13–7.18 *, m C3
′
6′ 128.8, CH 7.14–7.18 *, m 128.9, CH 7.13–7.18 *, m C2′
2′-Me 19.8, CH3 2.24, s C1′, C2′, C3′ 19.9, CH3 2.25, s C1′, C2′, C3′
* overlapped.
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MS, HMBC, and HMQC analyses suggested 1 contained one disubstituted aromatic ring, one
methyl, and pentenoic acid moieties (Figures S5 and S6). HMBC correlations were observed from two
methylene protons (2.41–2.44 ppm and 2.46–2.51 ppm) to a carboxylic carbon at 177.2 ppm, and two
olefinic carbons of C-4 and C-5 (129.7 and 129.8 ppm), as are given in Table 1. A correlation between
the Z-olefinic proton at 6.51 ppm (H-5) and one methylene carbon (C-3) at 23.5 ppm was also observed;
thus 1 was believed to possess 4,5-Z-pentenoic acid moiety in the structure. An HMBC correlation
between one methyl proton at 2.24 ppm and three aromatic carbons of C-1’, C-2’, and C-3’ (136.2, 136.2,
and 129.8 ppm, respectively), and between Z-olefinic protons and aromatic carbons, H-4 (5.70 ppm)
and C-1’ (136.2 ppm), and H-5 (6.51 ppm) and C-6’ (128.8 ppm), indicated 1 was an ortho-methyl
phenyl alkenoic acid compound, (Z)-5-(2-methylphenyl)-4-pentenoic acid (Figure 1). Differential NOE
of 1 was observed between a methyl proton and both an aromatic 3’-proton and an olefinic proton of
H-5 as well as between the two olefinic protons (Figure S7). The geometry of two substitutes of the
aromatic ring was confirmed by NOE correlations, as is shown in Figure 2. From some Streptomyces
strains, E-isomer of 1, (E)-5-(2-methylphenyl)-4-pentenoic acid was identified [33–35]; however, there
was no report on the Z-isomer (1) obtained from natural sources. Therefore, it was concluded that 1
was a novel natural product.
Figure 1. Antimicrobial compounds isolated from the broth extract of Streptomyces palmae CMU-AB204T.
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Figure 2. Observed COSY correlation (bold lines, in 2) and NOE correlation in AB204-A (1) and B (2).
AB204-B (2) was isolated as a pale yellow amorphous solid. It was readily soluble in the same
solvent as 1 and less soluble in water. The molecular formula of 2 was established as C14H18O2
(calculated value of 218.1329) based on NMR data and the HREIMS ion peak of m/z 218.1301 [M] +
(Figure S8), indicating compound 2 had one more C2H4 unit when compared to the molecular formula
of 1. The IR spectrum of 2 revealed the presence of C=O stretching frequency of dimeric carboxylic
acid moiety at 1706 cm−1, which was similar to the spectrum of 1 (Figure S9). The 1H NMR spectrum of
2 revealed four aromatic protons at 7.14–7.16 ppm, a pair of olefinic protons at 5.69 and 6.45 ppm, eight
methylene protons at 1.45, 1.63, 2.17, and 2.30 ppm and one methyl singlet signal at 2.25 ppm (Table 1,
Figure S10). The coupling constant of two olefinic protons (11.5 Hz) indicated a Z-configuration.
The 13C NMR spectrum of 2 showed 14 carbon signals: one carbonyl carbon at 177.6 ppm, eight
aromatic or olefinic carbons, four methylene carbons at 24.2, 27.8, 29.1, and 33.4 ppm, and one methyl
carbon at 19.9 ppm (Table 1, Figure S11). These data support the conclusion that the compound had a
closely related structure to 1. Each methylene signal was assigned by COSY, as is shown in Figure 2.
Eight methylene protons constructed a C4 alkyl chain, and COSY correlation confirmed the connection
between this C4 alkyl chain and Z-olefin (Figure S12). This connection was supported by HMBC and
HMQC spectra (Figures S13 and S14). HMBC correlations were observed from one olefinic proton
H-6 (5.69 ppm) to an aromatic carbon at C-1’ (136.7 ppm) and from singlet methyl proton at 2.25 ppm
to aromatic carbons at C-1’, C-2’, and C-3’. Therefore, one methyl moiety and one alkene chain were
substituted for an aromatic ring in the ortho position. HMBC correlation from two methylene protons
of the alkene chain at 1.63 and 2.30 ppm to the carbonyl carbon at 177.6 ppm, and a molecular formula
of 2, suggested that this compound had a carboxylic acid at the end of the alkene chain. The same NOE
correlation was observed in 1 and 2 (Figure 2 and Figure S15). Thus, the structure of 2 was assigned as
(Z)-7-(2-methylphenyl)-6-heptenoic acid, as is shown in Figure 1.
The structures of AB204-C (3) and AB204-D (4) were elucidated as a mixture of both compounds
because of the difficulty associated with further purification. MS spectra showed the molecular formulas
of 3 and 4 were C18H26O2 and C19H28O2, respectively (Figure S16). 1H NMR data suggested compounds
3 and 4 were analogs of 1 and 2, thus 3 and 4 might be (Z)-11-(2-methylphenyl)-10-undecenoic acid
and (Z)-12-(2-methylphenyl)-11-dodecenoic acid, respectively (Figure 1 and Figure S17).
AB204-E (5) and AB204-F (6) were obtained as a pale yellow amorphous solid. The accurate
mass and molecular formula of compounds 5 and 6 were analyzed by both HRESIMS and HREIMS.
Molecular ion peaks were exhibited at m/z 271.1705 [M +H]+ and 270.1616 [M]+ for 5, and m/z 271.1689
[M + H]+ and 270.1633 [M]+ for 6 (Figures S18–S21). These data suggest that both compounds had the
same molecular formula as C18H22O2 (calcd. 270.1620 for C18H22O2 and calcd. 271.1698 for C18H23O2).
The C=O stretching frequency band at 1685 cm−1 in the IR spectrum of 5 and 1684 cm−1 in the spectrum
of 6 was assigned as a carboxylic acid moiety (Figures S22 and S23). NMR spectra of both compounds
demonstrated a structural similarity. The assignment of 1H and 13C NMR spectra of 5 and 6 are given
in Table 2.
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Table 2. NMR spectroscopic data of AB204-E (5) and F (6) (δH, 500 MHz; δC, 125 MHz).
Carbon No.
5 (in CD3OD) 6 (in CDCl3)
δC, Type δH, Mult (J in Hz) HMBC δC, Type δH, Mult (J in Hz) HMBC
1 170.5, C 169.5, C
2 122.3, CH 5.99, d (15.5) C1, C4 115.8, CH 5.74, d (11.5) C1, C4
3 146.8, CH 7.41, dd (15.5, 11.0) C1, C5 147.3, CH 6.85, t (11.5) C1, C5
4 128.2, CH 6.95, dd (15.5, 11.0) C2, C5, C6 125.4, CH 8.04, dd (15.5, 11.5) C6
5 140.0, CH 7.13, d (15.5) C3, C7, C11 140.6, CH 7.08, d (15.5) C3, C7, C11
6 135.6, C 134.3, C
7 126.7, CH 7.67, m C9, C11 126.2, CH 7.72, m C9, C11
8 128.4, CH 7.26 *, m 127.1, CH 7.26 *, m C10
9 129.5, CH 7.26 *, m 128.6, CH 7.26 *, m C11
10 131.0, CH 7.15, m C8, C12 129.9, CH 7.17, m C6, C8, C12
11 138.7, C 137.5, C
12 128.3, CH 6.54, br.d (11.5) C6, C10, C14 127.0, CH 6.51, br.d (11.5) C10, C14
13 135.7, CH 5.83, dt (11.5, 7.5) C11 134.9, CH 5.81, dt (11.5, 7.5) C11
14 29.4, CH2 2.02, dtd (7.5, 7.5, 1.5)
C12, C13,
C15, C16 28.4, CH2 2.04, dtd (7.5, 7.5, 1.0)
C12, C13,
C15, C16
15 30.2, CH2 1.38, m
C13, C14,
C16, C17 29.2, CH2 1.37, tt (7.5, 7.5)
C14, C16,
C17
16 32.6, CH2 1.22, m C17 31.4, CH2 1.23 *, m C17
17 23.5, CH2 1.21, m C16 22.5, CH2 1.23 *, m C16
18 13.3, CH3 0.83, t (7.0) C16, C17 14.0, CH3 0.84, t (7.0) C16, C17
* overlapped.
1H NMR spectrum of 5 showed ten aromatic/olefinic protons, eight methylene protons, and one
methyl triplet proton at 0.83 ppm (Figure S24). In 13C NMR spectrum of 5, one calboxylic carbon at
170.5 ppm, twelve olefinic/aromatic carbons, four methylene carbons, and one methyl carbon were
measured (Figure S25). 1H NMR spectrum of 5 suggested the existence of two pairs of E-olefin assigned
by large coupling constants (15.5 Hz for each) and one pair of Z-olefin whose coupling constant was
11.5 Hz. Three partial structures were assigned by COSY correlation; one 1,2-substituted aromatic
ring, one 1,2-Z-heptene group, and one diene group (Figure S26). HMBC correlations between diene
protons of 5.99 and 7.41 ppm and a carbonyl carbon at 170.5 ppm, and between diene protons of 6.95
and 7.13 ppm and three aromatic carbons at positions C-6, C-7, and C-11 (135.6, 126.7, and 138.7 ppm,
respectively) indicated that one end of the diene was connected to a carboxylic carbon and the other
end of the diene was attached to an aromatic ring at position 6 (Figures S27 and S28). HMBC correlation
between Z-olefinic protons (5.83 and 6.54 ppm) of 1,2-Z-heptene and aromatic ring carbons at C-10 and
C-11 (131.0 and 138.7 ppm, respectively) suggested 1,2-Z-heptene moiety was connected to the aromatic
ring at C-11. These data support the structure of 5 as (2E,4E)-5-(2-(1Z)-heptenylphenyl)-2,4-pentadienoic
acid (Figure 1).
1H NMR and 13C NMR spectra of 6 suggested that the structure was almost the same as 5
(Figures S29 and S30). However, the 1H NMR spectrum clarified that only one pair of E-olefin existed,
while the other two pairs of olefin were identified as Z-configuration by analysis of coupling constants.
These data indicated that 6 was a stereoisomer of 5. COSY correlations revealed that two partial
structures of 6, one 1,2-substituted aromatic ring and one 1,2-Z-heptene moiety, were identical to those
of 5; however, a diene structure was constituted of both E and Z-olefins (Figure S31). The connection of
1,2-Z-heptene moiety to the aromatic ring at C-11 was confirmed by the HMBC spectrum (Figure 3,
Figures S32 and S33). HMBC correlations between Z-olefinic protons of the diene moiety and a
carboxylic carbon at 169.5 ppm and between one E-olefinic proton (7.08 ppm) of the diene moiety and
aromatic ring carbons at C-7 and C-11 (126.2 and 137.5 ppm, respectively) established the structure of 6
as (2Z,4E)-5-(2-(1Z)-heptenylphenyl)-2,4-pentadienoic acid, as is depicted in Figure 1.
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Figure 3. Observed COSY (bold lines) and HMBC correlations (arrows) in AB204-F (6). The same
correlations were observed in AB204-E (5).
To clarify the geometry of two substituted chains of 5 and 6, the differential NOE experiment was
conducted. NOE correlations between H-5 and H-12 were observed in both compounds (Figures S34
and S35), which supported the geometry of two side chains in 5 and 6, as is shown in Figure 4. This
is the first report of 5 and 6 obtained from natural sources. Qureshi et al. [36] found structurally
related compounds, MF-EA-705a and b, along with actinopyrone A from a broth extract of Streptomyces
MF-EA-705. The most related structures were found as cinnamoyl moieties of rare peptide compounds,
pepticinnamin E, WS9326A, and RP-1776 (skyllamycin A) [37–39].
Figure 4. NOE correlations in AB204-E (5) and AB204-F (6).
Compounds 7 and 8 were pale-yellow amorphous solids that were determined by HRESI-MS
analyses to have molecular formulas of C31H44O6 and C32H46O6, respectively (Figures S36 and S37).
The planar structures of 7 and 8 (Figure 1) were confirmed by NMR spectra (Figures S38 and S39)
as known compounds, anguinomycin A (7) [40] and leptomycin A (8) [41], which were known to be
relative structures. Compound 9 was a colorless oil, and the molecular formula of 9 was determined to
be C25H36O4 on the basis of HRESI-MS data and the signals of 1H NMR spectrum (Figures S40 and
S41). These data supported the structure of 9 to be actinopyrone A (9) as is shown in Figure 1 [42].
Physicochemical Properties of 1, 2, 5, and 6
Compound 1 (AB204-A): pale yellow amorphous solid; [α]D –3.4 (c 0.1, MeOH); UV (MeOH) λmax
(log ε) 204.5 (4.09), 235.5 (3.63) nm; IR (ATR) νmax 3014, 2923, 1706, 1654, 1409 cm−1; 1H and 13C NMR
(chloroform-d) see Table 1; HREIMS m/z 190.1000 [M]+ (calcd for C12H14O2, 190.0994).
Compound 2 (AB204-B): pale yellow amorphous solid; [α]D –0.3 (c 0.1, MeOH); UV (MeOH) λmax
(log ε) 204.5 (3.98), 235.5 (3.53) nm; IR (ATR) νmax 3011, 2925, 1706, 1653, 1457 cm−1; 1H and 13C NMR
(chloroform-d) see Table 1; HREIMS m/z 218.1301 [M]+ (calcd for C14H18O2, 218.1329).
Compound 5 (AB204-E): pale yellow amorphous solid; [α]D –13.4 (c 0.1, MeOH); UV (MeOH) λmax
(log ε) 204 (4.04), 251 (3.90), 309.5 (4.26) nm; IR (ATR) νmax 2956, 2924, 2857, 1684, 1617, 1277, 1000 cm−1;
1H and 13C NMR (methanol-d4) see Table 2; HREIMS m/z 270.1616 [M]+ (calcd for C18H22O2, 270.1620).
Compound 6 (AB204-F): pale yellow amorphous solid; [α]D –14.1 (c 0.1, MeOH); UV (MeOH) λmax
(log ε) 204 (3.76), 251 (3.51), 309.5 (3.86) nm; IR (ATR) νmax 2955, 2924, 2855, 1684, 1615, 1244, 958 cm−1;
1H and 13C NMR (chloroform-d) see Table 2; HREIMS m/z 270.1633 [M]+ (calcd for C18H22O2, 270.1620).
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3.2. Antimicrobial Activities of Isolated Compounds
Antimicrobial activities of the purified compounds, except for the mixture of AB204-C (3) and
AB204-D (4), were tested against four Gram-positive bacteria, five Gram-negative bacteria, two
yeasts, and three fungi using paper disk diffusion assay with an equal amount of each compound at
50 μg/disk. The results are shown in Table 3. All compounds did not show activity against E. coli
NIHJ, K. pneumonia ATCC 10031, P. vulgaris NBRC 3167, Ps. aeruginosa IFO 3080, and Sa. cerevisiae
ATCC 9763. AB204-A (1) and B (2) displayed a weak activity towards C. albicans ATCC 64548, A. niger
ATCC 6275, and G. boninense BCC 21330, with a clear zone range from 10.4 to 13.2 mm. However, they
did not affect the Gram-positive and Gram-negative bacteria. AB204-E (5) and AB204-F (6) displayed
no antifungal and antiyeast activities but showed good antibacterial activity against Gram-positive
bacteria and weak activity against the Gram-negative bacterium X. campestris pv. oryzae KB88, which is
a phytopathogenic strain. AB204-E (5) strongly inhibited K. rhizophila ATCC 9341, B. subtilis ATCC 6633,
M. smegmatis ATCC 607, and S. aureus ATCC 6538p with inhibition zones of 41.3, 35.3, 32.7, and 26.0 mm,
respectively, while AB204-F (6) showed a slightly lower activity against the same pathogens as is
presented in Table 3. Anguinomycin A (7) revealed potent inhibitory activity against the Gram-positive
bacterium K. rhizophila ATCC 9341 (19.1 mm), and two fungi, Mu. racemosus IFO 4581 (16.9 mm),
and G. boninense BCC 21330 (19.6 mm), while leptomycin A (8) showed stronger activity against these
pathogens at 30.6, 49.0, and 21.2 mm, respectively. Actinopyrone A (9) exhibited potent antifungal
activity against C. albicans ATCC 64548 and three fungal strains with the inhibition zone in a range of
11.9 to 23.9 mm (Table 3). These results suggest that the antibacterial and antifungal activities of the
S. palmae CMU-AB204T may have been displayed as a consequence of the contribution of all these
antimicrobial secondary metabolites.
Table 3. Antimicrobial activities of the pure compounds against fourteen microorganisms using an
equal amount of each compound at 50 μg/disk. Inhibition zone (mm) (Mean ± SD; n = 3) including
the diameter of the paper disk (8 mm) was measured after 24 and 48 h of incubation. 1, AB204-A;
2, AB204-B; 5, AB204-E; 6, AB204-F; 7, anguinomycin A; 8, leptomycin A; 9, actinopyrone A.
Microorganism
Inhibition Zone (mm) of Seven Pure Compounds
1 2 5 6 7 8 9
Gram-positive bacteria
Bacillus subtilis ATCC 6633 - - 35.3 ± 1.4 12.3 ± 1.8 - - -
Kocuria rhizophila ATCC 9341 - - 41.3 ± 2.0 17.5 ± 1.5 19.1 ± 1.9 30.6 ± 2.3 -
Mycobacterium smegmatis ATCC 607 - - 32.7 ± 1.2 14.0 ± 2.2 - - -
Staphylococcus aureus ATCC 6538p - - 26.0 ± 1.6 13.2 ± 1.9 - - -
Gram-negative bacteria
Escherichia coli NIHJ - - - - - - -
Klebsiella pneumonia ATCC 10031 - - - - - - -
Proteus vulgaris NBRC 3167 - - - - - - -
Pseudomonas aeruginosa IFO 3080 - - - - - - -
Xanthomonas campestris pv. oryzae KB 88 - - 10.6 ± 1.3 11.0 ± 2.2 - -
Yeasts
Candida albicans ATCC 64548 13.1 ± 1.6 10.4 ± 0.9 - - - - 20.8 ± 1.5
Saccharomyces cerevisiae ATCC 9763 - - - - - - -
Fungi
Mucor racemosus IFO 4581 - - - - 16.9 ± 1.7 49.0 ± 2.3 23.1 ± 1.6
Aspergillus niger ATCC 6275 11.5 ± 1.1 11.1 ± 1.2 - - - - 23.9 ± 1.8
Ganoderma boninense BCC 21330 11.0 ± 1.4 13.2 ± 2.0 - - 19.6 ± 1.6 22.1 ± 1.7 11.9 ± 1.0
4. Discussion
Several mechanisms have been proposed to control G. boninense causing BSR disease in oil
palm trees. However, none of them have successfully been treated or been shown to suppress the
disease [9]. The search for antifungal alternatives is representative of a potential solution that has drawn
significant interest. In this study, new compounds were identified during the isolation of anti-Ganoderma
substances from S. palmae CMU-AB204T. The assessment of antimicrobial activity of four new phenyl
alkenoic acids showed that AB204-A (1) and B (2) mildly inhibited the growth of fungi, G. boninense
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BCC 21330, Mu. racemosus IFO 4581, and A. niger ATCC 6275, while AB204-E (5) and F (6) displayed a
positive degree of activity against Gram-positive bacteria, B. subtilis ATCC 6633, K. rhizophila ATCC
9341, M. smegmatis ATCC 607, and S. aureus ATCC 6538p. New antifungal compounds, AB204-A (1)
and B (2), possessed similar structures to phenylethyl alcohol (PEA), an antifungal aromatic compound
that was obtained from Trichoderma virens 7b, which had significant potential as a biological control
agent for BSR [43]. These compounds may exhibit a mechanism in inhibiting fungi similar to PEA
which inhibits protein, DNA, RNA, and aminoacyl tRNA syntheses of fungi [44,45]. However, a mode
of action of novel compounds in controlling fungi should be confirmed in the future.
AB204-B (2) contained more C2H4 units than AB204-A (1), but it displayed antimicrobial activity
against the same pathogenic strains with similar inhibition zone sizes. This result indicated that the
presence of a longer chain of the carboxylic group in 2 had not been involved in the antimicrobial activity.
Biological activities of the E-isomer of AB204-A (1), (E)-5-(2-methylphenyl)-4-pentenoic acid was
previously reported to be an inactive compound against bacteria and fungi but the tested concentration
and the strain of tested microorganisms have not been indicated [33]. However, the difference of
an antimicrobial activity between (E)-5-(2-methylphenyl)-4-pentenoic acid and new compounds,
AB204-A (1) and AB204-B (2), revealed that the existence of Z-olefin in 1 and 2 had been involved in
their antifungal activity. The structures of a mixture of AB204-C (3) and AB204-D (4) were predicted
based on HREI-MS and 1H NMR spectra. In the future, the mixture should be reseparated using
other techniques, and additional data is needed to confirm their structures and antimicrobial activities.
AB204-E (5) and F (6) have an 1,2-Z-heptene moiety connected to the aromatic ring. These metabolites
have not shown antifungal activity but exhibited strong antibacterial activity when associated with this
moiety. Moreover, the existence of one pair of Z-olefin in the chain of the carboxylic group of AB204-E
(5), instead of the E and Z-olefins of AB204-F (6), increased the antibacterial activity of this compound.
Previously, Thong et al. [35] found two closely related compounds of 1–4, and they were isolated
from a Streptomyces that had been spontaneously acquired rifampicin resistance. These compounds
contained E-olefins and have both a methylbenzene unit and a 2-amino-3-hydroxycyclopent-2-enone
(C5N) moiety. The phenyl alkenoic acid-associated metabolites discovered by Thong et al. did
not display antibacterial activity against E. coli, M. luteus, S. aureus, and B. subtilis in testing with a
microplate assay at 100 μM or approximately 28.5 and 33.5 mg/mL, thus revealing similar results to
AB204-A (1) and B (2). Notably, the presence of a carboxylic acid moiety in the novel compounds,
and a C5N moiety in the known compounds, may not be involved in the antimicrobial activity. Based
on draft genome sequences of the rifampicin-resistant mutant (TW-R50–13), the methylbenzene moiety
may be biosynthesized by the expression of polyketide synthase (PKS) genes that are located at a
different locus from the biosynthetic genes for the C5N moiety [35]. The genes encoding for PKS
have been disclosed to complex biosynthetic mechanisms, which were involved in the production of
many metabolites in microorganisms [46]. Genome sequences would provide the data of potential
gene clusters to understand the metabolic pathways of S. palmae CMU-AB204T. Thus, the genome
sequences of this strain should be further studied to determine the presence of both silent and cryptic
secondary metabolite biosynthetic gene clusters that are able to synthesize the corresponding novel
natural products.
In addition to 1 and 2, other antifungal compounds, anguinomycin A (7), leptomycin A (8),
and actinopyrone A (9) obtained from the same broth of S. palmae CMU-AB204T, also displayed
anti-Ganoderma activity. The ability of S. palmae to produce a variety of antifungal compounds
was proven. This strain might produce each antifungal secondary metabolite depending on the
prevailing environmental conditions, such as nutritional source, incubation period, pH value,
and temperature [47,48]. Hence, the optimization of culture conditions should be studied in order
to obtain high yields of the antifungal metabolites. The protecting effect of S. palmae CMU-AB204T
against BSR has also been confirmed in a glasshouse experiment [49]. The results obtained from this
study strongly suggest that the antimicrobial secondary metabolites were involved in the mechanism
exhibiting anti-BSR effects by this Streptomyces strain.
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Although the new compounds obtained in this study showed moderate activity towards
G. boninense, they inhibited clinical bacterial pathogens and other phytopathogenic fungi, suggesting a
possible utility of the four new antimicrobial substances in both agricultural and medical treatments.
However, cytotoxicity to mammalian cell of both new compounds and three known compounds should
be tested before being applied to these compounds. The recovery of novel actinomycetes species,
especially the genus Streptomyces, has the potential to be a rich source of both new and known natural
products [50,51]. Notably, S. palmae CMU-AB204T was found to produce various bioactive metabolites.
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Abstract: Herbicides with new modes of action and safer toxicological and environmental profiles are
needed to manage the evolution of weeds that are resistant to commercial herbicides. The unparalleled
structural diversity of natural products makes these compounds a promising source for new herbicides.
In 2009, a novel nucleoside phytotoxin, albucidin, with broad activity against grass and broadleaf
weeds was isolated from a strain of Streptomyces albus subsp. chlorinus NRRL B-24108. Here, we report
the identification and heterologous expression of the previously uncharacterized albucidin gene
cluster. Through a series of gene inactivation experiments, a minimal set of albucidin biosynthetic
genes was determined. Based on gene annotation and sequence homology, a model for albucidin
biosynthesis was suggested. The presented results enable the construction of producer strains for
a sustainable supply of albucidin for biological activity studies.
Keywords: albucidin; herbicide; nucleoside; biosynthetic gene cluster; heterologous expression;
Streptomyces albus Del14
1. Introduction
Pesticides play an important role in modern agriculture. Among all chemicals being produced,
pesticides are in second place after fertilizers in their extent of use. A total of 2.4 billion kilograms
of pesticides were applied worldwide in 2007 [1]. Nevertheless, lack of weed control is still the most
topical issue. Among all pests, weeds have the largest negative effect on crop productivity [2,3].
In light of the rapidly increasing evolution of herbicide resistance, the need for new herbicides with
new modes of action (MOAs) and safer ecological profiles is growing [4,5].
From all new pesticide active ingredients registered by the Environmental Protection Agency
from 1997 to 2010, almost 70% have origins in natural products. Interestingly, only 8% of conventional
herbicides are natural product-derived [3,6]. The wide structural diversity of natural products and
their small amount of overlap with synthetic compounds imply their potential as lead structures
for the development of new pesticides [7–9]. This is further confirmed by the phytotoxin literature,
which suggests that natural products have many more MOAs than the commercial herbicides currently
possess [3].
A novel bleaching herbicide, albucidin, from the strain Streptomyces albus subsp. chlorinus NRRL
B-24108 was discovered in 2009 [10]. In this paper, we present the identification, heterologous
expression, and engineering of the albucidin gene cluster. We also propose the biosynthetic route that
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leads to the production of albucidin. The identified minimal set of biosynthetic genes allows for the
straightforward construction of overproducing strains for a high yield albucidin supply for biological
activity studies.
2. Materials and Methods
2.1. General Experimental Procedures
All strains, plasmids and BACs used in this work are listed in Tables S1 and S2. Escherichia coli
strains were cultured in LB medium [11]. Streptomyces strains were grown on soya flour mannitol agar
(MS agar) [12] and in liquid tryptic soy broth (TSB; Sigma-Aldrich, St. Louis, MO, USA). For albucidin
production, liquid SG medium [13] was used. The antibiotics kanamycin, apramycin, hygromycin,
ampicillin and nalidixic acid were supplemented when required.
2.2. Isolation and Manipulation of DNA
The previously constructed BAC library of Streptomyces albus subsp. chlorinus NRRL B-24108 was
used [14]. DNA manipulation, E. coli transformation and E. coli/Streptomyces intergeneric conjugation
were performed according to standard protocols [11,12,15]. BAC DNA was purified with the BACMAX™
DNA purification kit (Lucigen, Middleton, WI, USA). Restriction endonucleases were used according
to the manufacturer’s recommendations (New England Biolabs, Ipswich, MA, USA). All the strains
and plasmids are listed in the Tables S1 and S2, respectively.
2.3. Metabolite Extraction and Analysis
For metabolite extraction, Streptomyces strains were grown in 15 mL of TSB in a 100 mL baffled
flask for 1 day, and 1 mL of seed culture was used to inoculate 100 mL of SG production medium in
a 500 mL baffled flask. Cultures were grown for 7 days at 28 ◦C and 180 rpm in an Infors multitron
shaker. Albucidin was extracted from the culture supernatant with an equal amount of butanol,
evaporated, and dissolved in methanol. Albucidin production was analysed on a Bruker Amazon
Speed mass spectrometer coupled to UPLC Thermo Dionex Ultimate 3000 RS. Analytes were separated
either on a Waters ACQUITY BEH C18 column (1.7 μm, 2.1 mm × 30 mm) or on a Waters ACQUITY
BEH C18 column (1.7 μm, 2.1 mm × 100 mm). Water + 0.1% formic acid and methanol + 0.1% formic
acid were used as the mobile phases. For the determination of high-resolution mass, analytes were
analysed with a Thermo LTQ Orbitrap XL coupled to UPLC Thermo Dionex Ultimate 3000 RS. Analytes
were separated on a Waters ACQUITY BEH C18 column (1.7 μm, 2.1 mm × 100 mm) with water + 0.1%
formic acid and methanol + 0.1% formic acid as the mobile phase.
2.4. Chemical Mutagenesis
One millilitre of spore suspension of Streptomyces albus subsp. chlorinus NRRL B-24108 was
inoculated into 100 mL of SG medium in a 500 mL baffled flask and cultivated overnight at 28 ◦C and
180 rpm. The pH of the culture was adjusted to 8.5 with 1 M NaOH. Ten millilitres of culture was
transferred into three 50 mL falcon tubes. Then, 64 mg of wet NTG was dissolved in 16 mL of water.
Next, 6.666 mL, 4.285 mL and 1.765 mL of NTG stock solution were added to the tubes containing
culture to reach final NTG concentrations of 800 μg/mL, 600 μg/mL and 300 μg/mL, respectively.
The samples were incubated at 28 ◦C for 30 min in the overhead shaker. The mycelium was precipitated
by centrifugation, and the supernatant was discarded. The mycelium was washed twice with 5%
sodium thiosulfate solution. The treated samples were plated on MS agar plates and cultivated for 14
days at 28 ◦C. The spores were washed with water and plated in dilutions on MS agar. The plates with
spore dilutions were incubated for 10 days at 28 ◦C. Single colonies were picked on 30 mm plates with
SG agar. The plates were incubated for 14 days at 28 ◦C. Agar blocks were cut out from the plates and
transferred into 2 mL tubes. Albucidin was extracted from the agar blocks with 500 μL of butanol for
48 h. The extracts were analysed using HPLC-MS.
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2.5. Albucidin Isolation and 1H-NMR Spectroscopy
Streptomyces albus 1K1 was grown in 10 L of SG medium, and albucidin was extracted with butanol.
The dry extract was dissolved in 50 mL of water containing 5% acetonitrile and 0.1% formic acid.
The extract was loaded onto 3 C18 SPE columns (Discovery DSC-18 SPE 52607-U) equilibrated with
5% acetonitrile in water with 0.1% formic acid. The flowthrough was collected. The columns were
washed twice with 12 mL of 5% acetonitrile containing 0.1% formic acid. The flowthrough and the
wash fractions were combined and evaporated in a rotary evaporator. The presence of albucidin was
detected by HPLC-MS.
The dry material after the SPE purification step was dissolved in methanol and used for
size-exclusion chromatography. Separation was performed on a glass column (30 mm × 1000 mm)
packed with Sephadex LH-20 and methanol as the mobile phase. Fractions containing albucidin were
identified by HPLC-MS. Albucidin-containing fractions were combined and evaporated. The dry
extract was dissolved in 5 mL of 5% methanol in water containing 10 mM potassium phosphate buffer
pH 6.4.
HPLC separation was performed on a preparative HPLC Thermo Dionex Ultimate 3000 equipped
with a Macherey Nagel Nucleodur HTec C18 column (5 μm, 21 mm × 150 mm). A 10 mM potassium
phosphate buffer (pH 6.4) was used as solvent A, and 50% methanol in 10 mM phosphate buffer (pH
6,4) was used as solvent B. The following gradient at a flowrate of 15 mL/min was used for separation:
0 min–13% B, 20 min—25% B, 21 min–25% B, 24 min–100% B, 25 min–100% B, 28 min–13% B, 29 min–13%
B. Albucidin eluted at 18 min. The albucidin-containing fractions were pooled and evaporated.
For the final purification step, the dry material after HPLC purification was dissolved in 5 mL of
water and loaded onto a Sephadex LH-20 column (30 mm × 450 mm) previously equilibrated with
water. Water was used as the mobile phase. The fractions containing albucidin were identified by
HPLC-MS, pooled and evaporated.
The 1H-NMR spectra were recorded on a Bruker Avance 500 spectrometer (Bruker, BioSpin GmbH,
Rheinstetten, Germany) at 300 K equipped with a 5 mm BBO probe using deuterated trifluoroacetic
acid (Deutero, Kastellaun, Germany) as the solvent containing tetramethylsilane (TMS) as a reference.
Albucidin was measured in deuterated water (Deutero, Kastellaun, Germany). The chemical shifts
are reported in parts per million (ppm) relative to TMS. All spectra were recorded with the standard
1H pulse program using 128 scans. The structure of albucidin was confirmed by comparison of the
recorded 1H NMR data (Figure S1) with published data [10].
2.6. Construction of the 1K1 BAC Derivatives
The derivatives of 1K1 BAC with gene deletions were constructed using the RedET approach.
For this, the antibiotic resistance marker was amplified by PCR with primers harbouring overhang
regions complementary to the boundaries of the DNA to be deleted. The amplified fragment was used
for recombineering of the BAC. The recombinant BACs were analysed by restriction mapping and
sequencing. The primers used for recombineering purposes are listed in Table S3.
For the construction of BAC 1K1_LS, the ampicillin marker from pUC19 was amplified with the
primers LS-F/LS-R. For the construction of the BAC 1K1_RS, the hygromycin marker from pACS-hyg [16]
was amplified with the primers RS-F/RS-R. For the construction of the BACs 1K1_KO14, 1K1_KO15
and 1K1_KO16, the ampicillin cassette was amplified with the pairs of primers KO14-F/KO14-R,
KO15-F/KO15-R and KO16-F/KO16-R, respectively. For the construction of the BACs 1K1_KO7,
1K1_KO8, 1K1_KO9, 1K1_KO10, 1K1_KO11, 1K1_KO12 and 1K1_KO13, the ampicillin cassette was
amplified with the pairs of primers KO7-F/KO7-R, KO8-F/KO8-R, KO9-F/KO9-R, KO10-F/KO10-R,
KO11-F/KO11-R, KO12-F/KO12-R and KO13-F/KO13-R, respectively.
BAC 1K1_alb_act was constructed in two steps. First, 1K1_RS2 BAC was constructed from
1K1 using an ampicillin marker amplified with primers RS2-F/RS2-R. Then BAC 1K1_alb_act was
constructed by recombineering the BAC 1K1_RS2 using a hygromycin marker from pACS-hyg amplified
with the primers ACT-F/ACT-R.
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2.7. Genome Mining and Bioinformatics Analysis
The S. albus subsp. chlorinus genome was screened for secondary metabolite biosynthetic gene
clusters using the antiSMASH online tool [17] and the software Geneious [18]. The genomic sequence
of the albucidin producer S. albus subsp. chlorinus NRRL B-24108 was deposited in GenBank under
accession number VJOK00000000 [14].
3. Results and Discussion
3.1. Identification of the Albucidin Biosynthetic Gene Cluster
The aim of this study was to identify the biosynthetic genes leading to the production of the
nucleoside phytotoxin albucidin. For this purpose, the genome sequence of the producer strain of
Streptomyces albus subsp. chlorinus NRRL B-24108 was analysed by genome-mining software [17].
This analysis led to the identification of several putative nucleoside clusters. To prove the involvement
of these candidate clusters in albucidin production, they were heterologously expressed in a genetically
engineered cluster-free strain Streptomyces albus Del14 [19] and in Streptomyces lividans TK24 [20].
No albucidin production was detected in the extracts of the obtained strains, indicating that either the
expressed clusters were not involved in the biosynthesis of albucidin or they were not expressed in the
heterologous host environment. The inactivation of the candidate clusters in the natural albucidin
producer was not feasible because the strain is refractory to genetic manipulation. Considering
the difficulties in identifying the albucidin gene cluster using conventional methods, an alternative
approach using chemical mutagenesis was chosen.
For chemical mutagenesis of the albucidin-producing strain S. albus subsp. chlorinus NRRL
B-24108, 1-methyl-3-nitro-1-nitrosoguanidine (NTG) was used. The strain in the exponential growth
stage was treated with various NTG concentrations (800 μg/mL, 600 μg/mL and 300 μg/mL) for 30 min.
After mutagenesis, the cells were washed with 5% thiosulfate solution and plated in dilutions on
MS-agar medium for segregation of mutations. The spores of the obtained mutant populations were
washed and plated on MS-agar plates in dilutions to obtain single colonies. Altogether, 4000 individual
mutants were analysed for albucidin production. The mutants were cultivated on individual plates
with the production medium SG agar. The metabolites were extracted with butanol, and albucidin
production was assayed by HPLC-MS. Eight mutants that lost the ability to produce albucidin were
identified in the course of this screening: 6-238, 6-260, 6-389, 6-444, 6-612, 6-892, 8-610 and 8-639.
The genomic DNA of the obtained zero mutants was sequenced using Illumina technology. The point
mutations in the genomes of the mutants were detected by mapping the sequencing reads to the
reference genome of the wild type albucidin producer. Up to 100 transition mutations were identified
in the genomes of the mutant strains. By comparing the mutation patterns of the separate mutants,
a short genomic region was identified that was affected by point mutations in all analysed zero mutants,
implying its potential involvement in albucidin production (Figure S2). The identified region contains
two genes, SACHL2_05525 and SACHL2_05524, which encode putative radical SAM proteins and were
named albA and albB (Table 1, Figure 1b). The genes constitute a putative operon with the third gene
SACHL2_05523, which was named albC. The albC gene encodes a putative ribonucleoside-triphosphate
reductase and was not affected by point mutations in the analysed zero mutants of S. albus subsp.
chlorinus NRRL B-24108. The identified genes albA and albB were not a part of the nucleoside gene
clusters previously identified by genome mining and analysed in this study. Interestingly, these genes
were located within the DNA fragment annotated by genome mining software as a putative NRPS
gene cluster.
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Table 1. Genes encoded within the chromosomal fragment cloned in BAC 1K1.
Gene Locus Tag 1 Putative Function
1 SACHL2_05539 Hypothetical protein
2 SACHL2_05538 ABC transporter
3 SACHL2_05537 Transcriptional regulatory protein LiaR
4 SACHL2_05536 Hypothetical protein
5 SACHL2_05535 Hypothetical protein
6 SACHL2_05534 beta-lactamase/D-alanine carboxypeptidase
7 SACHL2_05533 Chondramide synthase
8 SACHL2_05532 Hypothetical protein
9 SACHL2_05531 Hypothetical protein
10 SACHL2_05530 Thymidylate kinase
11 SACHL2_05529 Pyruvate, phosphate dikinase
12 SACHL2_05528 Hypothetical protein
13 SACHL2_05527 Hypothetical protein
14 SACHL2_05526 Hypothetical protein
15; albA SACHL2_05525 Biotin synthase, radical SAM protein
16; albB SACHL2_05524 Radical SAM protein
17; albC SACHL2_05523 Ribonucleoside-triphosphate reductase
18 SACHL2_05522 Tyrocidine synthase 3
19 SACHL2_05521 Plipastatin synthase, subunit A
20 SACHL2_05520 Acyl carrier protein
21 SACHL2_05519 Demethylmenaquinone methyltransferase
22 SACHL2_05518 Linear gramicidin synthase, subunit D
23 SACHL2_05517 Hypothetical protein
24 SACHL2_05516 Acyl carrier protein
25 SACHL2_05515 Fatty-acid–CoA ligase
26 SACHL2_05514 Ribonucleotide-diphosphate reductase
27 SACHL2_05513 Hypothetical protein
28 SACHL2_05512 Tyrocidine synthase 3
29 SACHL2_05511 Hypothetical protein
1 The locus tags refer to the genome sequence of S. albus subsp. chlorinus NRRL B-24108 available under GenBank
accession number VJOK00000000.
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Figure 1. Chromosomal fragment of S. albus subsp. chlorinus NRRL B-24108 with the albucidin
biosynthetic genes. (a) Schematic representations of DNA fragments cloned in BACs 1K1 and 2D4;
(b) The genes encoded within the fragment cloned in BAC 1K1. The albA–C operon is marked in red;
and (c) Overview of the performed deletions within BAC 1K1.
To determine whether the identified genes albA and albB encode albucidin biosynthetic enzymes,
a BAC 1K1 containing the abovementioned genes (Figure 1a) was selected from the genomic library of
S. albus subsp. chlorinus NRRL B-24108. BAC 1K1 was transferred into the heterologous host strains
S. albus Del14 and S. lividans TK24 by conjugation, and the production profile of the obtained strains
S. albus 1K1 and S. lividans 1K1 was analysed by HPLC-MS. The production of the compound with
a high-resolution mass corresponding to albucidin could be detected in the extracts of S. albus 1K1
(Figure S3). No production could be detected in S. lividans 1K1.
Due to the lack of an albucidin standard, we set out to purify the compound identified in the
extracts of S. albus 1K1 for structure elucidation studies by NMR spectroscopy. The S. albus 1K1
strain was cultivated in 10 L of SG medium for 7 days. The culture supernatant was extracted with
equal amount of butanol, and the obtained extract was concentrated under vacuum. Four milligrams
of the compound was purified using size exclusion and reverse phase chromatography and used
for subsequent NMR studies. Analysis of the recorded NMR spectra of the purified compound
unequivocally demonstrated its identity as albucidin (Figure S1 and Figure 2a).
Figure 2. The structures of (a) albucidin and (b) oxetanocin A.
The production of albucidin by S. albus 1K1 gives evidence that the genes albA and albB identified
by chemical mutagenesis encode albucidin biosynthetic genes. The lack of albucidin production by S.
lividans 1K1 can be explained by differences in regulatory networks of the S. albus Del14 and S. lividans
TK24 strains.
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3.2. Identification of the Minimal Set of Albucidin Biosynthetic Genes
BAC 1K1, which leads to the production of albucidin under expression in the heterologous host
S. albus Del14, contains a 32 kb chromosomal fragment from the natural albucidin producer S. albus
subsp. chlorinus NRRL B-24108. Twenty-nine open reading frames were annotated in this 32 kb
region (Table 1, Figure 1b). Of these genes, only two, albA and albB, were affected by point mutations
in albucidin zero mutants identified in the course of the chemical mutagenesis studies. These two
genes constitute a putative operon with the gene albC, implying that either only the genes albA and
albB are necessary for albucidin production or that all three gene within the operon are required. To
experimentally determine the minimal set of albucidin biosynthetic genes, a series of gene deletions
was performed within the cloned region of 1K1 BAC.
The genes albA–C are located in the middle part of the chromosomal fragment cloned in
1K1 BAC. The alb operon is preceded by the genes SACHL2_05539–SACHL2_05526, followed
by the genes SACHL2_05522–SACHL2_05511 (Table 1). For the sake of simplicity, the 29 genes
SACHL2_05539–SACHL2_05511 cloned in the BAC 1K1 will be designated in the text according to their
sequence number (1 to 29). (Figure 1b) To determine which genes within the 1K1 cloned fragment are
essential for albucidin production, five deletions (LS, KO14, KO15, KO16 and RS) were performed in
the 1K1 BAC yielding the BACs 1K1_LS, 1K1_KO14, 1K1_KO15, 1K1_KO16 and 1K1_RS (Figure 1c).
In BAC 1K1_LS, the left shoulder encompassing genes 1–13 was substituted by an ampicillin resistance
marker (Figure 1c). The genes 14, albA (gene 15) and albB (gene 16) were substituted with the ampicillin
resistance gene in BACs 1K1_KO14, 1K1_KO15 and 1K1_KO16, respectively (Figure 1c). In the BAC
1K1_RS, the right shoulder encompassing genes albC (gene 17)-28 was substituted by the hygromycin
resistance marker (Figure 1c). The constructed BACs were transferred separately into the S. albus Del14
strain by conjugation, and the albucidin production of the resulting strains was assayed by HPLC-MS.
The deletion of gene 14 did not affect albucidin production in S. albus 1K1_KO14 (Figure S4B).
As expected from the results of chemical mutagenesis, inactivation of the genes albA (gene 15) and
albB (gene 16) completely abolished albucidin production in the strains S. albus 1K1_KO15 and S. albus
1K1_KO16 (Figure S4C,D). This unambiguously demonstrates the essential role of the genes albA and
albB in albucidin biosynthesis.
Deletion of the genes albC (gene 17)-28 did not affect albucidin production by the S. albus RS strain
(Figure S4F). It was expected from the gene annotation and results of chemical mutagenesis that the
genes 18–28 do not participate in albucidin biosynthesis. However, the dispensability of the gene albC
(gene 17) is surprising since it belongs to the same operon as the essential genes albA (gene 15) and albB
(gene 16). The deletion of the albC gene (gene 17) might be cross-complemented by an unidentified
gene in the genome of the host strain S. albus Del14.
Albucidin production was heavily abolished in the strain S. albus 1K1_LS (Figure S4E), implying
that at least one of the genes 1–13 that were deleted in the BAC 1K1_LS might be essential for albucidin
biosynthesis. No genes encoding regulatory proteins or structural enzymes that might participate
in nucleoside biosynthesis were identified in close proximity to the albA–C operon. To identify the
genes within the deleted LS region that influence albucidin production, a BAC 2D4 was isolated from
the genomic library of S. albus subsp. chlorinus NRRL B-24108. The chromosomal fragment cloned in
BAC 2D4 overlaps with the fragment cloned in BAC 1K1 and covers the albA–C operon (Figure 1a).
In contrast to 1K1, 2D4 BAC lacks genes 1–6, which are present in the deleted LS region. BAC 2D4 was
transferred into S. albus Del14. Albucidin production could be detected in the extracts of the obtained
strain S. albus 2D4 by HPLC-MS (Figure S5). This indicates that the genes 1–6 within the LS region
are not involved in albucidin production and that one of the genes among 7–13 is responsible for the
abolishment of albucidin production in S. albus 1K1_LS.
To identify which of the genes 7–13 is involved in albucidin biosynthesis, each of them was
individually substituted by an ampicillin resistance marker in 1K1 BAC yielding 1K1_KO7, 1K1_KO8,
1K1_KO9, 1K1_KO10, 1K1_KO11, 1K1_KO12 and 1K1_KO13 (Figure 1b,c). The constructed BACs were
transferred into the S. albus Del14 strain, and the albucidin production was analysed. The albucidin
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production levels of all obtained strains, except S. albus 1K1_KO12, were in the range of S. albus
1K1 harbouring the unmodified BAC (Figure S6). Albucidin production was abolished in S. albus
1K1_KO12 (Figure S6G), indicating that gene 12 is responsible for the detrimental effect of the LS
deletion on albucidin biosynthesis. No enzymatic activity could be assigned to the peptide product
of gene 12 using blast analysis. The product also did not show homology to any known regulatory
protein. Considering this, it was proposed that only the genes albA and albB encode structural enzymes
essential for albucidin production in the heterologous host S. albus Del14 and that the product of the
gene 12 elicits a regulatory effect on transcription of the albA–C operon through a mechanism that
is not understood. To prove this, a BAC 1K1_alb_act was constructed containing only albA–C genes
under the control of a strong promoter. The genes downstream of the albA–C operon (genes 18–28)
were substituted with the ampicillin resistance gene and the genes upstream of the operon (genes 1–14)
were substituted with the hygromycin resistance gene (Figure 1c). The hygromycin resistance gene
used was under the control of the strong synthetic promoter TS81 and did not contain a terminator at
its 3’-end [21]. The insertion of the hygromycin marker in front of the albA–C genes was performed in
the orientation, which enabled their read-through from the TS81 promoter and their transcriptional
activation. The constructed BAC 1K1_alb_act was transferred into the heterologous host strain S.
albus Del14. The production of albucidin was detected in the extracts of the obtained strain S. albus
1K1_alb_act by HPLC-MS (Figure S7). Three times increase of albucidin production was observed in
the strain S. albus 1K1_alb_act compared to S. albus 1K1 containing non-modified albucidin cluster
(Figure S7). Taking into account that the total recovered albucidin yield from the S. albus 1K1 strain was
approximately 0.4 mg/L, the calculated albucidin production by S. albus 1K1_alb_act corresponded to
1.2 mg/L. The albucidin production rate of 2 mg/L was reported for the original producer Streptomyces
albus subsp. chlorinus NRRL B-24108 [10].
Albucidin production by the strain S. albus 1K1_alb_act clearly demonstrates that the genes albA
and albB constitute the minimal set of the genes required for albucidin biosynthesis in heterologous
host S. albus Del14. The role of the gene albC in albucidin biosynthesis is not completely understood.
Because albC constitutes a single operon with albA and albB and its product shows homology to
nucleotide biosynthetic enzymes, it cannot be completely excluded that the albC is involved in albucidin
production in the natural producer. However, the deletion of albC has no effect on albucidin production
in heterologous host.
The identification of the minimal set of albucidin biosynthetic genes allows its expression in
various heterologous chassis strains as well as rational construction of albucidin overproducers.
The engineering of the albucidin biosynthetic genes can be performed in E. coli and the obtained
constructs can be heterologously expressed in Streptomyces hosts. In contrast to the genetically
intractable original albucidin producer Streptomyces albus subsp. chlorinus NRRL B-24108, commonly
used heterologous strains possess a well-established toolkit for their genetic manipulation. This
opens the possibility to engineer their metabolic network to increase the intracellular levels of
biosynthetic precursors and therefore to increase the production yields. The heterologous strains are
often characterized by the simplified metabolic background which provides better detection limits for
heterologously expressed compounds than the original producers, higher product yields and simplified
downstream processing. Construction of the albucidin overproducers based on heterologous expression
hosts is not necessarily limited to a rational approach. The chassis strains expressing heterologous
cluster may be also subjected to classical mutagenesis and screening for overproducing clones.
3.3. Proposed Biosynthetic Pathway of Albucidin
Structurally, albucidin is closely related to oxetanocin A (Figure 2b), which has been isolated from
the culture of Bacillus megaterium NK84-0218 [22]. Both compounds are the only known naturally
occurring nucleosides featuring four membered oxetane rings in their structure. From a structural
view, albucidin is 2′-dehydroxymethyl oxetanocin A. Two genes, oxsA and oxsB, encoding a putative
HD domain phosphohydrolase and a cobalamin-dependent S-adenosylmethionine radical enzyme
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have been reported to be responsible for oxetanocin biosynthesis [23]. dAMP, dADP and dATP were
identified as direct oxetanocin precursors [24]. The product of oxsB catalyses the contraction of the
deoxyribose ring, while the product of oxsA is responsible for the removal of one or multiple phosphates
from a phosphorylated 2′-deoxyadenosine derivative [24,25]. Through the simultaneous actions of
OxsA and OxsB, the phosphorylated 2′-deoxyadenosine is converted to the oxetanocin A precursor,
its aldehyde form, which must be reduced to complete biosynthesis [24]. This reaction is not encoded
by the genes within the oxetanocin A cluster and is likely to be carried by an unidentified enzyme of B.
megaterium NK84-0218.
Gene inactivation studies have given evidence that two genes, albA and albB, are required for
the production of albucidin. Both genes encode putative SAM radical proteins. At the protein level,
the albA gene shows homology to biotin synthases and the albB gene shows homology to the product
of the oxetanocin biosynthetic gene oxsB. Despite the high structural similarity of albucidin and
oxetanocin A, the homologue of the second oxetanocin biosynthetic gene oxsA cannot be found within
the albucidin cluster or in the genome of albucidin producer S. albus subsp. chlorinus NRRL B-24108.
The homology of the albB gene to oxsB implies that the product of albB might also be responsible for
the ring contraction reaction in albucidin biosynthesis. However, the structural differences between
albucidin and oxetanocin and the absence of an oxsA homologue imply substantial differences in
biosynthetic routes leading to the biosynthesis of the nucleosides. Due to the lack of an oxsA homologue
that is responsible for the dephosphorylation of adenine deoxyribonucleotides during oxetanocin
biosynthesis, we propose that deoxyadenosine is used instead of dAMP, dADP or dATP as a precursor
for albucidin production. The product of albB is likely responsible for the contraction of the deoxyribose
ring of deoxyadenosine (Figure 3) in a similar manner as its homologue OxsB catalyses oxetane
ring formation in oxetanocin A biosynthesis [24]. As a result of this reaction, the aldehyde form of
oxetanocine A is formed. The conversion of the latter into albucidin is likely to be catalysed by the
product of albA, which removes the aldehyde group from the 2’-position (Figure 3).
Figure 3. The proposed scheme of albucidin biosynthesis. 2′-Deoxyadenosine (1) is converted into the
aldehyde form of oxetanocin A (2) by the product of albB. The latter is then converted into albucidin (3)
by the product of albA.
In this paper, we report the identification, cloning, and heterologous expression of the albucidin
biosynthetic gene cluster from Streptomyces albus subsp. chlorinus NRRL B-24108. Albucidin is
a nucleoside phytotoxin featuring a rare oxetane ring in its structure. This metabolite shows herbicidal
activity against a broad spectrum of grass and broadleaf weeds. In treated plants, albucidin induces
metabolic perturbation, chlorosis, and bleaching [10]. The exact MOA of the compound remains
unknown. The identification of the albucidin cluster presented in this paper enables biosynthetic
studies of albucidin, optimization of its production as well as albucidin supply for the determination
of its MOA.
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4. Patents
(WO2018224939) Gene cluster for the biosynthesis of albucidin.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/2/237/s1,
Figure S1: 1H NMR spectrum of albucidin (500 MHz), Figure S2: The genes albA and albB with the mapped point
mutations identified in the course of NTG-mutagenesis, Figure S3: High resolution HPLC-MS analysis of albucidin
production by Streptomyces albus 1K1, Figure S4: HPLC-MS analysis of albucidin production by Streptomyces albus
strain harboring 1K1 BAC and its derivatives with gene deletions, Figure S5: HPLC-MS analysis of albucidin
production by Streptomyces albus 1K1 BAC (a) and Streptomyces albus 2D4 BAC (b), Figure S6: HPLC-MS analysis
of albucidin production by Streptomyces albus strain harboring 1K1 BAC and its derivatives with gene deletions,
Figure S7: HPLC-MS analysis of albucidin production by Streptomyces albus strain harboring full length 1K1 BAC
(a) and minimized 1K1_alb_act BAC, containing only transcriptionally activated albA–C operon (b), Table S1:
Bacterial strains used in the study, Table S2: Plasmids and BACs used in the study, Table S3: Primers used in this
study. References [26,27] are cite d in the supplementary materials.
Author Contributions: L.P., T.S., M.M., and A.L. designed the experiments; M.M. and B.R. performed the
experiments; M.S. performed structure elucidation studies; M.M., B.R., and A.L. analysed the data and wrote the
manuscript, and all authors reviewed the manuscript. All authors have read and agreed to the published version
of the manuscript.
Funding: This work was partially supported by the BMBF grant “MyBio” 031B0344B.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Malakof, D.; Stokstad, E. Infographic: Pesticide Planet. Science 2013, 341, 730–731.
2. Pimentel, D.; Zuniga, R.; Morrison, D. Update on the environmental and economic costs associated with
alien-invasive species in the United States. Ecol. Econ. 2005, 52, 273–288. [CrossRef]
3. Dayan, F.E.; Duke, S.O. Natural compounds as next-generation herbicides. Plant Physiol. 2014, 166, 1090–1105.
[CrossRef]
4. Duke, S.O. Why have no new herbicide modes of action appeared in recent years? Pest Manag. Sci. 2012, 68,
505–512. [CrossRef]
5. Heap, I. Global perspective of herbicide-resistant weeds. Pest Manag. Sci. 2014, 70, 1306–1315. [CrossRef]
6. Cantrell, C.L.; Dayan, F.E.; Duke, S.O. Natural products as sources for new pesticides. J. Nat. Prod. 2012, 75,
1231–1242. [CrossRef]
7. Duke, S.O.; Stidham, M.A.; Dayan, F.E. A novel genomic approach to herbicide and herbicide mode of action
discovery. Pest Manag. Sci. 2019, 75, 314–317. [CrossRef]
8. Harvey, A.L. Natural products as a screening resource. Curr. Opin. Chem. Biol. 2007, 11, 480–484. [CrossRef]
9. Koch, M.A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H.
Charting biologically relevant chemical space: A structural classification of natural products (SCONP). Proc.
Natl. Acad. Sci. USA 2005, 102, 17272–17277. [CrossRef]
10. Hahn, D.R.; Graupner, P.R.; Chapin, E.; Gray, J.; Heim, D.; Gilbert, J.R.; Gerwick, B.C. Albucidin: A novel
bleaching herbicide from Streptomyces albus subsp. chlorinus NRRL B-24108. J. Antibiot. 2009, 62, 191–194.
[CrossRef]
11. Green, M.R.; Sambrook, J. Molecular Cloning: A Laboratory Manual, 4th ed.; Cold Spring Harbor Laboratory
Press: New York, NY, USA, 2012.
12. Kieser, T.; Bibb, M.J.; Buttner, M.J.; Chater, K.F.; Hopwood, D.A. Practical Streptomyces Genetics; John Innes
Foundation: Norwich, UK, 2000.
13. Rebets, Y.; Ostash, B.; Luzhetskyy, A.; Hoffmeister, D.; Brana, A.; Mendez, C.; Salas, J.A.; Bechthold, A.;
Fedorenko, V. Production of landomycins in Streptomyces globisporus 1912 and S. cyanogenus S136 is regulated
by genes encoding putative transcriptional activators. FEMS Microbiol. Lett. 2003, 222, 149–153. [CrossRef]
14. Rodríguez Estévez, M.; Myronovskyi, M.; Gummerlich, N.; Nadmid, S.; Luzhetskyy, A. Heterologous
Expression of the Nybomycin Gene Cluster from the Marine Strain Streptomyces albus subsp. chlorinus NRRL
B-24108. Mar. Drugs 2018, 16, 435.
15. Mazodier, P.; Petter, R.; Thompson, C. Intergeneric conjugation between Escherichia coli and Streptomyces
species. J. Bacteriol. 1989, 171, 3583–3585. [CrossRef] [PubMed]
82
Microorganisms 2020, 8, 237
16. Myronovskyi, M.; Brötz, E.; Rosenkränzer, B.; Manderscheid, N.; Tokovenko, B.; Rebets, Y.; Luzhetskyy, A.
Generation of new compounds through unbalanced transcription of landomycin A cluster. Appl. Microbiol.
Biotechnol. 2016, 100, 9175–9186. [CrossRef] [PubMed]
17. Blin, K.; Medema, M.H.; Kottmann, R.; Lee, S.Y.; Weber, T. The antiSMASH database, a comprehensive
database of microbial secondary metabolite biosynthetic gene clusters. Nucleic Acids Res. 2017, 45, D555–D559.
[CrossRef]
18. Kearse, M.; Moir, R.; Wilson, A.; Stones-Havas, S.; Cheung, M.; Sturrock, S.; Buxton, S.; Cooper, A.;
Markowitz, S.; Duran, C.; et al. Geneious Basic: An integrated and extendable desktop software platform for
the organization and analysis of sequence data. Bioinformatics 2012, 28, 1647–1649. [CrossRef] [PubMed]
19. Myronovskyi, M.; Rosenkränzer, B.; Nadmid, S.; Pujic, P.; Normand, P.; Luzhetskyy, A. Generation of
a cluster-free Streptomyces albus chassis strains for improved heterologous expression of secondary metabolite
clusters. Metab. Eng. 2018, 49, 316–324. [CrossRef]
20. Rückert, C.; Albersmeier, A.; Busche, T.; Jaenicke, S.; Winkler, A.; Friðjónsson, Ó.H.; Hreggviðsson, G.Ó.;
Lambert, C.; Badcock, D.; Bernaerts, K.; et al. Complete genome sequence of Streptomyces lividans TK24. J.
Biotechnol. 2015, 199, 21–22. [CrossRef]
21. Siegl, T.; Tokovenko, B.; Myronovskyi, M.; Luzhetskyy, A. Design, construction and characterisation of
a synthetic promoter library for fine-tuned gene expression in actinomycetes. Metab. Eng. 2013, 19, 98–106.
[CrossRef]
22. Shimada, N.; Hasegawa, S.; Harada, T.; Tomisawa, T.; Fujii, A.; Takita, T. Oxetanocin, a novel nucleoside
from bacteria. J. Antibiot. 1986, 39, 1623–1625. [CrossRef]
23. Morita, M.; Tomita, K.; Ishizawa, M.; Takagi, K.; Kawamura, F.; Takahashi, H.; Morino, T. Cloning of
oxetanocin A biosynthetic and resistance genes that reside on a plasmid of Bacillus megaterium strain
NK84-0128. Biosci. Biotechnol. Biochem. 1999, 63, 563–566. [CrossRef] [PubMed]
24. Bridwell-Rabb, J.; Zhong, A.; Sun, H.G.; Drennan, C.L.; Liu, H.-W. A B12-dependent radical SAM enzyme
involved in oxetanocin A biosynthesis. Nature 2017, 544, 322–326. [CrossRef] [PubMed]
25. Bridwell-Rabb, J.; Kang, G.; Zhong, A.; Liu, H.-W.; Drennan, C.L. An HD domain phosphohydrolase active
site tailored for oxetanocin-A biosynthesis. Proc. Natl. Acad. Sci. USA 2016, 113, 13750–13755. [CrossRef]
[PubMed]
26. Grant, S.G.; Jessee, J.; Bloom, F.R.; Hanahan, D. Differential plasmid rescue from transgenic mouse DNAs into
Escherichia coli methylation-restriction mutants. Proc. Natl. Acad. Sci. USA 1990, 87, 4645–4649. [CrossRef]
27. Flett, F.; Mersinias, V.; Smith, C.P. High efficiency intergeneric conjugal transfer of plasmid DNA from
Escherichia coli to methyl DNA-restricting streptomycetes. FEMS Microbiol. Lett. 1997, 155, 223–229.
[CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Diversity and Bioactive Potential of Actinobacteria
from Unexplored Regions of Western Ghats, India
Saket Siddharth 1, Ravishankar Rai Vittal 1,*, Joachim Wink 2 and Michael Steinert 3
1 Department of Studies in Microbiology, University of Mysore, Manasagangotri, Mysore 570 006, India;
saketsiddharth@gmail.com
2 Microbial Strain Collection, Helmholtz Centre for Infection Research GmbH (HZI), Inhoffenstrasse 7,
38124 Braunschweig, Germany; joachim.wink@helmholtz-hzi.de
3 Institute of Microbiology, Technische Universität Braunschweig, 38106 Braunschweig, Germany;
m.steinert@tu-bs.de
* Correspondence: raivittal@gmail.com
Received: 3 February 2020; Accepted: 6 February 2020; Published: 7 February 2020
Abstract: The search for novel bioactive metabolites continues to be of much importance around the
world for pharmaceutical, agricultural, and industrial applications. Actinobacteria constitute one of
the extremely interesting groups of microorganisms widely used as important biological contributors
for a wide range of novel secondary metabolites. This study focused on the assessment of antimicrobial
and antioxidant activity of crude extracts of actinobacterial strains. Western Ghats of India represents
unique regions of biologically diverse areas called “hot spots”. A total of 32 isolates were obtained
from soil samples of different forest locations of Bisle Ghat and Virjapet situated in Western Ghats of
Karnataka, India. The isolates were identified as species of Streptomyces, Nocardiopsis, and Nocardioides
by cultural, morphological, and molecular studies. Based on preliminary screening, seven isolates
were chosen for metabolites extraction and to determine antimicrobial activity qualitatively (disc
diffusion method) and quantitatively (micro dilution method) and scavenging activity against DPPH
(2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
radicals. Crude extracts of all seven isolates exhibited fairly strong antibacterial activity towards
MRSA strains (MRSA ATCC 33591, MRSA ATCC NR-46071, and MRSA ATCC 46171) with MIC
varying from 15.62 to 125 μg/mL, whereas showed less inhibition potential towards Gram-negative
bacteria Salmonella typhi (ATCC 25241) and Escherichia coli (ATCC 11775) with MIC of 125–500 μg/mL.
The isolates namely S1A, SS5, SCA35, and SCA 11 inhibited Fusarium moniliforme (MTCC 6576) to a
maximum extent with MIC ranging from 62.5 to 250 μg/mL. Crude extract of SCA 11 and SCA 13
exhibited potent scavenging activities against DPPH and ABTS radicals. The results from this study
suggest that actinobacterial strains of Western Ghats are an excellent source of natural antimicrobial
and antioxidant compounds. Further research investigations on purification, recovery, and structural
characterization of the active compounds are to be carried out.
Keywords: Western Ghats; diversity; actinobacteria; antimicrobial; MRSA; antioxidants
1. Introduction
The quest for novel biologically active secondary metabolites from microorganisms continues to
rise due to emergence of drug resistance in pathogens causing life threatening diseases around the
globe [1]. Particularly, methicillin resistant Staphylococcus aureus (MRSA) and methicillin resistant
Staphylococcus epidermidis (MRSE) strains are not only exposed to hospital-acquired infections but
also to community-acquired infections [2]. The mortality and morbidity associated with these
infections are largely affecting economic conditions of patients and hospitals [3]. Therefore, there
is an urgent need for developing novel and effective antimicrobial agents to overcome or delay
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acquired resistance to existing drugs. Reactive oxygen species (ROS) play an important role as
signaling molecules involved in mitogenesis. However, high generation of ROS during aerobic
metabolism creates oxidative stress within the intracellular milieu causing oxidative damage to cells [4].
The oxidative stress caused is often associated with many human diseases including cancer, diabetes [5],
cardiovascular [6], and neurodegenerative diseases [7]. In order to withstand the oxidative stress
caused, cells or organisms make use of antioxidants, that are able to block or delay the damage caused
by several possible mechanisms such as halting chain reactions, preventing the formation of free
radicals, neutralizing the singlet oxygen molecule, promoting anti-oxidant enzymes, and inhibiting
pro-oxidative enzymes [8]. Formation of free radicals can be prevented by antioxidant systems present
within the cells. However, these defense mechanisms are insufficient to prevent the damages that arise,
therefore exogenous antioxidants through dietary intake and supplements are required [9]. Natural
antioxidants are found abundantly in metabolites produced by microorganisms. These products have
consistently been considered as mainstay for drugs with various interesting biological activities [10].
They are considered to be an excellent scaffold for the formulation and development of antibiotics,
antioxidants, immunomodulators, enzyme inhibitors, anticancer agents, plant growth hormones,
and insect control agents [11]. With many improved techniques under combinatorial chemistry for high
throughput findings of novel compounds, natural products from microbial sources have been screened
extensively and gained much attention owing to their massive chemical and biological diversity [12].
Under various screening strategies, the rate of discovery of natural products has increased many folds,
of which around 22,250 bioactive compounds are of microbial origin [13]. Among microorganisms,
actinomycetes have contributed nearly 45% of all the reported metabolites [14].
A major group of natural products from microbial origin have been identified from organisms
that inhabit the soil. Since soil itself is a mixture of minerals and organic matter, the filamentous
bacteria are predominantly more present in the gaps between the soil particles than their unicellular
counterparts [15]. Actinobacteria are ubiquitous in soils. They are responsible for biodegradation and
biodeterioration processes in nature. Their flexile and proven abilities have prompted biologists to
screen these organisms from unexplored niche habitats in order to obtain novel molecules [16].
Western Ghats of India is considered as one of the global biodiversity hotspots covering an area
of 180,000 km2 and harbors numerous species of plants, animals, and microbes [17]. The unique
biodiversity of Western Ghats is conserved and protected by wildlife sanctuaries, national parks,
and biosphere reserves situated in states where hill ranges run through, like Karnataka, Gujarat, Tamil
Nadu, Maharashtra, and Kerala [18]. The forest regions in Western Ghats are largely underexplored,
though in recent times few studies were carried out for bioprospection. Ganesan et al. [19] reported
larvicidal, ovicidal, and repellent activities of Streptomyces enissocaesilis (S12–17) isolated from Western
Ghats of Tamil Nadu, India. Actinobacterial strains isolated from Western Ghats soil of Tamil Nadu
were reported to produce antimicrobial compounds against range of pathogens [20]. In the present
study, the forest range in Western Ghats of Karnataka was studied for microbial population and
taxonomical identification of potential actinobacteria. An attempt was also made to characterize
microbial diversity for the potential to produce antioxidants and antimicrobial compounds.
2. Materials and Methods
2.1. Site, Sampling, Pre-Treatment, and Selective Isolation
Soil samples were collected from different forest locations of Bisle Ghat and Virajpet in Western
Ghats regions of Karnataka, India. The samples were collected from a depth of 15–25 cm in dry
sterile insulated containers and stored aseptically at 4 ◦C until subjected to plating. Samples were
air dried in a hot air oven (Equitron, India) at 50 ◦C for 72 h. Pre-treated samples were ground
aseptically with mortar and pestle and serially diluted up to 10−6 in 10-fold dilution. The aliquots
of each dilution (100 μL) were spread evenly on starch casein agar (SCA, Himedia, India) plates in
triplicates supplemented with cycloheximide (30 μg/mL) and nalidixic acid (25 μg/mL). The plates
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were incubated at 28 ± 2 ◦C for 14 days. Emerging colonies with different morphological characters
were selected and the purified strains were maintained on International Streptomyces Project (ISP-2,
Himedia, India) agar slants and stored at 4 ◦C as stock for further use.
2.2. Morphological Characterization of Isolates
Morphological characteristics of isolates were assessed by scanning electron microscopy (SEM).
Bacterial colonies were inoculated in ISP-2 medium and incubated at 28 ± 2 ◦C for 7 days. Cells
were centrifuged (Eppendorf, USA) at 8000× g for 10 min and pellet was resuspended in 2%–5%
gluteraldehyde (Sigma, Burlington, VT, USA) prepared in 0.1M phosphate buffer, pH 7.2. After
incubating samples for 30 min, supernatant was discarded and pellet was resuspended in 1% osmium
tetraoxide (Sigma, Burlington, VT, USA), incubated for 1 h and centrifuged at 5000 × g. To the pellet,
sterile water was added and centrifuged twice for 10 min at 5000 × g. For dehydration, the pellet was
resuspended in 35% ethanol for 10 min, 50% ethanol for 10 min, 75% ethanol for 10 min, 95% ethanol
for 10 min, and a final wash with 100% ethanol for 10 min. For SEM analysis, sterilized aluminum
stubs and cover slips were inserted into the SCA plates at an angle of about 45 ◦C. The plates with
stubs and coverslips were incubated at 37 ◦C for 24 h to check any contamination. After 24 h, isolates
were introduced along the line where the surface of the stub met the agar medium and incubated at
28 ± 2 ◦C for 7 days. The stubs were then carefully removed and coated under vacuum, with a film of
gold for 25–30 min and viewed on the scanning electron microscope (Zeiss Evo 40 EP, Germany).
2.3. Molecular Identification and Phylogenetic Analysis
The total genomic DNA of bacteria was extracted by phenol-chloroform method, quality checked
by agarose gel electrophoresis and quantified using NanoDrop1000 (Thermo-Scientific, USA). The PCR
amplification of 16S rRNA gene was carried out with universal primers: 27F (5′-AGA GTT TGA
TCC TGG CTC AG-3′) and 1492R (5′- ACG GCT ACC TTG TTA CGA CTT-3′) using the following
conditions: initial denaturation temperature was set at 95 ◦C for 5 min, followed by 35 cycles at same
temperature for 1 min, primer annealing at 54 ◦C for 1 min, and primer extension at 72 ◦C for 2 min.
The reaction mixture was kept at 72 ◦C for 10 min subsequently and then cooled to 4 ◦C. The PCR
products were checked in 1.5% agarose gel and visualized in a UV transilluminator (Tarsons, India)
and the gel imaging was done using a Gel documentation system (Bio-Rad, USA). The amplified
PCR products were sequenced using same set of primers (27F’ and 1492R’) on Applied Biosystems
3130 Genetic Analyzer (Applied Biosystems, USA). The genetic relationship between the strains was
determined by neighbor-joining tree algorithm method. The phylogenetic tree was constructed with a
bootstrapped database containing 1000 replicates in MEGA 7.0 software (Mega, Raynham, MA, USA).
The nearly complete 16S rRNA consensus sequences were deposited in the GenBank database.
2.4. Isolates Cultivation and Metabolites Extraction
Pure isolates were subcultured in Tryptone Yeast Extract broth as seed medium (ISP-1 medium,
Himedia, India) at 28 ◦C for 2 weeks prior to fermentation process. The production medium, ISP-2
was autoclaved at 121 ◦C and 1.5 atm for 15 min. Fermentation was carried out in 750 mL of (in 7 nos.
conical flasks −1000 mL) ISP-2 medium, shaking at 140 rev min−1 for 14 days at 28 ◦C, inoculated with
250 μL of seed medium. After incubation, the culture medium was split into mycelium and filtrate
by centrifugation at 12,000× g for 15 min. The cell free supernatant from each flask was subjected to
extraction thrice with equal volume of ethyl acetate (Qualigens Fine Chemicals Pvt. Ltd., San Diego,
USA) and the organic phase was concentrated by rotary vacuum evaporator (Hahn-Shin, Bucheon,
South Korea) at 50 ◦C. The crude concentrate was dried in a desiccator and suspended in methanol
prior to bioactivity screening assays.
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2.5. Antimicrobial Susceptibility Test
2.5.1. Disc Diffusion Assay
Antimicrobial susceptibility assay was carried out by disc diffusion method against
methicillin-resistance Staphylococcus aureus (MRSA ATCC 33591, MRSA ATCC NR-46071 and MRSA
ATCC 46171), Gram-negative bacteria (Salmonella typhi (ATCC 25241) and Escherichia coli (ATCC 11775))
and fungus (Fusarium moniliforme (MTCC 6576)). Gentamicin and Nystatin discs were used as positive
control. The sterile discs (6mm, Himedia) were impregnated with 30 μL of crude extract dissolved in
0.5% DMSO. Discs impregnated with 0.5% DMSO (Qualigens Fine Chemicals Pvt. Ltd., San Diego,
USA) were used as solvent control. The plates were left for 30 min at 4 ◦C to allow the diffusion of
extracts before they were incubated for 24–48 h at 37 ◦C. The clear zones of inhibition observed around
discs suggested antagonistic activity against test organisms and diameter of inhibition zones were
measured subsequently. The test was performed in triplicate.
2.5.2. Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentration assay was determined by micro broth dilution method as
previously reported by Siddharth and Rai [21]. The serially diluted fraction of extracts with sterile
Mueller Hinton broth (Himedia, India) was added to pre coated microbial cultures in 96-well micro
titer plates to give a final concentration of 1–3.8 μg/mL. The titer plate was incubated for 24 h at 37 ◦C.
The lowest concentration of extract which completely inhibited the bacterial growth (no turbidity) was
considered as MIC. Each test was done in triplicate.
2.6. Antioxidant Assays
2.6.1. 2,2-diphenyl-1-picrylhydrazyl Radical Scavenging activity (DPPH)
DPPH radical scavenging activity of crude extracts was examined based on a previously described
method by Siddharth and Rai [22]. Crude extracts at varying concentrations (7.81–1000 μg/mL)
were reacted with freshly prepared DPPH in methanol (60 mM, Sigma, USA). Reaction mixture was
incubated at room temperature for 30 min in the dark prior to the measurement of absorbance at
520 nm. The radical scavenging activity was expressed as IC50 (μg/mL). The percentage scavenging of
DPPH radicals was computed by the following equation:
DPPH scavenging effect (%) = [(Ao − A1)/Ao] × 100 (1)
where, Ao = Absorbance of control, A1 = Absorbance of crude extracts. Trolox (Sigma) was used as a
reference compound whereas methanol was used as blank.
2.6.2. 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) Radical Scavenging Activity (ABTS)
ABTS radical scavenging activity was performed according to the method developed by
Ser et al. [23] with slight modifications. Crude extracts at concentrations (7.81–1000 μg/mL) were
mixed with ABTS (Sigma, USA) cation complex and incubated in dark at room temperature for 30 min.
The absorbance was measured at 415 nm. The radical scavenging activity was expressed as IC50
(μg/mL). The percentage inhibition of ABTS*+ radicals were computed by using following equation:
ABTS*+ scavenging effect (%) = [(Ao − A1)/Ao] × 100 (2)
where, Ao = Absorbance of control, A1 = Absorbance of crude extracts. Trolox (Sigma) was used as a
positive reference.
3. Results and Discussion
Soil is among the most productive habitat colonized by a large number of organisms.
The rhizosphere soil in the vicinity of plant roots provides essential nutrients in the form of exudates
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which favors the growth of microbial communities [24]. Soil microbes are a major source of a number
of natural products including clinical important antibiotics, immunomodulators, enzyme inhibitors,
antioxidants, anti-tumor and anticancer agents. Actinobacteria are abundant in soil, species of
Streptomyces in particular represent the dominance over other microbes present in soil and play a vital
role in recycling of materials and production of important metabolites [25]. Rare actinobacteria genera
such as Nocardia, Nocardiopsis, and Nocardioides are also encountered in soils, though their presence
is subjected to conditions of soil such as salinity and alkalinity [26]. The rapid emergence of drug
resistant pathogens urges the exploration of new niche habitats for the isolation of new microbial
species which can contribute to the uncovering of novel, safe, effective, and broad spectrum bioactive
compounds [27].
3.1. Isolation, Morphological, and Molecular Characterization of Actinobacterial Isolates
In this study, from forest soil of Bisle Ghat and Virajpet of Western Ghats region of Karnataka,
we targeted the isolation of different genera of actinobacteria in search of new natural products (Table 1).
A total of 32 actinobacterial isolates were recovered on Starch casein agar and Actinomycetes isolation
agar. Of them, seven isolates grown on starch casein agar medium showing marked antimicrobial
activity against test organisms in primary screening were characterized on the basis of cultural,
morphological, and molecular characteristics. The colonies of isolates revealed diverse morphological
appearances with varied spore color, aerial and substrate mycelium, and colony morphology (Table 2
and Figure 1). Scanning electron microscope examination showed chains of smooth and spiny spores
in oval, round, and spiral ornamentation (Figure 2). The molecular identification of isolates by
amplification of 16S-rRNA gene was done by using universal primers 27F’ and 1492R’ (Figure S1).
In 16S-rRNA sequencing, alignment of the nucleotide sequences of strain S1A, SS4, SS5, SS6, and SCA35
exhibited a similarity of 98.32%, 99.71%, 99.70%, 99.72%, and 99.35% with closely related Streptomyces
species, respectively. The strain SCA11 was considered to represent a species of the genus Nocardiopsis,
since it was closely related to Nocardiopsis species with 98.99% sequence similarity. The nucleotide
sequence of strain SCA13 showed 98.28% similarity with the closely related Nocardioides sp. (Table 3).
The phylogenetic relatedness of strains with their closely related species obtained by neighbor-joining
method is shown in Figures 3–5.
Table 1. Actinobacterial isolates and sampling areas in Western Ghats regions of Karnataka, India.
Name Sample Code Sampling Area Latitude (N) Longitude (E) Elevation (m)
Streptomyces Sp. S1A Bisle Ghat, HassanDistrict 12
◦71′88.04” 75◦68′70.02” 802
Streptomyces Sp. SS4 Bisle Ghat, HassanDistrict 12
◦72′00.89” 75◦68′41.42” 752
Streptomyces Sp. SS5 Bisle Ghat, HassanDistrict 12
◦71′24.30” 75◦68′04.74” 710
Streptomyces Sp. SS6 Virajpet, MadikeriDistrict 12
◦19′75.83” 75◦79′52.93” 885
Streptomyces Sp. SCA35 Virajpet, MadikeriDistrict 12
◦18′83.38” 75◦83′06.79” 864
Nocardiopsis Sp. SCA11 Virajpet, MadikeriDistrict 12
◦21′21.64” 75◦80′24.84” 830
Nocardioides Sp. SCA13 Virajpet, MadikeriDistrict 12
◦18′47.27” 75◦76′24.17” 798
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Streptomyces Sp. S1A SCA None Powdery White Cream
Streptomyces Sp. SS4 SCA None Cottony Dark Grey Grey
Streptomyces Sp. SS5 SCA None Cottony Grey Cream
Streptomyces Sp. SS6 SCA Pink Rough Pale red Pink
Streptomyces Sp. SCA35 SCA None Powdery White Cream
Nocardiopsis Sp. SCA11 SCA None Powdery Cream Light brown
Nocardioides Sp. SCA13 SCA None Raised White White
Figure 1. Morphological characterization of actinobacterial isolates on starch casein agar plates.
Table 3. Molecular identification (based on 16S rRNA amplification) of actinobacterial strains isolated
from Western Ghats.
Source Organism GenBank Accession No % Similarity
Soil Streptomyces Sp. S1A KU921223 98.32%
Soil Streptomyces Sp. SS4 MF668120 99.71%
Soil Streptomyces Sp. SS5 MF925722 99.70%
Soil Streptomyces Sp. SS6 MF925723 99.72%
Soil Streptomyces Sp. SCA35 MN176654 99.35%
Soil Nocardiopsis Sp. SCA11 MG934272 98.99%
Soil Nocardioides Sp. SCA13 MG934273 98.28%
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Figure 2. Scanning electron micrograph of strains (A) S1A, (B) SCA11, (C) SS4, (D) SS5, (E) SS6,
(F) SCA35, (G) SCA13; scale bar represents 5 μm.
Figure 3. Phylogenetic analysis of isolate Nocardiopsis sp. strain SCA11. Neighbor-joining phylogenetic
tree showing evolutionary relationship of selected isolate based on 16S r-RNA sequence alignments.
Bootstrap values at the nodes indicate collated values based on 1000 resampled datasets. Bar indicates
0.0005 substitutions per nucleotide position.
3.2. Antimicrobial and Antioxidant Potential of Isolates
In this study, all seven isolates showed antibacterial activity against at least one test bacterium.
All isolates inhibited MRSA strains significantly (MRSA ATCC 33591, MRSA ATCC NR-46071,
and MRSA ATCC 46171), whereas showed less inhibition potential against Gram-negative bacteria
Salmonella typhi (ATCC 25241) and Escherichia coli (ATCC 11775). The isolates namely S1A, SS5,
SCA35, and SCA 11 inhibited Fusarium moniliforme (MTCC 6576) to a maximum extent (Figure 6).
The minimum inhibition concentration (MIC) ranges from 15.62 to 125 μg/mL for MRSA strains,
125–500 μg/mL for Gram-negative bacteria, and 62.5–250 μg/mL for fungi (Table 4). Numerous
studies have reported antimicrobial activity of actinobacterial species. Sengupta et al. [28] reported
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potential antimicrobial activity of three isolates against Pseudomonas aueroginosa, Enterobacter aueroginosa,
Salmonella typhi, Salmonella typhimurium, Escherichia coli, Bacillus subtilis, and Vibrio cholera. Satheeja and
Jebakumar [29] reported isolation of Streptomcyes species from a mangrove ecosystem for antibacterial
activity against clinical isolates of MRSA, methicillin-susceptible Staphylococcus aureus (MSSA),
and Salmonella typhi. Vu et al. [30] reported antimicrobial activity of Streptomyces cavourensis YBQ59
against methicillin-resistant Staphylococcus aureus ATCC 33591 and methicillin-resistant Staphylococcus
epidermidis ATCC 358984. Dashti et al. [31] reported the co-cultivation of Actinokineospora sp.EG49
and Nocardiopsis sp.RV163 and metabolites produced were tested for antimicrobial activity against
the range of pathogens. The bioactive metabolite from Streptomyces cyaneofuscatus M-169 showed
significant inhibition of Gram-positive bacteria with MIC value of 0.03 μg/mL [32]. It has been
shown that actinobacterial isolates from Western Ghats exhibit antimicrobial activity. The Streptomyces
species from Agumbe [33], Streptomyces sp. RAMPP-065 from Kudremukh [34], and Streptomyces sp.
GOS1 isolated from Western Ghats of Agumbe, Karnataka [35] exhibited remarkable antimicrobial
activity. In earlier studies, Streptomyces species isolated from Kodachadri were found to possess
antifungal activity [33]. Each extract was evaluated for scavenging activity against DPPH and
ABTS radicals for antioxidant activity. Crude extract of strain SCA11 showed potent scavenging
activity against DPPH radicals with IC50 (μg/mL) 30.91 ± 0.25, whereas SCA13 showed remarkable
scavenging activity against ABTS radicals with IC50 (μg/mL) 37.91 ± 0.17. Trolox as a standard showed
significant activity with IC50 (μg/mL) 11.07 ± 0.06 and 9.87 ± 0.01 against DPPH and ABTS radicals,
respectively (Table 5). Similar studies were carried out for the detection of compounds with antioxidant
activity from Streptomyces spp., dihydroherbimycin A [36], 5-(2,4-dimethylbenzyl)pyrrolidin-2-one [37].
Ser et al. [38] reported antioxidant activity of pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro extracted
from Streptomyces mangrovisoli, a novel Streptomyces species isolated from a mangrove forest in Malaysia.
Narendhran et al. [39] successfully reported antioxidant potential of phenol, 2,4-bis(1,1-dimethylethyl) in
Streptomyces cavouresis KUV39 isolated from vermicompost samples. Tian et al. [40] reported antioxidant,
antifungal, and antibacterial activity of p-Terphenyls isolated from halophilic actinobacteria Nocardiopsis
gilva YIM 90087. Current findings indicated the bioactive potential of actinobacterial isolates from
Western Ghats region of Karnataka. The isolates were found to possess significant antimicrobial activity
against Gram-positive MRSA bacteria, Gram-negative bacteria, and fungal pathogens. They also
exhibited potent scavenging activity against DPPH and ABTS radicals suggesting their antioxidant
potential. It is anticipated that findings of the study will be useful in the discovery of novel species of
actinobacteria for a potential source of bioactive compounds from underexplored environments.
Figure 4. Phylogenetic analysis of isolate Nocardioides sp. strain SCA13. Neighbor-joining phylogenetic
tree showing evolutionary relationship of selected isolate based on 16S r-RNA sequence alignments.
Bootstrap values at the nodes indicate collated values based on 1000 resampleddatasets. Bar indicates
0.001 substitutions per nucleotide position.
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Figure 5. Neighbor-joining phylogenetic tree showing evolutionary relationship between isolates
S1A, SS4, SS5, SS6, and SCA35 based on 16S r-RNA sequence alignments. Bootstrap values at the
nodes indicate collated values based on 1000 resampled datasets. Bar indicates 0.005 substitutions per
nucleotide position.
93
Microorganisms 2020, 8, 225
 
Figure 6. Antimicrobial activity of actinobacterial isolates against (A) MRSA ATCC NR 46071, MRSA
ATCC NR 46171, and MRSA ATCC 33591 (B) Escherichia coli ATCC 11775 and Salmonella typhi ATCC
25241, (C) Fusarium moniliforme MTCC 6576.
Table 4. Minimum inhibitory concentration (MIC inμg/mL) of actinobacterial isolates against pathogenic
test organisms.
Organisms















Streptomyces Sp. S1A 15.62 15.62 62.5 125 >500 62.5
Streptomyces Sp. SS4 62.5 31.25 125 250 >500 -
Streptomyces Sp. SS5 31.25 125 15.62 250 250 125
Streptomyces Sp. SS6 31.25 62.5 62.5 250 125 -
Streptomyces Sp. SCA35 62.5 15.62 125 >500 125 250
Nocardiopsis Sp. SCA11 31.25 15.62 31.25 250 >500 125
Nocardioides Sp. SCA13 62.5 62.5 125 250 125 -






Streptomyces Sp. S1A 189.40 ± 0.12 156.81 ± 0.06
Streptomyces Sp. SS4 98.29 ± 0.32 123.48 ± 0.13
Streptomyces Sp. SS5 86.45 ± 0.04 114.87 ± 0.29
Streptomyces Sp. SS6 114.15 ± 0.03 164.04 ± 0.07
Streptomyces Sp. SCA35 65.86 ± 0.49 49.11 ± 0.73
Nocardiopsis Sp. SCA11 30.91 ± 0.25 48.24 ± 0.30
Nocardioides Sp. SCA13 42.30 ± 0.10 37.91 ± 0.17
Trolox (Standard) 11.07 ± 0.06 9.87 ± 0.01
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4. Conclusions
The present study was successful in determining the diversity and bioactive potential of
actinobacterial isolates from Western Ghats region of Karnataka. Relatively underexplored forest
regions of Western Ghats of Karnataka are found to be promising resources for the discovery of
natural bioactive metabolites. The isolates showed significant antimicrobial activity against pathogenic
Gram-positive MRSA bacteria, Gram-negative bacteria, and fungi. They were also found to possess
antioxidant potential. Our studies encourage the exploration of diverse ecosystems for the isolation of
new species for novel and biologically active compounds. Further studies are under progress to purify
and characterize the crude extracts that may result in the economic production of bioactive compounds
for pharmaceutical applications.
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Abstract: The rhizosphere, an important battleground between beneficial microbes and pathogens,
is usually considered to be a good source for isolation of antagonistic microorganisms. In this
study, a novel actinobacteria with broad-spectrum antifungal activity, designated strain NEAU-H2T,
was isolated from the rhizosphere soil of wheat (Triticum aestivum L.). 16S rRNA gene sequence
similarity studies showed that strain NEAU-H2T belonged to the genus Streptomyces, with high
sequence similarities to Streptomyces rhizosphaerihabitans NBRC 109807T (98.8%), Streptomyces populi
A249T (98.6%), and Streptomyces siamensis NBRC 108799T (98.6%). Phylogenetic analysis based on 16S
rRNA, atpD, gyrB, recA, rpoB, and trpB gene sequences showed that the strain formed a stable clade
with S. populi A249T. Morphological and chemotaxonomic characteristics of the strain coincided
with members of the genus Streptomyces. A combination of DNA–DNA hybridization results and
phenotypic properties indicated that the strain could be distinguished from the abovementioned
strains. Thus, strain NEAU-H2T belongs to a novel species in the genus Streptomyces, for which
the name Streptomyces triticiradicis sp. nov. is proposed. In addition, the metabolites isolated from
cultures of strain NEAU-H2T were characterized by nuclear magnetic resonance (NMR) and mass
spectrometry (MS) analyses. One new compound and three known congeners were isolated. Further,
genome analysis revealed that the strain harbored diverse biosynthetic potential, and one cluster
showing 63% similarity to natamycin biosynthetic gene cluster may contribute to the antifungal
activity. The type strain is NEAU-H2T (= CCTCC AA 2018031T = DSM 109825T).
Keywords: Streptomyces triticiradicis sp. nov.; antifungal activity; rhizosphere soil; new compound;
genome analysis
1. Introduction
It is well known that plant pathogenic fungi can cause a tremendous loss of global agricultural
production [1]. Despite synthetic fungicides being effective and playing an indispensable role against
pathogenic fungi, the available antifungal agents are far from satisfactory as a result of several drawbacks,
such as severe drug resistance, drug-related toxicity, and many other problems [2]. Therefore, novel
antifungal agents and antagonistic microorganisms are needed to effectively control the fungal diseases
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of agricultural crops. Natural products and their derivatives, in particular secondary metabolites
derived from Streptomyces, have always been valuable sources for lead discovery in medicinal and
agricultural chemistry because their novel scaffolds can provide new modes of action [3,4]. Members of
the genus Streptomyces species are gram-positive, filamentous, and sporulating actinobacteria containing
a number of biosynthetic gene clusters, indicating their potential ability to produce large numbers of
secondary metabolites with diverse biological activities [5,6], and they represent the source of 75% of
clinically useful antibiotics presently available [7]. Many Streptomyces species have been successfully
developed as commercial biofungicides based on Streptomyces griseoviridis [8]. Thus, Streptomyces are
still an attractive and indispensable resource for drug discovery.
The rhizosphere is an environment where pathogenic and beneficial microorganisms constitute
a major influential force on plant growth and health, which differs from the bulk soil [9]. Plants not
only provide nutrients for microbial growth but also change the microbial diversity and increase the
numbers of bioactive microorganisms in the rhizosphere. The rhizosphere provides an excellent place
for pursuing actinobacteria producing novel antibiotics [10,11]. During our search for antagonistic
actinobacteria from the rhizosphere soil of wheat (Triticum aestivum L.), the strain NEAU-H2T was
isolated, which showed broad inhibitory activities against phytopathogenic fungi. Based on the
polyphasic taxonomy analysis, this strain was classified as representative of a novel species in the genus
Streptomyces. In addition, the secondary metabolites of this strain were investigated by spectroscopic
and genomic analyses.
2. Materials and Methods
2.1. Isolation of Actinobacterial Strain
Strain NEAU-H2T was isolated from the rhizosphere soil of wheat (Triticum aestivum L.) collected
from Zhumadian, Henan Province, Central China (32◦98′ N, 114◦02′ E). The root sample was air-dried
for 24 h at room temperature, and then the surface soil was shaken off gently. After, the sample was
shaken at 250 rpm in 100 mL of sterile water with glass beads for 30 min at 20 ◦C and then filtered
with a single layer of gauze to obtain the rhizosphere soil suspension. The suspension was serially
diluted and spread on cellulose-proline agar (CPA) [12] supplemented with cycloheximide (50 mg·L−1)
and nalidixic acid (20 mg·L−1), and cultured at 28 ◦C for 3 weeks. Strain NEAU-H2T was isolated and
purified on the International Streptomyces Project (ISP) medium 3 [13], and maintained as glycerol
suspensions (20%, v/v) at −80 ◦C.
2.2. Morphological and Biochemical Characteristics
Gram staining was performed by the Hucker method [14]. Morphological characteristics were
observed by light microscopy (Nikon ECLIPSE E200, Nikon Corporation, Tokyo, Japan) and scanning
electron microscopy (Hitachi SU8010, Hitachi Co., Tokyo, Japan) using cultures grown on ISP 3 agar
at 28 ◦C for 2 weeks. Samples for scanning electron microscopy were prepared as described by
Jin et al. [15]. Cultural characteristics were determined on the ISP media 1–7 [13], Bennett’s agar [16],
Czapek’s agar [17], and Nutrient agar [18] after 2 weeks at 28 ◦C. The color of substrate mycelium,
aerial mycelium, and diffusible pigment on the different tested media were determined using color
chips from the ISCC-NBS color charts [19]. Temperature tolerance for growth was evaluated at 4, 10,
15, 20, 25, 28, 35, 37, 40, and 45 ◦C on ISP 3 agar after incubation for 2 weeks. The pH range for growth
(pH 3.0–12.0, at intervals of 1.0 pH unit) was tested in GY broth [20] using the buffer system described
by Zhao et al. [21] and NaCl tolerance (0%–15% (w/v) in 1% intervals) for growth was determined after
2 weeks growth in GY broth at 28 ◦C with shaking at 250 rpm. Hydrolysis of Tweens (20, 40, and 80)
and production of urease were tested according to the method of Smibert and Krieg [14]. The utilization
of sole carbon and nitrogen sources were determined following the methods of Gordon et al. [22]. The
decomposition of cellulose, hydrolysis of starch, coagulation of milk, aesculin, reduction of nitrate,
liquefaction of gelatin, and production of H2S were examined as described previously [23].
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2.3. Chemotaxonomic Analysis
The freeze-dried cells used for chemotaxonomic analysis were obtained from cultures grown in GY
medium on a rotary shaker for seven days at 28 ◦C. Cells were acquired and washed twice with sterile
distilled water and freeze-dried. The isomer of diaminopimelic acid (DAP) in the cell wall hydrolysates
was derivatized and analyzed by HPLC (Agilent TC-C18 Column, 250 × 4.6 mm, i.d. 5 μm) with
a mobile phase consisting of acetonitrile/phosphate buffer (0.05 mol·L−1, pH 7.2, 15:85, v/v), and a
flow rate of 0.5 mL·min−1 at a column temperature of 28 ◦C [24]. An Agilent G1321A fluorescence
detector was used to detect the peak with a 365 nm excitation and 455 nm longpass emission filters.
The whole-cell sugars were analyzed according to Lechevalier [25]. The polar lipids were extracted
and examined by two-dimensional TLC (thin-layer chromatography, Qingdao Marine Chemical Inc.,
Qingdao, China) and identified according to the method of Minnikin et al. [26]. Menaquinones were
extracted and purified from freeze-dried biomass following the methods of Collins [27]. The extracts
were analyzed by HPLC-UV (Agilent Extend-C18 Column, 150 × 4.6 mm, i.d. 5 μm, 1.0 mL·min−1
acetonitrile: iso-propyl alcohol = 60:40) at 270 nm [28]. Fatty acid methyl esters were performed by
GC-MS according to the method of Xiang et al. [29] and identified with the NIST 14 database.
2.4. Phylogenetic Analysis
Strain NEAU-H2T was grown on ISP 3 agar plates for one week at 28 ◦C. Then, it was inoculated
into 250-mL baffle Erlenmeyer flasks containing 50 mL of GY broth and cultivated for two days at 28 ◦C
with shaking at 250 rpm. After that, the total DNA was extracted according to the lysozyme-sodium
dodecyl sulfate-phenol/chloroform method [30]. The primers and procedure for PCR amplification
were carried out as described by Yi et al. [31]. The PCR product was purified and cloned into the
vector pMD19-T (Takara, Shiga, Japan) and sequenced using an Applied Biosystems DNA sequencer
(model 3730XL, Applied Biosystems Inc., Foster City, CA, USA). Almost full-length 16S rRNA gene
sequence (1519 bp) was multiply aligned in MEGA (Molecular Evolutionary Genetics Analysis) using
the Clustal W algorithm and trimmed manually if necessary. Phylogenetic trees were constructed
with neighbor-joining [32] and maximum likelihood [33] algorithms using MEGA software version
7.0 (Kumar S, Philly, PA, USA) [34]. The stability of the topology of the phylogenetic tree was
assessed using the bootstrap method with 1000 repetitions [35]. A distance matrix was calculated
using Kimura’s two-parameter model [36]. All positions containing gaps and missing data were
eliminated from the dataset (complete deletion option). The calculation of 16S rRNA gene sequence
similarities between strains was carried out on the basis of pairwise alignment using the EzBioCloud
server (https://www.ezbiocloud.net/) [37]. Phylogenetic relationships of strain NEAU-H2T were also
confirmed using sequences for five individual housekeeping genes (atpD, gyrB, recA, rpoB, and trpB).
These sequences of housekeeping genes of strain NEAU-H2T were obtained from the Whole Genome
sequences. The sequences of each locus were aligned using the software package MEGA version 7.0
and trimmed manually at the same position before being used for further analysis. Phylogenetic
analysis was performed as described above.
2.5. DNA–DNA Relatedness Tests
The total DNA was extracted according to the method in the Section 2.4. The harvested
DNA was detected by agarose gel electrophoresis and quantified by a Qubit 2.0 Fluorometer
(Thermo Scientific, Ashville, NC, USA). The Illumina Novaseq PE150 (Illumina, San Diego, CA,
USA) platform was used to perform whole-genome sequencing. A-tailed, ligated to paired-end
adaptors, and PCR-amplified samples with a 350-bp insert were used for the library construction at the
Beijing Novogene Bioinformatics Technology Co., Ltd. Illumina PCR adapter reads and low-quality
reads from the paired end were filtered with a quality control step by our own compling pipeline. All
good-quality paired reads were assembled by the SOAP (Short Oligonucleotide Alignment Program)
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denovo [38,39] (https://github.com/aquaskyline) into a number of contigs. After that, the filter reads
were handled by the next step of the gap closing.
Because of a lack of the whole genome sequence of strains Streptomyces rhizosphaerihabitans NBRC
109807T and Streptomyces siamensis NBRC 108799T, a DNA–DNA relatedness test was carried out as
described by De Ley et al. [40] under consideration of modifications [41] with a model Cary 100 Bio
UV/VIS-spectrophotometer (Hitachi U-3900, Hitachi Co., Tokyo, Japan) and a temperature controller.
The DNA hybridization samples were diluted to OD260 around 1.0 using 0.1 × SSC (saline sodium
citrate buffer), then sheared using a JY92-II ultrasonic cell disruptor (ultrasonic time 3s, interval time
4 s, 90 times). The DNA renaturation rates were measured in 2 × SSC at 70 ◦C. This experiment was
repeated three times to calculate the average value. The DNA–DNA relatedness value was determined
between the genomes of strain NEAU-H2T and Streptomyces populi A249T (PJOS01000000) using the
genome-to-genome distance calculator (GGDC 2.0) at http://ggdc.dsmz.de [42]. Genome mining
analysis was performed with antiSMASH (version 4.0, Blin K, Oxford, UK) [43].
2.6. In Vitro Antifungal Activity Test
Antifungal screening was performed against 10 different phytopathogenic fungi: Sclerotinia
sclerotiorum, Exserohilum turcicum, Colletotrichum orbiculare, Corynespora cassiicola, Rhizoctonia
solani, Fusarium graminearum, Fusarium oxysporum, Sphacelotheca reiliana, Curvularia lunata, and
Helminthosporium maydis. Ten phytopathogenic fungi were preserved in the Key Laboratory of
Agricultural Microbiology within the Heilongjiang province, China. Antifungal activity of strain
NEAU-H2T was assessed using the dual culture plate assay [44]. The strain was point-inoculated
at the margin of potato dextrose agar (PDA) [45] plates and cultivated for three days at 28 ◦C, after
which a fresh mycelial PDA agar plug of the fungus was transferred into the opposite margin of the
corresponding plate. Inhibition of hyphal growth of the fungus was recorded after incubated for seven
days at 28 ◦C. The percentage inhibition rates were calculated using the formula: Inhibition rate (%)
=Wi/W × 100%, where Wi is the width of inhibition and W is the width between the pathogen and
actinobacteria. The assay was repeated three times and the average was calculated.
2.7. Isolation and Characterization of Secondary Metabolites
Strain NEAU-H2T was grown on ISP 3 agar plates for five days at 28 ◦C. Then, it was inoculated
into 250-mL baffle Erlenmeyer flasks containing 50 mL of tryptone soy broth (TSB) and cultivated for
one day at 28 ◦C with shaking at 250 rpm. After that, aliquots (15 mL) of the culture were transferred
into 1-L baffled Erlenmeyer flasks filled with 250 mL of the production medium (tryptone 0.1%, glucose
3%, beef extract 0.5%, 0.25% CaCO3, 0.5% NaCl, 0.1% minor elements concentrate (FeSO4·7H2O
1.0 g, CuSO4·5H2O 0.45 g, ZnSO4·7H2O 1.0 g, MnSO4·4H2O 0.1 g, K2MoO4 0.1 g, distilled water 1 L),
pH 7.2–7.4), and cultured at 30 ◦C for six days with shaking at 250 rpm.
The fermentation broth (25 L) was centrifuged (4000 rev/min, 20 min), and the supernatant was
extracted with ethylacetate three times. The ethylacetate extract was evaporated under reduced
pressure at temperatures within 40 ◦C to yield an oily crude extract (5.0 g). The mycelia were
extracted with methanol (1 L) and then concentrated in vacuo to remove the methanol to yield the
aqueous concentrate. The mycelia concentrate was extracted with ethylacetate (1 L × 3) to afford
1.0 g of crude extract after removing the ethylacetate. Both extracts displayed most of the similar
secondary metabolites based on HPLC analyses. Thus, they were combined for further purification.
The samples were applied to reverse-phase HPLC analysis eluted with a flow rate of 1 mL·min−1 over
a 28 min gradient with water and methanol (T = 0 min, 10% methanol; T = 20.0 min, 100% methanol;
T = 24.0 min, 100% methanol; T = 24.1 min, 10% methanol; T = 28.0 min, 10% methanol) and at 25 ◦C.
The crude extract (6.1 g) was subjected to silica gel CC using a successive elution of petroleum
ether/ethylacetate (1:0, 10:1, 5:1, 1:1 and 0:1, v/v) to yield A−F fractions. Fraction D (petroleum ether/
ethylacetate = 1:1, v/v) was subjected to semipreparative HPLC (YMC- Hydrosphere C18 column,
250 mm × 10 mm i.d., 5 μm, 0–20.0 min CH3OH:H2O = 35:55, v/v, 3 mL/min) to afford 1 (tR = 25.4 min,
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2.2 mg) and 2 (tR = 30.4 min, 2.6 mg). Compound 4 (tR = 17.2 min, 5.5 mg) was obtained from the
fraction C (petroleum ether/ethylacetate = 5:1, v/v) by semipreparative HPLC (YMC-Triart C18 column,
250 mm × 10 mm i.d., 5 μm, CH3OH:H2O = 25:75, v/v, 3 mL/min). Fraction E (petroleum ether/
ethylacetate = 0:1, v/v) was further purified by semipreparative HPLC (YMC-Hydrosphere C18 column,
250 mm × 10 mm i.d., 5 μm, 0–15.0 min, CH3OH:H2O = 25:75; 15.1–30 min, CH3OH:H2O = 35:65, v/v,
3 mL/min) to give compound 3 (tR = 21.4 min, 2.0 mg).
NMR spectra were recorded in methanol-d4 or DMSO-d6 using a Bruker AVANCE III-600 or a
Bruker AVANCE III-400 spectrometer (Bruker Corp., Karlsruhe, Germany) and TMS was used as the
internal standard. HR-ESI-MS data were obtained using an Agilent G6230 Q-TOF mass instrument
(Agilent Technologies Inc. Santa Clara, CA, USA). Thin-layer chromatography (TLC) was performed
using precoated silica gel GF254 plates (Qingdao Marine Chemical Inc., Qingdao, China), and spots
were visualized by UV light (254 nm) and colored by iodine, or by spraying heated silica gel plates
with 10% H2SO4 in ethanol. Semipreparative HPLC was conducted on a HITACHI Chromaster system
(Hitachi-DAD, Tokyo, Japan).
2.8. In Vitro Antifungal Activity Test of Compounds
The fungi were retrieved from the storage tube and cultured for seven days at 28 ◦C on PDA. All
fungi were further cultured for one week to get new mycelium for the antifungal assays in PDA at
28 ◦C. The medium was mixed with the pathogenic fungi suspension at about 45 ◦C, ensuring the
abundance of the strains was about 108 cfu/mL. Next, the mixture was poured on 9-cm Petri dishes.
The tested compounds were dissolved in DMSO at a concentration of 2 mg/mL. Each filter paper (5 mm
in diameter) was impregnated with 10 μL of the tested compounds. The inoculated Petri dishes were
cultured for 3 to 4 d at 28 ◦C. DMSO served as a blank control. The assay was measured three times.
The inhibition diameter was measured by the cross bracketing method [46].
3. Results and Discussion
3.1. Polyphasic Taxonomic Characterization of NEAU-H2T
Morphological observation of the two-week culture of strain NEAU-H2T grown on ISP 3 medium
revealed that it had characteristics typical of the genus Streptomyces [47]. Aerial and substrate
mycelium were well developed without fragmentation. Spiral spore chains with spiny surfaced spores
(0.8–1.0 × 1.0–1.3 μm) were borne on the aerial mycelium (Figure 1). Strain NEAU-H2T exhibited good
growth on ISP 1–4, ISP 7, and Nutrition agar media; moderate growth on Bennett’s and Czapek’s
agar media; and poor growth on ISP 5 and ISP 6 media. The colony colors varied from white to
moderate yellow. A dark grayish olive pigment was produced on ISP 6 medium. The detailed cultural
characteristics of strain NEAU-H2T are shown in Table S1. Strain NEAU-H2T was found to grow at a
temperature range of 4 to 40 ◦C (optimum temperature 28 ◦C), pH 5 to 10 (optimum pH 7), and NaCl
tolerance of 0% to 9% (optimum NaCl of 0% to 1%). The physiological and biochemical properties of
strain NEAU-H2T are given in Table 1 and the species description.
103


































































































































































































































































































































































































































































































































































































































































































































































































































































































Microorganisms 2020, 8, 77
 
Figure 1. Scanning electron micrograph of strain NEAU-H2T grown on International Streptomyces
Project (ISP) medium 3 (ISP 3 ) for 2 weeks at 28 ◦C; Bar 1 μm.
Chemotaxonomic analyses revealed that strain NEAU-H2T also exhibited the typical characteristics
of the genus Streptomyces [47]. It contained LL-diaminopimelic acid as cell wall diamino acid, indicating
that the strain is of cell wall chemotype I [51]. The whole-cell sugar was found to contain glucose.
The phospholipid profile consisted of diphosphatidylglycerol (DPG), phosphatidylethanolamine (PE),
phosphatidylinositol (PI), phosphatidylinositolmannosides (PIM), and an unidentified phospholipid
(PL), corresponding to phospholipid type II [52] (Figure S1). The major cellular fatty acids (>10%)
were iso-C16:0 (21.6%), anteiso-C15:0 (19.4%), iso-C15:0 (16.9%), and anteiso-C17:0 (13.0 %), which is fatty
acid type IIc [53]; minor amounts of C16:1ω7c (8.5 %), C16:0 (7.5 %), iso-C14:0 (7.2%), C17:0 cyclo (2.1%),
C17:1ω8c (2.1%), C18:0 (1.2%), and C15:0 (0.5%) were also present. The menaquinones detected were
MK-9(H8) (57.5%), MK-9(H6) (32.3%), and MK-9(H4) (10.2%), which have been reported for most
species of the genus Streptomyces [47].
EzBioCloud analysis suggests that strain NEAU-H2T belongs to the genus Streptomyces. The novel
strain shared the highest 16S rRNA gene sequence similarities with S. rhizosphaerihabitans NBRC 109807T
(98.8%), S. populi A249T (98.6%), and S. siamensis NBRC 108799T (98.6%). In the neighbor-joining
phylogenetic tree based on 16S rRNA gene sequences, strain NEAU-H2T formed a separate clade
with S. populi A249T (Figure 2), a relationship also recovered by the maximum likelihood algorithm
(Figure S2). To further clarify the affiliation of strain NEAU-H2T to closely related strains, phylogenetic
trees were constructed from the concatenated sequence alignment of the five housekeeping genes
based on the neighbor-joining and maximum likelihood algorithms (Figure 3 and Figure S3), which
showed the same topology as the 16S rRNA gene tree. Furthermore, the concatenated sequences of
atpD-gyrB-recA-rpoB-trpB were used to calculate pairwise distances well above 0.007 (Table S2) for
the related species, which was considered to be the threshold for species determination [54]. Based
on the 16S rRNA gene sequence similarities and phylogenetic trees, S. rhizosphaerihabitans NBRC
109807T, S. populi A249T, and S. siamensis NBRC 108799T were selected as the closely related strains for
subsequent comparative analysis.
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Figure 2. Neighbor-joining tree based on 16S rRNA gene sequences (1418 bp) showing the relationship
of strain NEAU-H2T (in bold) with related taxa, which are the top 50 type strains of Streptomyces
species of gene sequence similarities based on analysis using EzTaxon-e. Filled circles indicate branches
that were also recovered using the maximum likelihood methods. Only bootstrap values above
50% (percentages of 1000 replications) are indicated. Allostreptomyces psammosilenae YIM DR4008T
(KX689228) was used as an outgroup. Bar, 0.01 nucleotide substitutions per site.
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Figure 3. Neighbor-joining tree based on multilocus sequence analysis (MLSA)analysis of the
concatenated partial sequences (2060 bp) from five housekeeping genes (atpD, gyrB, recA, rpoB,
and trpB) of strain NEAU-H2T (in bold) with related taxa. Filled circles indicate branches that
were also recovered using the maximum likelihood methods. Only bootstrap values above 50%
(percentages of 1000 replications) are indicated. Kitasatospora setae KM-6054T was used as an outgroup.
Bar, 0.02 nucleotide substitutions per site.
The assembled genome sequence of strain NEAU-H2T was found to be 9,921,301 bp long and
composed of 135 contigs with an N50 of 167,996 bp, a DNA G+C content of 71.5 mol%, and a coverage of
152.0×. It was deposited into GenBank under the accession number WBKG00000000. Detailed genomic
information is presented in the Table S3. DNA–DNA hybridization was employed to further clarify
the relatedness between strain NEAU-H2T and S. rhizosphaerihabitans NBRC 109807T and S. siamensis
NBRC 108799T. The DNA–DNA relatedness values were 33.3 ± 2.5% and 44.5 ± 3.5%, respectively.
Digital DNA–DNA hybridization was employed to clarify the relatedness between strain NEAU-H2T
and S. populi A249T. The level of DNA–DNA relatedness between them was 56.5 to 62.1%. According
to the description proposed by Wayne et al. [55], the relatedness values are below the threshold value
of 70% for assigning bacterial strains to the same genomic species.
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Besides the genotypic evidence above, some obvious differences can also be found between
strain NEAU-H2T with its closely related strains regarding several phenotypic and chemotaxonomic
characteristics. Strain NEAU-H2T could be easily distinguished from its most closely related species
by cultural characteristics, such as colony colors and diffusible pigment production (Table S1 and
Figure S4). Morphological characteristics, including spore chain and surface ornamentation, could
also distinguish the isolate from its closely related strains (Table 1). In addition, the isolate was able
to grow at 4 ◦C, in contrast to its closely related strains, which could not. The novel strain could
not utilize l-serine, l-tyrosine, l-arabinose, and meso-inositol while the closely related species could.
Strain NEAU-H2T was found to contain both PI and PIM in its phospholipid profile, which could
distinguish it from S. siamensis NBRC 108799T and S. populi A249T. The presence of MK-9(H4) could
differentiate the isolate from S. rhizosphaerihabitans NBRC 109807T. Most notably, the whole-cell sugar
of strain NEAU-H2T was evidently different from that of S. rhizosphaerihabitans NBRC 109807T and
S. populi A249T, with the only presence of glucose. The detailed characteristics of strain NEAU-H2T in
comparison with its closely related strains are listed in Table 1.
Therefore, it is evident from the genotypic, phenotypic, and chemotaxonomic data that strain
NEAU-H2T represents a novel species of the genus Streptomyces, for which the name Streptomyces
triticiradicis sp. nov. is proposed.
3.2. Description of Streptomyces triticiradicis sp. nov.
Streptomyces triticiradicis (tri.ti.ci.ra’di.cis. L. neut. n. triticum wheat; L. fem. n. radix a root; N.L.
gen. n. triticiradicis of a wheat root).
This is an aerobic gram-staining-positive actinomycete that forms well-developed, branched
substrate hyphae and aerial mycelium that differentiate into spiral spore chains consisting of spiny
surfaced spores. It has good growth on ISP 1–4, ISP 7 and Nutrient agar media, moderate growth on
Bennett’s and Czapek’s agar media, and poor growth on ISP 5 and ISP 6 media. A dark grayish olive
pigment is produced on ISP 6 medium. Growth is observed at temperatures between 4 and 40 ◦C, with an
optimum temperature of 28 ◦C. Growth occurs in the pH range from 5.0 to 10.0 (optimum pH 7.0) with
0% to 9.0% (w/v) NaCl tolerance (optimum 0%–1%). It is positive for coagulation of milk; decomposition
of cellulose; hydrolysis of aesculin, starch, and Tweens (20, 40, and 80); and production of H2S and
urease; but negative for liquefaction of gelatin, production of catalase, and reduction of nitrate.
l-alanine, l-arginine, l-asparagine, l-aspartic acid, creatine, l-glutamic acid, l-glutamine glycine,
l-proline, and l-threonine are utilized as sole nitrogen sources but not l-serine or l-tyrosine. d-Fructose,
d-galactose, d-glucose, lactose, d-maltose, d-mannose, d-raffinose, l-rhamnose, and d-sucrose are
utilized as sole carbon sources but not l-arabinose, dulcitol, meso-inositol, d-mannitol, d-ribose,
d-sorbitol, or d-xylose. The cell wall contains LL-diaminopimelic acid as diagnostic diamino acid
and the whole cell hydrolysate contains glucose. The major menaquinones are MK-9(H8), MK-9(H6),
and MK-9(H4). The polar lipids profile contains DPG, PE, PI, PIM, and PL. Major fatty acids (>10%)
are iso-C16:0, anteiso-C15:0, iso-C15:0, and anteiso-C17:0. The DNA G + C content of the type strain
is 71.5 mol%.
The type strain is NEAU-H2T (= CCTCC AA 2018031T = DSM 109825T), isolated from
the rhizosphere soil of wheat (Triticum aestivum L.) collected from Zhumadian, Henan Province,
Central China. The GenBank/EMBL/DDBJ accession number for the 16S rRNA gene sequence
of strain NEAU-H2T is MN512450. This Whole Genome Shotgun project has been deposited at
DDBJ/ENA/GenBank under the accession WBKG00000000. The version described in this paper is
version WBKG01000000.1.
3.3. Antifungal Activity Evaluation
Strain NEAU-H2T showed a wide range of inhibitory effects on the mycelial growth of the
10 tested phytopathogenic fungi (Figure 4A). It displayed significant inhibitory effects against four
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phytopathogenic fungi, including C. orbiculare, C. cassiicola, S. sclerotiorum, and E. turcicum, with the





Figure 4. Antifungal activity of strain NEAU-H2T against the tested fungi. (A) Dual culture plate assay
against tested fungi; (B) Inhibition rate against the tested fungi.
3.4. Identified of Secondary Metabolites from Strain NEAU-H2T
Only major components were identified from the liquid fermentation extract. Compound 1 was
obtained as white amorphous powder, and its molecular formula, C12H13NO3, was determined by
high resolution electrospray ionization mass spectrometry (HRESIMS) data (m/z 242.0792 [M + Na]+,
calculatedd for 242.0788), corresponding to 7 degrees of unsaturation (Figure S5). The 1H NMR showed
the presence of five aromatic protons with signals at δH 8.29 (s, 1H), 8.27 (d, J = 7.3 Hz, 1H), 7.46
(d, J = 7.4 Hz, 1H), 7.24 (td, J = 7.2, 1.2 Hz, 1H), and 7.21 (td, J = 7.2, 1.2 Hz, 1H), which indicated
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a three-substituted indole moiety (Table 2, Figure S5). The 13C NMR and HSQC spectra revealed
12 carbons, which were classified into one methyl (δC 17.9), five sp2 methines (δC 135.8, 124.5, 123.4,
122.9, 112.9), three sp2 quaternary carbons (δC 138.2, 127.3, 116.3), and two oxygenated tertiary carbons
(δC 79.7 and 71.1) and a carbonyl carbon (δC 197.2) (Figure S5).
Table 2. 1H (600 MHz) and 13C (150 MHz) NMR Data of 1 in CD3OD.
No. δC δH (mult, J in Hz) 1H-1H COSY HMBC (H→C)
2 135.8 8.29 (s, 1H) C-3, 3a, 7a, 8
3 116.3
3a 127.3
4 122.9 8.27 (d, J = 7.3 Hz, 1H) H-5 C-6
5 123.4 7.21 (td, J = 7.2, 1.2 Hz, 1H) H-5, H-6 C-4, 6, 3a, 7
6 124.5 7.24 (td, J = 7.2, 1.2 Hz, 1H) H-5, H-7 C-4, 7a
7 112.9 7.46 (d, J = 7.4 Hz, 1H) H-6 C-5, 3a
7a 138.2
8 197.2
9 79.7 4.74 (d, J = 4.8 Hz, 1H) H-10 C-11, 10, 8
10 71.1 4.10 (m, 1H) H-11, H-9 C-11, 8
11 17.9 1.16 (d, J = 6.4 Hz, 3H) H-10 C-10, 9
* δC or H: chemical shift; J: coupling constant; COSY: correlated spectroscopy; HMBC: 1H detected heteronuclear
multiple bond correlation.
The 1H-1H COSY and HSQC spectra of 1 showed two spin-coupling systems, H-9/H-10/H-11 and
H-4/H-5/H-6/H-7 (Figure 5B). The HMBC cross-peaks from H-5 to C-3a, from H-6 to C-7a, and from
H-2 to C-3/3a/C-7a further revealed the presence of an indole moiety. Cross-peaks from H-9 to C-8 and
from H-10 to C-8 were observed in the HMBC spectrum, which suggested a 2,3-dihydroxybutanone
connected with indole moiety at C-3 (Figure 5B). Therefore, the planar structure 1 was elucidated as
depicted in Figure 5A.
Figure 5. (A)The structure of compounds 1–4; (B) 2D NMR correlations of 1.
Compound 2 was isolated as a colorless powder, HRESIMS m/z 235.0532 [M +Na]+(calculated
for C9H12N2O2S, 235.0512); 1H NMR data (600 MHz) δH 7.03 (1H, dd, J = 2.4, 1.4 Hz, H-7), 6.96 (1H,
dd, J = 3.9, 1.3 Hz, H-9), 6.20 (1H, dd, J = 3.8, 2.5 Hz, H-8), 3.13 (2H, t, J = 6.7 Hz, H-4), 3.38 (2H, t,
J = 6.7 Hz, H-3), 1.92 (3H, s, H-1); 13C NMR data (150 MHz, CD3OD) δC 181.9 (C-5), 173.5 (C-2), 131.2
(C-6), 125.7 (C-7), 116.4 (C-9), 111.1 (C-8), 40.7 (C-3), 28.2 (C-4), and 22.5 (C-1) (Figure S6). Compound 2
was proven to be 3-Acetylamino-N-2-thienyl-propanamide by direct comparison of these data with
those from the literature [56].
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Compound 3: 1H NMR data (600 MHz, DMSO-d6) δH 8.37 (1H, s, H-8), 8.21 (1H, s, H-2), 5.90
(1H, d, J = 5.9 Hz, H-1′), 4.55 (2H, t, J = 5.4 Hz, H-2′), 4.14 (1H, m, H-3′), 3.95 (1H, q, J = 3.3 Hz, H-4′),
3.67 (1H, dd, J = 12.1, 3.5 Hz, H-5′), 3.55 (1H, dd, J = 12.1, 3.5 Hz, H-5′); 13C NMR data (150 MHz,
DMSO-d6) δC 154.3 (C-6), 151.7 (C-2), 149.9 (C-4), 138.6 (C-8), 119.8 (C-5), 87.8 (C-1′), 85.8 (C-4′), 73.6
(C-2′), 70.5 (C-3′), and 61.6 (C-5′) (Figure S7). Compound 3 was proven to be ß-adenosine by direct
comparison of these data with those from the literature [57].
Compound 4: 1H NMR data (400 MHz, CD3OD) δH 6.94 (1H, s, H-4), 6.85 (1H, d, J = 2.7 Hz, H-2),
6.18 (1H, m, H-3); 13C NMR (100 MHz, CD3OD) δC164.6 (C-6), 124.4 (C-2), 124.1 (C-5), 116.6 (C-4), and
110.6 (C-3) (Figure S8). Compound 4 was proven to be 2-minaline by direct comparison of these data
with those from the literature [58].
3.5. Mining the Biosynthetic Potential of the Strain
All the compounds were evaluated for their antifungal activity, which showed no significant
inhibitory activity. In order to further discover the biosynthetic potential of the strain, we performed
draft genome sequencing analysis. AntiSMASH analysis led to the identification of 38 putative
gene clusters in the genome of strain NEAU-H2T. Eleven clusters were identified belonging to a
family of polyketide synthases (PKSs), including four type I PKSs, one type II PKS, and three type III
PKSs. Likewise, further genome sequence analysis revealed eight additional gene clusters comprising
modular enzyme coding genes, such as non-ribosomal peptide synthetase (NRPS, four clusters) and
hybrid PKS-NRPS genes (four clusters). Other gene clusters included seven terpene gene clusters,
three bacteriocin gene clusters, two siderophore gene clusters, one lanthipeptide gene cluster, one
lassopeptide gene cluster, one melanin gene cluster, one ectoine gene cluster, and three butyrolactone
gene clusters.
The important feature of NRPs is their ability to use nonproteinogenic amino acids as building
blocks. By using such building blocks, NRPSs are able to produce peptides with diverse structures and
bioactivities. As such, many NRPSs have been developed into pharmaceuticals, such as vancomycin,
daptomycin, and β-lactam [59].
However, only a few metabolites were isolated and identified in culture broth under laboratory
conditions from strain NEAU-H2T. One answer is that most biosynthetic gene clusters of secondary
metabolites are cryptic in culture broth under conventional laboratory culture conditions [60].
In addition, an active ingredient has not been isolated, possibly due to the low production of these
metabolites under our culture conditions.
One of the secondary metabolite biosynthetic gene clusters of strain NEAU-H2T shows a 63%
similarity to the biosynthetic gene cluster of natamycin, which is a 26-membered polyene macrolide
antifungal agent produced by Streptomyces chattanoogensis L10, and the macrolide core was synthesized
by five PKSs (ScnS0, ScnS1, ScnS2, ScnS3, and ScnS4) in turn [61]. Natamycin is currently widely
used as an antifungal agent in human therapy and the food industry [62]. However, considering
the poor quality of the genome sequence, with a large number of contigs, this may not be related
to the antifungal active components identified with antibiotics and secondary metabolite analysis
shell–antiSMASH. In the following research, we will focus on the study of secondary metabolites
using activity tracking, amplification fermentation, and other approaches involving modification of
the nutrient conditions in the medium and the genetic recombination of biosynthetic gene clusters.
4. Conclusions
A novel strain, NEAU-H2T, with antifungal activity was isolated from the rhizosphere soil of
wheat (Triticum aestivum L.). Four compounds, including one new compound, along with three
known congeners (3-Acetylamino-N-2-thienyl-propanamide, β-adenosine, 2-minaline), were isolated.
Morphological and chemotaxonomic features together with phylogenetic analysis and genomes
suggested that strain NEAU-H2T belonged to the genus Streptomyces. Cultural and biochemical
characteristics combined with DNA–DNA relatedness values clearly revealed that strain NEAU-H2T
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was differentiated from its closely related strains. Based on the polyphasic taxonomic analysis, it is
suggested that strain NEAU-H2T represents a novel species of the genus Streptomyces, for which the
name Streptomyces triticiradicis sp. nov. is proposed. The type strain is NEAU-H2T (=CCTCC AA
2018031T = DSM 109825T).
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Abstract: Much recent interest has arisen in investigating Streptomyces isolates derived from the marine
environment in the search for new bioactive compounds, particularly those found in association with
marine invertebrates, such as sponges. Among these new compounds recently identified from marine
Streptomyces isolates are the octapeptidic surugamides, which have been shown to possess anticancer
and antifungal activities. By employing genome mining followed by an one strain many compounds
(OSMAC)-based approach, we have identified the previously unreported capability of a marine
sponge-derived isolate, namely Streptomyces sp. SM17, to produce surugamide A. Phylogenomics
analyses provided novel insights on the distribution and conservation of the surugamides biosynthetic
gene cluster (sur BGC) and suggested a closer relatedness between marine-derived sur BGCs than
their terrestrially derived counterparts. Subsequent analysis showed differential production of
surugamide A when comparing the closely related marine and terrestrial isolates, namely Streptomyces
sp. SM17 and Streptomyces albidoflavus J1074. SM17 produced higher levels of surugamide A than
S. albidoflavus J1074 under all conditions tested, and in particular producing >13-fold higher levels
when grown in YD and 3-fold higher levels in SYP-NaCl medium. In addition, surugamide A
production was repressed in TSB and YD medium, suggesting that carbon catabolite repression (CCR)
may influence the production of surugamides in these strains.
Keywords: genome mining; OSMAC; phylogenomics; secondary metabolites; surugamides;
surugamide A; marine sponge-associated bacteria; Streptomyces; albidoflavus phylogroup
1. Introduction
Members of the Streptomyces genus are widely known to be prolific producers of natural products.
Many of these compounds have found widespread use in the pharmaceutical industry as antibiotics,
immunosuppressant, antifungal, anticancer, and anti-parasitic drugs [1]. However, there continues to
be an urgent need to discover new bioactive compounds, and especially antibiotics, primarily due to
the emergence of antibiotic resistance in clinically important bacterial pathogens [2,3]. In particular,
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the increase in multi-resistant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) has focused
research efforts to develop new antibiotics to treat these priority antibiotic-resistant bacteria [4].
Up until relatively recently, marine ecosystems had largely been neglected as a potential source for
the discovery of novel bioactive compounds, in comparison to terrestrial environments, primarily due
to issues of accessibility [5]. Marine sponges are known to host a variety of different bacteria and
fungi, which produce a diverse range of natural products, including compounds with antiviral,
antifungal, antiprotozoal, antibacterial, and anticancer activities [5,6]. Marine sponge-associated
Streptomyces spp. are a particularly important source of bioactive compounds, with examples including
Streptomyces sp. HB202, isolated from the sponge Halichondria panicea, which produces mayamycin,
a compound with activity against Staphylococcus aureus [7]; and streptophenazines G and K, with activity
against Bacillus subtilis [8]; together with Streptomyces sp. MAPS15, which was isolated from Spongia
officinalis, which produces 2-pyrrolidine, with activity against Klebsiella pneumoniae [9]. Additionally,
our group has reported the production of antimycins from Streptomyces sp. SM8 isolated from
the sponge Haliclona simulans, with antifungal and antibacterial activities [10,11]. In further work,
we genetically characterised 13 Streptomyces spp. that were isolated from both shallow and deep-sea
sponges, which displayed antimicrobial activities against a number of clinically relevant bacterial and
yeast species [12,13]. Amongst these strains, the Streptomyces sp. SM17 demonstrated an ability to
inhibit the growth of E. coli NCIMB 12210, methicillin-resistant S. aureus (MRSA), and Candida spp.,
when employing deferred antagonism assays [12,13].
Among other clinically relevant natural products derived from marine Streptomyces isolates
are the recently identified surugamides family of molecules. The cyclic octapeptide surugamide A
and its derivatives were originally identified in the marine-derived Streptomyces sp. JAMM992 [14],
and have been shown to belong to a particularly interesting family of compounds due not only to their
relevant bioactivity, but also due to their unusual metabolic pathway involving D-amino acids [14–16].
Since their discovery, concerted efforts have been employed in order to chemically characterise
these compounds and determine the genetic mechanisms involved in their production [14,15,17–20].
The surugamides and their derivatives have been shown to possess a number of bioactivities, with the
surugamides A–E and the surugamides G–J being shown to possess anticancer activity by inhibiting
bovine cathepsin B, a cysteine protease reported to be involved in the invasion of metastatic tumour
cells [14,16]; while another derivative, namely acyl-surugamide A, has been shown to possess
anti-fungal activity [16]. It has been determined that the non-ribosomal peptide synthase-encoding
surABCD genes are the main biosynthetic genes involved in the biosynthesis of surugamides and
their derivatives [19], with these genes being involved in the production of at least 20 different
compounds [16]. Surugamides A–E have been reported to be produced by the surA and surD genes,
while the linear decapeptide surugamide F has been shown to be produced by the surB and surC genes,
involving a unique pattern of intercalation of the biosynthetic genes [19]. Further metabolic pathways
studies have reported that the expression of the surABCD gene cluster is strongly regulated by the
surR transcriptional repressor [16], while the cyclisation of the cyclic surugamides has been shown to
involve a penicillin binding protein (PBP)-like thioesterase encoded by the surE gene [17,18,21].
Although apparently widespread in marine-derived Streptomyces isolates [18,19], the production
of surugamides has also been reported in the S. albidoflavus strain J1074 [16,22], a derivative of the
soil isolate S. albus G [23,24]. The S. albidoflavus strain J1074 is a well-characterised Streptomyces
isolate, which is frequently used as a model for the genus and has commonly been successfully
employed in the heterologous expression of biosynthetic gene clusters (BGCs) [25–29]. This strain was
originally classified as an S. albus isolate, however, due to more recent taxonomy studies, it has been
reclassified as a S. albidoflavus species isolate [30,31]. Interestingly, surugamides and their derivatives
have been shown to only be produced by S. albidoflavus J1074 under specific conditions, such as
when employing chemical stress elicitors [16], and more recently when cultivating the strain in a
soytone-based liquid-based medium SG2 [22].
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In a previous study [32], we reported that the S. albidoflavus J1074 and Streptomyces sp.
SM17 possessed morphological and genetic similarities. Differences were observed, however, when both
strains were exposed to high salt concentrations using culture media, such as TSB or ISP2, in which
the marine sponge-derived strain SM17 grew and differentiated more rapidly in comparison with
the soil strain S. albidoflavus J1074, which appeared to have trouble growing and differentiating when
salts were present in the growth medium [32]. Genome mining based on the prediction of secondary
metabolites BGCs also showed many similarities between the two strains [32]. Among these predicted
BGCs, both the S. albidoflavus J1074 and Streptomyces sp. SM17 isolates appeared to possess the sur BGC,
encoding for the production of surugamides A/D. Due to the fact that marine-derived Streptomyces
isolates have been shown to produce good levels of surugamides when grown under standard
conditions [18,19], and that production of surugamides and derivatives can be induced in the presence
of chemical stress elicitors in S. albidoflavus J1074 [16], it appears likely that marine-derived Streptomyces
isolates and their sur BGCs could share genetic similarities that might help to optimise production of
the compound. To investigate this possibility we 1) employed genome mining approaches together
with phylogenomics in order to better characterise the SM17 strain, and to investigate the distribution
and differences/similarities between marine- (or aquatic saline-) and terrestrial-derived sur BGCs
and sur BGC-harbouring microorganisms; and 2) experimentally compared the metabolic profiles
of surugamide A production between a marine (SM17) and a terrestrial (J1074) Streptomyces isolate.
With respect to the latter, we employed an "one strain many compounds" (OSMAC)-based approach,
which has been shown to be a useful strategy in eliciting production of natural products from silent
gene clusters by employing different culture conditions [33,34]; together with analytical chemistry
methods such as liquid chromatography–mass spectrometry to monitor production of surugamide A
in both S. albidoflavus J1074 and Streptomyces sp. SM17.
2. Materials and Methods
2.1. Bacterial Strains and Nucleotide Sequences
The Streptomyces sp. SM17 strain was isolated from the marine sponge Haliclona simulans, from
the Kilkieran Bay, Galway, Ireland, as previously described [13]. The Streptomyces albidoflavus J1074
strain was provided by Dr Andriy Luzhetskyy (Helmholtz Institute for Pharmaceutical Research
Saarland, Saarbrücken, Germany). Their complete genome sequences are available from the GenBank
database [35] under the accession numbers NZ_CP029338 and NC_020990, for Streptomyces sp. SM17
and S. albidoflavus J1074, respectively. The surugamides biosynthetic gene cluster (sur BGC) sequence
used as a reference for this study was the one previously described in Streptomyces albidoflavus LHW3101
(GenBank accession number: MH070261) [18]. Other genomes used in this study’s analyses were
obtained from the GenBank RefSeq database [35].
2.2. Phylogenetic Analyses
The NCBI BLASTN tool [36,37] was used to determine the closest 30 Streptomyces strains with
complete genome available in the GenBank RefSeq database [35] to the Streptomyces sp. SM17.
Then, phylogeny analysis was performed with the concatenated sequences of the 16S rRNA,
and the housekeeping genes atpD, gyrB, recA, rpoB, and trpB. The sequences were aligned using
the MAFFT program [38], and the phylogeny analysis was performed using the MrBayes program [39].
In MrBayes, the general time reversible (GTR) model of nucleotide substitution was used [40],
with gamma-distributed rates across sites with a proportion of invariable sites, with 1 million
generations sampled every 100 generations. Final consensus phylogenetic tree generated by MrBayes
was processed using MEGA X [41], with a posterior probability cut-off of 95%.
Phylogeny analysis of the surugamides biosynthetic gene cluster (sur BGC) was performed by
using the S. albidoflavus LHW3101 sur BGC nucleotide sequence as reference [18] and searching for
similar sequences on the GenBank RefSeq database using the NCBI BLASTN tool [35–37], only taking
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into account complete genomes. The genome regions with similarity to the S. albidoflavus LHW3101
sur BGC undergone phylogeny analysis using the same aforementioned tools and parameters.
2.3. Prediction of Secondary Metabolites Biosynthetic Gene Clusters
In order to assess the similarities and differences between the Streptomyces isolates belonging to
the albidoflavus phylogroup, in regard to their potential to produce secondary metabolites, BGCs were
predicted in their genomes, using the antiSMASH (version 5 available at https://docs.antismash.
secondarymetabolites.org/) program [42]. The predicted BGCs were then processed using the
BiG-SCAPE program (version 20190604, available at https://git.wageningenur.nl/medema-group/BiG-
SCAPE) [43], with the MiBIG database (version 1.4 available at https://mibig.secondarymetabolites.org/)
as reference [44], and similarity clustering of gene cluster families (GCFs) was performed. The similarity
network was processed using Cytoscape (version 3.7.1, available at https://cytoscape.org/) [45].
2.4. Gene Synteny Analysis
The genome regions previously determined to share similarities with the S. albidoflavus LHW3101
sur BGC were manually annotated, for the known main biosynthetic genes (surABCD), the penicillin
binding protein (PBP)-like peptide cyclase and hydrolase surE gene, and the gene with regulatory
function surR [15–19,21]. This was performed using the UniPro UGENE toolkit (version 1.32.0,
available at http://ugene.net/) [46], the GenBank database, and the NCBI BLASTN tool (available at
https://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed on June 2019) [35–37]. The gene synteny and reading
frame analysis was performed using the UniPro UGENE toolkit [46] and the Artemis genome browser
(version 18.0.0, available at https://www.sanger.ac.uk/science/tools/artemis) [47].
2.5. Diagrams and Figures
All the Venn diagrams presented in this study were generated using the Venn package in R [48,49],
and RStudio [50]. All the images presented in this study were edited using the Inkscape program
(available from https://inkscape.org/).
2.6. Strains Culture, Maintenance, and Secondary Metabolites Production
The same culture media and protocols were employed for both isolates Streptomyces sp. SM17 and
Streptomyces albidoflavus J1074. Glycerol stocks were prepared from spores collected from soya-mannitol
(SM) medium after 8 days of cultivation at 28 ◦C and preserved at −20 ◦C. To verify the secondary
metabolites production profile, spores were cultivated for 7 days on SM agar medium at 28 ◦C, then
pre-inoculated in 5 mL TSB medium, and cultivated at 28 ◦C and 220 rpm for 2 days. Then, 10% (v/v)
of the pre-inoculum was transferred to 30 mL of the following media: TSB; SYP-NaCl (1% starch, 0.4%
yeast extract, 0.2% peptone, and 0.1% NaCl); YD (0.4% yeast extract, 1% malt extract, and 4% dextrin
pH 7.0); P1 (2% glucose, 1% soluble starch, 0.1% meat extract, 0.4% yeast extract, 2.5% soy flour, 0.2%
NaCl, and 0.005% K2HPO4 pH 7.3); P2 (1% glucose, 0.6% glycerol, 0.1% yeast extract, 0.2% malt extract,
0.6% MgCl2.6H2O, 0.03% CaCO3, and 10% sea water); P3 (2.5% soy flour, 0.75% starch, 2.25% glucose,
0.35% yeast extract, 0.05% ZnSO4 × 7H2O, and 0.6% CaCO3 pH 6.0); CH-F2 (2% soy flour, 0.5% yeast
extract, 0.2% CaCO3, 0.05% citric acid, 5% glucose, and pH 7.0); SY (2.5% soluble starch, 1.5% soy flour,
0.2% yeast extract, and 0.4% CaCO3 pH 7.0); Sporulation medium (2% soluble starch and 0.4 yeast
extract); and Oatmeal medium (2% oatmeal). These were cultivated at 28 ◦C and 220 rpm for 4 days in
TSB; and for 8 days in SYP-NaCl, YD, SY, P1, P2, P3, CH-F2, Sporulation, and Oatmeal media. Once
the bioprocess was completed, the broth was frozen at −20 ◦C for further chemical analysis.
2.7. Metabolic Profiling, Compound Isolation, and Chemical Structure Analysis
The Streptomyces broth of TSB, SYP-NaCl, and YD medium cultures (180 mL) was exhaustively
extracted using a solvent mixture of 1:1 MeOH:DCM yielding a crude extract (3.89 g). This crude
120
Microorganisms 2019, 7, 394
extract was first separated using SPE on C18 bonded silica gel (Polygoprep C18 (Fisher Scientific,
Dublin, Ireland) 12%C, 60 Å, 40–63 μm), eluting with varying solvent mixtures to produce five fractions:
H2O (743.62 mg), 1:1 H2O:MeOH (368.6 mg), MeOH (15.4 mg), 1:1 MeOH:DCM (10.9 mg), DCM
(8.2 mg). The final three fractions (MeOH, 1:1 MeOH:DCM, DCM, 34.5 mg) were then combined and
subject to analytical reverse phase HPLC on a Waters Symmetry (VWR, Dublin, Ireland) C18 5 μm,
4.6 × 250 mm column. The column was eluted with 10% MeCN (0.1% TFA)/90% H2O (0.1% TFA) for
5 min, then a linear gradient to 100% MeCN (0.1% TFA) over 21 min was performed. The column
was further eluted with 100% MeCN (0.1% TFA) for 6 min. After the HPLC was complete, a linear
gradient back to 10% MeCN (0.1% TFA)/90% H2O (0.1% TFA) over 1 min and then further elution of
10% MeCN (0.1% FA)/90% H2O (0.1% FA) for 4 min was performed. This yielded pure surugamide A
(0.8 mg). Surugamide A was characterised using MS and NMR data to confirm the structure for use as
an analytical standard.
Surugamide A was quantified in the broth using LC-MS analysis on an Agilent UHR-qTOF 6540
(Agilent Technologies, Cork, Ireland) mass spectrometer. The column used for separation was Waters
equity UPLC BEH (Apex Scientific, Kildare, Ireland) C18 1.7 μm 2.1 × 75 mm. The column was eluted
with 10% MeCN (0.1% FA)/90% H2O (0.1% FA) for 2 min, then a linear gradient to 100% MeCN (0.1%
FA) over 6 min was performed. The column was further eluted with 100% MeCN (0.1% FA) for 4 min.
After the UPLC was complete, a linear gradient back to 10% MeCN (0.1% FA)/90% H2O (0.1% FA) over
1 min and then further elution of 10% MeCN (0.1% FA)/90% H2O (0.1% FA) for 3 min was performed
before the next run. The MS detection method was positive ion. A calibration curve was produce using
the LC-MS method above and injecting the pure surugamide A at seven concentrations (100, 25, 10, 2,
1, 0.2, 0.1 mg/L). Thirty millilitres of each Streptomyces strain in broth were extracted using a solvent
mixture of 1:1 MeOH:DCM three times to yield a crude extract. These extracts were resuspended in
MeOH and filtered through PTFE 0.2 μm filters (Sigma Aldrich, Arklow, Ireland) before being subject
to the above LC-MS method.
The surugamide A calibration standards 1–7 and the six extracts were analysed using the Agilent
MassHunter Quantification software package. This allowed the quantification of surugamide A in
the extracts based on the intensity of peaks in the chromatogram with matching retention time and
exact mass.
3. Results and Discussion
3.1. Multi-locus Sequence Analysis and Taxonomy Assignment of the Streptomyces sp. SM17 Isolate
In order to taxonomically characterise the Streptomyces sp. SM17 isolate based on genetic evidence,
multi-locus sequence analysis (MLSA) [51] employing the 16S rRNA sequence, in addition to five
housekeeping genes, namely atpD (ATP synthase subunit beta), gyrB (DNA gyrase subunit B), recA
(recombinase RecA), rpoB (DNA-directed RNA polymerase subunit beta), and trpB (tryptophan
synthase beta chain) was performed, in a similar manner to a previous report [32]. A similarity search
was performed in the GenBank database [35], using the NCBI BLASTN tool [36,37], based on the 16S
rRNA nucleotide sequence of the SM17 isolate. The top 30 most similar Streptomyces species for which
complete genome sequences were available in GenBank were selected for further phylogenetic analysis.
The concatenated nucleotide sequences [51,52] of the 16S rRNA and the aforementioned five
housekeeping genes, were first aligned using the MAFFT program [38], and the phylogeny analysis was
performed using the MrBayes program [39]. The general time reversible (GTR) model of nucleotide
substitution with gamma-distributed rates across sites with a proportion of invariable sites was
applied [40], with 1 million generations sampled every 100 generations. The final phylogenetic tree
was then processed using MEGA X [41], with a posterior probability cut-off of 95% (Figure 1).
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Figure 1. Phylogenetic tree of the concatenated sequences of the 16S rRNA and the housekeeping
genes atpD, gyrB, recA, rpoB, and trpB, from the Streptomyces sp. SM17 together with 30 Streptomyces
isolates for which complete genome sequences were available in the GenBank database. Analysis was
performed using MrBayes, with a posterior probability cut-off of 95%. 1) albidoflavus phylogroup. 2)
Clade including the neighbour isolate Streptomyces koyangensis strain VK-A60T. The strains SM17 and
J1074 are indicated with asterisks.
The resulting phylogenetic tree clearly indicates the presence of a clade that includes the isolates
Streptomyces albidoflavus strain J1074; Streptomyces sp. SM17; Streptomyces albidoflavus strain SM254;
Streptomyces sampsonii strain KJ40; Streptomyces sp. FR-008; and Streptomyces koyangensis strain VK-A60T
(clade 2 in Figure 1). In addition, this larger clade contains a sub-clade (clade 1 in Figure 1) that
includes Streptomyces isolates similar to the strain Streptomyces albidoflavus J1074. The J1074 strain is a
well-studied Streptomyces isolate widely used as a model for the genus and for various biotechnological
applications, including the heterologous expression of secondary metabolites biosynthetic gene clusters
(BGCs) [25–29]. This isolate was originally classified as “Streptomyces albus J1074”, but due to recent
taxonomy data, it has been reclassified as Streptomyces albidoflavus J1074 [30,31]. Hence, in this study,
this strain will be referred to as Streptomyces albidoflavus J1074, and this clade will from now on be
referred to as the albidoflavus phylogroup (Figure 1).
Interestingly, members of the albidoflavus phylogroup were all isolated from quite different
environments. The Streptomyces albidoflavus strain J1074 stems from the soil isolate Streptomyces albus
G [23,24]. The Streptomyces sampsonii strain KJ40 was isolated from rhizosphere soil in a poplar
plantation [53]. The Streptomyces sp. strain FR-008 is a random protoplast fusion derivative of
two Streptomyces hygroscopicus isolates [54]. On the other hand, two of these strains were isolated
from aquatic saline environments, with Streptomyces sp. SM17 being isolated from the marine
sponge Haliclona simulans [13]; while the Streptomyces albidoflavus strain SM254 strain was isolated
from copper-rich subsurface fluids within an iron mine, following growth on artificial sea water
(ASW) [55]. The fact that these isolates, although derived from quite distinct environmental niches,
simultaneously share significant genetic similarities is interesting, and raises questions about their
potential evolutionary relatedness.
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3.2. Analysis of Groups of Orthologous Genes in the Albidoflavus Phylogroup
In an attempt to provide further genetic evidence with respect to the similarities shared among
the members of the albidoflavus phylogroup (Figure 1), a pan-genome analysis was performed to
determine the number of core genes, accessory genes, and unique genes present in this group of isolates.
The Roary program was employed for this objective [56], which allowed the identification of groups of
orthologous and paralogous genes (which from now on will be referred to simply as “genes”) present
in the set of albidoflavus genomes, with a protein identity cut-off of 95%, which is the identity value
recommended by the Roary program manual when analysing organisms belonging to the same species.
A total of 7565 genes were identified in the albidoflavus pan-genome, and among these a total of
5177 were determined to be shared among all the albidoflavus isolates (i.e., the core genome) (Figure 2).
This represents a remarkably high proportion of genes that appear to be highly conserved between all
the isolates, representing approximately 68.4% of the pan-genome. Additionally, when considering the
genomes individually (Table S1), the core genome accounts for approximately 84.5% of the FR-008
genome; 88.5% of J1074; 85.5% of KJ40; 86.7% of SM17; and 83.7% of the SM254 genome. On the other
hand, the accessory genome (i.e., genes present in at least two isolates) was determined to consist
of 1055 genes (or ~13.9% of the pan-genome); while the unique genome (i.e., genes present in only
one isolate) was determined to consist of 1333 genes (or ~17.6% of the pan-genome). This strikingly
high conservation of genes present in their genomes together with the previous multi-locus phylogeny
analysis are very strong indicators that these microorganisms may belong to the same species.
Figure 2. Venn diagram representing the presence/absence of groups of orthologous genes in the
organisms belonging to the albidoflavus phylogroup.
An additional pan-genome analysis similar to the aforementioned analysis was also performed
including the Streptomyces koyangensis strain VK-A60T in the dataset (Figure S1), which was an
isolate shown to be a closely related neighbour to the albidoflavus phylogroup (Figure 1, clade 2).
When compared to the previous analysis, the pan-genome analysis including the VK-A60T isolate
showed significant changes in the values representing the core genome, which changed from 5177
genes (Figure 2) to 3912 genes (Figure S1), with an additional 1273 genes also shared among all of
the albidoflavus isolates (Figure S1). The results also showed a much larger number of genes uniquely
present in the VK-A60T genome than in the other genomes, with 2059 unique genes identified from
a total of 6245 CDSs present in the VK-A60T genome in total, or approximately a third of its total
number of genes (Figure S1). This proportion of unique genes present in the VK-A60T genome is
considerably higher than the proportions of unique genes observed in the other albidoflavus phylotype
genomes (Figure 2), which accounted for approximately only 2.5% of the total number of genes in
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SM17; 4.2% in J1074; 4.9% in KJ40; 5% in FR-008; and 5.1% in SM254. Taken together, these results
further demonstrate the similarities between the isolates belonging to the albidoflavus phylogroup,
while the VK-A60T isolate is clearly more distantly related.
Thus, from previous studies [30,31] and in light of the phylogeny analysis and further genomic
evidence presented in this study, it is likely that all the isolates belonging to the albidoflavus phylogroup
are in fact members of the same species. It is reasonable to infer that, for example, the isolates in the
albidoflavus phylogroup that possess no species assignment thus far (i.e., strains SM17 and FR-008) are
indeed members of the albidoflavus species. Also, it is possible that the Streptomyces sampsonii KJ40 has
been misassigned, and possibly requires reclassification as an albidoflavus isolate.
Misassignment and reclassification of Streptomyces species is a common issue, and an increase
in the quantity and the quality of available data from these organisms (e.g., better-quality genomes
available in the databases) will provide better support for taxonomy claims, or correction of these
when new information becomes available [31,57–59].
3.3. Prediction of Secondary Metabolites Biosynthetic Gene Clusters in the Albidoflavus Phylogroup
Isolates belonging to the albidoflavus phylogroup have been reported to produce bioactive
compounds of pharmacological relevance, such as antibiotics. As mentioned previously, the Streptomyces
albidoflavus strain J1074 is the best described member of the albidoflavus phylogroup to date.
As such, several of secondary metabolites produced by this isolate have been identified, including
acyl-surugamides and surugamides with antifungal and anticancer activities, respectively [16]; together
with paulomycin derivatives with antibacterial activity [60]. The Streptomyces sp. FR-008 isolate has
been shown to produce the antimicrobial compound FR-008/candicidin [61,62]; while the Streptomyces
sampsonii KJ40 isolate has been shown to produce a chitinase that possesses anti-fungal activity against
plant pathogens [53]. On the other hand, although no bioactive compounds have been characterised
from Streptomyces albidoflavus SM254, this isolate has been shown to possess anti-fungal activity,
specifically against the fungal bat pathogen Pseudogymnoascus destructans, which is responsible for
the White-nose Syndrome [55,63]. The Streptomyces sp. SM17 isolate has also previously been shown
to possess antibacterial and antifungal activities against clinically relevant pathogens, including
methicillin-resistant Staphylococcus aureus (MRSA) [13]. However, no natural products derived from
this strain have been identified and isolated until now.
In order to further in silico assess the potential of these albidoflavus phylogroup isolates to produce
secondary metabolites, and also to determine how potentially similar or diverse they are within this
phylogroup, prediction of secondary metabolites biosynthetic gene clusters (BGCs) was performed
using the antiSMASH (version 5) program [42]. The antiSMASH prediction was processed using the
BiG-SCAPE program [43], in order to cluster the BGCs into gene cluster families (GCFs), based on
sequence and Pfam [64] protein families similarity, and also by comparing them to the BGCs available
from the minimum information about a biosynthetic gene cluster (MiBIG) repository [44] (Figure 3).
When compared to known BGCs from the MiBIG database, a significant number of BGCs predicted
to be present in the albidoflavus phylogroup genomes could potentially encode for the production
of novel compounds, including those belonging to the non-ribosomal peptide synthetase (NRPS)
and bacteriocin families of compounds (Figure 3). The presence/absence of homologous BGCs in
the albidoflavus isolates’ genomes was determined using BiG-SCAPE and is represented in Figure 4.
Interestingly, the vast majority of the BGCs predicted in the albidoflavus phylogroup are shared among
all of its members (15 BGCs); while another large portion (8 BGCs) are present in at least two isolates
(Figure 4). Among the five members of the albidoflavus phylogroup, only the J1074 strain and the SM17
strain appeared to possess unique BGCs when compared to the other strains. Three unique BGCs were
predicted to be present in the J1074 genome: a predicted type I polyketide synthase (T1PKS)/NRPS
without significant similarity to the BGCs from the MiBIG database; a predicted bacteriocin, which also
did not show any significant similarity to the BGCs from the MiBIG database; and a BGC predicted to
encode for the production of the antibiotic paulomycin, with similarity to the paulomycin-encoding
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BGCs from Streptomyces paulus and Streptomyces sp. YN86 [65], which has also been experimentally
shown to be produced by the J1074 strain [60]. One BGC predicted to encode a type III polyketide
synthase (T3PKS)—with no significant similarity to the BGCs from the MiBIG database—was also
identified as being unique to the SM17 genome.
Figure 3. Biosynthetic gene clusters (BGCs) similarity clustering using BiG-SCAPE. Singletons, i.e.,
BGCs without significant similarity with the BGCs from the minimum information about a biosynthetic
gene cluster (MiBIG) database or with the BGCs predicted in other genomes, are not represented.
Figure 4. Venn diagram representing BGCs presence/absence in the genomes of the members of the
albidoflavus phylogroup, determined using antiSMASH and BiG-SCAPE.
Importantly, BGCs with similarity to the surugamide A/D BGC from “Streptomyces albus J1074”
(now classified as S. albidoflavus) from the MiBIG database [16] were identified in all the other genomes
of the members of the albidoflavus phylogroup. This raises the possibility that this BGC may be
commonly present in albidoflavus species isolates. However, as only a few complete genomes of isolates
belonging to this phylogroup are currently available, further data will be required to support this
hypothesis. Nevertheless, these results further highlight the genetic similarities of the isolates belonging
to the albidoflavus phylogroup, even with respect to their potential to produce secondary metabolites.
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3.4. Phylogeny and Gene Synteny Analysis of Sur BGC Homologs
In parallel to the previous phylogenomics analysis performed with the albidoflavus phylogroup
isolates, sequence similarity and phylogenetic analyses were performed, using the previously described
and experimentally characterised Streptomyces albidoflavus LHW3101 surugamides biosynthetic gene
cluster (sur BGC, GenBank accession number: MH070261) as a reference [18]. The aim was to assess
how widespread in nature the sur BGC might be, and the degree of genetic variation, if any; that might
be present in sur BGCs belonging to different microorganisms.
Nucleotides sequence similarity to the sur BGC was performed in the GenBank database [35],
using the NCBI BLASTN tool [36,37]. It is important to note that, since the quality of the data is crucial
for sequence similarity, homology, and phylogeny inquiries, only complete genome sequences were
employed in this analysis. For this reason, for example, the marine Streptomyces isolate in which
surugamides and derivatives were originally identified, namely Streptomyces sp. JAMM992 [14],
was not included, since its complete genome is not available in the GenBank database.
The sequence similarity analysis identified five microorganisms that possessed homologs to the
sur BGC and had their complete genome sequences available in the GenBank database: Streptomyces
sp. SM17; Streptomyces albidoflavus SM254; Streptomyces sp. FR-008; Streptomyces albidoflavus J1074;
and Streptomyces sampsonii KJ40. Notably, these results overlapped with the isolates belonging to the
previously discussed albidoflavus phylogroup (Figure 1), further highlighting the possibility that the sur
BGC may be commonly present in and potentially exclusive to the albidoflavus species.
Phylogenetic analysis was performed in the genomic regions determined to be homologs to the
Streptomyces albidoflavus LHW3101 sur BGC, using the MrBayes program [39] (Figure 5). Although a
larger number of sequences should ideally be employed in this type of analysis, these results suggest the
possibility of a clade with aquatic saline environment-derived sur BGCs (Figure 5). Thus, these aquatic
saline environment-derived sur BGCs are likely to share more genetic similarities amongst each
other, rather than with those derived from terrestrial environments. Since this analysis took into
consideration the whole genome regions that contained the sur BGCs of each isolate, it is likely that
the similarities and differences present in these regions involve not only coding sequences (CDSs) for
biosynthetic genes and/or transcriptional regulators, but also could include promoter regions and other
intergenic sequences.
Figure 5. Consensus phylogenetic tree of the sur BGC region of the S. albidoflavus LHW3101 reference sur
BGC sequence, plus five Streptomyces isolates determined to have sur BGC homologs, generated using
MrBayes and Mega X, with a 95% posterior probability cut-off. Aquatic saline environment-derived
isolates are highlighted in cyan.
With this in mind, the genomic regions previously determined to share homology with the sur
BGC from S. albidoflavus LHW3101 were further analysed, with respect to the genes present in the
surrounding region, the organisation of the BGCs, together with the overall gene synteny (Figure 6).
Translated CDSs predicted in the region were manually annotated using the NCBI BLASTP tool [36,37],
together with GenBank [35] and the CDD [66] databases. These included the main biosynthetic genes,
namely surABCD, the transcriptional regulator surR, and the thioesterase surE—all of which had
previously been reported to have roles in the biosynthesis of surugamides and their derivatives [15–19]
(Figure 6).
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Figure 6. Gene synteny of the sur BGC region, including the reference sur BGC nucleotide sequence
(LHW3101) and each of the albidoflavus phylogroup genomes. Arrows at different positions represent
genes transcribed in different reading frames.
Interestingly, this result indicated that the gene synteny of the biosynthetic genes as well as
the flanking genes is highly conserved, with the exception to the 3’ flanking region of the BGC
from S. sampsonii KJ40. Notably, even the reading frames of the surE gene and the surABCD genes
are conserved amongst all the genomes. As indicated by the numbers in Figure 6, the 5’ region
in all the genomic regions consisted of: 1) A MbtH-like protein, which have been reported to be
involved in the synthesis of non-ribosomal peptides, antibiotics, and siderophores, in Streptomyces
species [67,68]; 2) a putative ABC transporter, which is a family of proteins with varied biological
functions, including conferring resistance to drugs and other toxic compounds [69,70]; 3) a BcrA family
ABC transporter, which is a family commonly involved in peptide antibiotics resistance [71,72]; 4) a
hypothetical protein; followed by 5) the transcriptional repressor SurR, which has been experimentally
demonstrated to repress the production of surugamides [16]; 6) a hypothetical membrane protein; 7)
the thioesterase SurE, which is homologous to the penicillin binding protein, reported to be responsible
for the cyclisation of surugamides molecules [21]; and finally 8–11) the main surugamides biosynthetic
genes surABCD, all of which encode non-ribosomal peptide synthetase (NRPS) proteins [19]. The 3’
flanking region consisted of: 12) A predicted multi-drug resistance (MDR) transporter belonging
to the major facilitator superfamily (MFS) of membrane transport proteins [73,74]; 13) a predicted
TetR/AcrR transcriptional regulator, which is a family of regulators reported to be involved in antibiotic
resistance [75]; 14) a hypothetical protein; and 15) another predicted MDR transporter belonging to the
MFS superfamily. In contrast, the 3’ flanking region of the KJ40 strain sur BGC, consisted of: 16) A group
of four hypothetical proteins, which may represent pseudogene versions of the first MDR transporter
identified in the other isolates (gene number 12 in Figure 6); 17) a predicted rearrangement hotspot
(RHS) repeat protein, which is a family of proteins reported to be involved in mediating intercellular
competition in bacteria [76]; 18) a hypothetical protein; and 19) a MDR transporter belonging to the
MFS superfamily, which, interestingly, is a homolog of protein number 15, which is present in all the
other isolates.
The conserved gene synteny observed in the sur BGC genomic region, particularly those positioned
upstream of the main biosynthetic surABCD genes, together with the observation that even the reading
frames of the surE and the surABCD genes are conserved among all the genomes analysed, coupled with
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the previous phylogenetic and pan-genome analyses, suggest the following. Firstly, it is very likely that
these strains share a common ancestry and that the sur BGC genes had a common origin. Secondly, there
is a strong evolutionary pressure ensuring the maintenance of not only gene synteny, but also of the
reading frames of the main biosynthetic genes involved in the production of surugamides. The latter
raises the question of which other genes in this region may be involved in the production of these
compounds, or potentially conferring mechanisms of self-resistance to surugamides in the isolates,
particularly since many of the genes have predicted functions that are compatible with the transport
of small molecules and with multi-drug resistance. These observations are particularly interesting
considering that these strains are derived from quite varied environments and geographic locations.
3.5. Growth, Morphology, Phenotype, and Metabolism Assessment of Streptomyces sp. SM17 in Complex Media
In order to assess the metabolic potential of the SM17 strain [77], particularly with respect to
the production of surugamide A, the isolate was cultivated in a number of different growth media,
within an OSMAC-based approach [33,34]. While the SM17 strain was able to grow in SYP-NaCl, YD,
SY, P1, P2, P3, and CH-F2 liquid media, the strain was unable to grow in Oatmeal and Sporulation
media. The latter indicated an inability to metabolise oat and starch when nutrients other than yeast
extract are not present. Morphologically, the SM17 strain formed cell aggregates or pellets in TSB, YD,
and SYP-NaCl, while this differentiation was not observed in the other media. Preliminary chemical
analyses of these samples, employing liquid chromatography–mass spectrometry (UPLC-DAD-HRMS),
indicated that secondary metabolism in SM17 was not very active when the strain was cultivated in SY,
P1, P2, P3, and CH-F2 media. In contrast, significant production of surugamides was evidenced in the
extracts from TSB, SYP-NaCl, and YD media, with characteristic ions at m/z 934.6106 (surugamide A)
and 920.5949 (surugamide B) [M +Na]+, which correlated with the formation of cell pellets and the
production of natural products, as previously described in other Streptomyces strains [77,78].
3.6. Differential Production of Surugamide A by Streptomyces sp. SM17 and S. albidoflavus J1074
To confirm the production of surugamide A by the SM17 isolate, extracts from the TSB, SYP-NaCl,
and YD media were combined and purified using high-performance liquid chromatography (HPLC).
The structures of the major compounds of the extract were subsequently analysed using nuclear
magnetic resonance (NMR) spectroscopy, which allowed for the identification of the chemical
structure of the surugamide A molecule as major metabolite by comparison with reference NMR data
(Figure 7) [14].
Figure 7. Structure of surugamide A isolated from SM17 grown in TSB, SYP-NaCl, and YD medium
with annotated 1H NMR spectrum obtained in CD3OD at 500 MHz.
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The isolates Streptomyces sp. SM17 and S. albidoflavus J1074 were subsequently cultivated in the
aforementioned media in which the SM17 strain had been shown to be metabolically active, namely the
TSB, SYP-NaCl, and YD media. This was performed in order to assess whether there were any
significant differences in the production of surugamide A when different growth media are employed
for the production of this compound, and to compare the levels of surugamide A produced by the
SM17 and the J1074 isolates. The MeOH/DCM (1:1) extracts from the aforementioned cultures of SM17
and J1074 were subjected to liquid chromatography–mass spectrometry (UPLC-HRMS) to quantify
the levels of surugamide A being produced under each condition (Table 1), using a surugamide A
standard calibration curve (Figure S2).
Table 1. Surugamide A production by SM17 and J1074 measured using different media.
Strain Media Percent (w/w) of Extract Concentration of Surugamide A (mg/L)
Corrected in 5 mg/mL of Extract
SM17 TSB 2.44% 122.01
SM17 SYP-NaCl 10.60% 530.15
SM17 YD 1.13% 56.27
J1074 TSB 0.27% 13.32
J1074 SYP-NaCl 3.55% 176.82
J1074 YD 0.09% 4.26
The LC-MS quantification analysis (Table 1) indicated that both strains were capable of producing
surugamide A in all the conditions tested. However, the SM17 strain appeared to produce considerably
higher yields of the compound when compared to J1074, in all the conditions analysed. In addition,
the S. albidoflavus J1074 isolate appeared to produce quite low levels of surugamide A when grown in
TSB and YD media, accounting for less than 1% (w/w) of the extracts from these media. Interestingly,
higher yields of surugamide A were produced in the SYP-NaCl medium in both strains, when compared
with the levels of surugamide A produced by these strains when grown in TSB and the YD media
(Table 1). In the SM17 culture in SYP-NaCl, surugamide A accounted for 10.60% (w/w) of the extract,
compared to 2.44% and 1.13% from TSB and YD, respectively; while in J1074 it accounted for 3.55%
(w/w) of the extract from the SYP-NaCl culture, compared to 0.27% and 0.09% from TSB and YD,
respectively (Table 1). These results provide further insights into factors that are potentially involved
in regulation the biosynthesis of surugamide A, in the albidoflavus phylogroup and in Streptomyces sp.
SM17 in particular.
Firstly, it appears likely that surugamide A biosynthesis may be regulated, at least in part,
by carbon catabolite repression (CCR). Carbon catabolite repression is a well-described regulatory
mechanism in bacteria that controls carbon metabolism [79–82], and which has also been reported to
regulate the biosynthesis of secondary metabolites in a number of different bacterial species, including
in Streptomyces isolates [83–86]. While the TSB and the YD media contain glucose and dextrins as
carbon sources, respectively; the complex polysaccharide starch is the carbon source in the SYP-NaCl
medium. Therefore, it is reasonable to infer that glucose and dextrin may repress the production of
surugamide A in Streptomyces sp. SM17 and in Streptomyces albidoflavus J1074, while starch does not.
Further evidence for this can be found when considering the different production media previously
employed in the production of surugamides by different Streptomyces isolates. For example, in the
original research that led to the discovery of surugamides in Streptomyces sp. JAMM992 [14], the PC-1
medium (1% starch, 1% polypeptone, 1% meat extract, 1% molasses, pH 7.2) was employed for
production of these compounds. Similar to the SYP-NaCl medium employed in our study, the PC-1
medium also contains starch as the carbon source, together with another complex carbon source,
namely molasses. Likewise, for the production of surugamides in S. albidoflavus strain LHW3101 [18],
the TSBY medium (3% tryptone soy broth, 10.3% sucrose, 0.5% yeast extract) was employed, which
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utilises sucrose as its main carbon source. In contrast, when elicitors were employed to induce the
production of surugamides and their derivatives in the J1074 strain [16], by activating the sur BGC,
which appeared to be silent in this isolate, the R4 medium (0.5% glucose, 0.1% yeast extract, among
other non-carbon related components) was employed, which utilises glucose as its main carbon supply,
and, as shown in this study, it potentially represses the production of surugamide A. Thus, from these
previous reports and from our observations, it appears likely that CCR plays an important role in
regulating the biosynthesis of surugamides.
Secondly, it is important to note the presence of salts in the form of NaCl in the SYP-NaCl medium.
As previously mentioned, genetic and phylogenetic analyses of the sur BGC indicated similarities
between those BGCs belonging to aquatic saline-derived Streptomyces isolates (Figure 5), together with
the likelihood that these sur BGCs might have had a common origin. Thus, it is plausible that this
origin may have been marine, and hence the presence of salts in the growth medium may also have an
influence on the biosynthesis of surugamide A. Different concentrations of salts in the form of NaCl in
the culture medium have also previously been shown to impact on the chemical profile of metabolites
produced in the marine-obligate bacteria Salinispora arenicola [87].
Nevertheless, it is interesting to observe that, despite the repression/induction of the biosynthesis
of surugamide A observed when different media were employed, the SM17 isolate clearly produces
considerably higher amounts of surugamide A when compared to S. albidoflavus J1074—reaching yields
up to >13-fold higher in the YD medium, and around 3-fold higher when grown in the SYP-NaCl
medium (Table 1).
4. Conclusions
Marine-derived bacteria, particularly those isolated in association with marine invertebrates,
such as sponges, have been shown to be reservoirs of bioactive molecules, including those with
antibacterial, antifungal, and anticancer activities. Among these newly identified bioactive compounds,
the surugamides and their derivatives are of particular interest due to their clinically relevant
bioactivities, i.e., anticancer and antifungal, and their original metabolic pathway.
Based on genome mining, this study identified the previously unreported capability of the marine
sponge-derived isolate Streptomyces sp. SM17 to produce surugamide A and also sheds new light on
factors such as the carbon catabolite repression (CCR) that may be involved in regulating production
of this molecule. Phylogenomics analysis indicated that the sur BGC is commonly present in members
of the proposed albidoflavus phylogroup, and that the sur BGCs present in different isolates derived
from varied environmental niches may possess a common ancestry. Although high quality genomic
data from this proposed albidoflavus phylogroup are still lacking, results presented here suggest that
the sur BGCs derived from Streptomyces isolated from aquatic saline environment are more similar to
each other, when compared to those isolated from terrestrial environments.
Chemical analysis was performed in order to assess differential production of surugamide A
when comparing a marine Streptomyces isolate with a terrestrial Streptomyces isolate, namely SM17 and
J1074 strains, respectively, following an OSMAC-based approach employing different culture media.
This analysis showed that not only the marine-derived isolate SM17 was capable of producing more
surugamide A when compared to J1074 under all the conditions tested, but also that the biosynthesis
of surugamide A is likely to be influenced by the CCR, and potentially by the presence of salts in
the growth medium. These results also highlight the importance of employing an OSMAC-based
approach even when analysing the production of known compounds, since there is a clear difference
in the yields of surugamide A obtained when employing different culture media. Thus, it is possible to
gain further insights into the production of bacterial types of compounds by 1) discovering strains that
possess a higher capability to produce these compounds; 2) establishing optimal conditions for the
biosynthesis of their production; and 3) providing a better understanding of the genetic and regulatory
mechanisms potentially underpinning the production of these compounds.
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Abstract: Ralstonia solanacearum is a major phytopathogenic bacterium that attacks many crops and
other plants around the world. In this study, a novel actinomycete, designated strain NEAU-SSA
1T, which exhibited antibacterial activity against Ralstonia solanacearum, was isolated from soil
collected from Mount Song and characterized using a polyphasic approach. Morphological and
chemotaxonomic characteristics of the strain coincided with those of the genus Streptomyces. The 16S
rRNA gene sequence analysis showed that the isolate was most closely related to Streptomyces
aureoverticillatus JCM 4347T (97.9%). Phylogenetic analysis based on 16S rRNA gene sequences
indicated that the strain formed a cluster with Streptomyces vastus JCM4524T (97.4%), S. cinereus
DSM43033T (97.2%), S. xiangluensis NEAU-LA29T (97.1%) and S. flaveus JCM3035T (97.1%). The cell
wall contained LL-diaminopimelic acid and the whole-cell hydrolysates were ribose, mannose and
galactose. The polar lipids were diphosphatidylglycerol (DPG), phosphatidylethanolamine (PE),
hydroxy-phosphatidylethanolamine (OH-PE), phosphatidylinositol (PI), two phosphatidylinositol
mannosides (PIMs) and an unidentified phospholipid (PL). The menaquinones were MK-9(H4),
MK-9(H6), and MK-9(H8). The major fatty acids were iso-C17:0, C16:0 and C17:1 ω9c. The DNA
G+C content was 69.9 mol %. However, multilocus sequence analysis (MLSA) based on five other
house-keeping genes (atpD, gyrB, recA, rpoB, and trpB), DNA–DNA relatedness, and physiological and
biochemical data showed that the strain could be distinguished from its closest relatives. Therefore,
it is proposed that strain NEAU-SSA 1T should be classified as representatives of a novel species
of the genus Streptomyces, for which the name Streptomyces sporangiiformans sp. nov. is proposed.
The type strain is NEAU-SSA 1T (=CCTCC AA 2017028T = DSM 105692T).
Keywords: Streptomyces sporangiiformans sp. nov.; antibacterial activity; multilocus sequence analysis;
Ralstonia solanacearum
1. Introduction
Ralstonia solanacearum is the causal agent of bacterial wilt, one of the most devastating plant
pathogenic bacteria around the world [1], which has an unusually wide host range, infecting over
200 plant species [2], including many important agricultural crops such as potato, tomato, banana
and pepper. Even though different approaches have been developed to control bacterial wilt, we
still lack an efficient and environmentally friendly control measure for most of the host crops [3].
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Therefore, the search and discovery of novel, environmentally friendly, commercially significant,
naturally bioactive compounds are in demand to control this disease at present.
The actinobacteria are known to produce biologically active secondary metabolites, including
antibiotics, enzymes, enzyme inhibitors, antitumour agents and antibacterial compounds [4–6].
The genus Streptomyces, within the family Streptomycetaceae, is the largest genus of the phylum
Actinobacteria, first proposed by Waksman and Henrici (1943) [7] and currently encompasses more
than 800 species with valid published names (http://www.bacterio.net/streptomyces.html), which are
widely distributed in soils throughout the world. Therefore, members of novel Streptomyces species
are in demand as sources of novel, environmentally friendly, commercially significant, naturally
bioactive compounds [8,9]. During our search for antagonistic actinobacteria from soil in Mount
Song, an aerobic actinomycete, strain NEAU-SSA 1T with inhibitory activity against phytopathogenic
bacterium Ralstonia solanacearum was isolated and subjected to the polyphasic taxonomy analysis.
Results demonstrated that the strain represents a novel species of the genus Streptomyces, for which the
name Streptomyces sporangiiformans sp. nov. is proposed.
2. Materials and Methods
2.1. Isolation of Actinomycete Strain
Strain NEAU-SSA 1T was isolated from soil collected from Mount Song (34◦29′ N, 113◦2′ E),
Dengfeng, Henan Province, China. The soil sample was air-dried at room temperature for 14 days
before isolation for actinomycetes. After drying, the soil sample was ground into powder and then
suspended in sterile distilled water, followed by a standard serial dilution technique. The diluted
soil suspension was spread on humic acid-vitamin agar (HV) [10] supplemented with cycloheximide
(50 mg L−1) and nalidixic acid (20 mg L−1). After 28 days of aerobic incubation at 28 ◦C, colonies were
transferred and purified on the International Streptomyces Project (ISP) medium 3 [11], and maintained
as glycerol suspensions (20%, v/v) at −80 ◦C for long-term preservation.
2.2. Morphological and Physiological and Biochemical Characteristics of NEAU-SSA 1T
Gram staining was carried out by using the standard Gram stain, and morphological characteristics
were observed using light microscopy (Nikon ECLIPSE E200, Nikon Corporation, Tokyo, Japan) and
scanning electron microscopy (Hitachi SU8010, Hitachi Co., Tokyo, Japan) using cultures grown
on ISP 3 agar at 28 ◦C for 6 weeks. Samples for scanning electron microscopy were prepared as
described by Jin et al. [12]. Cultural characteristics were determined on the ISP 1 agar [11], ISP media
2–7 [8], Czapek’s agar [13], Bennett’s agar [14], and Nutrient agar [15] after 14 days at 28 ◦C. Color
determination was done with color chips from the ISCC-NBS (Inter-Society Color Council-National
Bureau of Standards) color charts [16]. Growth at different temperatures (10, 15, 20, 25, 28, 32, 35,
40, 45, and 50 ◦C) was determined on ISP 3 medium after incubation for 14 days. Growth tests for
pH range (pH 4.0–12.0, at intervals of 1.0 pH unit) and NaCl tolerance (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
15, and 20%, w/v) were tested in GY (Glucose-Yeast extract) medium [17] at 28 ◦C for 14 days on a
rotary shaker. The buffer systems were: pH 4.0–5.0, 0.1 M citric acid/0.1 M sodium citrate; pH 6.0–8.0,
0.1 M KH2PO4/0.1 M NaOH; pH 9.0–10.0, 0.1 M NaHCO3/0.1 M Na2CO3; and pH 11.0–12.0, 0.2 M
KH2PO4/0.1 M NaOH. Hydrolysis of Tweens (20, 40, and 80) and production of urease were tested as
described by Smibert and Krieg [18]. The utilization of sole carbon and nitrogen sources, decomposition
of cellulose, hydrolysis of starch and aesculin, reduction of nitrate, coagulation and peptonization of
milk, liquefaction of gelatin, and production of H2S were examined as described previously [19,20].
2.3. Chemotaxonomic Analysis of NEAU-SSA 1T
Biomass for chemotaxonomic studies was prepared by growing the organisms in GY medium
in shake flasks at 28 ◦C for 5 days. Cells were harvested using centrifugation, washed with distilled
water, and freeze-dried. The isomer of diaminopimelic acid (DPA) in the cell wall hydrolysates was
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derivatized and analyzed using an HPLC (High Performance Liquid Chromatography) method [21]
with an Agilent TC-C18 Column (250 × 4.6 mm i.d. 5 μm; Agilent Technologies, Santa Clara, CA, USA)
that had a mobile phase consisting of acetonitrile: 0.05 mol L−1 phosphate buffer pH 7.2 (15:85, v/v)
at a flow rate of 0.5 mL min−1. The peak detection used an Agilent G1321A fluorescence detector
(Agilent Technologies, Santa Clara, CA, USA) with a 365 nm excitation and 455 nm longpass emission
filters. The whole-cell sugars were analyzed according to the procedures developed by Lechevalier
and Lechevalier [22]. The polar lipids were examined using two-dimensional TLC (Thin-Layer
Chromatography) and identified using the method of Minnikin et al. [23]. Menaquinones were
extracted from the freeze-dried biomass and purified according to Collins [24]. Extracts were analyzed
using a HPLC-UV method [25] with an Agilent Extend-C18 Column (150 × 4.6 mm, i.d. 5 μm; Agilent
Technologies, Santa Clara, CA, USA) at 270 nm. The mobile phase was acetonitrile-iso-propyl alcohol
(60:40, v/v). To determine cellular fatty acid compositions, the strain NEAU-SSA 1T was cultivated
in GY medium in shake flasks at 28 ◦C for 4 days. Fatty acid methyl esters were extracted from
the biomass as described by Gao et al. [26] and analyzed using GC-MS according to the method of
Xiang et al. [27].
2.4. Phylogenetic Analysis of NEAU-SSA 1T
For DNA extraction, strain NEAU-SSA 1T was cultured in GY medium for 3 days to the early
stationary phase and harvested using centrifugation. The chromosomal DNA was extracted according
to the method of sodium dodecyl sulfate (SDS)-based DNA extraction [28]. PCR amplification
of the 16S rRNA gene sequence was carried out using the universal bacterial primers 27F
(5′-AGAGTTTGATCCTGGCTCAG-3´) and 1541R (5´-AAGGAGGTGATCCAGCC-3´) under conditions
described previously [29,30]. The PCR product was purified and cloned into the vector pMD19-T
(Takara) and sequenced using an Applied Biosystems DNA sequencer (model 3730XL, Applied
Biosystems Inc., Foster City, California, USA). The almost complete 16S rRNA gene sequence of strain
NEAU-SSA 1T (1412bp) was obtained and compared with type strains available at the EzBioCloud
server (https://www.ezbiocloud.net/), retrieved using NCBI BLAST (National Center for Biotechnology
Information, Basic Local Alignment Search Tool; https://blast.ncbi.nlm.nih.gov/Blast.cgi;) and then
submitted to the GenBank database. Phylogenetic trees were constructed based on the 16S rRNA
gene sequences of strain NEAU-SSA 1T and related reference species. Sequences were multiply
aligned in Molecular Evolutionary Genetics Analysis (MEGA) software version 7.0 using the Clustal
W algorithm and trimmed manually where necessary. Phylogenetic trees were constructed with
neighbor-joining [31] and maximum likelihood [32] algorithms using MEGA [33]. The stability of the
topology of the phylogenetic tree was assessed using the bootstrap method with 1000 repetitions [34].
A distance matrix was generated using Kimura’s two-parameter model [35]. All positions containing
gaps and missing data were eliminated from the dataset (complete deletion option). 16S rRNA
gene sequence similarities between strains were calculated on the basis of pairwise alignment using
the EzBioCloud server [36]. To further clarify the affiliation of strain NEAU-SSA 1T to its closely
related strains, phylogenetic relationships of the strain NEAU-SSA 1T were also confirmed using
sequences of five individual housekeeping genes (atpD, gyrB, recA, rpoB, and trpB) for core-genome
analysis. The sequences of NEAU-SSA 1T and its related strains were obtained from the genomes or
GenBank/EMBL/DDBJ (European Molecular Biology Laboratory/DNA Data Bank of Japan). GenBank
accession numbers of the sequences used are given in Table 1. The sequences of each locus were
aligned using MEGA 7.0 software and trimmed manually at the same position before being used for
further analysis. Trimmed sequences of the five housekeeping genes were concatenated head-to-tail
in-frame in the order atpD-gyrB-recA-rpoB-trpB. Phylogenetic analysis was performed as described
above. Genome mining for bioactive secondary metabolites was performed using “antibiotics and
secondary metabolite analysis shell” (antiSMASH) version 4.0 [37].
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2.5. Draft Genome Sequencing and Assembly of NEAU-SSA 1T
For draft genome sequencing and assembly, the genomic DNA of strain NEAU-SSA 1T was
extracted using the method of SDS-based DNA extraction [28]. The harvested DNA was detected
using agarose gel electrophoresis and quantified using Qubit® 2.0 Fluorometer (Thermo Scientific).
Whole-genome sequencing was performed on the Illumina HiSeq PE150 (Illumina, San Diego, CA, USA)
platform. A-tailed, ligated to paired-end adaptors, and PCR amplified samples with a 350 bp insert
were used for the library construction at the Beijing Novogene Bioinformatics Technology Co., Ltd.
Illumina PCR adapter reads and low-quality reads from the paired-end were filtered using a quality
control step using our own compling pipeline. All good-quality paired reads were assembled using the
SOAP (Short Oligonucleotide Alignment Program) denovo [38,39] (https://github.com/aquaskyline)
into a number of scaffolds. Then, the filter reads were handled by the next step of the gap-closing.
2.6. DNA–DNA Relatedness Tests
Because of a lacking number of genome sequences of Streptomyces aureoverticillatus JCM4347T,
Streptomyces vastus JCM4524T, S. cinereus DSM43033T, and S. xiangluensis NEAU-LA29T, DNA–DNA
relatedness tests between strain NEAU-SSA 1T and those strains were carried out as described by De
Ley et al. [40] under consideration of the modifications described by Huss et al. [41], using a model
Cary 100 Bio UV/VIS-spectrophotometer (Hitachi U-3900, Hitachi Co., Tokyo, Japan) equipped with a
Peltier-thermostatted 6× 6 multicell changer and a temperature controller with in situ temperature probe
(Varian). The genomic DNAs of strain NEAU-SSA 1T and its closely related species—S. aureoverticillatus
JCM4347T, S. vastus JCM4524T, S. cinereus DSM43033T, and S. xiangluensis NEAU-LA29T—were
extracted using the method of SDS-based DNA extraction [28]. The concentration and purity of
these DNA samples were determined by measuring the optical density (OD) at 260, 280, and 230 nm.
The DNA samples used for hybridization were diluted to OD260 around 1.0 using 0.1 × SSC (saline
sodium citrate buffer), then sheared using a JY92-II ultrasonic cell disruptor (ultrasonic time 3 s, interval
time 4 s, 90 times; Ningbo Scientz Biotechnology Co., Ltd, Ningbo, China). The DNA renaturation rates
were determined in 2 × SSC at 70 ◦C. The experiments were performed with three replications and the
DNA–DNA relatedness value was expressed as a mean of the three values. Several genomic metrics
are now available to distinguish between orthologous genes of closely related prokaryotes, including
the calculation of average nucleotide identity (ANI) and digital DNA–DNA hybridization (dDDH)
values [42,43]. In the present study, ANI and dDDH values were determined from the genomes of
strain NEAU-SSA 1T and S. flaveus JCM3035T (JOCU00000000) using the ortho-ANIu algorithm from
Ezbiotaxon and the genome-to-genome distance calculator (GGDC 2.0) at http://ggdc.dsmz.de.
2.7. In Vitro Antibacterial Activity Test
The antibacterial activity of strain NEAU-SSA 1T against two pathogenic bacteria (Micrococcus
luteus and Ralstonia solanacearum) was evaluated using the agar well diffusion method [44] with the
cultures growth on ISP 3 medium at 28 ◦C for four weeks as follows: All the spores and mycelia
were collected from one ISP 3 plate (diameter, 9mm) and then extracted using 1 mL methanol with an
ultrasonic step (300 W, 30–60 min). Afterwards, 200 μL methanol extract or methanol was added to the
agar well, and methanol was used as the control. To further investigate the antibacterial components
produced by NEAU-SSA 1T, the strain was cultured in tryptone-glucose-soluble starch-yeast extract
medium (tryptone 0.2%, glucose 1%, soluble starch 0.5%, yeast extract 0.2%, NaCl 0.4%, K2HPO4 0.05%,
MgSO4.7H2O 0.05%, CaCO3 0.2%, w/v, pH 7.0–7.4), and the inhibitory activity was tested. Briefly,
strain NEAU-SSA 1T was inoculated into MB medium and incubated at 28 ◦C for seven days in a
rotary shaker. The supernatant (100 mL for this study) was obtained via centrifugation at 8000 rpm
and 4 ◦C for 10 min and subsequently extracted by using an equal volume of ethyl acetate. Then,
the extract was dried in a rotary evaporator at 40 ◦C and eluted with proper volume methanol (1 mL
used in this study). The cell precipitate was extracted with an equal volume of methanol and also
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condensed as above. After that, the antibacterial activity was evaluated using the agar well diffusion
method, and each well contained 200 μL of the methanol extract. To examine the effect of temperature
on antibacterial activity, the ten-fold dilution methanol extract was placed in a water bath at 40, 60, 80,
and 100 ◦C for 30 min, and then cooled to room temperature. The antibacterial activity was evaluated
using the agar well diffusion method.
3. Result and Discussion
3.1. Polyphasic Taxonomic Characterization of NEAU-SSA 1T
The morphological characteristics of strain NEAU-SSA 1T showed that the strain had the typical
characteristics of the genus Streptomyces. Observation of 6-week cultures of strain NEAU-SSA 1T
grown on ISP 3 medium revealed that it formed well-developed, branched substrate hyphae and aerial
mycelia. Sporangia consisted of cylindrical, and rough-surfaced spores (0.6–0.8 μm × 0.9–1.6 μm)
were produced on aerial mycelia, but spore chains were not observed (Figure 1). Strain NEAU-SSA 1T
exhibited good growth on ISP 3, ISP 4, ISP 7, and Nutrient agar media; moderate growth on ISP 1,
ISP 2, ISP 5, ISP 6, and Czapek’s agar media; and poor growth on Bennett’s agar medium. The cultural
characteristics of strain NEAU-SSA 1T is shown in Table S1. Strain NEAU-SSA 1T grew well between
pH 6.0 and 11.0, with an optimum pH of 7.0. The range of temperature of the strain was determined
to be 15–45 ◦C, with the optimum growth temperature being 28 ◦C. The strain grew in the presence
of 0–6% NaCl (w/v) with an optimal level of 0–1% (w/v). Detailed physiological characteristics are
presented in the species description (Table 2 and Table S1).
 
Figure 1. Scanning electron micrograph of strain NEAU-SSA 1T grown on ISP 3 agar for 6 weeks at
28 ◦C; Scale bar represents 1 μm.
Chemotaxonomic analyses revealed that strain NEAU-SSA 1T exhibited characteristics that are
typical of representatives of the genus Streptomyces. The strain was found to contain LL-diaminopimelic
acid as diamino acid. The whole-cell hydrolysates of the strain were determined to contain ribose,
mannose, and galactose. The menaquinones of strain NEAU-SSA 1T were MK-9(H4) (29.5%), MK-9(H6)
(41.2%), and MK-9(H8) (29.4%). The cellular fatty acid profile of strain NEAU-SSA 1T was composed
of iso-C17:0 (30.9%), C16:0 (26.4%), C17:1ω9c (19.9%), C15:0 (7.8%), C17:0 (4.4%), C14:0 (3.3%), iso-C16:0
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(1.7%), anteiso-C15:0 (1.7%), C18:1ω9c (1.7%), C16:0 1-OH (1.2%), and iso-C18:0 (1.1%). The polar
lipids of the strain consisted of diphosphatidylglycerol (DPG), phosphatidylethanolamine (PE),
hydroxy-phosphatidylethanolamine (OH-PE), phosphatidylinositol (PI), two phosphatidylinositol
mannosides (PIMs), and an unidentified phospholipid (PL) (Supplementary Figure S1). All the
chemotaxonomic data are consistent with the assignment of strain NEAU-SSA 1T to the genus
Streptomyces.
Table 2. Differential characteristics of strain NEAU-SSA 1T, S. aureoverticillatus JCM 4347T, S. vastus
JCM4524T, S. cinereus DSM43033T, S. xiangluensis NEAU-LA29T, and S. flaveus JCM3035T.
Characteristic 1 2 3 4 5 6a
Decomposition of cellulose + – – – + ND
Production of H2S – – – – – +
Tween 20 – + – – – ND
Tween 40 + + – – + ND
Tween 80 + + – – + ND
Liquefaction of gelatin + – – – – ND
Growth temperature (°C) 15–45 10–45 20–40 20–40 20–40 10–37
pH range for growth 6–11 5–12 6–10 6–9 6–9 ND
NaCl tolerance range (w/v, %) 0–6 0–15 0–5 0–5 0–6 0–7
Carbon source utilization
D-fructose + + – – + +
D-galactose + + – – + +
Lactose + + – – + +
D-maltose + + – – + ND
L-rhamnose + + – + + +
D-ribose – + – – – –
D-sorbitol – + – + – ND
D-mannose + + + – + +
Raffinose + + + – + +
L-arabinose – – – – – +
D-xylose – – – – – +
Myo-inositol + + + – + +
Nitrogen source utilization
L-glutamine + + – – + ND
Glycine – + + + – ND
L-threonine + + – – – +
L-tyrosine – – – + + ND
L-arginine + + + + – +
L-asparagine + + + + – ND
L-serine + + + + – +
L-proline + + + + – –
Strains: 1—NEAU-SSA 1T; 2—S. aureoverticillatus JCM 4347T; 3—S. vastus JCM4524T; 4—S. cinereus DSM43033T;
5—S. xiangluensis NEAU-LA29T; 6—S. flaveus JCM3035T. Abbreviation: +, positive; –, negative. All data are from
this study except where marked. a Data from Michael Goodfellow et al. [45].
Sequence analysis of the 16S rRNA gene showed that strain NEAU-SSA 1T were affiliated
with the genus Streptomyces and most closely related to S. aureoverticillatus JCM 4347T (97.9%).
Phylogenetic analysis based on 16S rRNA gene sequences indicated that the strain formed a cluster
with S. vastus JCM4524T (97.4%), S. cinereus DSM43033T (97.2%), S. xiangluensis NEAU-LA29T (97.1%),
and S. flaveus JCM3035T (97.1%) in the neighbor-joining tree (Figure 2), a relationship also recovered
by the maximum-likelihood algorithm (Figure S2). Phylogenetic trees based on the neighbor-joining
and maximum-likelihood algorithms were constructed from the concatenated sequence alignment of
the five housekeeping genes (Figure 3 and Figure S3), and had the same topology as the 16S rRNA
gene tree. Moreover, pairwise distances calculated for NEAU-SSA 1T and the related species using
the concatenated sequences of atpD-gyrB-recA-rpoB-trpB were well above 0.007 (Table S2), which is
considered to be the threshold for species determination by Rong et al. [46]. DNA–DNA hybridization
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was employed to further clarify the relatedness between the strain and S. aureoverticillatus JCM 4347T,
S. vastus JCM4524T, S. cinereus DSM 43033T, and S. xiangluensis NEAU-LA29T. Results showed that
strain NEAU-SSA 1T shared DNA–DNA relatedness of 37.1 ± 3.4% with S. aureoverticillatus JCM
4347T, 35.4 ± 4.3% with S. vastus JCM 4524T, 33.1 ± 4.1% with S. cinereus DSM 43033T, and 29.0 ± 4.9%
with S. xiangluensis NEAU-LA29T. Digital DNA–DNA hybridization was employed to clarify the
relatedness between strain NEAU-SSA 1T and S. flaveus JCM 3035T. The level of digital DNA–DNA
hybridization between them was 24.9 ± 2.4%. These five values are all below the threshold value of
70% recommended by Wayne et al. [47] for assigning strains to the same genomic species. Similarly,
a low ANI value of 80.99% was found between strain NEAU-SSA 1T and S. flaveus JCM 3035T, a result
well below the threshold used to delineate prokaryote species [48,49].
The assembled genome sequence of strain NEAU-SSA 1T was found to be 10,364,704 bp long
and composed of 352 contigs with an N50 of 59,982 bp, a DNA G+C content of 69.9 mol % and
a coverage of 200x. It was deposited into GenBank under the accession number VCHX00000000.
The 16S rRNA gene sequence from the whole genome sequence shared a 100% similarity with that
from PCR sequencing, suggesting that the genome sequence was not contaminated. Detailed genomic
information is presented in the Table S3.
Comparison of phenotypic characteristics between strain NEAU-SSA 1T and its closely related
species—S. aureoverticillatus JCM 4347T, S. vastus JCM4524T, S. cinereus DSM 43033T, S. xiangluensis
NEAU-LA29T, and S. flaveus JCM 3035T—was performed to differentiate these strains (Table 2).
Differential cultural characteristics included: NaCl tolerance of the strain was up to 5.0%, which is
lower than that of S. aureoverticillatus JCM 4347T (15%) and S. flaveus JCM 3035T (7%); and the strain could
grow at pH 11.0, while S. vastus JCM4524T, S. cinereus DSM 43033T, and S. xiangluensis NEAU-LA29T
could not. Other phenotypic differences included the production of H2S; decomposition of cellulose;
liquefaction of gelatin; growth temperature; hydrolysis of Tweens (20, 40, and 80); and utilization of
L-arabinose, D-galactose, D-fructose, D-maltose, lactose, L-rhamnose, D-ribose, D-sorbitol, D-mannose,
raffinose, D-xylose, myo-inositol, L-glutamine, glycine, L-threonine, L-tyrosine, L-serine, L-proline,
L-asparagine, and L-arginine.
On the basis of morphological, physiological, chemotaxonomic, and phylogenetic results, strain
NEAU-SSA 1T is considered to represent a novel species within the genus Streptomyces, for which the
name Streptomyces sporangiiformans is proposed.
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Figure 2. Neighbor-joining tree showing the phylogenetic position of strain NEAU-SSA 1T (1412 bp) and
the related species of the genus Streptomyces based on 16S rRNA gene sequences. The out-group used
was Kitasatospora setae LM-6054T. Only bootstrap values above 50% (percentages of 1000 replications)
are indicated. Asterisks indicate branches also recovered in the maximum-likelihood tree. Scale bar
represents 0.005 nucleotide substitutions per site.
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Figure 3. Neighbor-joining tree based on MLSA analysis of the concatenated partial sequences
from five housekeeping genes (atpD, gyrB, recA, rpoB, and trpB) of isolate NEAU-SSA 1T (in bold)
and related taxa. Only bootstrap values above 50% (percentages of 1000 replications) are indicated.
Kitasatospora setae LM-6054T was used as an out-group. Asterisks indicate branches also recovered in
the maximum-likelihood tree. Scale bar represents 0.02 nucleotide substitutions per site.
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3.2. Description of Streptomyces sporangiiformans sp. nov.
Streptomyces sporangiiformans (spo.ran.gi.i.for’mans. N.L. neut. n. sporangium; L. pres. part.
formans forming; N.L. part. adj. sporangiiformans forming sporangia).
Gram-stain-positive, aerobic actinomycete that formed well-developed, branched substrate
hyphae and aerial mycelia. Sporangia consisted of cylindrical and rough surfaced spores (0.6–0.8 μm
× 0.9–1.6 μm) were produced on aerial mycelia, but spore chains were not observed. Good growth
on ISP 3, ISP 4, ISP 7, and Nutrient agar media; moderate growth on ISP 1, ISP 2, ISP 5, ISP 6,
and Czapek’s agar media; and poor growth on Bennett’s agar medium. Growth occurred at pH values
between 6.0 and 11.0, the optimum being pH 7.0. Tolerates up to 6.0% NaCl and grows optimally in
0–1% (w/v) NaCl. Growth was observed at temperatures between 15 and 45 ◦C, with an optimum
temperature of 28 ◦C. Positive for decomposition of Tweens (40 and 80) and cellulose, hydrolysis of
aesculin and starch, liquefaction of gelatin and production of urease; and negative for coagulation
and peptonization of milk, hydrolysis of Tween 20, production of H2S, and reduction of nitrate.
D-fructose, D-galactose, D-glucose, inositol, lactose, D-maltose, D-mannose, D-raffinose, L-rhamnose,
and D-sucrose were utilized as sole carbon sources, but not L-arabinose, dulcitol, D-ribose, D-sorbitol,
or D-xylose. L-alanine, L-arginine, L-asparagine, L-aspartic acid, creatine, L-glutamic acid, L-glutamine,
L-proline, L-serine, and L-threonine were utilized as sole nitrogen sources, but not glycine or L-tyrosine.
Cell wall contained LL-diaminopimelic acid and the whole-cell hydrolysates were ribose, mannose, and
galactose. The polar lipids contained diphosphatidylglycerol (DPG), phosphatidylethanolamine (PE),
hydroxy-phosphatidylethanolamine (OH-PE), phosphatidylinositol (PI), two phosphatidylinositol
mannosides (PIMs), and an unidentified phospholipid (PL). The menaquinones were MK-9(H4),
MK-9(H6), and MK-9(H8). Major fatty acids were iso-C17:0, C16:0, and C17:1ω9c.
The type strain was NEAU-SSA 1T (=CCTCC AA 2017028T = DSM 105692T), isolated from soil
collected from Mount Song, Dengfeng, Henan Province, China. The DNA G+C content of the type strain
was 69.9 mol %, calculated from the assembly for the draft genome sequence. The GenBank/EMBL/DDBJ
accession number for the 16S rRNA gene sequence of strain NEAU-SSA 1T is MH842151. This
Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under the accession
VCHX00000000. The version described in this paper is version VCHX00000000.2.
3.3. Antibacterial Activity of NEAU-SSA 1T against Ralstonia solanacearum
Strain NEAU-SSA 1T exhibited antibacterial activity against Ralstonia solanacearum with inhibitory
zone diameters of 23 mm (Figure 4a). However, no inhibitory effect on the growth of Micrococcus luteus
(Figure 4b) was observed. Comparison of the antibacterial activity of the extract of the supernatant with
that of the cell pellet suggested that the antibacterial substances of strain NEAU-SSA 1T were in both the
supernatant and cell pellet since the extracts all showed inhibition of the growth of Ralstonia solanacearum
with the inhibitory zone diameters of 31.5 and 26.4 mm, respectively (Figure 5a,b). The antibacterial
substances in the supernatant were stable after they were placed in a water bath at 40 and 60 ◦C for
30 min, while they did not show antibacterial activity after 80 and 100 ◦C bath (Figure 6a), which
indicated that they were sensitive to temperature. In contrast, the antibacterial substances in the cell
pellet were insensitive to temperature (Figure 6b), which demonstrated that the antibacterial substances
in the supernatant and cell pellet were different. The antiSMASH analysis led to the identification
of 49 gene clusters, including 24 gene clusters that showed very low similarity to the known gene
clusters of mediomycin A, cremimycin, primycin, ibomycin, naphthomycin, lasalocid, informatipeptin,
polyoxypeptin, kutznerides, anisomycin, paulomycin, himastatin, desotamide, nystatin, tiacumicin B,
oxazolomycin, and 4-Z-annimycin. Therefore, the relationships between the corresponding secondary
metabolites produced by NEAU-SSA 1T and the antibacterial activity are still ambiguous. Streptomyces
are well known as important biological resources for their biologically active secondary metabolites,
which play important roles in protecting plants against pathogens [50]. Strain NEAU-SSA 1T,
which shows a stronger antibacterial activity against Ralstonia solanacearum, is a novel species of the
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genus Streptomyces, and possesses 24 lower similarity gene clusters. Therefore, it is interesting and
significant to isolate and identify the secondary metabolites of the strain in further studies.
Figure 4. The antibacterial activity of strain NEAU-SSA 1T against Ralstonia solanacearum (a) and
Micrococcus luteus (b).
 
Figure 5. The antibacterial activity of the extract of the supernatant (a) and cell pellet of strain
NEAU-SSA 1T (b) against Ralstonia solanacearum.
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Figure 6. The effect of temperature on the antibacterial activity of the extract of the supernatant (a) and
cell pellet of strain NEAU-SSA 1T (b) against Ralstonia solanacearum.
4. Conclusions
A novel strain NEAU-SSA 1T that exhibited antibacterial activity against Ralstonia solanacearum
was isolated from a soil sample. Morphological features, phylogenetic analysis based on 16S rRNA
gene sequences, and multilocus sequence analysis based on five other house-keeping genes (atpD,
gyrB, recA, rpoB, and trpB) suggested that strain NEAU-SSA 1T belonged to the genus Streptomyces.
Physiology and biochemical characteristics, together with DDH relatedness values and ANI values,
clearly indicated that strain NEAU-SSA 1T could be differentiated from the closely related strains S.
aureoverticillatus JCM 4347T, S. vastus JCM 4524T, S. cinereus DSM 43033T, S. xiangluensis NEAU-LA29T,
and S. flaveus JCM 3035T. Based on the polyphasic analysis, it is proposed that strain NEAU-SSA 1T
should be classified as representatives of a novel species of the genus Streptomyces, for which the name
Streptomyces sporangiiformans sp. nov. is proposed. The type strain is NEAU-SSA 1T (=CCTCC AA
2017028T = DSM 105692T).
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/7/9/360/s1,
Figure S1: Maximum-likelihood tree showing the phylogenetic position of strain NEAU-SSA 1T (1412 bp) and
the related species based on 16S rRNA gene sequences. The out-group used was Kitasatospora setae LM-6054T.
Only bootstrap values above 50% (percentages of 1000 replications) are indicated. Bar, 0.01 nucleotide substitutions
per site. Figure S2: Maximum-likelihood tree based on MLSA analysis of the concatenated partial sequences
from five housekeeping genes (atpD, gyrB, recA, rpoB, and trpB) of isolate NEAU-SSA 1T and related taxa. Only
bootstrap values above 50% (percentages of 1000 replications) are indicated. Kitasatospora setae LM-6054T was
used as an out-group. Bar, 0.05 nucleotide substitutions per site. Table S1. Growth and cultural characteristics of
strain NEAU-SSA 1T. Table S2: MLAS distance values for selected strains in this study. Table S3: General features
of the genome sequence of the type strain NEAU-SSA 1T.
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Abstract: The present study was conducted to examine the influence of a pathogen Sclerotinia
sclerotiorum (Lib.) de Bary on the actinobacterial community associated with the soybean roots.
A total of 70 endophytic actinobacteria were isolated from the surface-sterilized roots of either
healthy or diseased soybeans, and they were distributed under 14 genera. Some rare genera,
including Rhodococcus, Kribbella, Glycomyces, Saccharothrix, Streptosporangium and Cellulosimicrobium,
were endemic to the diseased samples, and the actinobacterial community was more diverse in
the diseased samples compared with that in the heathy samples. Culture-independent analysis of
root-associated actinobacterial community using the high-throughput sequencing approach also
showed similar results. Four Streptomyces strains that were significantly abundant in the diseased
samples exhibited strong antagonistic activity with the inhibition percentage of 54.1–87.6%. A
bioactivity-guided approach was then employed to isolate and determine the chemical identity
of antifungal constituents derived from the four strains. One new maremycin analogue, together
with eight known compounds, were detected. All compounds showed significantly antifungal
activity against S. sclerotiorum with the 50% inhibition (EC50) values of 49.14–0.21 mg/L. The higher
actinobacterial diversity and more antifungal strains associated with roots of diseased plants indicate
a possible role of the root-associated actinobacteria in natural defense against phytopathogens.
Furthermore, these results also suggest that the root of diseased plant may be a potential reservoir of
actinobacteria producing new agroactive compounds.
Keywords: Sclerotinia sclerotiorum (Lib.) de Bary; diseased soybean root; antifungal activity;
actinobacterial community; new agroactive compounds
1. Introduction
Sclerotinia stem rot (SSR) caused by a fungus Sclerotinia sclerotiorum (Lib.) de Bary is a highly
destructive disease leading to serious economic losses to crops throughout the world. This fungus
can infect over 400 plant species, including many economically important crops and vegetables [1–3].
Generally, the development of resistant cultivars is a long-term approach for controlling the disease [2,4].
However, the disease has yet been difficult to control because of the limited resource of the resistant
genes. Therefore, fungicides have been used as the auxiliary method for controlling SSR in practice [5].
The benzimidazole and dicarboximide fungicides were the most efficient fungicides in controlling
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SSR [6]. However, the continuous use of these fungicides with high concentration can amplify the
resistant level of phytopathogens [7–9]. Thus, development of new antifungal agents would be a
constant need for controlling the disease.
Endophytic microorganisms residing inside plants have been found in majority of plant species [10].
A growing body of literature recognizes that some of these microorganisms are involved in plant
defense against the phytopathogens through a range of mechanisms, including competition for an
ecological niche or a substrate, secretion of antibiotics and lytic enzymes, and induction of systemic
resistance (ISR) [11,12]. Recent studies on plant-microbe interactions reveal that plants can specifically
attract bacteria for their ecological and evolutionary benefit by secreting root exudates [13–15]. It
has even been postulated that plants can recruit beneficial microorganisms from soil to counteract
pathogen assault [16,17]. For example, it has previously been observed that colonization of the roots of
Arabidopsis by beneficial rhizobacteria Bacillus subtilis FB17 was greatly stimulated when leaves were
infected by Pseudomonas syringae pv. tomato [18].
The phylum Actinobacteria consists of a wide range of Gram-positive bacteria with high
guanine-plus-cytosine (G + C) content. Actinobacterial species are known to produce a vast diversity
of active natural products including antibiotics, antitumor gents, enzymes and immunosuppressive
agents, which have been widely used in pharmaceutical, agricultural and other industries [19,20].
Recently, endophytic actinobacteria have attracted significant interest for their capacity to produce
abundant bioactive metabolites, which may contribute to their host plants by promoting growth
and health [21,22]. A vast majority of endophytic actinobacteria have been isolated from a variety
of plants including various crop plants, medicinal plants, and different woody tree species [23–28].
Further, recent cultivation-independent analysis using 16S rRNA gene-based methods revealed that
actinobacteria can be specifically enriched in plant roots, and are more abundant in diseased plants
than in healthy plants, which may provide probiotic functions for the host plants [29–31]. Thus, it is
hypothesized that endophytic actinobacteria from disease plants may be a promising source for the
discovery of new antifungal agents against S. sclerotiorum.
This prospective study was designed to test the above hypothesis by (i) using culture-independent
and dependent methods to compare the generic diversity and antifungal activity of root-associated
endophytic actinobacteria of field-growing healthy and diseased plants soybean plants and (ii)
identifying antifungal metabolited produced by the outstanding actinobacteria isolated.
2. Materials and Methods
2.1. Plant Materials
Root samples were collected from soybean (cultivar: Hefeng-50) plants identified as SSR
symptomatic (diseased) or asymptomatic (healthy) based on typical symptoms in a heavily infected
soybean field in Suihua, Heilongjiang province, North China (46.63◦ N 126.98◦ E). The diseased samples
showed lesions encircling up to 1/3 of stem diameter referring to a severity scale of three [32]. Each
healthy plant and diseased plant located as close neighbors were determined as one group. The
samples were brought to the lab in a cooler with ice in July 2017 and were processed immediately.
2.2. Isolation of Endophytic Actinobacteria
Three groups of root samples were used for isolation of endophytic actinobacteria. The root
samples were air dried for 24 h at room temperature and then washed in water with an ultrasonic step
(160 W, 15 min) (KH-160TDV, Hechuang, China) to remove the surface soils and adherent epiphytes
completely. After drying, the sample was cut into pieces of 5–10 mm in length and then subjected to a
seven-step surface sterilization procedure: A 60-sec wash in sterile tap water containing cycloheximide
(100 mg/L) and nalidixic acid (20 mg/L), followed by a wash in sterile water, a 5 min wash in 5% (v/v)
NaOCl, a 10 min wash in 2.5% (w/v) Na2S2O3, a 5 min wash in 75% (v/v) ethanol, a wash in sterile
water and a final rinse in 10% (w/v) NaHCO3 for 10 min. After being thoroughly dried under sterile
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conditions, the surface-sterilized samples were subjected to continuous drying at 100 ◦C for 15 min.
The sample was then cut up in a commercial blender and ground with a mortar and pestle, employing
1 mL of 0.5 M potassium phosphate buffer (pH 7.0) per 100 mg tissue. Tissue particles were allowed
to settle down at 4 ◦C for 20–30 min, and an aliquot of 200 μL supernatants were spread on a series
of isolation media and incubated at 28 ◦C for 2–3 weeks. Each isolation medium was supplemented
with nalidixic acid (20 mg/L) and cycloheximide (50 mg/L) to inhibit the growth of Gram-negative
bacteria and fungi. Five isolation media: Humic acid-vitamin (HV) agar [33], Gause’s synthetic agar
no. 1 [34], dulcitol-proline agar (DPA) [35], cellulose-proline agar [36], and amino acid agar (serine
0.05%, threonine 0.05%, alanine 0.05%, arginine 0.05%, agar powder 2%, pH 7.2–7.4) were selected for
the isolation. After 14 days of aerobic incubation at 28 ◦C, the actinobacterial colonies were transferred
onto oatmeal agar (International Streptomyces Project medium 3, ISP3) [37] and repeatedly re-cultured
until pure cultures were obtained, and maintained as glycerol suspensions (20%, v/v) at −80 ◦C.
2.3. Phenotypic and Molecular Characterization of Actinobacterial Isolates
The purified colonies were cultivated on ISP 3 at 28 ◦C for two weeks, and then grouped according
to their phenotypic characteristics, including the characteristics of colonies on plates, color of aerial and
substrate mycelium, spore mass color, spore chain morphology, and production of diffusible pigment.
Those colonies with the same characteristics were classified as one species. The number of species
was counted to compare the diversity of root-associated endophytic actinobacteria from healthy and
diseased soybean.
Different phenotypic isolates were further subjected to 16S rRNA gene sequence analysis for the
genus and species identification. The total DNA was extracted using the lysozyme-sodium dodecyl
sulfate-phenol/chloroform method [38]. The primers and procedure for PCR amplification were carried
out as described by Kim et al. [39]. The PCR products were purified and ligated into the vector
pMD19-T (Takara Biomedical Technology, Beijing, China) and sequenced by an Applied Biosystems
DNA sequencer (model 3730XL). The almost full-length 16S rRNA gene sequences (~1500 bp) were
obtained and aligned with multiple sequences obtained from the GenBank/EMBL/DDBJ databases using
CLUSTAL X 1.83 software. Phylogenetic tree was constructed with neighbor-joining method [40] using
Molecular Evolutionary Genetics Analysis (MEGA) software version 7.0 [41]. The bootstrap method
with 1000 repetitions was using to assess the topology of the phylogenetic tree [42]. Phylogenetic
distances were calculated according to the Kimura two-parameter model [43]. The 16S rRNA gene
sequence similarities were determined using the EzBiocloud server [44]. The obtained gene sequences
have been deposited in the GenBank database.
2.4. Screening for Antagonistic Actinobacteria
The phytopathogenic S. sclerotiorum strain used in this study was kindly provided by the Soybean
Research Institute of Northeast Agricultural University (Harbin, China). Antagonistic activity of
isolates were evaluated through the dual culture plate assay [45]. The isolates were point-inoculated
at the margin of potato dextrose agar (PDA) [46] plates and incubated for three days at 28 ◦C, after
which a fresh mycelial PDA agar plug of the fungus was transferred to the opposite margin of the
corresponding plate. After additional days of incubation at 20 ◦C for seven days, inhibition of hyphal
growth of the fungus was scored. The inhibition rates were calculated as follows:
Inhibition rate (%) =Wi/W × 100% (1)
where Wi is the width of inhibition and W is the width between the pathogen and actinobacteria. Each
test was repeated three times and the average was calculated.
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2.5. Isolation and Characterization of Antifungal Compounds
The antifungal compounds were isolated using an in vitro antifungal activity-guided method [47].
The active isolates were inoculated into 250 mL flask containing 50 mL of tryptone soy broth (TSB) [48]
and cultivated for two days at 28 ◦C with shaking at 200 rpm. Then, 12.5 mL of the seed culture was
transferred into 1 L Erlenmeyer flask containing 250 mL of the fermentation medium (soluble starch
1%, dextrose 2%, tryptone 0.5%, yeast extract 0.5%, NaCl 0.4%, K2HPO4 3H2O 0.05%, MgSO4 7H2O
0.05%, CaCO3 0.5%, pH 7.2–7.4) and incubated at 28 ◦C for seven days with shaking at 200 rpm. The
fermentation broth (20 L) was centrifuged (4000 rev/min, 20 min), and the supernatant and bacterial
biomass were extracted with ethylacetate and methanol, respectively. Both extracts were concentrated
by a rotary evaporator under reduced pressure until dry and mixed after dissolving their dried residues
with methanol.
The crude extracts were divided into seven fractions using column fractionation packed with
silica gel (200−300 mesh, Qingdao Marine Chemical Inc., Qingdao, China) eluting with petroleum
ether/ethylacetate (20:1, 10:1, 5:1, 3:1, 2:1, 1:1 and 0:1). The bioactive fractions were then subjected to
Sephadex LH-20 (Pharmacia, Uppsala, Sweden) and eluted with methanol to obtain several subfractions.
The active subfractions were further separated by semipreparative HPLC (Hitachi-DAD, Tokyo, Japan)
using a YMC-Triart C18 column (250 × 10 mm i.d., 5 μm) at a flow rate of 3.0 mL/min, and the potent
active principles were finally isolated.
Structural determination of the active compounds were made according to spectroscopic analysis.
NMR spectra were measured with a Bruker Avance III-600 spectrometer in CDCl3 or CD3OD using
TMS as internal standard. The ESI-MS spectrum was taken on a Waters Xevo TQ-S ultrahigh pressure
liquid chromatography triple quadrupole mass spectrometer. The HR-ESI-MS spectrum was acquired
with an Agilent G6230 Q-TOF mass instrument. The UV spectrum was recorded in chloroform using
a Shimadzu UV-2401PC UV-VIS spectrophotometer. The IR spectrum was obtained using a Bruker
Tensor 27 FTIR. Optical rotation was determined in chloroform using a JASCO P-1020 polarimeter. The
ECD spectrum was measured on a Chirascan circular dichroism spectrometer (Applied Photophysics
Corporation Limited, Leatherhead, UK).
2.6. Antifungal Assay of Elucidated Bioactive Compounds
The active compounds were dissolved in methanol and diluted to different concentrations, which
were then added to PDA medium. A fresh fungal plug of the fungus (5 mm in diameter) was placed in
the center of the agar plate and incubated at 20 ◦C. Experiments were performed in triplicate, and the
plate with the same amount of methanol was used as control. When the control plate was covered
completely with fungal mass, the percentage of inhibition was calculated with the formula as follows:
Inhibition (%) = (1 − D/Dc) × 100 (2)
where D is average diameter of the treatment and Dc is average diameter of the control. Data were
subjected to linear regression analysis, and the effective concentrations required for 50% inhibition
(EC50) were calculated.
2.7. Culture-Independent Community Analysis
Total community DNA was extracted from three groups of surface-sterilized root samples using
FastDNA®SPIN for soil kit (MP Biomedicals, Solon, CA, USA) according to the manufacturers’
instructions. The purity and concentration of DNA were detected using NanoPhotometer
spectrophotometer (Implen, München, Germany) and Qubit 2.0 Flurometer (Life Technologies, Carlsbad,
CA, USA). Bacterial DNA pyrosequencing was based on ~460 bp amplicons generated by the PCR
primers: 341F (5′-CCTACGGGNGGCWGCAG-3′) and 805R (5′-GACTACHVGGGTATCTAATCC-3′)
with the barcode spanning the hypervariable regions V3-V4 of the 16S rRNA gene The PCR reaction
was carried out in 30 μL reactions with 15 μL of Phusion High-Fidelity PCR Master Mix (New England
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Biolabs, Ipswich, MA, USA), 0.2 μM of forward and reverse primers, and about 10 ng template DNA.
Thermal cycling conditions were 95 ◦C for 3 min, followed by 25 cycles of 95 ◦C for 30 s, 55 ◦C for 30 s,
and 72 ◦C for 30 s, with a final extension at 72 ◦C for 10 min. PCR products was mixed in equidensity
ratios. Then, mixture PCR products was purified with GeneJET Gel Extraction Kit (Thermo Scientific,
Fermentas, Germany).
Sequencing libraries were generated using NEB Next Ultra DNA Library Prep Kit for Illumina
(New England Biolabs, Ipswich, Massachusetts, USA) following the manufacturer’s recommendations
and index codes were added. The library quality was assessed on the Qubit@ 2.0 Fluorometer and
Agilent Bioanalyzer 2100 system (Agilent Technologies, Palo Alto, CA, USA). At last, the library was
sequenced on an Illumina MiSeq platform and 250 bp paired-end reads.
When the sequencing was finished, we needed to filter the raw data to secure the quality, which
mainly included the following steps: (1) Cut the polluted adapter, (2) remove low quality reads,
specifically reads with average quality less than 19, based on the Phred algorithm, and (3) remove the
reads with N base exceeding 5%.
According to overlap of the clean data, we spliced the paired reads by using the PEAR software [49]
to merged sequences. The sequences were then removed Chimeras and clustered into operational
taxonomic units (OTUs) by UCLUST [50] based on 97% pairwise identity. Taxonomic classification of
the representative sequence for each OTU was done using a RDP classifier or QIIME’s closed reference
strategy against the 16S rRNA gene database [51].
2.8. Statistical Analysis
Statistical analyses were performed via SPSS software, version 18.0. Means were compared via
analysis of variance one-way ANOVA using the least significant differences test (LSD, p < 0.05). The
data were reported as means ± standard deviation.
3. Results
3.1. Isolation and Distribution of Endophytic Actinobacteria
A total of 1574 endophytic actinobacterial colonies were successfully isolated. Based on their
phenotypic characteristics, the colonies were preliminary classified into 70 species. Among the 70 species,
15 species were from healthy soybean roots, 27 species were from diseased soybean roots, and 28 species
were shared by healthy and diseased soybean roots. The diversity of actinobacteria from diseased
soybean root were greater than those from healthy soybean root. 16S rRNA gene sequence analysis
of the 70 isolates revealed that they were distributed under 14 genera: Streptomyces, Micromonospora,
Actinomadura, Nonomuraea, Microbacterium, Rhodococcus, Promicromonospora, Microbispora, Kribbella,
Mycolicibacterium, Glycomyces, Saccharothrix, Streptosporangium and Cellulosimicrobium within the class
Actinobacteria. Streptomyces was the most frequently isolated genus (58%, 41 isolates), followed by
Micromonospora (5 isolates) and Nonomuraea (4 isolates). Some rare genera, including Rhodococcus,
Kribbella, Glycomyces, Saccharothrix, Streptosporangium and Cellulosimicrobium, were endemic to the
diseased samples (Figure 1). The 16S rRNA gene sequences were deposited in GenBank with accession
numbers: MH919371–MH919374 and MN058215–MH058280.
3.2. In Vitro Antagonism of S. sclerotiorum and Identification of Bioactive Strains
Strains DAAG3-11, DGS1-1, DDPA2-14 and DGS3-15 exhibited strong antagonistic activity against
S. sclerotiorum, with inhibition activity rates ranging from 54.1% to 87.6% (Figure 2). Strains DGS1-1,
DDPA2-14 and DGS3-15 were from diseased soybean roots. For strain DAAG3-11, 176 colonies were
from diseased soybean roots, whereas 11 colonies were from healthy soybean roots. Based on the 16S
rRNA gene sequences, strains DAAG3-11, DGS1-1, DDPA2-14 and DGS3-15 were closely related to
Streptomyces sporoclivatus, Streptomyces cavourensis, Streptomyces capitiformicae and Streptomyces pratensis,
respectively (Table 1).
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Figure 1. Neighbor-joining phylogenetic tree of 16S rRNA gene sequences from 70 endophytic
actinobacteria in this study and their phylogenetic neighbors. Numbers at nodes are bootstrap values
(percentages of 1000 replications); only values > 50% are shown. GenBank accession numbers of 16S
rRNA gene sequences are shown next to isolate names. A branch indicated by the same color belongs
to the same genus. Isolates indicated by green and purple are endemic to the healthy and diseased
samples, respectively. Isolates shared by healthy and diseased samples are indicated with red.
 
Figure 2. Dual culture plate assay between four endophytic actinobacteria against S. sclerotiorum.
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Table 1. Antagonistic potential endophytic actinobacteria isolated from healthy and diseased soybean
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* Values are the means±SE (n= 4). Data within the same column followed by different letters are significantly different.
3.3. Identification and Activity Evaluation of the Antifungal Compounds
An antifungal activity-guided separation of the components of four active strains against S.
sclerotiorum, using the in vitro antifungal assay, led to the isolation of nine compounds as their active
principles (Figure 3). Out of the nine compounds, compounds 1 and 2 were from strain DAAG3-11,
compound 3 was from strain DGS1-1, compounds 4–7 were from strain DGS3-15, and compounds 8
and 9 were from strain DDPA2-14. Compounds 1–8 are known compounds, which structures were
elucidated as azalomycins F4a (1) [52], azalomycins F5a (2) [52], bafilomycin B1 (3) [53], actinolactomycin
(4) [54], dimeric dinactin (5) [55], tetranactin (6) [56], dinactin (7) [56] and maremycin G (8) [57] by
analysis of their spectroscopic data and comparison with literature values (Figure S1). Compound 9 is
a new maremycin analogue.
Compound 9 was obtained as a yellow, amorphous powder. Its molecular formula C22H27N3O4S
was determined by high resolution electrospray ionization mass spectrometry (HRESIMS) data (m/z
468.1555, [M + Na]+, calculated for 468.1564), corresponding to 11 degrees of unsaturation. The IR
spectrum indicated the presence of hydroxy (3424 cm−1) and carbonyl (1720, 1682 cm−1) groups. The
1H NMR data (Table 2) of 9 suggested the presence of one 1, 2-disubstituted benzene system at δH 7.43
(1H, d, J = 7.8 Hz, H-4), 7.12 (1H, td, J = 7.6, 1.0 Hz, H-5), 7.37 (1H, td, J = 7.7, 1.2 Hz, H-6) and 6.89 (1H,
d, J = 7.9 Hz, H-7). The 1H NMR data of 9 also revealed the presence of two methyl signals at δH 2.17,
(3H, s, H-23) and δH 3.23, (3H, s, H-25). 13C NMR spectrum of 9 showed 11 sp2-carbons including
three carbonyls at δC 204.84 (C-21), 178.33 (C-2), 168.5 (C-13) and eight aromatic or olefinic carbons at
δC 152.27 (C-16), 142.83 (C-9), 130.36 (C-7), 130.01 (C-4), 125.53 (C-5), 123.24 (C-6), 109.08 (C-8), 100.43
(C-17). In the sp3-carbon region, the spectrum showed three methine at δC 42.84 (C-10), 52.94 (C-11),
52.8 (C-14), four methylene at δC 27.04 (C-18), 21.04 (C-19), 38.79(C-20), 38.75(C-22), and three methyl
carbons at δC 16.36 (C-23), 8.92 (C-24), 26.65 (C-25).
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Figure 3. The structures of compounds 1–9.
Comparison the NMR data of 9 with FR900452 [58], an indole diketopiperazine motif linked with
a cyclopentenone moiety, which was isolated from the fermentation broth of Streptomyces sp. B9173,
implied that 9 was identified as a reduced form of FR900452 in which the cyclopentenone moiety is
hydrogenated to cyclopentanone. As shown in Figure 4, the accurate assignments of all protons and
carbons for compound 9 were preformed through the correlations in 2D-NMR spectra (1H–1H COSY,
HSQC and HMBC, Figure S2). The HMBC couplings Me-25/C-9/C-2, H-5/C-3, and H-10/C-2/C-3/C-4,
along with 1H–1H COSY correlations of H-5/H-6/H7/H-8, revealed N-methyl-2-oxindole unit. In
addition, 1H–1H COSY correlations of H-18/H-19/H-20, as well as the HMBC cross peaks H-18/C-17/C-16,
H-20/C-21, demonstrated that oxopiperazinyl moiety was linked to C-16/C-17 on the cyclopentenone
moiety. 1H–1H COSY correlations of Me-24/H-10/H-11, together with the HMBC correlations
from Me-24/C-3/C-10/C-11, indicated that N-methyl-2-oxindole unit was linked to C-10/C-5 on the
oxopiperazinyl moiety. The 1H and 13C NMR spectroscopic data of 9 were also indicative of methyl
mercaptomethylene moieties [δC 38.75, δH-CH2 3.17 (1H, m), 2.83 (1H, dd, 14.0, 8.2), δC-CH3 16.36,
δH-S-CH3 2.15 (3H, s)]. The HMBC cross peaks Me-23/C22, H-22/C-14/C-13, along with 1H–1H COSY
correlations of H-22/H-14, evidenced that methyl mercaptomethylene moieties were linked to C-14
on the oxopiperazinyl moieties, respectively. Therefore, the planar structure of 9 was elucidated as a
reduced form of FR900452, depicted in Figure 3.
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Table 2. 1H NMR and 13C NMR data of compound 9 in CDCl3.




5 125.53 7.43 (1H, d, 7.8)
6 123.24 7.12 (1H, td, 7.6, 1.0)
7 130.36 7.37 (1H, td, 7.7, 1.2)
8 109.08 6.89 (1H, d, 7.9)
9 142.83
10 42.84 2.06 (1H, m)
11 52.94 5.36 (1H, s)
12 11.01 (brs)
13 168.23




18 27.04 2.24 (1H, s)
2.44 (1H, ddd, 13.9, 8.4, 3.8)
19 21.04 1.83 (2H, m)
20 38.79 2.28 (2H, m)
21 204.84
22 38.75 3.17 (1H, m)
22 2.83 (1H, dd, 14.0, 8.2)
23 16.36 2.15 (3H, s)
24 8.92 1.19 (3H, d, 7.0)
25 26.65 3.23 (3H, s)
Figure 4. Key 1H–1H COSY, HMBC and ROESY correlations of compound 9.
The relative configuration of compound 9 was determined by interpretation of its ROESY NMR
spectrum. The correlations of H-14/Me-24, and H-10/H-11, indicated that H-14 and Me-24 were
α-oriented, whereas H-10 and H-11 were β-oriented (Figure 4). Based on the close skeleton, the
comparison of ECD spectra between 9 and N-demethylmaremycin B [57], and the largely consistent
data supported that the configurations of 3-OH was α-oriented. Ultimately, the absolute configuration
of was identified as 3S, 10R, 11R, 14R, resulting from the same trends of cotton effects (CEs) in the
experimental ECD spectra of 9 and N-demethylmaremycin B.
The in vitro antifungal activity of compounds 1–9 against S. sclerotiorum was determined at various
concentrations. All compounds showed significantly antifungal activity against S. sclerotiorum with
the EC50 values ranging from 49.14 mg/L to 0.21 mg/L (Table 3). Thus, it further confirmed that these
compounds were the main antifungal constituents produced by the four active strains.
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Table 3. EC50 values of active compounds against S. sclerotiorum.





















Values are the means± SE (n= 9). Data within the same column followed by different letters are significantly different.
3.4. Culture-Independent Communities
A total of 4116 OTUs containing 745708 high-quality reads were detected in the soybean root
microbiome. The raw sequencing reads for this project were submitted to the National Center for
Biotechnology Information Short Read Archive under accession numbers SRR8056376–SRR8056381.
The predominant bacterial phyla were Proteobacteria, Bacteroidetes and Actinobacteria in the soybean
roots. To compare the microbial communities obtained in healthy and diseased root samples from each
group, the relative abundance of order Rhizobiales that can improve rhizobial nodulation and nitrogen
fixation was significantly greater in the healthy samples, whereas the order Actinobacteria were more
abundant in the diseased samples (Figure 5).
Figure 5. Analysis of culture-independent endophytic communities at order level in the soybean roots.
DE, diseased sample; RE, healthy sample.
4. Discussion
The multifaceted approach adopted in this study, linking culture-independent and
culture-dependent analysis, showed that actinobacteria were more abundant or diverse in the
diseased soybean roots. This finding was in agreement with the previous study that the phylum
Actinobacteria was higher in ‘Candidatus Liberibacter asiaticus’-infected citrus samples compared
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with that in healthy samples [31]. Another similar study also showed that potato plants infected
with Erwinia carotovora subsp. atroseptica increased bacterial diversity [59]. The higher diversity
of endophytic actinobacteria in diseased but healthy plants suggests that they may be involved in
pathogen defense [60]. Indeed, extensive research has shown that endophytic actinobacteria has the
capacity to control plant pathogens [22]. The in vitro antagonism assays demonstrated that four strains
showed strong antifungal activity against S. sclerotiorum. Among the four antagonistic strains, all
colonies of three strains were absolutely from diseased soybean roots, and another strain was also
significantly enriched in diseased soybean roots compared to healthy soybean roots. A similar study
has also shown that the rhizosphere soil of diseased tomato plant harbored a high percentage of
antagonists [61]. Studies over the past few years have provided important information that plants
possess a sophisticated defense mechanism by actively recruiting root-associated microbes from
soil upon pathogen attack [18,62]. By adjusting the quantity and composition of its root secretion,
plants can determine the composition of the root microbiome by affecting microbial diversity, density,
and activity [63,64]. Our results seem to be consistent with previous observations. However, those
strains with antagonistic activity in vitro may not be simply translated into biocontrol bacteria. Their
biocontrol effects are influenced by various factors. For example, the antagonistic strains should reach
a certain amount inside the plants to demonstrate a significant biocontrol effect [65,66]. Moreover, their
secondary metabolite producing ability inside the plants may be influenced by plant physiological
environment. Therefore, further work is required to assess the biocontrol efficiency in vivo and
root-colonizing capacity of antagonistic strains by pathogen infection.
To learn more about the chemical nature of the antifungal activity, nine active compounds
including six macrolides, two diketopiperazines and one 2-oxonanonoids, were finally obtained. Out
of which, bafilomycin B1 (3) showed strongest inhibitory activity against S. sclerotiorum. Bafilomycin
B1 has been reported to be produced by several Streptomyces strains and to show inhibitory activity
against various fungi in vitro, such as Rhizoctonia solani, Aspergillus fumigatus, Botrytis cinerea, Penicillium
roqueforti, and so on [67,68]. The antifungal activity of this compound against S. sclerotiorum was first
reported in this paper. Azalomycins F4a (1) and F5a (2) were first isolated from the broth of Streptomyces
hygroscopicus var. azalomyceticus [69]. Azalomycins F complex, including azalomycins F3a, F4a and F5a
showed remarkable antifungal activity against asparagus (Asparagus officinalis) pathogens Fusarium
moliniforme and Fusarium oxysporumas as well as powdery mildew pathogen Botrytis spp. [70]. The
antifungal activity of the pure compound was first demonstrated in our research. Azalomycins possess
broad-spectrum antibacterial and antifungal activities, and almost all of them were produced by
Streptomyces, which were isolated repeatedly from soil and plant roots in the field by our laboratory
(data no shown). This emphasizes the possible importance of Streptomyces producing azalomycins to
protect plants against phytopathogens. A mixture of dinactin (7), trinactin and the major component
tetranactin (6) is known as commercial pesticides polynactin (liuyangmycin in China), which can
effectively control spider mites under wet conditions [71]. In addition, tetranactin (6) also exhibited
significant antifungal activity against plant pathogen Botrytis cinerea with a minimum inhibitory
concentration (MIC) of 24 μg·mL–1 [72]. Besides dinactin (7) and tetranactin (6), the monomer (4) and
dimer (5) of polynactin were also isolated in this study, all of which were active against S. sclerotiorum.
The antifungal activities of actinolactomycin (4), dimeric dinactin (5) and dinactin (7) have not been
reported as yet. The findings reported here shed new light on the application of polynactin. Natural
indole diketopiperazines exhibited a wide range of biological activities including antitumor [73],
antibacterial [74], antifungal [75] and antiviral activities [76]. FR900452 is sulfur-containing indole
diketopiperazines that showed specific and potent inhibitory activity against the platelet aggregation
induced by platelet-activating factor [77]. Maremycin G (8) and compound 9, structurally related
to FR900452, showed significant antifungal activity against S. sclerotiorum. To our knowledge, this
is the first report of the antifungal property of maremycins. Further research is needed to confirm
the efficacy of in vivo disease control provided by the nine active compounds under laboratory and
field conditions.
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5. Conclusions
In summary, we report that soybean infected by S. sclerotiorum (Lib.) de Bary had a higher
populations of actinobacteria and enhanced root colonization of antagonistic populations. In addition,
eight known compounds and one new compound that exerted significant antifungal activity against
S. sclerotiorum were obtained. These findings suggest that diseased plant samples could be a potential
source for screening novel agroactive compounds, which contribute to a better understanding of
plant–microbe interactions and provide new strategies for the development of agricultural antibiotics.
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Abstract: Coinciding with the increase in sequenced bacteria, mining of bacterial genomes for
biosynthetic gene clusters (BGCs) has become a critical component of natural product discovery.
The order Myxococcales, a reputable source of biologically active secondary metabolites, spans
three suborders which all include natural product producing representatives. Utilizing the
BiG-SCAPE-CORASON platform to generate a sequence similarity network that contains 994 BGCs
from 36 sequenced myxobacteria deposited in the antiSMASH database, a total of 843 BGCs with lower
than 75% similarity scores to characterized clusters within the MIBiG database are presented. This
survey provides the biosynthetic diversity of these BGCs and an assessment of the predicted chemical
space yet to be discovered. Considering the mere snapshot of myxobacteria included in this analysis,
these untapped BGCs exemplify the potential for natural product discovery from myxobacteria.
Keywords: myxobacteria; biosynthetic gene clusters; natural product discovery
1. Introduction
Ubiquitous to soils and marine sediments, bacteriovorous myxobacteria display organized social
behaviors and predation strategies [1–4]. Perhaps intrinsic to their role as predators, myxobacteria
are a critical source of diverse secondary metabolites that exhibit unique modes-of-action across a
broad range of biological activities [5]. Distinct from other bacterial sources, the vast majority of the
60 species within the order Myxococcales produce natural products [5,6]. This gifted diversity of
secondary metabolite producing representatives has established myxobacteria as a prolific resource
for drug discovery efforts perhaps only second to Actinomycetales [7,8]. Bolstered by the observed
lack of overlap between actinomycetal and myxobacterial drug-like metabolites, the potential to
discover novel specialized metabolites from myxobacteria remains considerably high [7,8]. Herein,
we report a survey of all myxobacterial natural product biosynthetic gene clusters (BGCs) deposited
in the antiSMASH database and provide an account of all BGCs with and without characterization
and assigned metabolites in an effort to observe the capacity for discovery from readily cultivable,
sequenced myxobacteria [9,10]. Such analysis provides an assessment of the potential associated
with the continued discovery efforts as well as development and application of methodologies to
activate situational or cryptic secondary metabolism not functional during axenic cultivation [11,12].
A homology network of 994 BGCs from 36 sequenced myxobacterial genomes was constructed using
the combined BiG-SCAPE-CORe Analysis of Syntenic Orthologues to prioritize Natural products
biosynthetic gene clusters (CORASON) platform [13]. BiG-SCAPE facilitates the exploration of
calculated BGC sequence similarity networks and provides the opportunity to visualize biosynthetic
diversity across datasets [13]. Gene cluster families (GCFs) rendered by BiG-SCAPE are connected
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by edges that indicate shared domain types, sequence similarity, and similarity of domain pair-types
amongst input BGCs [13]. Comparative analysis against the Minimum Information about a Biosynthetic
Gene Cluster (MIBiG) repository (v1.4) indicates an untapped reservoir of BGCs that encompasses
a broad range of biosynthetic diversity [14]. The 36 Myxococcales within the antiSMASH database
currently span all 3 suborders with 26 Cystobacterineae, 7 Sorangineae, and 3 Nannocystineae included.
Considering that the myxobacteria within the antiSMASH database minimally represent the breadth
of the order Myxococcales, these observations not only support thorough investigation of identified
myxobacteria and the presented biosynthetic space but also continued efforts for the identification and
subsequent exploration of new myxobacteria [1,3].
2. Materials and Methods
Dataset. All BGCs associated with the order Myxococcales, a total of 994 BGCs from 36
myxobacteria, were downloaded as .gbk files from the publicly available antiSMASH database
(https://antismash-db.secondarymetabolites.org) [9]. The original genome sequence data for all
included myxobacteria are also publicly available and can be accessed at the National Center for
Biotechnology Information, U.S. National Library of Medicine (https://www.ncbi.nlm.nih.gov/genome/
browse#!/prokaryotes/myxobacteria).
BIG-SCAPE-CORASON analysis. BiG-SCAPE version 20181005 (available at: https://git.
wageningenur.nl/medema-group/BiG-SCAPE) was utilized locally to analyse the 994 BGCs as
individual .gbk files downloaded from the antiSMASH database (1/30/2019) [9,13]. BiG-SCAPE analysis
was supplemented with Pfam database version 31 [15]. The singleton parameter in BiG-SCAPE was
selected to ensure that BGCs with distances lower than the default cutoff distance of 0.3 were included
in the corresponding output data. The MIBiG parameter in BiG-SCAPE was set to include the MIBiG
repository version 1.4 of annotated BGCs [14]. The hybrids-off parameter was selected to prevent
hybrid BGC redundancy. Generated network files separated by BiG-SCAPE class were combined for
visualization using Cytoscape version 3.7.1; annotations associated with each BGC were included
into Cytoscape networks by importing curated tables generated by BiG-SCAPE [16]. Phylogenetic
trees provided by CORASON were generated during BiG-SCAPE analysis. Annotated network and
table files including GCF associations are provided as Supplementary files. All BGCs with sequence
similarities to deposited MIBiG clusters ≥75% were indicated and annotated using Cytoscape. An
annotated .cys Cytoscape file is included as Supplementary Material. All associated .network and
.tsv files are provided as Supplementary Materials. All histograms were generated GraphPad Prism
version 7.0d for Mac OS X, GraphPad Software, San Diego, California, USA, www.graphpad.com.
3. Results
3.1. BiG-SCAPE Analysis of BGCs from Sequenced Myxobacteria
A sequence similarity network calculated using BiG-SCAPE consisted of 994 total BGCs as unique
nodes from 36 myxobacteria and included 1035 edges (included self-looped nodes) representing
homology across 753 GCFs (Figure 1). Of these 994 BGCs from the antiSMASH database, a total of
124 were determined to be located on contig edges by antiSMASH. Clusters determined to be on
contig edges could contribute to redundancy within our analysis. While no 2 BGCs from an individual
myxobacterium were found within a GCF, this does not preclude a single BGC split across multiple
contigs from being included multiple times. A total of 613 singletons without homology using a
similarity cutoff of 0.30 were also included in the network to appropriately depict all myxobacterial
BGCs within the antiSMASH database [9,13]. Predicted BGC classes included 64 type I or modular
polyketide synthases (t1PKS), 57 PKS categorized by antiSMASH as “PKSother” that includes all
non-modular categories of PKSs, 125 nonribosomal peptide synthetases (NRPS), 166 hybrid PKS-NRPS,
245 ribosomally synthesized and post-translationally modified peptides (RiPPs), 149 terpene clusters, 3
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saccharide clusters, and 185 clusters not belonging to any of the aforementioned classes that antiSMASH
categorizes as “Others” clusters [9,10].
Figure 1. Sequence similarity network of 994 myxobacterial BGCs deposited in the antiSMASH database
generated by BiG-SCAPE and rendered with Cytoscape [9,10,13,14,16]. All GCFs that include at least 1
BGC with sequence similarity greater than ≥75% to a characterized cluster deposited in the MIBiG
repository are boxed in grey (excluding 25 geosmin BGCs) [9,14]. Totals for BGC class diversity and
BGCs (including 25 geosmin BGCs identified as 22 Terpene and 3 Other clusters) with and without
homology to MIBiG clusters as well as color reference provided (right).
While hybrid PKS-NRPS pathways that include both PKS and NRPS domains are organized into a
specific separate grouping, all other hybrid pathways that include more than one BGC are categorized
in the Others class [9,13]. The Others-associated BGCs included clusters with 133 predicted products
as well as 52 hybrid BGCs (Figure 2). This breadth of biosynthetic diversity from just 36 myxobacteria
includes 23 out of 52 BGC-types currently designated by antiSMASH [9,10].
3.2. Discovered Metabolites from Myxobacteria and Associated BGCs
Of the 994 BGCs analysed, 151 possess sequence similarities ≥75% with annotated BGCs in the
MIBiG repository (v 1.4) [14]. Sequence similarities from the antiSMASH database are provided by
KnownClusterBlast analysis of BGCs within the database against characterized pathways within
the MIBiG repository [9,14,17,18]. As these BGCs produce characterized metabolites or potentially
analogues thereof (Figure 3), a total of 85% of the BGCs within the network might produce yet to
be discovered metabolites [19–43]. Considering the range in quality across the 36 total genomes
and draft genomes incorporated in the antiSMASH database, we also considered additional BGCs
with similarity scores lower than 75% that had similarities with MIBiG clusters reported from
myxobacteria identified by antiSMASH. This analysis provided an additional 23 BGCs that might
produce metabolites with overlapping chemical diversities to the products delineated within the MIBiG
repository (Figure 4) [44–58]. Of these 23 BGCs omitted from our original analysis, only 10 would have
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been included if our sequence similarity cutoff had been lowered to 67% sequence similarity. Including
this inference, 82% of the BGCs within the network lack any association with a reported myxobacterial
metabolite. The biosynthetic diversity of these mapped BGCs includes 5 t1PKS, 10 NRPS, 37 hybrid
PKS-NRPS, 4 PKSother, 51 terpene clusters, and 44 Others (Figure 1).
 
Figure 2. Sequence similarity network of myxobacterial BGCs classified as Others in the antiSMASH
database with predicted product type and totals (right) [9].
Figure 3. Secondary metabolites associated with BGCs determined to possess ≥75% sequence similarity
to characterized clusters in MIBiG [17–41].
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Figure 4. Secondary metabolites associated with known BGCs from myxobacteria with sequence
similarity to BGCs included in the MIBiG dataset below the 75% similarity cutoff [42–56].
While the vast majority of BGCs were considered singletons or unclustered individual nodes
without sequence similarity to other analysed BGCs, GCFs with more than 1 member BGC often shared
sequence similarities with characterized MIBiG clusters. Interestingly, BGCs with high sequence
similarity to specific MIBiG clusters were not always assigned the same cluster class nor were they
included within an individual GCF. For example, 9 GCFs that include a single BGC with high homology
to the myxochelin BGC were assigned as NRPS, hybrid PKS-NRPS, and Others type clusters [33,39].
Trees generated by CORASON provide the phylogenetic diversity associated with these myxochelin
BGCs (Figure S1) [13]. Analysis of these trees indicated that such wholesale affiliation with each of these
GCFs led to inclusion of BGCs that were in fact not related to the myxochelin BGC but instead shared
proximal similarity to a BGC within the family that also included a neighbouring myxochelin-like BGC
(Figure S1) [33,39]. While this omits unexplored BGCs and demonstrates the limitations of our totals,
this only supports our conclusion that a vast wealth of biosynthetic space from myxobacteria remains
unexplored. Other BGCs observed across multi-member GCFs included: 26 BGCs within 11 GCFs
homologous to a carotenoid cluster from Myxococcus xanthus, 24 BGCs and 4 GCFs associated with the
characterized VEPE/AEPE/TG-1 biosynthetic pathway from M. xanthus DK1622, and 11 BGCs across 5
GCFs with similarity to the hybrid PKS-NRPS DKxanthene cluster [19,20,24,30,31]. While all of the
BGCs included in this charted biosynthetic space might not correlate to the corresponding metabolites
associated with each MIBiG cluster, we consider this a rigorous assessment that provides a conservative
estimate of uncharacterized BGCs and remaining opportunity for natural product discovery.
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4. Discussion
This survey assesses the potential to discover novel metabolites from these myxobacteria and
depicts unexplored biosynthetic space. Perhaps the most obvious absence in the 151 BGCs associated
with characterized BGCs was that no RiPP clusters with sequence similarity to MIBiG clusters were
observed [59–61]. However, there are no myxobacterial RiPP BGCs currently deposited in the MIBiG
database, and crocagin A produced by Chondromyces crocatus is the only myxobacterial RiPP discovered
to date [62]. Considering the 245 uncharacterized BGCs predicted to produce RiPPs within our network,
myxobacteria are an excellent resource for the discovery of RiPPs. Also, with respect to notable outliers,
no sequence similarities were observed for the 3 saccharide BGCs that include the aminoglycoside and
aminocyclitol subtypes [63–65]. All other BGCs considered unexplored accounted for the vast majority
of BGCs within each cluster class, including the following: 92% of t1PKS, 98% of PKSother, 92% of
NRPS, 81% of terpene clusters, 78% of hybrid PKS-NRPS, and 76% of Others. Interestingly, within the
BGCs assigned to the Others class, 3 butyrolactone and 1 homoserine lactone clusters were identified.
Specialized metabolites belonging to these types of clusters are typically quorum-signaling molecules
produced by Streptomyces and numerous non-myxobacterial Proteobacteria respectively [66–69].
Although putative quorum signal receptors are present within myxobacterial genomes and exogenous
homoserine lactones increase the predatory behavior of M. xanthus, no metabolite associated with
these quorum signaling systems has been reported from a myxobacteria [70,71].
5. Conclusions
The continued discovery of novel, biologically active bacterial metabolites is required to address
the need for antimicrobials and anticancer therapeutics. Assessment of biosynthetic space within
the growing amount of genome data from myxobacteria can provide insight to direct responsible
discovery efforts [72–75]. This survey likely underestimates the unexplored biosynthetic space from
myxobacteria. However, the vast discrepancies between BGCs with and without sequence similarity
to characterized pathways suggests continued discovery of novel metabolites from this subset of 36
myxobacteria and exemplifies the outstanding potential associated with the Myxococcales at large.
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Abstract: In the present study, marine actinobacteria Streptomyces sp.S2A was isolated from the Gulf
of Mannar, India. Identification was carried out by 16S rRNA analysis. Bioactive metabolites
were extracted by solvent extraction method. The metabolites were assayed for antagonistic
activity against bacterial and fungal pathogens, inhibition of α-glucosidase and α-amylase enzymes,
antioxidant activity and cytotoxic activity against various cell lines. The actinobacterial extract
showed significant antagonistic activity against four gram-positive and two gram-negative pathogens.
Excellent reduction in the growth of fungal pathogens was also observed. The minimum inhibitory
concentration of the partially purified extract (PPE) was determined as 31.25 μg/mL against
Klebsiella pneumoniae, 15.62 μg/mL against Staphylococcus epidermidis, Staphylococcus aureus and
Bacillus cereus. The lowest MIC was observed against Micrococcus luteus as 7.8 μg/mL. MIC against
fungal pathogens was determined as 62.5 μg/mL against Bipolaris maydis and 15.62 μg/mL against
Fusarium moniliforme. The α-glucosidase and α-amylase inhibitory potential of the fractions were
carried out by microtiter plate method. IC50 value of active fraction for α-glucosidase and α-amylase
inhibition was found to be 21.17 μg/mL and 20.46 μg/mL respectively. The antioxidant activity of
partially purified extract (PPE) (DPPH, ABTS, FRAP and Metal chelating activity) were observed and
were also found to have significant cytotoxic activity against HT-29, MDA and U-87MG cell lines.
The compound analysis was performed using gas chromatography-mass spectrometry (GC-MS) and
resulted in three constituents; pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl)-, being
the main component (80%). Overall, the strain possesses a wide spectrum of antimicrobial, enzyme
inhibitory, antioxidant and cytotoxic activities which affords the production of significant bioactive
metabolites as potential pharmacological agents.
Keywords: marine actinobacteria; Streptomyces sp.; enzyme inhibition; antimicrobial; antioxidant;
cytotoxicity; GC-MS; pyrrolopyrazines
1. Introduction
The microbial natural products are a source of several important drugs of high therapeutic value.
Going back to the history of drugs of the first choice, it suggests that novel chemical moieties forming
the backbone of bioactive compounds are primarily obtained from natural sources [1]. The microbial
natural products are a source of several important drugs of high therapeutic value, namely antitumor
agents [2], antibiotics [3], immunosuppressive agents [4], and enzyme inhibitors [5]. The majority
of commercially available pharmaceutical products are secondary metabolites or their derivatives
produced by bacteria, fungi and actinobacteria [6]. Among producers of important metabolites,
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actinobacteria have proven to be most prolific source accounting for more than two-third of available
clinical products of several medical uses [7]. Actinobacteria are filamentous gram-positive bacteria
with high G + C content [8]. They are characterized by complex morphological differentiation and are
considered as an intermediate group of bacteria and fungi [9]. Their presence in various ecological
habitats and marine environments has enabled research communities to exploit their tremendous
potential as the richest source of pharmaceutical and biologically active products [10]. Therefore, they
are contemplated as the most economical and biotechnologically beneficial prokaryotes.
Secondary metabolites are organic compounds having no direct role in the vegetative growth and
the development of the organism. About 40–45% of active metabolites produced by the microorganisms
are contributed by various genera of actinobacteria and are currently in clinical use [11]. Over the
last few decades, actinobacterial metabolites have been used as a template for the development of
anticancer agents, antibiotics, enzyme inhibitors, immunomodulators and plant growth hormones [12].
Among important genera of actinobacteria, Streptomyces is the most dominant and prolific source
of bioactive metabolites with the broad spectrum of activity. Of 10,000 known compounds, genus
Streptomyces alone accounts for nearly 7500 compounds, while the rare actinobacterial genera including
Nocardia, Micromonospora, Streptosporangium, Actinomadura, Saccharopolyspora and Actinoplanes represent
2500 compounds [13]. Although the majority of the actinobacterial bioactive metabolites come from
terrestrial habitats, recent studies on actinobacteria from diverse habitats have suggested new chemical
entities and bioactive compounds [14]. Moreover, the possibility of finding a novel bioactive molecule
from the terrestrial habitat has diminished over the years [15]. The marine ecosystem is an untapped
and underexploited source for the discovery of novel metabolites. Species isolated from marine
environments have found to be different in physiological, biochemical and molecular characteristics
from their terrestrial counterparts and therefore might produce novel metabolites [16]. With the
increase in resistance among pathogens and unavailability of novel metabolites from terrestrial sources,
marine-derived drugs could be of great importance. However, the distribution of actinobacteria in
the marine ecosystem has not been explored much and the knowledge about the marine-derived
metabolites remains elusive. But, recent outbreaks about the marine actinobacterial-derived bioactive
metabolites with distinct lead molecules have made a significant contribution in drug discovery and
may lead to the development of new drugs in future.
The present work therefore aimed to investigate the potential of secondary metabolites produced
by marine actinobacteria Streptomyces sp.S2A and their characterization.
2. Materials and Methods
2.1. Sample Collection
Marine sediment samples were collected from Gulf of Mannar Marine National Park (Latitude
9.127823◦ N, Longitude 79.466155◦ E), Rameshwaram, India. The collected sediment samples
were brought to the laboratory in sterile zip-lock plastic bags and stored at 4 ◦C until further use.
The sediments were pre-treated with CaCO3 and kept in hot air oven at 55 ◦C for 20 min [17].
2.2. Actinobacterial Isolates
Isolation of the actinobacterial strain was determined by serial dilution method on starch
casein agar (Himedia, New Delhi, India) supplemented with nalidixic acid (25 μg/mL) and nystatin
(50 μg/mL). The plates were incubated at 28 ◦C for 7 days. After incubation, individual colonies were
maintained on ISP-2 slants and stored at 4 ◦C for further use. The ornamentation of the spore chain
was analyzed by SEM.
2.3. Molecular Identification of Actinobacteria
Genomic DNA extraction of the strain was done using the phenol-chloroform method. The
selected colony was grown in ISP-2 (International Streptomyces Project) broth on the rotary shaker
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(140 rpm, Hahn-Shin, Bucheon, South Korea) at 28 ◦C, pH 7.2 for 14 days. The cells were harvested by
centrifugation at 8000 rpm for 10 min and the pellet was washed twice with normal saline. Washed
pellet was suspended in 10 mM Tris-HCl (pH 8, Merck, Burlington, VT, USA) and lysozyme (2.5 mg/Ml,
Sigma, Burlington, VT, USA), incubated at 37 ◦C for 1 h and was re-suspended in lysis buffer (50 mM
Tris, 10 mM ethylenediaminetetraacetic acid (EDTA, Qualigens Fine Chemicals Pvt. Ltd., San Diego,
CA, USA), 1% sodium dodecyl sulfate (SDS, Sigma)) and proteinase K (1 mg/mL, Sigma) and incubated
for 1 h at 50 ◦C. 400 μL of phenol (Tris-saturated, Himedia, New Delhi, India) was added and mixed
vigorously for 2 min. After centrifugation, the upper aqueous layer was transferred to the fresh tube
(Tarsons, Kolkata, India), followed by the addition of CHCl3 (Sigma) and isoamyl alcohol (Merck)
(24:1) and centrifuged at 1000 rpm for 15 min (4 ◦C). To the supernatant 50 μL of NaCl (5M) and twice
the volume of absolute alcohol (Himedia) was added and kept for overnight incubation. Again, it was
centrifuged at 14,000 rpm for 15 min and the pellet was washed with 70% alcohol. Pellet was air dried
to remove traces of ethanol (EtOH, Himedia) and was suspended in 30 μL of Tris-EDTA (TE) buffer
(Himedia). DNA was analyzed by 1% agarose gel electrophoresis (Bio-Rad, Hercules, CA, USA).
16S rRNA gene amplification was carried out using universal primer set, 27F (5′-AGAGTTTGA
TCCTGGCTCAG-3′) and 1492R (5′-ACGGCTACCTTGTTACGACTT-3′). The PCR conditions were
programmed as follows: Initial denaturation at 95 ◦C for 5 min; followed by 35 cycles at 95 ◦C for 1 min,
primer annealing at 54 ◦C for 1 min, extension at 72 ◦C for 1 min. Final extension was done at 72 ◦C for
10 min and was kept for cooling at 10 ◦C. The amplified products were determined at 1.8% agarose gel
electrophoresis. The sequence was compared with similar 16S rRNA sequences obtained from BLAST
search in National Center for Biotechnology Information (NCBI) database and the phylogenetic tree
was constructed by the neighbor joining tree algorithm using MEGA 7.0 software (Mega, Raynham,
MA, USA).
2.4. Fermentation
Isolate Streptomyces sp.S2A was inoculated in ISP-2 broth (Himedia) and kept for incubation at
the rotary shaker (140 rpm, 28 ◦C) for 14 days. The culture broth obtained was extracted thrice with
ethyl acetate (EA, Fisher Scientific, Madison, WI, USA) and concentrated under the rotary evaporator
at 50 ◦C.
2.5. Antimicrobial Assays
2.5.1. Disc Diffusion Method
Antimicrobial activity of active fraction was assessed by disk diffusion method against
Staphylococcus epidermidis (MTCC 435), Staphylococcus aureus (MTCC 740), Bacillus cereus (MTCC 1272),
Escherichia coli (MTCC 40), Klebsiella pneumoniae (MTCC 661), Micrococcus luteus (MTCC 7950)
Aspergillus flavus (MTCC 2590), Fusarium moniliforme (MTCC 6576), Bipolaris maydis and
Alternaria alternata (MTCC 1362). The sterile discs (6 mm, Himedia) were impregnated with 30 μL of
crude extract. The pathogens were inoculated in Mueller-Hinton broth (24 h for bacteria, Himedia)
and Sabouraud Dextrose both (72 h for fungi, Himedia). The well-grown bacterial and fungal cultures
were plated on Mueller-Hinton agar and Potato Dextrose agar respectively (Himedia). Sterile discs
loaded with extract were placed on the plate. Chloramphenicol discs (Himedia) were used as positive
control for antibacterial assay, while nystatin discs (Himedia) were used for the antifungal assay. Discs
impregnated with dimethyl sulfoxide (DMSO, Himedia) were used as the solvent control. The plates
were incubated at 37 ◦C and room temperature (for test bacteria and fungi respectively) and the zone
of inhibition was measured.
2.5.2. Determination of Minimum Inhibitory Concentration
The minimum inhibitory concentration (MIC) value of the partially purified extract (PPE) was
determined by micro dilution method. Bacterial and fungal pathogens were grown in sterile broth and
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10 μL of log phase culture was added into 96 well micro titre plates. Partially purified fractions were
dissolved in 1% DMSO and serially diluted to give required concentrations (1 mg/mL–3.9 μg/mL).
Diluted fractions and sterile broth were added into pre-coated microbial cultures, making up a total
of volume of 200 μL. The plate was incubated at 37 ◦C and room temperature (for test bacteria and
fungi respectively).
2.6. Antioxidant Assays
2.6.1. 2,2-diphenyl-1-picrylhydrazyl Radical Scavenging Activity (DPPH)
DPPH free radicals are highly stable and widely used to evaluate the radical scavenging activity
of the antioxidants. Scavenging activity is based upon the reduction of DPPH radicals by hydrogen
donating antioxidant compounds by forming DPPH-H. Radical scavenging activity of the ethyl acetate
extract of the strain S2A was examined based on the previously described method by Ser et al. with
minor changes [18]. Varying concentration of S2A extract was dissolved in methanol and reacted with
freshly prepared DPPH solution (60 Mm, Sigma). The reaction mixture was incubated for 30 min
in the dark. The absorbance was measured at 520 nm. Decreasing absorbance of DPPH solution
indicates an increase in radical scavenging activity. The scavenging activity (%) was calculated using
the following equation:
DPPH scavenging activity (%) = [(Ao − A1)/Ao] × 100,
where Ao is the absorbance of control (blank) and A1 is the absorbance of the sample. Methanol was
used as a blank whereas trolox (Sigma) was used as the reference compound [19].
2.6.2. Metal Chelating Activity
The metal chelating activity was examined by measuring the ability of the compound to compete
with ferrozine for Fe2+, complex of which can be quantified spectrophotometrically. Metal chelating
activity was measured by the method previously described by Adjimani and Asare with minor
modifications [20]. Assay measures the reduction in the color intensity as a result of disruption of
ferrous ion and ferrozine complexes. Briefly, varying concentration of extract was added to 0.15 mL
of 2 mM FeCl2. The reaction was initiated with the addition of 5 mM ferrozine (Sigma), followed by
the incubation at the room temperature for 10 min. The absorbance was measured at 562 nm. The
percentage of inhibition was calculated using the following equation:
Metal chelating activity (%) = [(Ao − A1)/Ao] × 100,
where Ao is the absorbance of control and A1 is the absorbance of the sample. EDTA was used as a
positive control.
2.6.3. 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) Radical Scavenging Activity (ABTS)
ABTS (Sigma) scavenging activity is based upon the reduction of ABTS* radicals by compounds
having lower redox potential than that of ABTS. The 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) (ABTS) radical scavenging assay was carried out according to the method developed by
Ser et al. [21]. Initially, ABTS stock solution (7 mM) was mixed with potassium persulfate (2.45 Mm,
Himedia) to form ABTS cation complex for 12 h. The ABTS complex solution was added to varying
concentrations of the extract preloaded in a 96-well microplate. The reaction was kept for incubation at
room temperature for 20 min and the absorbance was measured at 734 nm. The percentage scavenging
activity was calculated using the following formula:
ABTS radical scavenging activity (%) = [(Ao − A1)/Ao] × 100,
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where Ao is the absorbance of control and A1 is the absorbance of the sample. Trolox (Sigma) was used
as a positive control.
2.6.4. Ferric Reducing Antioxidant Power (FRAP) Assay
This assay determined the reduction of ferric ions to ferrous ions which was monitored
spectrophotometrically at 593 nm. The FRAP assay was performed according to the method previously
described by Benzy and Strain with minor modification [22], based on the reduction of ferric complex
to ferrous complex by the antioxidants. Initially, FRAP reagent was prepared by adding acetate buffer
(pH 3.6), 10 mM TPTZ (Sigma) and 20 mM FeCl3 (Himedia) at a ratio of 10:1:1. The reaction was
started with the addition of varying concentration of extracts to the FRAP reagent. The mixture was
then incubated at 37 ◦C for 10 min and absorbance was measured at 593 nm. Trolox was used as the
positive control. The final FRAP values were expressed as Trolox equivalent antioxidant capacity (μM
TE/g sample).
2.7. Enzyme Inhibitory Activities
2.7.1. Inhibition Assays for α-glucosidase Activity
The α-glucosidase inhibition was determined by the 96-well microtiter plate method based on
the calorimetric assay as previously described by Vinholes et al. [23]. α-glucosidase enzyme solution
(2U mL−1, Sigma) was prepared in 100 mM phosphate buffer (pH 7.0). Ethyl acetate extracts were
used in concentrations ranging from 10–100 μg mL−1. 2 mM of para-nitrophenyl-α-D-glucopyranoside
(Sigma) was prepared in 50 mM phosphate buffer (pH 7.0). 50 μL of the partially purified fraction was
pre-incubated with an equal volume of yeast enzyme at 37 ◦C for 5 min, followed by the addition of
30 μL of pNPG and further incubation for 30 min. After incubation, 100 μL of stopping reagent (0.1 M
Na2CO3) was added to cease the reaction. Color produced was quantified by UV spectrophotometer
(Shimadzu, Kyoto, Japan) at 405 nm. Each experiment was performed in triplicate. Acarbose (Sigma)
was used as a positive control, whereas purified fraction was replaced by phosphate buffer in control.
Reaction mixture without enzyme was taken as blank. The percentage inhibition (%) was determined
by the formula:
percentage inhibition (%) =
absorbance of control − absorbance of sample
absorbance of control
× 100
2.7.2. Inhibition Assays for α-amylase Activity
The α-amylase inhibition was determined by 96-well microtiter plate method based on
calorimetric assay as previously described by Balasubramaniam et al. [24]. Equal volume of test
samples (5 mg mL−1) and α-amylase solution (0.5 mg mL−1, Sigma) prepared in 30 mM phosphate
buffer (pH 7.0) was pre- incubated at 37 ◦C for 10 min. 50 μL of 0.5% starch solution was added
and incubated for 10 min at 37 ◦C. 120 μL of DNS reagent (Sigma) was added to stop the reaction.
The reaction mixture was incubated at 95 ◦C for 5 min, cooled to room temperature. Absorbance was
measured at 540 nm in a microplate reader. Acarbose at the concentration 2 mg mL−1 was taken as
positive control. The inhibition percentage of amylase was determined by the formula reported in the
previous paragraph.
2.8. Cytotoxicity Assay
The human cell lines HT-29 (Colon cancer), MDA (Breast cancer) and U-87 MG (Brain cancer)
were procured from National Centre for Cell Science, Pune, India. The cell lines were cultured and
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) in T-flasks in the incubator
at 37 ◦C and internal atmosphere of 95% air and 5% CO2. The cytotoxicity was determined by
standard MTT dye assay, according to the method described by Carmichael et al. [25]. Briefly, varying
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concentration of extracts were dissolved in 1% DMSO and treated to cells seeded in 96 well tissue
culture plates. The plates were kept for incubation at 37 ◦C for 24 h, MTT solution (Sigma) was added
and incubated for 4 h at 37 ◦C. The amount of purple formazan crystals resulting from the reduction of
MTT dye by succinic dehydrogenase in mitochondria of the viable cells was determined by measuring
OD at 570 nm. The IC50 value was calculated using graph pad prism. Each assay was performed
in triplicate.
2.9. Gas Chromatography-Mass Spectrometry (GC-MS)
The analysis of the volatile constituents in extracts was determined by GC-MS technique (Perkin
Elmer Clarus, USA). Perkin Elmer Clarus 680 employed a fused silica column, packed with Elite-5MS
and the compounds were separated using helium as a carrier gas at a constant flow of 1 mL/min. The
injector temperature was kept at 260 ◦C. Oven temperature was set as follows: 60 ◦C (2 min); followed
by 300 ◦C at the rate of 10 ◦C min−1. The spectrum thus obtained was compared with the database of
the already known spectrum of components stored in GC-MS NIST library. The infrared spectrum of
the extract was analyzed by FT-IR spectrophotometer in the range of 400–4000 cm−1.
3. Results
3.1. Isolation and Molecular Identification of the Strain
Marine sediment from Gulf of Mannar was pre-treated with physical and chemical methods.
Grown on SCA and ISP-2 medium, the cultural characteristics were identical on either of them.
The aerial hyphae were white in color and substrate mycelium was colorless. SCA and ISP-2
culture plates did not show any pigment diffusion. Micromorphological studies of strain using SEM
showed smooth spore ornamentation and rectiflexibilis spore morphology (Figure 1). The genomic
DNA of the strain was isolated using the phenol-chloroform method and examined for 16S r-RNA
sequence. The amplified sequences were subjected to BLAST analysis using the megablast tool of
Genebank at NCBI under the accession number (KU921225). The BLAST search revealed that the strain
belonged to Streptomyces sp. The highest similarity value index was found between the sequences of
Streptomyces sp.S2A and Streptomyces griesoruber (100%). The neighbor-joining phylogenetic tree was
drawn using MEGA 7.0 (Figure 2).
Figure 1. (A) Scanning electron micrograph showing spore ornamentation in Streptomyces sp.S2A;
(B) Microscopic image of Streptomyces sp.S2A under 100×.
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Figure 2. Phylogenetic tree of Streptomyces sp.S2A and the relationships with the closest species based
on 16S rRNA gene sequencing using the neighbor-joining method.
3.2. Antimicrobial Assays
3.2.1. Disc Diffusion Method
Antagonistic characteristics of the bioactive extract of Streptomyces sp.S2A showed potent
antagonistic activity against bacterial and fungal pathogens (Table 1). Of six bacterial pathogens,
the highest inhibition activity was manifested against Micrococcus luteus and Staphylococcus epidermidis
(16 mm). Susceptibility of Bacillus cereus, Klebsiella pneumoniae and Staphylococcus aureus to
bioactive compounds was highly noticeable (14 mm). Escherichia coli was less susceptible to the
compound (10 mm). Among fungal pathogens, reduction in mycelial growth was not seen against
Aspergillus flavus and Alternaria alternata whereas inhibitory activity was significantly observed against
Fusarium moniliforme and Bipolaris maydis (See Supplementary Figure S1).
Table 1. Antimicrobial activity and MIC (μg/mL) of Streptomyces sp.S2A by broth dilution method.
Test Microorganisms Zone of Inhibition (mm) MIC (μg/mL)
Bacteria Extract Antibiotics (Chloramphenicol)
Klebsiella pneumoniae MTCC 661 14 ± 0.4 30 ± 1.1 31.25
Micrococcus luteus MTCC 7950 16 ± 0.8 28 ± 1.6 7.81
Escherichia coli MTCC 40 10 ± 0.8 22 ± 1.9 15.62
Bacillus cereus MTCC 1272 14 ± 1.2 25 ± 1.1 15.62
Staphylococcus epidermidis MTCC 435 16 ± 0.4 23 ± 1.8 15.62
Staphylococcus aureus MTCC 740 14 ± 0.8 24 ± 0.8 15.62
Fungi (Nystatin)
Aspergillus flavus MTCC 2590 - - -
Bipolaris maydis 14 ± 1.2 20±1.2 31.25
Alternaria alternata MTCC 1362 - - -
Fusarium moniliforme MTCC 6576 18 ± 1.2 22±1.0 7.81
3.2.2. Determination of Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentration of the extract was determined as 31.25 μg/mL
against Klebsiella pneumoniae, 15.62 μg/mL against Staphylococcus epidermidis, Staphylococcus aureus,
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Bacillus cereus and Escherichia coli. Lowest MIC was observed against Micrococcus luteus as 7.8 μg/mL.
The solvent DMSO (1%) had no significant inhibitory activity against pathogens. MIC against
fungal pathogens was determined as 62.5 μg/mL against Bipolaris maydis and 15.62 μg/mL against
Fusarium moniliforme. (Table 1).
3.3. Antioxidant Assays
3.3.1. DPPH Radical Scavenging Activity
The highest inhibition concentration of radical scavenging activity of the extract was found to be
56.55 ± 3.1%, as compared to the trolox that was found to be 74.73 ± 1.13%. The IC50 value for DPPH
radical scavenging activity of the extract was 0.86 mg (Table 2).





% Inhibition Absorbance IC50 (mg/mL)
DPPH
1.0 56.55 ± 3.1 -
0.50 32.33 ± 1.4 - 0.86
0.25 17.29 ± 1.6 -
Metal chelating
2.0 59.98 ± 2.12 -
1.0 37.50 ± 2.36 - 1.56
0.50 24.90 ± 2.11 -
0.25 18.40 ± 1.4 -
ABTS
0.10 42.48 ± 3.1 -
0.05 30.24 ± 3.74 - 0.011




0.06 - 0.145 -
0.04 - 0.060
0.02 - 0.028
3.3.2. Metal Chelating Activity
The study showed the decrease in the formation of ferrozine-Fe2+ complex with increase in the
concentration of the extract. It showed the significant chelating activity measuring from 18.40 ± 1.4%
to 59.98 ± 2.12% at the concentration ranging from 0.25–2 mg/mL (Table 2).
3.3.3. ABTS Radical Scavenging Activity
This assay showed the significant increase in the scavenging activity with increase in the
concentration of the extract, thus decolorized the blue-green color of ABTS* back into ABTS, which is
colorless. The IC50 value for ABTS radical scavenging activity of the extract was 11.77 μg (Table 2).
3.3.4. Ferric Reducing Antioxidant Power (FRAP) Assay
The increase in absorbance was observed with the increase in the concentration of the extract
suggesting the significant antioxidant activity (Table 2).
3.4. In Vitro Enzyme Inhibition Assay
The EA extract exhibited α-amylase and α-glucosidase inhibitory activity in a dose-dependent
manner. Acarbose was used as a standard. IC50 value of EA extract for α-glucosidase and α-amylase
inhibition was found to be 21.17 and 20.46 respectively, whereas that of acarbose was 15.47 and
18.15 μg/mL respectively (Tables 3 and 4).
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6.25 29.12 ± 0.33 36.44 ± 0.58
12.5 38.54 ± 0.77 45.27 ± 0.34
25 55.1 ± 1.16 21.17 62.19 ± 1.10 15.47
50 68.4 ± 1.55 78.52 ± 1.99
100 72.31 ± 1.01 86.83 ± 2.01
200 81.74 ± 2.65 94.22 ± 2.33











6.25 16.44 ± 0.21 20.19 ± 0.78
12.5 34.77 ± 0.44 40.05 ± 0.10
25 59.29 ± 1.15 20.46 64.44 ± 1.45 18.15
50 74.32 ± 1.09 87.57 ± 1.33
100 81.13 ± 1.34 97.03 ± 1.10
200 88.67 ± 1.93 97.84 ± 1.78
3.5. Cytotoxicity Assay
The tested results of the extract against cell lines were shown in (See Supplementary Figure S2).
The results revealed that the extract showed varying efficacy against cell lines. The highest activity
against U-87 at 100 μg/mL was found to be 59.63 ± 1.9%. It also showed significant activity against
MDA and HT-29 with cell inhibition was found to be 55.23 ± 1.09% and 52.31 ± 2.4% respectively at
100 μg/mL (Table 5). Overall, the results suggested the potential cytotoxic activity against various
cell lines.
Table 5. Cytotoxic activity of extract of Streptomyces sp.S2A against HT-29, MDA and U-87 MG.
Concentration (μg/mL)
Inhibition %
U-87 MG MDA HT-29
5 13.76 ± 1.81 3.57 ± 1.76 18.51 ± 3.89
10 16.51 ± 2.01 10.71 ± 3.75 21.76 ± 2.32
20 19.26 ± 3.79 15.0 ± 4.10 23.15 ± 1.96
50 36.19 ± 2.11 30.95 ± 2.87 35.31 ± 2.77
100 59.63 ± 1.90 55.23 ± 1.09 52.31 ± 2.40
IC50 (μg/mL) 93.32 80.02 88.68
3.6. Gas Chromatography-Mass Spectrometry (GC-MS)
Analysis of components of the active fraction with the highest activity by GC-MS analysis implied
nine peaks at the retention time of (i) 17.239; (ii) 17.309; (iii) 20.811; (iv) 21.311; (v) 21.406; (vi) 21.586;
(vii) 22.071; (viii) 22.126; (ix) 24.257. Further examination of MS peaks revealed m/z at 168, 259, 210
and 350. According to NIST library search, peak retentions at 21.311, 21.406 and 21.586 correspond to
single compound i.e., pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl) (Figure 3). Other
tentatively identified compounds were diphenylmethane, 2-Isopropyl-1-Phenyl-3-Pyrrolidin-1-yl
Propane-1,3-Dione and Benzene, 1′1-tetradecyclidenebis (The GC-MS spectrum indicated the ions at
70 and 154 corresponded to molecule C7H10NO2 and C4H8 ions (See Supplementary Figures S3 and
S4). The spectrum was similar to that of pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl)
spectra in the GC-MS library and a study reported by Yang et al. [26]. The FT-IR spectrum of the
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partially purified metabolite showed the characteristic functional groups such as NH stretching peak
of a primary amine at 3313.20 cm−1. The functional group at 2923.91 cm−1 corresponded to strong C-H
stretching in alkanes. The peak at 1646.10 cm−1 was assigned to C-N stretch in primary amine. The
absorption peak at 1516.05 cm−1 was assigned to C=C stretch in an alkene. The peak at 1454.69 cm−1
was assigned to C-H bend in alkanes. The peak at 1240.27 cm−1 was assigned to C-O stretch. The
absorption peak at 1033.54 cm−1 was assigned to the ether. The peak ranging from 605.8 cm−1 to
701.09 cm−1 was assigned to strong C-H bend in alkenes (Figure 4).
Figure 3. Chemical structure of the compound pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl).
Figure 4. FT-IR spectrum of the active extract of Streptomyces sp.S2A.
4. Discussion
With this outlook, the present investigation was carried out to identify bioactive compound
from marine actinobacteria exhibiting antagonistic activity against bacterial and fungal pathogens,
enzyme inhibition activity, antioxidant and cytotoxic activity. Streptomyces sp.S2A isolated from marine
sediment of Gulf of Mannar produced white aerial mycelium to colorless substrate mycelium on
SCA medium. Shirling and Gottileb [27] reported that the pigmentation paradigm could be used
for the classification and identification. However, there was no pigment pattern observed with the
isolate. Extraction of metabolites with ethyl acetate yielded the dark color residue. Purification by
silica gel column chromatography resulted in six fractions, of which one fraction exhibited significant
activity. The antagonistic activity of the bioactive compound showed the high zone of inhibition against
Micrococcus luteus and Staphylococcus epidermidis (16 mm). Moderate activity was observed against
Bacillus cereus, Klebsiella pneumoniae and Staphylococcus aureus (14 mm). Susceptibility of Escherichia coli
to the compound was found to be weaker (10 mm). Inhibitory potential of the bioactive compound
against fungal pathogens showed good activity against Fusarium moniliforme and Bipolaris maydis,
whereas no zone of inhibition was observed against Aspergillus flavus and Alternaria aleternata. MIC was
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used to determine the efficacy of the compound at different concentration. The reduction in the growth
of bacterial pathogens was observed with the concentration ranging from 7.8–31.25 μg/mL. MIC of
the compound showed excellent antifungal activity against Fusarium moniliforme and Bipolaris maydis.
Ethyl acetate extract of Streptomyces sp.S2A also showed significant α-glucosidase and α-amylase
inhibition activity, though IC50 of the extract were less than that of acarbose. Antioxidant and cytotoxic
activities of the extract was determined by the DPPH, ABTS, FRAP and metal chelating assays and
against HT-29, MDA and U-87 MG cell lines. The results thus obtained showed the presence of potent
antioxidant and anticancer agents.
The partial chemical composition relates to the metabolite was detected by GC-MS. The
chromatogram of fraction A43 showed a total of nine peaks. Of all, the major constituent was
pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl)-, constituted 80.7% and this may be the
active principle compound. The other chemical compound was identified as diphenylmethane (6%),
2-Isopropyl-1-Phenyl-3-Pyrrolidin-1-yl-Propane-1,3-Dione (2%) and Benzene, 1′1-tetradecyclidenebis
(2%). Pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl is a peptide derivative of
diketopiperazine with the molecular weight as 210 and empirical formula as C11H18N2O2. All the
bioassays mentioned in the above paragraph were confirmed with the commercially available purified
compound: pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl). Antimicrobial and the
cytotoxic activity of the purified compound were found to be significantly higher the partially purified
compound, whereas the enzyme inhibition potential of the partially purified compound against
α-glucosidase and α-amylase were better in comparison with commercial compound. The mass
spectrum of the commercial compound corresponds to 70.0315 m/z and 154.0152, which is same as
shown by the compound present in partially purified extract (See Supplementary Figures S5 and S6,
Tables S1–S3).
Pyrrolopyrazines are known for their wide range of biological activities such as antioxidant,
anti-angiogenesis, anti-tumor and antimicrobial [28]. Manimaram et al. reported the presence of
antibacterial metabolite, pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl) in the crude
extract of Streptomyces sp. VITMK1 isolated from mangrove soil [29]. Antifouling potential of
pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl) against Vibrio halioticoli and Loktanella
honkongensis was studied by Dash et al. [30]. Sponge-derived marine bacteria significantly inhibited
the larval settlement of Balanus amphitrite and Hydroides elegans. Another marine bacteria isolated
from the sponge, Spongia officinalis showed the potent antibacterial and antifungal activity of
pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl) [31]. Diketopiperzines derivatives
present in marine Streptomyces sp. had shown good anti-H1N1 activity [32]. Mithun and Rao also
reported the presence of pyrrolopyrazines in Micrococcus luteus with anti-cancer activity against
HCT-15 cell line [33]. Presence of pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl)
was detected in Streptomyces sp. MUM 256 isolated from the mangrove forest in Malaysia.
This compound was reported to possess antioxidant and anticancer activities [34]. Anti-cancer
metabolites were also reported from Streptomyces malaysiense sp.MUSC 136 isolated from the
mangrove ecosystem. The bioactive metabolite exhibited strong antioxidant activity and high
cytotoxic activity against HCT-116 cells [35]. The first report on marine Staphylococcus sp. derived
pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl) was reported by Lalitha et al. [36].
Purified metabolite was potentially active against lung (A549) and cervical (HeLa) cancer cells
in a dose-dependent manner. Thus, the present study suggested that the pyrrolopyrazines
derivative pyrrolo[1–a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl) may account for the
observed antagonistic, antioxidant, and cytotoxic activities in marine actinobacteria, Streptomyces
sp.S2A. The results obtained in the current study demonstrate that bioactive metabolites produced
by marine actinobacteria have tremendous potential for pharmaceutical product and are a subject of
future investigation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/6/3/72/s1.
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Abstract: Polyketides are a large group of secondary metabolites that have notable variety in their
structure and function. Polyketides exhibit a wide range of bioactivities such as antibacterial,
antifungal, anticancer, antiviral, immune-suppressing, anti-cholesterol, and anti-inflammatory
activity. Naturally, they are found in bacteria, fungi, plants, protists, insects, mollusks, and sponges.
Streptomyces is a genus of Gram-positive bacteria that has a filamentous form like fungi. This genus
is best known as one of the polyketides producers. Some examples of polyketides produced
by Streptomyces are rapamycin, oleandomycin, actinorhodin, daunorubicin, and caprazamycin.
Biosynthesis of polyketides involves a group of enzyme activities called polyketide synthases (PKSs).
There are three types of PKSs (type I, type II, and type III) in Streptomyces responsible for producing
polyketides. This paper focuses on the biosynthesis of polyketides in Streptomyces with three
structurally-different types of PKSs.
Keywords: Streptomyces; polyketides; secondary metabolite; polyketide synthases (PKSs)
1. Introduction
Polyketides, a large group of secondary metabolites, are known to possess remarkable variety,
not only in their structure, and but also in their function [1,2]. Polyketides exhibit a wide range
of bioactivities such as antibacterial (e.g., tetracycline), antifungal (e.g., amphotericin B), anticancer
(e.g., doxorubicin), antiviral (e.g., balticolid), immune-suppressing (e.g., rapamycin), anti-cholesterol
(e.g., lovastatin), and anti-inflammatory activity (e.g., flavonoids) [3–9]. Some organisms can produce
polyketides such as bacteria (e.g., tetracycline from Streptomyces aureofaciens) [10], fungi (e.g., lovastatin
from Phomopsis vexans) [11], plants (e.g., emodin from Rheum palmatum) [12], protists (e.g., maitotoxin-1
from Gambierdiscus australes) [13], insects (e.g., stegobinone from Stegobium paniceum) [14], and mollusks
(e.g., elysione from Elysia viridis) [15]. These organisms could use the polyketides they produce as
protective compounds and for pheromonal communication in the case for insects.
Since the beginning of the 1940s, the history of antibiotics has greatly related to microorganisms.
One of the groups of bacteria that produce many important antibiotics is Actinobacteria. Actinobacteria
are Gram-positive, have high GC content, and comprise various genera known for their secondary
metabolite production, such as Streptomyces, Micromonospora, Kitasatospora, Nocardiopsis, Pseudonocardia,
Nocardia, Actinoplanes, Saccharopolyspora, and Amycolatopsis [16,17]. Their most important genus is
Streptomyces, which has a filamentous form like fungi and has become a source of around two-thirds of
all known natural antibiotics [18]. Among the antibiotics produced by Streptomyces, polyketides are
one group of the very important compounds. Some examples of polyketides produced by Streptomyces
are rapamycin (produced by Streptomyces hygroscopicus), oleandomycin (produced by Streptomyces
Microorganisms 2019, 7, 124; doi:10.3390/microorganisms7050124 www.mdpi.com/journal/microorganisms195
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antibioticus), actinorhodin (produced by Streptomyces coelicolorA3(2)), daunorubicin (produced by
Streptomyces peucetius) and caprazamycin (produced by Streptomyces sp. MK730-62F2) [19–23].
Biosynthesis of polyketides is very complex because the process involves multifunctional enzymes
called polyketide synthases (PKSs). The mechanism of PKS is similar to fatty acid synthase (FAS).
The process includes many enzymatic reactions with different enzymes such as acyltransferase (AT),
which has a role in catalyzing the attachment of the substrate (e.g., acetyl or malonyl) to the acyl carrier
protein (ACP), and ketosynthase (KS), which catalyzes the condensation of substrates attached in ACP.
After condensation of the substrates, the reaction continues by incorporating ketoreductase (KR), which
reduces keto ester, dehydratase (DH), which dehydrates the compound, and enoylreductase (ER),
which reduces the carbon-carbon double bond in the molecule (Figure 1). Unlike in FAS, the process
catalyzed by KR, DH, and ER is optional in PKSs, which can give the various structures of polyketides
with keto groups, hydroxy groups, and/or double bonds in different locations of the molecule [24–26].
In Streptomyces, there are three types of PKSs (type I, type II, and type III) [27–29]. This review describes
the biosynthesis of polyketides in Streptomyces with three distinct types of PKSs. The focus is only
on the Streptomyces genus because it is one of the most important producers of bioactive compounds
and one of the most well-studied microbes in terms of polyketide biosynthesis. To the best of our
knowledge, this is the first review that describes the three types of PKSs that are involved in the
biosynthesis of polyketides in Streptomyces.
Figure 1. Scheme of the reaction occurring in polyketide synthases (PKSs). ACP, acyl carrier protein; AT,
acyltransferase; KS, ketosynthase; KR, ketoreductase; DH, dehydratase; ER, enoylreductase. Adapted
with permission of Portland Press, from Vance, S.; Tkachenko, O.; Thomas, B.; Bassuni, M.; Hong,
H.; Nietlispach, D.; Broadhurst, W. Sticky swinging arm dynamics: studies of an acyl carrier protein
domain from the mycolactone polyketide synthase. Biochem. J. 2016, 473, 1097–1110 [30].
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2. Polyketide Synthases Type I
The type I polyketide synthases (type I PKSs) involve huge multifunctional proteins that have
many modules containing some domains, in which a particular enzymatic reaction occurs (Figure 2).
Each module has the responsibility of performing one condensation cycle in a non-iterative way.
Because this system works with some modules, it is also called modular PKS. The essential domains
existing in each module are acyltransferase (AT), keto synthase (KS), and acyl carrier protein (ACP)
which collaborate to produce β-keto ester intermediate. In addition, the other domains that may be
present in the module are β-ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER), which
are responsible for keto group modification. In the process of producing polyketide, the expanding
polyketide chain is transferred from one module to another module until the completed molecule is
liberated from the last module by a special enzyme [2,26,31].
Figure 2. Structure of type I PKSs with three modules and 15 domains. ACP, acyl carrier protein; AT,
acyltransferase; KS, ketosynthase; KR, ketoreductase; DH, dehydratase; ER, enoylreductase.
Furthermore, type I PKSs are generally responsible for producing macrocyclic polyketides
(macrolides), although there was also a study reporting that type I PKSs are also involved in the
biosynthesis of linear polyketide tautomycetin [32]. Macrolide belongs to a polyketide compound
characterized by a macrocyclic lactone ring, which has various bioactivities such as antibacterial,
antifungal, immunosuppressing, and anticancer. As an antibacterial agent, macrolide works by
inhibiting protein synthesis by binding to the 50S ribosomal subunit and blocking the translocation
steps of protein synthesis [8,27,33]. Some examples of macrolides produced by Streptomyces are
rapamycin, FK506, spiramycin, avermectin, methymycin, narbomycin, and pikromycin, as shown
in Figure 3 [34–37]. These compounds were produced by multifunctional polypeptides encoded by
a biosynthetic gene cluster. The list of some polyketides produced by Streptomyces with their huge
multifunctional proteins can be seen in Table 1.
2.1. Biosynthesis of Rapamycin
Rapamycin is a 31-membered ring macrolide produced by Streptomyces hygroscopicus isolated
firstly from the soil of Easter Island (Chile) in the South Pacific Ocean. It is a hydrophobic compound
and known as an antifungal compound against Candida albicans, Cryptococcus neoformans, Aspergillus
fumigatus, Fusarium oxysporum, and some pathogenic species from the genus Penicillium. The antifungal
mechanism of this compound has been described by diffusing into the cell and binding to intracellular
receptor immunophilin FKB12. The FKBP12-rapamycin complexes inhibit enzymes required for signal
transduction and cell growth. These enzymes are TOR (target of rapamycin) kinases that are conserved
and very important for cell cycle progression. Interestingly, it was also reported that rapamycin has
not only antifungal activity, but also anticancer and immunosuppressant activity [8,27,38,39].
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Figure 3. Some of the macrolides produced by Streptomyces.
Rapamycin is synthesized by type I PKS rapamycin synthase (RAPS) [40]. The rapamycin-PKS
gene cluster (rapPKS) is 107.3 kb in size and has three remarkably large ORFs (open reading frames),
rapA, rapB, and rapC which encode multifunctional protein RAPS1 (~900 kDa), RAPS2 (~1.07 MDa),
and RAPS3 (~660 kDa), respectively. Protein RAPS1 comprises four modules for polyketide chain
extension; protein RAPS2 contains six modules responsible for continuing the process of polyketide
chain elongation until C-16; and RAPS3 possesses four modules that have a role in completing
the polyketide fraction of the rapamycin molecule. Overall, these three giant proteins encompass
70 domains or enzymatic functions, and because of this, rapamycin PKSs are considered as the most
complex multienzyme system discovered so far [26,27,34].
In rapamycin PKSs, there is a loading domain (LD) before module 1. In LD, there are three
domains, i.e., coenzyme A ligase (CL), enoylreductase (ER), and acyl carrier protein (ACP) domain,
which are considered to play a role in activating, reducing a free shikimic-acid-derived moiety starter
unit, and finally passing it to the ketosynthase (KS) domain of the first module, respectively. The
extender units required for producing rapamycin are malonyl-CoA and methylmalonyl-CoA. The
mechanism of transferring from the last domain in rapamycin PKSs and cyclisation of polyketide
molecule is assisted by pipecolate-incorporating enzyme (PIE), as depicted in Figure 4. This enzyme
(170 kDa) is encoded by gene rapP, which is also located in the rapPKS gene cluster [26,27,34].
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Table 1. Some polyketides produced by Streptomyces and their type I PKSs.
Polyketide Structure Producer Type I PKSs Ref.
Avermectin 16-membered ring macrolide Streptomyces avermitilis AVES1-4 [41]
Chalcomycin 16-membered ring macrolide Streptomyces bikiniensis ChmGI-V [42]







FK506 (Tacrolimus) 23-membered ring macrolide Streptomyces tsukubaensis,
Streptomyces sp. MA6858
FkbABC [35,45]











14- membered ring macrolide
Streptomyces venezuelae PikAI-IV [37]
Pimaricin 26-membered ring polyene
macrolide
Streptomyces natalensis PIMS0 and PIMS1 [47]
Rapamycin 31- membered ring macrolide Streptomyces
hygroscopicus
RAPS1-3 [34]
Spiramycin 16- membered ring macrolide Streptomyces ambofaciens SrmGI-V [36]
Tautomycetin Linear Streptomyces sp. CK4412 TmcA and TmcB [32]
Tylosin 16- membered ring macrolide Streptomyces fradiae TYLGI-V [48]
2.2. Biosynthesis of Avermectin
Avermectin is a 16-membered ring macrolide and one of the notable anthelmintic compounds
produced by Streptomyces avermitilis [41,49]. The biosynthesis of avermectin involves type I PKSs
(AVES1, AVES2, AVES3, and AVES4). AVES1 (414 kDa) contains one loading domain and two modules;
AVES2 (666 kDa) consists of four modules; AVES 3 (575 kDa) comprises three modules; and AVES4
(510 kDa) has three modules. The process of avermectin biosynthesis includes assembling of the
polyketide-derived initial aglycon (6, 8a-seco-6, 8a-deoxy-5-oxoavermectin aglycons) by AVES1–4,
alteration of the initial aglycon to avermectin aglycons, and, as the last step, the glycosylation
of avermectin aglycons to produce avermectins. The starter unit for avermectin biosynthesis is
isobutyryl-CoA (derived from valine) or 2-methylbutyryl-CoA (derived from isoleucine), whereas
the extender units involved in the production of avermectin are seven malonyl-CoAs (for acetate
units) and five methylmalonyl-CoAs (for propionate units). The nucleotide sequence of the avermectin
biosynthetic gene cluster comprises 18 ORFs spanning a distance of 82 kb, in which four large ORFs
encode the avermectin polyketide synthase (AVES1, AVES2, AVES3, and AVES4) and some of the
14 ORFs encode polypeptides having important roles in avermectin biosynthesis [41].
2.3. Biosynthesis of Candicidin
Candicidin is a 38-membered ring polyene macrolide produced by Streptomyces griseus IMRU
3570 that has antifungal activity. Like the other polyene compounds, the antifungal mechanism of
candicidin is also by disrupting the fungal cell membrane. Candicidin has both the amino sugar
mycosamine and the aromatic component p-aminoacetophenone in its macrolide structure [43,50].
The candicidin biosynthetic gene cluster (<205 kb) was cloned and partially sequenced. Four
genes, canP1, canP3, canP2 (incomplete), and canPF (incomplete), were determined as genes encoding
parts of type I PKSs (CanP1, CanP2, CanP3, and CanPF). CanP1 contains one loading domain and one
module; CanP2 consists of three modules; and CanP2 comprises six modules. CanPF hypothetically
serves as one end of the PKS gene cluster. The starter unit is PABA (p-aminobenzoic acid), and the
extender units are four methylmalonyl-CoAs and 17 malonyl-CoAs. At the end of the process in
PKS, the molecule is released by thioesterase (CanT). In the next step, the compound is cyclized to
become candicidin aglycone, oxidized by P450 monooxygenase (CanC) with aid from ferredoxin
(CanF). The last step is glycosylation by adding mycosamine to the structure [43,44].
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Figure 4. Biosynthesis of rapamycin. ACP, acyl carrier protein; AT, acyltransferase; KS, ketosynthase;
KR, ketoreductase; DH, dehydratase; ER, enoylreductase; PIE, pipecolate-incorporating enzyme.
Adapted with permission from Schwecke, T.; Aparicio, J.F.; Molnár, I.; König, A; Khaw, L.E.;
Haydock, S.F.; Oliynyk, M.; Caffrey, P.; Cortés, J.; Lester, J.B. The biosynthetic gene cluster for
the polyketide immunosuppressant rapamycin. Proc. Natl. Acad. Sci. USA 1995, 92, 7839–7843,
doi:10.1073/pnas.92.17.7839 [34]. Copyright (1995) National Academy of Sciences, U.S.A. Adapted
with permission of The Royal Society of Chemistry 2001, from Staunton, J.; Weissman, K.J. Polyketide
biosynthesis: A millennium review. Nat. Prod. Rep. 2001, 18, 380–416 [26]; permission conveyed
through Copyright Clearance Center, Inc.
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2.4. Biosynthesis of Tautomycetin
Tautomycetin, firstly isolated from Streptomyces griseochromogenes and then from Streptomyces sp.
CK4412, is an antifungal compound and an activated T cell-specific immunosuppressive compound.
The inhibition of T-cells’ proliferation is by the apoptosis mechanism. Unlike the other type I
polyketide-derived compounds, tautomycetin has a linear structure [32,51].
The tautomycetin (TMC) biosynthetic gene cluster (~70 kb) has two ORFs that encode type I
PKSs (Tmc A and TmcB). TmcA has six modules including the loading module, and TmcB has four
modules, the TE (thioesterase) domain of which is located in TmcB. TE domain is responsible for
releasing the intermediate chain of the compound from the PKS. The biosynthesis of TMC requires
malonyl-CoA as a starter unit and the extender units such as 4 malonyl-CoAs, 4 methylmalonyl-CoAs,
and 1 ethylmalonyl-CoA. After being released from PKS, the intermediate compound is modified by
post-PKS mechanisms such as hydroxylation, decarboxylation, dehydration, and esterification with
the cyclic C8 dialkylmaleic anhydride moiety [32].
3. Polyketide Synthases Type II
The type II polyketide synthases (type II PKSs) are responsible for producing aromatic
polyketide. Based on the polyphenolic ring system and their biosynthetic pathways, the aromatic
polyketides produced by type II PKSs generally are classified into seven groups, i.e., anthracyclines,
angucyclines, aureolic acids, tetracyclines, tetracenomycins, pradimicin-type polyphenols, and
benzoisochromanequinones [52].
Anthracyclines consists of a linear tetracyclic ring system with quinone–hydroquinone groups in
rings B and C. Angucyclines have an angular tetracyclic ring system. The aureolic acids have a tricyclic
chromophore. Tetracyclines contain a linear tetracyclic ring system without quinone–hydroquinone groups
in rings B and C. Tetracenomycins have a linear tetracyclic ring system with the quinone group in ring B.
Pradimicin-type polyphenols are considered as extended angucyclines. Benzoisochromanequinones
contain a quinone derivative from the isochroman structure [52]. Some examples of aromatic
polyketide produced by Streptomyces are actinorhodin (benzoisochromanequinones), doxorubicin
(anthracyclines), jadomycin B (angucyclines), oxytetracycline (tetracyclines), mithramycin (aureolic
acids), tetracenomycin C (tetracenomycins), and benastatin A (pradimicin-type polyphenols)
(Figure 5) [28,52–57].
Unlike type I PKSs that involve huge multifunctional proteins that have many modules
containing domains and perform the enzymatic reaction in a non-iterative way, the type II PKSs have
monofunctional polypeptides and work iteratively to produce aromatic polyketide. However, like the
type I PKS, the type II PKSs also comprise the acyl carrier protein (ACP) that functions as an anchor
for the nascent polyketide chain. In addition to possessing ACP, the type II PKSs also consists of two
ketosynthases units (KSα and KSβ) that work cooperatively to produce the poly-β-keto chain. The
KSα unit catalyzes the condensation of the precursors; on the other hand, the role of KSβ in the type II
PKSs is as a chain length-determining factor. The three major systems (ACP, KSα, and KSβ) are called
“minimal PKS” that work iteratively to produce aromatic polyketide. The other additional enzymes
such as ketoreductases, cyclases, and aromatases cooperate to transform the poly-β-keto chain into
the aromatic compound core. Furthermore, the post-tailoring process is conducted by oxygenases
and glycosyl and methyl transferases [52,58–60]. The list of some aromatic polyketides produced by
Streptomyces with their type II PKSs can be seen in Table 2.
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Figure 5. Some aromatic polyketides produced by Streptomyces.
3.1. Biosynthesis of Doxorubicin
Doxorubicin was isolated from Streptomyces peucetius in the early of 1960s. It belongs to
anthracyclines that have a tetracyclic ring containing quinone and a hydroquinone group in their
structure. Doxorubicin is one of the important drugs for the treatment of cancer such as breast cancer,
childhood solid tumors, soft tissue sarcomas, and aggressive lymphomas. There are some proposed
mechanisms for how doxorubicin kills the cancer cells: (i) intercalation of DNA and interference of
topoisomerase-II-mediated DNA repair; and (ii) formation of free radicals and their deterioration of
cell components such as cellular membranes, DNA, and proteins [61–63].
Daunorubicin (DNR)-doxorubicin (DXR) type II PKSs, encoded by dps genes in Streptomyces
peucetius, are involved in the formation of doxorubicin. The biosynthesis of doxorubicin requires one
propionyl-CoA as the starter unit and nine malonyl-CoAs as the extender units. The process involves
two “minimal PKSs” (DpsC-DpsD-DpsG and DpsA-DpsB-DpsG) to produce a 21-carbon decaketide as
an intermediate compound. The repetitive process is conducted by KSα (DpsA), KSβ (DpsB), and ACP
(DpsG). The next process employs several enzymes such as ketoreductase (DpsE), cyclases (DpsF, DpsY,
and DnrD), oxygenase (DnrG and DnrF), and methyl transferase (DnrC) to produce ε-rhodomycinone,
an important intermediate of doxorubicin biosynthesis. The remaining steps to synthesize doxorubicin
utilize glycosyltransferase (DnrS) with the thymidine-diphospho (TDP) derivative of l-daunosamine,
methyl esterase (DnrP), oxygenase (DoxA), and methyl transferase (DnrK) (Figure 6) [60,64–68].
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Figure 6. Biosynthesis of doxorubicin. Adapted with permission of The Royal Society of Chemistry
2009, from Chan, Y.A.; Podevels, A.M.; Kevany, B.M.; Thomas, M.G. Biosynthesis of polyketide synthase
extender units. Nat. Prod. Rep. 2009, 26, 90–114 [60]; permission conveyed through Copyright Clearance
Center, Inc.








Medermycin octaketide Streptomyces sp. K73 Med-1,2,23 [69,70]
Doxorubicin decaketide Streptomyces peucetius DpsABCDG [60,65]
Oxytetracycline decaketide Streptomyces rimosus OxyABCD [71]
Gilvocarcin decaketide Streptomyces griseoflavus Gö 3592 GilABC [72]
Oviedomycin decaketide Streptomyces antibioticus OvmPKS [73]
Chartreusin decaketide Streptomyces chartreusis ChaABC [74]
Cervimycin decaketide Streptomyces tendae HKI-179 CerABC [75,76]
Resistomycin decaketide Streptomyces resistomycificus RemABC [77]
Chromomycin decaketide Streptomyces griseus subsp. griseus CmmPKS [78,79]
Hedamycin dodecaketide Streptomyces griseoruber HedCDE [80,81]
Fredericamycin pentadecaketide Streptomyces griseus ATCC 49344 FdmFSGH [82,83]
3.2. Biosynthesis of Medermycin
Medermycin is a benzoisochromanequinone (BIQ) antibiotic, isolated from Streptomyces sp. K73.
It has high activity against some Gram-positive bacteria such as Staphylococcus aureus, Staphylococcus
epidermidis, Sarcina lutea, Bacillus subtilis, and Bacillus cereus. Besides antibiotic activity, medermycin
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also has potent activity as a platelet aggregation inhibitor. Because of its unique ability to give
different colors in acidic and alkaline aqueous solution, medermycin is considered as an indicator type
antibiotic [69,70,84].
Biosynthesis of medermycin requires eight malonyl-CoAs and a sugar molecule, angolosamine,
which is derived from the deoxyhexose (DOH) pathway. In the first step of biosynthesis, the minimal
PKS that consists of ACP (encoded by the med-ORF23 gene), KSα (encoded by med-ORF1), and KSβ
(encoded by med-ORF2) forms an octaketide moiety. The next process employs several enzymes such
as keto reductase, aromatase, cyclase, enoyl reductase, and oxygenase/hydroxylase to produce the
aglycone compound dihydrokalafungin. The aglycone structure then is combined by C-glycosyl
transferase with an angolosamine structure to yield the final structure medermycin [69].
3.3. Biosynthesis of Hedamycin
Hedamycin is a pluramycin antitumor antibiotic, produced by Streptomyces griseoruber. This
aromatic polyketide has a planar anthrapyrantrione chromophore, two amino sugars in its structure
(α-l-N,N-dimethylvancosamine and β-d-angolosamine), and a bisepoxide-containing a side chain.
The compound could inhibit 50% of human cancer cell growth at a subnanomolar concentration in
three days. It is a monofunctional DNA alkylating agent, and because of its low therapeutic index,
hedamycin is not clinically used [81,85].
Biosynthesis of hedamycin uses twelve malonyl-CoAs and two amino sugars, vancosamine and
an angolosamine moiety. The minimal type II PKSs of hedamycin biosynthesis consist of HedC
(KSα), HedD (CLF), and HedE (ACP). Uniquely, the initial process involves type I PKSs (HedT and
HedU proteins) that produce the 2,4-hexadienyl primer unit from three malonyl-CoAs, and then,
it is transferred to the minimal type II PKSs of hedamycin biosynthesis. After that, a dodecaketide
structure is formed by processing nine malonyl-CoAs. The structure then is modified with keto
reductase, aromatase/cyclase, and oxygenase into the aglycone compound. In the last step, two
glycosyltransferases are used for incorporating two amino sugars to produce hedamycin [80,81].
3.4. Biosynthesis of Fredericamycin
Fredericamycin, isolated from Streptomyces griseus ATCC 49344, is an aromatic polyketide that
contains a spirocyclic structure. It has moderate antitumor and cytotoxic activity in various cell
lines. These bioactivities are suggested because of the blockage of topoisomerases I and II or the
peptidyl-prolyl cis-trans isomerase Pin1 [83].
The biosynthesis of fredericamycin employs the minimal type II PKSs that contains KSα (FdmF
and FdmS), KSβ (FdmG), and ACP (FdmH). There are two alternative mechanisms for chain initiation
in the biosynthesis of fredericamycin. The first one requires acetyl-CoA and two malonyl-CoAs to
produce the hexadienyl-priming unit. The second mechanism is by utilizing butyryl- or crotonyl-CoA
and one malonyl-CoA to yield the hexadienyl-priming unit. The next step is carried out by processing
twelve malonyl-CoAs as extender units to give the pentadecaketide intermediate, and then, the cyclases
and oxygenases modify the intermediate compound into the final product [82,83,86].
4. Polyketide Synthases Type III
Unlike the type I and type II PKSs, the type III PKSs do not utilize ACP as an anchor for the
production of polyketide metabolite. In this case, acyl-CoAs are used directly as substrates for
generating polyketide compounds. In order to create polyketides, this system contains enzymes that
construct homodimers and catalyzes many reactions such as priming, extension, and cyclization in an
iterative way. With this fact, the type III PKSs are the simplest structures among the other types of
PKSs. The type III PKSs found in bacteria were reported the first time in1999, and before that time, the
type III PKSs were known only to be detected in plants [87–89].
Some studies previously revealed that type III PKSs could also be identified in the
Streptomyces such as RppA, found in Streptomyces griseus, which is responsible in the synthesis of
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1,3,6,8-tetrahydroxynaphthalene (THN) [90]. Gcs, identified in Streptomyces coelicolor A3(2), is reported
to have an important role in the biosynthesis of germicidin [91]. SrsA, encoded by the srsA gene and
isolated from Streptomyces griseus, is known to have an important role in the biosynthesis of phenolic
lipids, i.e., alkylresorcinols and alkylpyrones [29].
The type III PKS Ken2, isolated from Streptomyces violaceoruber, was suggested to be involved in
the production of 3,5-dihydroxyphenylglycine (3,5-DHPG). This compound is a nonproteinogenic
amino acid needed for the formation of kendomycin and several other glycopeptide antibiotics such as
balhimycin, chloroeremomycin, and also vancomycin [92]. Cpz6, encoded by the cpz6 gene and isolated
from Streptomyces sp. MK730–62F2, was reported to be engaged in the biosynthesis of caprazamycins
by producing a group of new triketidepyrenes (presulficidins) [93]. Moreover, another finding also
suggested that DpyA catalyzes the formation of alkyldihydropyrones in Streptomyces reveromyceticus
(Figure 7) [94].
Figure 7. Some compounds produced by type III PKSs.
4.1. Biosynthesis of Germicidin
Germicidin, a pyrone-derived polyketide, is produced by a type III PKS germicidin synthase
(Gcs) and is known to inhibit spore germination. Germicidin A, produced by Streptomyces
viridochromogenes and Streptomyces coelicolor, prevents the spore germination reversibly at a very
low concentration (40 pg/mL). The mechanism of inhibition is suggested by affecting the sporal
respiratory chain and blocking Ca2+-activated ATPase, thus resulting in inadequate energy for spore
germination. Furthermore, germicidin A also has antibacterial properties against various Gram-positive
bacteria [95,96].
Although many bacterial type III PKSs use only malonyl-CoA as both starter and extender units,
the type III PKS Gcs, which is responsible for germicidin biosynthesis, is suggested to have the ability
to utilize either acyl-ACP or acyl-CoA such as medium-chain acyl-CoAs (C4–C8) as starter units and
malonyl-CoA, methylmalonyl-CoA, and ethylmalonyl-CoA as extender units [97,98]. In the first step,
the starter unit is transacylated onto the cysteine residue of Gcs, and then, Gcs catalyzes the condensation
reaction between the starter unit and extender unit concomitantly with the decarboxylation process,
resulting in β-ketoacyl-CoA. The process continues with β-ketoacyl-CoA, which transacylates back
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onto the cysteine residue of Gcs (repetitive process) and subsequently undergoes a condensation
reaction with either methylmalonyl-CoA or ethylmalonyl-CoA simultaneously with decarboxylation to
formulate β,δ-diketothioester of CoA or a triketide intermediate. In the end of the reaction, cyclization
of the β,δ-diketothioester of CoA is carried out to produce various types of germicidins (Figure 8) [91].
Figure 8. Biosynthesis of germicidins. Gcs: germicidin synthase. Adapted with permission from
Song, L.; Barona-Gomez, F.; Corre, C.; Xiang, L.; Udwary, D.W.; Austin, M.B.; Noel, J.P.; Moore, B.S.;
Challis, G.L. Type III polyketide synthase β-ketoacyl-ACP starter unit and ethylmalonyl-coA extender
unit selectivity discovered by Streptomyces coelicolor genome mining. J. Am. Chem. Soc. 2006, 128,
14754–14755 [91]. Copyright 2006 American Chemical Society.
4.2. Biosynthesis of Tetrahydroxynaphthalene
Tetrahydroxynaphthalene or THN is a small aromatic compound that is produced by utilizing
type III PKSs (RppA). The biosynthesis process of THN requires five molecules of malonyl-CoA to form
a pentaketide intermediate structure, and then, it is cyclized and aromatized to yield THN product.
Spontaneous oxidation of THN may result flaviolin (red pigment) [90,99,100].
4.3. Biosynthesis of Dihydroxyphenylglycine
In order to synthesize 3,5-dihydroxyphenylglycine (3,5-DHPG), four malonyl-CoAs are needed,
and the process is catalyzed by type III PKS (Ken2 or DpgA), which leads to the formation of the
intermediate tetraketide compound. The tetraketide further is modified by hydratase/dehydratase,
and oxidase/thioesterase to form 3,5-dihydroxyphenylacetic acid. The final step involves transaminase
and tyrosine, as the amino group donor, to yield 3,5-DHPG, which is known as a nonproteinogenic
amino acid [92,100,101].
4.4. Biosynthesis of Alkylresorcinol
The alkylresorcinol biosynthesis in Streptomyces griseus is catalyzed by SrsA. The reaction needs
fatty acid (starter unit), one methylmalonyl-CoA, and two malonyl-CoAs (extender unit), and the
intermediate structure is tetraketide. The tetraketide structure then transforms into the aromatic
compound nonenzymatically (alkylresorcinol). This reaction may occur because of the nucleophilic
attack on the thioester group by the methine carbon of the intermediate tetraketide compound [29].
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5. Conclusions
Streptomyces has various systems in order to produce polyketides with different structures and
functions. Knowing the polyketide structures, activities, producing enzymes, starter units, extender
units, and the structural genes are very important in the development of new drugs. Some mechanisms
of polyketide biosynthesis in Streptomyces that have been reported previously could provide strong
basic knowledge not only for the biosynthesis investigation of the new polyketides, but also engineering
the producing system in the future.
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Abstract: The discovery of new antibiotics is mandatory with regard to the increasing number of
resistant pathogens. One approach is the search for new antibiotic producers in nature. Among
actinomycetes, Bacillus species, and fungi, myxobacteria have been a rich source for bioactive
secondary metabolites for decades. To date, about 600 substances could be described, many of them
with antibacterial, antifungal, or cytostatic activity. But, recent cultivation-independent studies on
marine, terrestrial, or uncommon habitats unequivocally demonstrate that the number of uncultured
myxobacteria is much higher than would be expected from the number of cultivated strains. Although
several highly promising myxobacterial taxa have been identified recently, this so-called Great Plate
Count Anomaly must be overcome to get broader access to new secondary metabolite producers.
In the last years it turned out that especially new species, genera, and families of myxobacteria
are promising sources for new bioactive metabolites. Therefore, the cultivation of the hitherto
uncultivable ones is our biggest challenge.
Keywords: myxobacteria; diversity; uncultured; secondary metabolites; new antibiotics
1. Introduction
We know little about the real diversity of myxobacteria in the environment. How many
myxobacteria are cultivable under standard laboratory conditions? How many resist these cultivation
efforts and lie undiscovered in the ground? After an introduction to myxobacteria, the status of
antibiotics, myxobacterial secondary metabolites, the Great Plate Count Anomaly phenomenon,
and microbial biogeography, the diversity of cultivable and uncultivated myxobacteria in different
habitats is presented. Therefore, numerous sequences from the NCBI database were analysed. The
intent of this review is to draw attention to the high amount of undiscovered myxobacteria and
encourage further discovery and isolation of these hidden treasures with regard to their potential as
new antibiotic producers.
2. Biology and Phylogeny of Myxobacteria
Myxobacteria are soil dwelling deltaproteobacteria and are distributed all over the world.
Temperate zones, tropical rain forests, arctic tundra, deserts, acidic soils [1–3], marine and other
saline environments [4–7], and even caves [8], for example, are appropriate habitats. Myxobacteria can
be isolated from various natural sources as soil, bark, rotting wood, leaves of trees, compost [9], or
dung of herbivores [1,10]. They live aerobically, except the only described facultative anaerobic genus
and species, Anaeromyxobacter dehalogenans [11]. Nevertheless, it is highly likely that further facultative
or even strictly anaerobic myxobacteria exist, which hitherto withstand the common isolation efforts.
Currently the monophyletic order Myxococcales comprises 3 suborders, 10 families, 29 genera, and 58
species (Figure 1).
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Figure 1. Monophyletic order Myxococcales (delta-proteobacteria), suborders, families, and genera of
myxobacteria (status May 2018). The number of species within the genera is mentioned in brackets
(original graphic from Corinna Wolf, modified by K. I. Mohr).
Myxobacteria are fascinating because of their extraordinary social lifestyle, which is unique in the
bacterial domain. Under appropriate environmental conditions, vegetative cells move in swarms by
gliding over solid surfaces [12]. Myxobacteria do not have flagella, but two motility systems, used
for locomotion, and well studied in Myxococcus xanthus, are known: social (S-) motility, powered
by retraction of type IV pili is responsible for the movement of cells which travel in groups [13]. In
addition, extracellular matrix polysaccharide (EPS), also referred to as fibrils, are used. Therefore, the
intrinsic polarity of rod-shaped cells lays the foundation, and each cell uses two polar engines for
gliding on surfaces. It sprouts retractile type IV pili from the leading cell pole and secretes capsular
polysaccharide through nozzles from the trailing pole [14]. On the other hand, slime secretion enables
cell movements, when cells were isolated from the group (adventurous A-motility) [15]. For a detailed
description of myxobacterial gliding mechanisms see Nan et al. [13] and Faure et al. [16].
Due to their nutritional behavior and based on their specialization in degradation of
biomacromolecules, members of the order Myxococcales can be divided into two groups: predators
(the majority), which are able to lyse whole living cells of other microorganisms by exhausting
lytic enzymes, and cellulose-decomposers, the latter are represented by the genera Sorangium and
Byssovorax [12]. But, as mentioned for the (facultative) anaerobic myxobacteria, it is also highly likely
that further cellulose-degrading genera exist, which successfully resisted standard cultivation attempts.
If nutrients become rare, the cells undergo an impressive process of cooperative morphogenesis.
Cells agglomerate and form species-specific fruiting bodies by directed cell movement [12]. These
fruiting bodies consist of one to several sporangioles [1]. The architecture of these fruiting bodies ranges
from simple, single sporangioles (M. xanthus, Cystobacter spp.), stalked sporangioles (M. stipitatus), or
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even delicate tree-like structures of high complexity (Chondromyces spp.; Stigmatella spp.) [10]. Colors
of cells/fruiting bodies vary from milky, yellow, orange, red, brown to even black (Figure 2) [1].
 
Figure 2. Variation of myxobacterial fruiting bodies. Genus/species, strain designation, (agar
medium) are mentioned. (a) Myxococcus xanthus Mxx42 (P); (b) Cystobacter ferrugineus Cbfe48 (VY/2);
(c) Archangium sp. Ar7747 (VY/2); (d) Chondromyces sp. (Stan 21 with filter); (e) Sorangium sp. Soce
1462 degrading filter paper on Stan 21 agar; (f) Polyangium sp. Pl3323 (VY/2); (g) Cystobacter fuscus
Cbf18 (VY/2); (h) Corallococcus coralloides Ccc379 (VY/2).
A known function of these mainly carotenoid or melanoid pigments is to provide protection
against photo-oxidation [17]. Within the fruiting bodies, most of the vegetative cells die and serve as
food for the remaining cells, which convert into short and hardy myxospores, especially resistant to
desiccation [18,19]. These spores are not as heat-resistant as Bacillus spores, but they can survive in the
environment and are able to germinate under appropriate conditions even after decades of resting [1].
Therefore, it is possible to isolate myxobacteria from dried environmental samples, which were stored
for several years at room temperature [10]. A fruiting body consists of 105–106 cells [18]. This ensures
that the new cycle starts with a sufficient amount of cells, necessary for the typical collaborative
feeding [20]. A further very interesting feature of myxobacteria is their ability to produce a large
number and variety of secondary metabolites, as described in the next section.
In 1892, Thaxter was the first who described myxobacteria in literature [19]. He found out that
Chondromyces crocatus was a bacterium and he had discovered its unicellular vegetative stage. This
was spectacular, because until such time, C. crocatus had been considered a slime mold for more than
20 years [14]. Studies by Bauer [21], Kofler [20], Jahn [22,23], and Kühlwein [24] followed in the early
20th century. Myxobacteria have always fascinated scientists due to their social behavior, including
cooperative swarming, group predation, and multicellular fruiting body formation. Myxococcus xanthus
for example has become one of the model systems for the study of prokaryotic development [25].
Today, beside their capabilities to produce promising bioactive secondary metabolites, myxobacteria
are of utmost importance in elucidating multicellular behavior in bacteria, as well as working out
social evolution theory.
3. Current Status of Antibiotics and Myxobacterial Secondary Metabolites
Before the first antibiotics were commercially available in the early 20th century, people were
delivered helplessly to various kinds of infections like pest, cholera, and tuberculosis, which often
reached epidemic proportions and have cost the lives of millions of people [26]. In 1940, quinine
was used against malaria, the arsenic derivative arsphenamine, Salvarsan, was used against syphilis,
and sulfa drugs like Prontosil were used against mainly Gram-positive cocci infections. However,
most agents of infectious diseases were still untreatable. The situation improved radically with the
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detection of the first beta-lactam antibiotic, penicillin, produced by the mold Penicillium rubens [27].
Henceforth, soil organisms like fungi [28] and bacteria [29] as producers of secondary metabolites
with bioactive properties moved into the focus of research. The Golden Age of Antibiotics started.
Aminoglycosides [30], tetracyclines [31], and macrolides [32] are only some examples of important
antibiotic classes, discovered in those days. Numerous pharmaceutical companies participated on
large-scale screening activities of antibiotic producing organisms, mainly actinobacteria [33]. However,
in most cases, it took only a few years from the launch of a new antibiotic to the detection of the first
resistant germs [34]. Incorrect use in human medicine, incorrectly prescribed antibiotics, extensive
agricultural use and fast spread of resistant bacteria caused by increasing mobility led to substantial
problems with multi-drug resistant bacteria. Some of the most problematic germs belong to the
so-called ESKAPE-panel: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter spp, are mainly responsible for nosocomial
infections. Since the 1960s more and more companies retracted from the time- and cost-consuming
screening procedures. Of the 18 largest pharmaceutical companies, 15 abandoned the antibiotic
field [35]. Indeed, from the late 1960s through the early 1980s, the pharmaceutical industry introduced
many new antibiotics to solve the resistance problem. After that the antibiotic pipeline began to dry
up and fewer new drugs were brought to market [36]. This led to a dangerous bottleneck of currently
available reserve-antibiotics and a widely held concern over the lack of innovation and productivity in
the research and development of novel bioactive substances [37]. Eligible countermeasures include the
development of synthetic and semi-synthetic drugs, evaluation of rediscovered drugs and the classical
screen of natural secondary metabolite producers. Here, especially new genera and species are of
great interest [38]. But for natural production of secondary metabolites in large-scale fermentation
processes the corresponding producer strains have to be isolated from nature. Maintenance, cultivation,
and upscale are challenging. Beside the appropriate expertise and equipment for fermentation and
isolation of substances from the fermenter broth, for every producer strain the specific biotic and abiotic
conditions need to be determined. Myxobacteria for instance are one of the most promising natural
product producers, but demanding with regard to isolation and large-scale cultivation. Successful
handling of these organisms places special challenges to microbiologists and biotechnologists in
equal measure.
Myxobacteria are among the best natural product producers, together with actinomycetes [39],
Bacillus species [40], and fungi [31]. Even shortly after their discovery, scientists described predatory
and cellulolytic action of myxobacteria. Already in 1947, Singh complained that many antibiotics were
isolated from various groups of microorganisms, except myxobacteria [41]. He observed that some
species of the Myxococcaceae lyse living bacteria, including Gram-negatives such as Pseudomonas
fluorescens and Bacterium (Escherichia) coli, and concluded that a detailed study of myxobacteria may
be profitable in discovering new antibiotics. In 1955, Mathews and Dudani investigated the lysis of
human pathogenic bacteria by myxobacteria [42] and in 1962, Noren and Raper described the antibiotic
activity of myxobacteria in relation to their bacteriolytic capacity [43]. But, it took another 15 years
until the first antifungal metabolite, ambruticin, was isolated from a Sorangium strain (Figure 3) [44].
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Figure 3. Sorangium sp. strain Soce 1014, an ambruticin-producer, swarming on VY/2-agar and
the structure of ambruticin A, the first secondary metabolite which was isolated and described
from myxobacteria.
The majority of myxobacterial compounds are polyketides, non-ribosomal polypeptides, and their
hybrids, terpenoids, phenyl-propanoids, and alkaloids [45]. Many of these substances show promising
activities against bacteria [46,47], viruses [48], fungi [49], cancer cells [50] immune cells [51], and
malaria [52], respectively, as well as unusual modes of action [53]. Many strains produce metabolites
belonging to multiple structural classes, as well as a number of chemical variants on each basic
scaffold [48]. Whole-genome sequencing of several myxobacterial strains like Sorangium cellulosum [54]
and Myxococcus xanthus [55] has revealed that the secondary metabolite potential is far greater than
that suggested by fermentation under standard laboratory conditions.
It is, of course, possible to isolate new substances from known (myxobacterial) species [51,52].
But again: the low hanging fruit have long been harvested and it is more likely to find new substances
in new families, genera and species [53,56–61]. The study of Hoffmann et al. confirmed this [41]. The
authors found a correlation between taxonomic distance and the production of distinct secondary
metabolite families, and supported the idea that the chances of discovering novel metabolites are
greater by examining strains from new genera rather than additional representatives within the same
genus. For comprehensive overviews about secondary metabolites produced by myxobacteria and
their mode of action, I recommend Weissman and Müller [48] and Herrmann et al. [49].
4. The Great Plate Count Anomaly and Microbial Biogeography
Based on cultivation, approximately only 1% of the naturally occurring bacterial community is
known and characterized so far [62]. Most bacterial groups remain uncultured and uncharacterized,
because appropriate culture conditions are lacking [63]. This Great Plate Count Anomaly is the
oldest unresolved microbiological challenge. The Austrian microbiologist Heinrich Winterberg was
the first who described this phenomenon in 1898 [64]. Winterberg observed that the number of
microbial cells in his samples did not match the number of colonies formed on nutrient media. Since
Winterberg, numerous authors who investigated bacterial communities in different habitats confirmed
this phenomenon. The establishment of culture independent analytical methods in the early 1990s
greatly expanded the dimension of knowledge about the bacterial diversity again [65]. Estimations,
that about 80% of bacteria resist standard laboratory cultivation approaches were obsolete after
publication of the first culture-independent analyses of bacterial communities, which were based on
16S rRNA-coding genes. Now, the estimated amount of uncultivable species has increased to 90–99%
and it can be assumed that many of these uncultured bacteria could be probably a source for new
antibiotics [66].
Notwithstanding the frequent discovery and description of new species/genera, the real number
of myxobacteria is unknown. The current knowledge about the diversity of organisms is always just a
snapshot. However, several (NCBI) 16S rRNA-sequences of cultures belong to the order Myxococcales,
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but are only distantly related to valid type strains (up to 12% distance) and therefore probably belong to
new species, genera, or even families. One example: “Anaeromyxobacter dehalogenans” strain WY75 (Acc.
no. KC921178) was isolated from ginger foundation soil and shows highest similarity (87.4%) to the
type strain of Sandaracinus amylolyticus. It is therefore at least a representative of a new myxobacterial
family (Figure 4). Nevertheless, as long as a valid publication of such strains in taxonomic journals
as for example IJSEM or Antonie van Leeuwenhoek is absent, even the current diversity of cultivable
myxobacteria is not fully reflected.
 
Figure 4. Neighbour joining tree with myxobacterial type strains shows the phylogenetic position of
strain WY75, cultivated from ginger foundation soil, within the Sorangiineae suborder. Comparison of
16S rRNA sequences revealed only 87.4% similarity to the next myxobacterial type strain S. amylolyticus.
Accession numbers are in brackets. Bar, 0.1 substitutions per nucleotide position.
Although there are numerous reports about cultivable myxobacteria in soils and other habitats [1],
it has to be considered that myxospores may tolerate considerable environmental extremes. Most
isolation techniques involve the cultivation of extensively dried samples [10]. Species which are present
in the sample as vegetative cells will probably not survive this process and therefore will not grow on
the isolation plates. Also, and irrespective of the detection method used, it is difficult to determine
whether myxobacteria were present as dormant spores or metabolically active vegetative cells in the
environmental sample taken [12]. The standard procedure to isolate myxobacteria is drying the sample
(soil, plant material, etc.) at 30 ◦C to reduce growth of undesired bacteria and fungi, and subsequent
placement on water agar with E. coli-bait (to attract predators) and on Stan 21 agar with filter paper
(for cellulose decomposers), respectively (Figure 5). As the degradation of biomacromolecules like
microbial cells (E. coli bait) or cellulose requires a sufficient amount of viable myxobacterial cells in the
sample, underrepresented species will probably not be able to start growing.
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Figure 5. Common isolation procedure for myxobacteria: Soil/environmental sample is placed on a.
Stan 21 with filter paper to enrich cellulose decomposing strains and b. on water agar with E. coli bait
(cross) for predators. Numerous transfers of fruiting bodies/swarm edge material to fresh plates are
necessary to purify myxobacteria.
As was mentioned at the beginning, myxobacteria live in various habitats. It is recommended,
but not mandatory, to investigate uncommon habitats from different geographic regions with regard to
new secondary metabolite producers. But, already within microscale areas of environmental samples,
different strains of one myxobacterial species show surprising genetic differences, as biogeographical
studies of myxobacteria revealed. Biogeography is the study of the distribution of organisms across
space and time [67]. As mentioned by Ramette and Tiedje, prokaryotic biogeography is “the science
that documents the spatial distribution of prokaryotic taxa in the environment at local, regional,
and continental scales” [68]. Hanson et al. propose that four processes, selection, drift, dispersal,
and mutation, create and maintain microbial biogeographic patterns on inseparable ecological and
evolutionary scales [69]. For example, Bacteria and Archaea are globally distributed [70]. At the
class level, the β-proteobacteria, cyanobacteria, actinobacteria, and flavobacteria have been shown to
display worldwide distribution in marine or terrestrial ecosystems [71–73]. According to Hedlund
and Staley, at the genus level, many prokaryotes have a cosmopolitan distribution in their respective
habitats [74]. Recent global surveys indicate that most bacteria are restricted to broad habitat types, as
there is little overlap among bacterial taxa found in soils, sediments, freshwater, and seawater [75,76].
Dawid gave a comprehensive overview about the ecology and global distribution of myxobacteria
in the macroscale range [1]. The study was based on data given in the literature as well as on his
own analyses of almost 1400 soil samples from 64 countries and all continents. The study found that
an exceptionally high average species number was determined for soils from countries that belong
to the winter rain climates of the Mediterranean type, the permanent wet rain forest climates and
the tropical semi-desert climates. However, soils of countries with cold temperate coniferous forest
climates and cool temperate intermediate climates with peat mosses and coniferous forests harbor
a low average number of species. Jiang et al. determined biogeographic patterns of myxobacterial
taxa in deep-sea sediments [77]. They screened DNA from four different depths for myxobacteria-like
16S rRNA genes and provided the first evidence, that marine myxobacteria are phylogenetically
distinct from terrestrial species. Brinkhoff et al. studied the biogeography and phylogenetic diversity
of marine myxobacteria and found a deep-branching monophyletic cluster of exclusively marine
myxobacteria within the Myxococcales [78]. Wielgoss et al. sequenced the genomes of 22 Myxococcus
xanthus isolates from a 16 × 16-cm-scale patch of soil. They found out “that two closely related
M. xanthus clades inhabiting the same centimeter-scale patch of soil, display strong sexual isolation,
with homologous recombination occurring frequently between members within each clade, but with
almost no detectable levels of genetic exchange occurring across clades” [79]. Kraemer et al. resolved
the micro biogeography of social identity and genetic relatedness in local populations of M. xanthus at
small spatial scales [80]. The study comprises samples taken from fruiting bodies, neighboring fruiting
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bodies separated by millimeters, neighborhoods of fruiting bodies separated by centimeters and finally
soil patches separated by meters and kilometers. They found out that “relatedness decreases greatly
with spatial distance even across the smallest scale transition and that both, social relatedness and
genetic relatedness are maximal within individual fruiting bodies at the micrometer scale but are
much lower already across adjacent fruiting bodies at the millimeter scale.” What will this mean
with regard to myxobacteria and natural product research? The cellulose degrading genus/species
Sorangium cellulosum serves as an example: already in 2003, the myxobacterial strain collection of the
HZI (former GBF) comprises 7000 strains from which 23.2% belong to S. cellulosum. On the other
side, S. cellulosum strains produced 48.4% of all known secondary metabolites described so far from
myxobacteria [81]. This means that closely related strains also have huge potential to produce different
chemical and biological bioactive metabolites [48,49] and that the search for new antibiotic producers
can be successful in both, small and large scale. For a comprehensive overview about biogeographic
patterns of myxobacteria, I refer to Velicer et al. [82]. For a deeper insight to prokaryotic biogeography,
see the study of Ramette and Tiedje [73] and the review of Hanson et al. [74].
With regard to numerous studies based on cultivation-dependent approaches, the number of
publications that focus on the non-cultivable myxobacteria is comparatively small. Nevertheless, there
are about 4000 (often unpublished) 16S rRNA sequences deposited at the NCBI database which are
mentioned to be “uncultured Myxococcales”. Under consideration of further myxobacteria-related
sequences which are just deposited as “uncultured (delta) proteobacterium” [83] or even “uncultured
bacterium”, the true extent of uncultivated myxobacteria can just be surmised. Most of the deposited
sequences are “by-products” from cultivation-independent studies of bacterial communities in general,
without special focus on Myxococcales.
To give an impression about the diversity of cultivable and uncultivable myxobacteria in different
habitats, published and unpublished 16S rRNA sequences from NCBI are compared with each other
and the results are summarised subsequently.
5. Distribution of Myxobacteria in Different Habitats
5.1. Terrestrial Habitats
Myxobacteria are optimally adapted to terrestrial habitats, which manifests as a wide range
of different phenotypes, such as social swarming and gliding, fruiting-body formation, resting
myxospores, excretion of secondary metabolites with antibiotic or antifungal activity into the
environment, as well as predation or cellulose decomposition. It is therefore not surprising that
the majority of known species (and secondary metabolite producers) was isolated or detected from
soil samples. In 1947, Singh investigated myxobacteria in soils and composts, their distribution,
number, and lytic action on bacteria [44]. From soils of Great Britain, he isolated species of Myxococcus,
Chondrococcus (later renamed to Corallococcus) and Archangium and estimated that the numbers of
myxobacteria ranged from 2000 to 76,400/gram in soil. In an actively decomposing compost of sludge
and straw, the number of Myxococcus fulvus was more than 500,000/g. Singh was also the first who
detected the potential of myxobacteria to produce antibiotics.
In 2005, Wu et al. were the first to explore the diversity of myxobacteria (in a soil niche) by
cultivation-independent methods with myxobacteria-specific primers and probes [84]. Moreover, in
the latter study members of Myxococcus, Corallococcus, Cystobacter, and Nannocystis were cultivated.
Nevertheless, screening a special library using Cystobacterineae- and Sorangiineae-specific probes
and subsequent sequence analyses revealed a somewhat higher number of myxobacteria within the
sample, from which many show only minor similarity to known species. Therefore, even in this first
cultivation-independent study about Myxococcales, the authors suggested that myxobacteria in nature
are much more diverse than were ever known, even in a single soil sample.
Jiang et al. investigated fruiting and non-fruiting myxobacteria and gave a phylogenetic
perspective of cultured and uncultured members of this group [85]. The authors analysed the diversity
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of myxobacteria in campus garden soil and found out that many undescribed relatives exist in nature
and concluded that there are two forms: the fruiting and the non-fruiting types. They postulated
that most of the uncultured myxobacteria might represent taxa, which rarely form fruiting bodies, or
may lack some or all of the developmental genes needed for fruiting body formation. The majority
of sequences from the cultivation-independent approach are only distantly related to known genera
and species. As myxobacteria are widespread in terrestrial habitats, consequently, they are frequently
detected in those cultivation-independent studies on microbial diversity. Even in uncommon habitats
like adult worker ants myxobacteria were detected [86].
In our study about myxobacteria in two geographically distant locations, namely sand from
Kiritimati Island and German compost, we also compared the diversity of cultivable myxobacteria to
those from cultivation-independent clone libraries [9]. The study revealed an overrepresentation of the
genera Myxococcus and Corallococcus with standard cultivation methods (Figure 6).
 
Figure 6. Myxobacterial cultures isolated from Kiritimati sand (a,d) and German compost (b–f)
modified from Mohr et al. [9]. (a) Corallococcus (Myxococcus) macrosporus, (b) Corallococcus sp.,
(c) Myxococcus sp. (d) Archangium gephyra, (e) Corallococcus sp., (f) Polyangium fumosum.
However, phylogenetic analyses of the 16S rRNA gene sequences from clones revealed a great
potential of undescribed myxobacteria in both sampling sites. Several OTUs (operational taxonomic
units; groups of sequences with ≥97% similarity) represented unknown taxa exclusively detected by
cultivation-independent analyses, but not by cultivation. Furthermore, clone library analyses indicated
that the myxobacterial community of the investigated samples is predominantly indigenous.
Most of the known myxobacterial secondary metabolites were previously isolated from
terrestrial myxobacteria, because the majority of strains was isolated from (moderate) terrestrial
habitats. However, myxobacteria are extremely adaptable and can also be found in demanding
environments like acidic soils, fresh water, oceans and salines, anaerobic/microaerophilic, and extreme
habitats, respectively.
5.2. Acidic and Alkaline Habitats
Acidic wetlands have a major impact on the global carbon and water cycles. With high acidity
(pH 3.5 to 5.0), low temperatures, and extremely low concentrations of mineral nutrients (5 to 50 mg
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per liter), wetlands are moderate to extreme habitats. Their microbial diversity remains poorly
understood, because only microbial populations involved in CH4 cycling, i.e., methanotrophic bacteria
and methanogenic archaea, have attracted considerable research interest. Other members of the
microbial communities in acidic Sphagnum peatlands remain largely unknown [87].
The pH range for growth of the majority of myxobacteria is rather narrow, approximately 6.5–8.5.
Therefore, they are common in soils of pH 6–8 (neutral to slightly alkaline pH). However, acidic
or alkaline habitats also seem to be suitable for myxobacteria [10]. Even in 1977, Hook isolated
ten species from waters of an alkaline bog and adjacent soils [88] like Archangium, Corallococcus,
Melittangium, Myxococcus, and Sorangium (former Polyangium). Corallococcus coralloides, (formerly
Myxococcus coralloides) was dominant in the terrestrial samples. With pH between 6.0 and 8.7, the
investigated habitats were between slightly acidic and slightly alkaline. In 1979, Rückert also described
C. coralloides as the predominant species in soils of pH 4.1–4.9 and as dominant as M. fulvus in soils of
pH 3.0–3.5 [89]. In alpine acidic soils C. coralloides was the third-most dominant species behind two
Myxococcus species. But, Rückert also noted that the overall myxobacterial diversity in acidic soils (pH
3.5–4.9) was less than in slightly acidic or neutral environments (pH 5.0–7.8). In 1984, Dawid isolated
Myxococcus xanthus, M. virescens and Polyangium sp., but no cellulolytic species from undisturbed
Sphagnum bogs of the Hohen Venn, Belgium [3].
Mohr et al. studied myxobacteria in peat bog and fen with cultivation and cultivation-independent
methods [2]. Therefore, 38 moor samples of soil, water, plant residues, mud, and feces-material
(Figure 7a–c) were screened using standard as well as moor-adjusted cultivation conditions (low pH,
low temperature, moor-water for preparation of agar plates), screening numerous replicates over
several years. The pH of moor samples analyzed in this study was between 4.0 and 7.0 and therefore
comparable to those from the other studies. But almost exclusively species of the genus Corallococcus
could be isolated from acidic soils of the Harz-region (Figure 7d,e). A Sorangium strain was detected
on a raw culture plate with filter (Figure 7f), but could not be purified. In addition, the community
composition of acidic high moor and fen revealed by cultivation-independent 16S rRNA clone library
analysis gave a rather different picture of the myxobacterial diversity.
 
Figure 7. (a) Brockenfeld high moor; (b) fen Am Sandbeek; (c) Brockenfeld high moor scarp. Isolated
Corallococcus sp. strains from moors (d) strain B19, (e) strain B2t-1. (f) Sorangium cellulosum (orange)
on a raw culture plate (Stan 21 with filter) inoculated with soil material from moor. Pictures are from
Mohr et al. (2017) and modified [2].
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Phylogenetic analyses of clone sequences revealed a high diversity of undescribed myxobacteria
in high moor and fen. Many sequences represent totally unknown taxa. However, numerous clones
were closely related to sequences from other cultivation-independent studies of eubacterial diversity
in which samples from peat swamp, wetlands peat bog, Sphagnum moss, pine forest, acidic fen soil,
and forest soil were analysed (Figure 8). As mentioned above, cultivation exclusively revealed strains
from the genus Corallococcus (but from almost all analysed samples).
Figure 8. Part of a distance tree showing some myxobacterial type strains, some representative clone
sequences and one representative culture sequence from our study [2] as well as sequences from
uncultivated myxobacteria from other studies. Red: clones from Brockenfeld high moor; blue: clones
from fen Am Sandbeek; green: representative culture from Brockenfeld high moor. Accession numbers
are given in brackets. Origin of sequences from uncultured myxobacteria are mentioned. Bar, 0.1
substitutions per nucleotide position.
To my knowledge, no publications about (bioactive) secondary metabolites from myxobacteria
isolated from acidic or alkaline habitats are available. However, we screened 21 Corallococcus
spp.-strains from the moor study for production of bioactive metabolites. Raw extracts of all strains
showed high activity against Gram positives (Micrococcus luteus, Staphylococcus aureus, Bacillus subtilis,
and Mycobacterium sp.), the yeasts Saccharomyces pombe and Rhodotorula glutinis, as well as against the
filamentous fungi Mucor hiemalis, but no activity against Gram negatives. HPLC analyses of the raw
extracts revealed three dominant peaks. By HPLC-fractionation of bioactive extracts and subsequent
HPLC-MS analyses the already known substances dibenzylpyrazine, myxothiazol A, and myxothiazol
Z/A-methylester, respectively, were identified (data not published). In summary, the moor habitat is
a promising source and of high interest with regard to the cultivation of prospective new bioactive
secondary metabolite-producing myxobacteria.
5.3. Freshwater Habitats
In natural aquatic environments, microbial cells often build complex, surface-attached biofilm
communities. Within the water body or pelagic zone of unpolluted freshwaters, the number and
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diversity of bacteria is normally lower than on the available substrates. Myxobacteria glide in swarms
over solid surfaces. If it is possible, they prefer attached in contrast to planktonic living.
Only very few studies about myxobacteria in fresh water habitats are published. In the
1960th/1970th several studies dealt with nonpathogenic or pathogenic non-fruiting “myxobacteria”
as colonizers of freshwater fish [90]. However, these publications deal with strains of the
Cytophaga-group, which do not belong to the Myxococcales, but to the Cytophaga—Flavobacterium—
Bacteroides group. No myxobacterial pathogens are published. Reichenbach mentioned that
myxobacteria can also be isolated from fresh water, but explained these findings with soil organisms
notoriously exchange into water bodies, being regularly washed or blown in and often surviving there
periodically or permanently [12].
In 2012, Li and co-workers investigated the myxobacterial community in freshwater lake
mud using high-throughput 454 pyrosequencing and myxobacteria-enriched libraries with
Cystobacterineae- and Sorangiineae-specific primer pairs, respectively, and reported that myxobacteria
were one of the major bacterial groups in the lake mud [91]. Phylogenetic analysis showed that
the limnetic myxobacteria exhibit closer relationships to their soil than to their marine relatives,
but there are also exclusive taxa of limnetic myxobacteria. The major conclusion was that the
unclassified Myxococcales in the lake mud comprise a large portion of the microbiota and exhibit
high species diversity. Kou et al. analysed bacterial communities in sediments of freshwater (Poyang
Lake) in China. There, Anaeromyxobacter dehalogenans turned out to be a main part of the bacterial
community composition (1–14.6%) [92]. In another study about methanogenic microbial communities
in sediments of Amazonian lakes using terminal restriction fragment length polymorphism (T-RFLP)
and pyrosequencing, the proteobacteria revealed as the most abundant phylum in all lake sediments.
Delta-proteobacteria (mainly Myxococcales, Syntrophobacteriales and sulfate/sulfur-reducing bacteria)
dominated this habitat [93]. In 2014, Kandel et al. investigated the abundance, diversity, and seasonal
dynamics of predatory bacteria in aquaculture zero discharge systems by cultivation-independent
analyses and found out that in addition to the detected Bdellovibrio and similar organisms, other
potential predators were highly abundant, especially from the Myxococcales [94].
In the absence of cultures which are verifiable natural fresh water inhabitants, up to now,
no (bioactive) metabolites have been isolated from limnic strains. However, the above-mentioned
detection of exclusively limnic taxa [95] suggest that also the habitat fresh water could be a promising
source for the cultivation of new secondary metabolite producing myxobacteria.
5.4. Marine/Saline Environments
Covering more than roughly 78% of the earth’s surface, water is the most prevalent natural
substance, of which approximately 97.5% is salt water in the world’s oceans [96]. The salt tolerance of
myxobacteria is low in general. It was assumed for a long time that myxobacteria exclusively live in
terrestrial habitats. Indeed, even in 1963, Brockman observed fruiting myxobacteria in sand samples
from an ocean beach in South Carolina [97]. Species of the already known terrestrial genera Archangium,
Chondrococcus (Corallococcus), Chondromyces, Myxococcus, and Polyangium, could be cultivated. As late
as 2002 with Haliangium ochraceum and H. tepidum, the first myxobacterial genus was isolated and
described from coastal salt marshes. The strains differ from known terrestrial myxobacteria with regard
to salt requirements (2–3% NaCl) and the presence of anteiso-branched fatty acids [4]. Other genera,
exclusively detected in marine habitats like Plesiocystis [5], Enhygromyxa [6], and Pseudenhygromyxa [7]
(all Nannocystineae-suborder) followed (Figure 9).
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Figure 9. Marine myxobacterial type strains on agar plates. (a) Haliangium tepidum (DSM 14436T) on
VY/2SWS, (b) Enhygromyxa salina (DSM 15217T) on VY/4SWS, (c) Pseudenhygromyxa salsuginis (DSM
21377T) on 1102, (d) Plesiocystis pacifica (DSM 14875T) on VY/2SWS.
In 2010, Jiang et al. investigated the diversity of marine myxobacteria in comparison to
terrestrial soil myxobacteria [82]. Therefore, they established myxobacteria enriched libraries of
16S rRNA gene sequences from four deep-sea sediments and a hydrothermal vent and identified 68
different myxobacteria related sequences from randomly sequenced clones of these libraries. The
authors concluded that the myxobacterial sequences were diverse but phylogenetically similar at
different locations and depths. However, they separate from terrestrial myxobacteria at high levels
of classification.
In 2012, the study of Brinkhoff and co-workers gave an impressive insight to the marine
myxobacterial community [83]. They detected a cluster of exclusively marine myxobacteria (marine
myxobacteria cluster, MMC) in sediments of the North Sea, but not in the limnetic section of the Weser
estuary and other freshwater habitats. In a quantitative real-time PCR approach, the authors found
out that the MMC constituted up to 13% of total bacterial 16S rRNA genes in surface sediments of
the North Sea. In addition, in a global survey including sediments from the Mediterranean Sea, the
Atlantic, Pacific, and Indian Oceans, and various climatic regions, the MMC appears in most samples
and to a water depth of 4300 m, but there was no synteny to other myxobacterial genomes. The
study of Brinkhoff et al. showed that the MMC is an important and widely distributed but largely
unknown component of marine sediment-associated bacterial communities. Figure 10 shows some
representative clones from different marine habitats mentioned in the Brinkhoff study. The 17 clones
show 95.1–100% similarity to each other and 88–91% to the next type strain Sandaracinus amylolyticus.
This implies that members of the MMC cluster do at least belong to new genera if not even families,
but presumably belong to the Sorangiineae suborder. However, the genus Sandaracinus was published
shortly after the Brinkhoff study, so this relative was not mentioned there.
In 2013, Zhang et al. isolated fifty-eight terrestrial and salt-tolerant myxobacteria from the
saline-alkaline soils collected from Xinjiang, China [95]. Based on morphology and 16S rRNA
gene sequences, the authors identified species of Myxococcus, Cystobacter, Corallococcus, Sorangium,
Nannocystis, and Polyangium. They reported that all the strains grew better with 1% NaCl than without
salt; some Myxococcus strains even grow with 2% NaCl.
Li et al. (2014) chose a cultivation-independent approach to analyze the diversity of myxobacteria
from saline-alkaline soils of Xinjiang, China, too. A semi-nested PCR-denaturing gradient gel
electrophoresis (DGGE) based on the taxon-specific gene mglA (a key gene involved in gliding
motility) was used [98]. In accordance to previous studies, Li et al. also suggested that there are
still many viable, but under standard laboratory conditions uncultured myxobacterial strains in the
investigated saline-alkaline habitat. Natural product classes discovered from marine Myxococcales
strains include polyketides, hybrid polyketide-nonribosomal peptides, degraded sterols, diterpenes,
cyclic depsipeptides, and alkylidenebutenolides [99]. Four genera of marine/saline origin are known so
far (Figure 10) and from two, Haliangium and Enhygromyxa, numerous (bioactive) secondary metabolites
could be isolated [100]: Haliangicin [101], salimabromide [102], salimyxins, enhygrolides [103], and
haliamide [104]. The above-mentioned data reveal that marine/saline environments as oceans harbor
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an enormous potential of new myxobacteria. These organisms are an unexplored resource of novel
antibiotics of novel chemical scaffolds, as mentioned by Albataineh and Stevens, who highlighted the
need for continued discovery and exploration of marine myxobacteria as producers of novel natural
products [104].
 
Figure 10. Neighbour joining tree of myxobacterial type strains (16S rRNA-genes), some representative
clones from the MMC-cluster (blue) and the next cultivated relative Sandaracinus amylolyticus. Genera
isolated from marine environment are in green blue. Suborders of the order Myxococcales, origin of
clones, and accession numbers are shown. Bar, 0.1 substitutions per nucleotide position.
5.5. Facultative or Strictly Anaerobic Myxobacteria
All known myxobacteria live aerobically, with one exception: The facultative-anaerobic genus
Anaeromyxobacter comprises one species, A. dehalogenans. The type strain was isolated from stream
sediment and grows with acetate as electron donor and 2-chlorophenol (2-CPh) as electron acceptor [11].
Since 2002, several strains of Anaeromyxobacter were isolated from various habitats. Flooded rice
field soil [105], uranium contaminated surface environment [106], corrosion material of drinking
water pipelines [107], arsenic-contaminated soils [108], or chemically and electro-chemically enriched
sodic-saline soil (unpublished) served as sources for the cultivation of Anaeromyxobacter-strains. A total
of 23 sequences designated as Anaeromyxobacter (sequence lengths > 1000 bp) are available from the
NCBI database (FJ90053–FJ90062, FJ90048, FJ90049, FJ90051, EF067314, AJ504438, KF952446, AF382397,
AF382399, AF382400, FJ939131, KF952441, KF952438, KC921178) and were added to a phylogenetic tree
of myxobacterial type strains. A similarity matrix calculated with arb (www.arb-home.de) revealed
98.4–100% similarity (on basis of 16S rRNA gene) for 20 of these strains to the type strain of A.
dehalogenans. Assuming that the standard value for the definition of a new species is 98.65% [109]
and 94% for a new genus, respectively, the above-mentioned 20 cultures probably do belong to A.
dehalogenans. However, strains OnlyC-B2 (KF952441) and SSS-B8 (KF952438) show only 96.3% and
96.0% similarity to the corresponding type strain (but 99.4% to each other) and putatively represent a
new species. One culture, isolated from ginger foundation soil, and also designated as A. dehalogenans
(KC921178), shows only 86% similarity to the next cultivated (myxobacterial) type strain Vulgatibacter
incomptus. This culture definitely represents at least a new family if not even a new suborder of
myxobacteria (unpublished).
In summary, there are currently two cultivated species of Anaeromyxobacter, but only one is validly
described. But what about further facultative or even strictly anaerobic myxobacteria?
The NCBI search for 16S rRNA gene sequences of “uncultured Anaeromyxobacter” revealed more
than 1200 hits. Nevertheless, not all sequences designated as “Uncultured Anaeromyxobacter” are close
relatives of Anaeromyxobacter, as a revision of randomly selected sequences revealed. For example: the
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sequence GU271851, mentioned as “Uncultured Anaeromyxobacter”, shows 91% similarity to the next
type strain Haliangium tepidum, but only 87% to the type strain of A. dehalogenans [110]. Clone GU271788,
also mentioned as A. dehalogenans, shows 92% to the next type strain, Sorangium cellulosum, but only
86% to Anaeromyxobacter [111]. On the other hand, there are probably numerous sequences deposited
at NCBI which are close relatives of Anaeromyxobacter. However, these sequences are just mentioned as
“uncultivated Myxococcales”, “uncultivated (delta) proteobacteria” or “uncultured bacterium clone”
such as clone EUB_19 (FJ189540), which shows 98.7% [112] or clone A_Ac-2_16 (EU307085), which
shows 97.8% similarity to the next type strain: A. dehalogenans [113]. In 2009, Thomas et al. analysed
the diversity and distribution of Anaeromyxobacter strains in a uranium-contaminated environment by
mainly cultivation-independent methods. Phylogenetic analyses of the clone and culture sequences
revealed that there are at least three distinct Anaeromyxobacter clusters at the IFC (Integrated Field-Scale
Subsurface Research Challenge) site near Oak Ridge, whereby two sides are exclusively represented
by clones. As mentioned above, quantitative PCR assay and pyrosequencing analysis of 16S rRNA
genes also revealed A. dehalogenans as a part of the microbial community in the sediment of Poyang
Lake, the largest freshwater lake in China [95].
To get an impression about the diversity of uncultured Anaeromyxobacter, I added about 80 clone
sequences from NCBI with corresponding designation to a phylogenetic tree of myxobacterial type
strains (data not shown). The clones revealed 90.0–100% similarity on the basis of 16S rRNA gene to
the type strain of A. dehalogenans (AF382396). Figure 11 shows the affiliation of some representative
clones. These clones represent at least several new genera, if not even families of myxobacteria, which
are probably also facultative or strictly anaerobic and which could not be cultivated so far.
 
Figure 11. Neighbour joining tree of some myxobacterial type strains (16S rRNA-genes) and
some representative clones. All clones show highest relationship to the next cultivated relative
A. dehalogenans. All families of the Cystobacterineae suborder, origin of samples, and accession numbers
of clones/cultures are shown. Bar, 0.1 substitutions per nucleotide position.
Although the 16S affiliation of clones does not give any information about metabolism of
the corresponding organism, high similarities to aerobic or anaerobic cultures indicate similar
metabolic capabilities. However, no bioactive secondary metabolites have been described so far from
Anaeromyxobacter strains, which is certainly because anaerobic isolation, cultivation, and large scale
fermentation requires special efforts regarding equipment and microbiological skills and experience.
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5.6. Moderate to Extreme Hot or Cold Environments
Myxobacteria are mesophilic and grow well at 30 ◦C, although their temperature range is much
wider. For most myxobacterial strains, the growth temperatures is between 4 ◦C and 44 ◦C. Usually
vegetative cells cannot survive temperatures above 45 ◦C, but myxospores suspended in water tolerate
58–60 ◦C. This property can be used to be purify myxobacteria from mesophilic accompaniment
organisms [12]. A moderate terrestrial habitat was investigated by Brockman in 1976 [114], who
isolated strains of Archangium, Chondromyces, Cystobacter, Myxococcus, Polyangium, and Stigmatella from
arid Mexican soils. He reported a greater species diversity from regions with higher annual rainfall
(400–800 mm compared to 200–400 mm). Moderate thermophilic myxobacteria of Cystobacterineae
and Sorangiineae-suborders, which grew very fast at temperatures of 42 ◦C–44 ◦C, were isolated from
soil samples of semiarid and warm climates by Gerth and Müller [115] (Figure 12). One strain even
grew at 48 ◦C, whereas the majority of the described species grows best at 30 ◦C.
 
Figure 12. Moderately thermophilic strains of Sorangium on VY/2 agar. (a) GT47 and (b) GT 41, isolated
by Dr. K. Gerth.
Recently, a new Nannocystis species, N. konarekensis, was isolated from an Iranian desert [111].
The strain shows an optimal growth temperature at 37 ◦C, in contrast to the other known Nannocystis
species N. pusilla and N. exedens, which show optimal growth at 30 ◦C. Iizuka et al. reported about
enrichment and phylogenetic analysis of moderately thermophilic myxobacteria. During their search
for thermophilic myxobacteria in geothermal environments, four strains that grew at temperatures
up to 50 ◦C (optimum 45 ◦C–49 ◦C) could be isolated from various hot springs in Japan [116]. Three
of the cultures were from fresh water hot springs and one was from a coastal saline spring. Even
after repeated enrichment procedures, other thin film-like spreading bacteria accompanied the strains.
PCR, cloning, and sequencing of 16S genes revealed that all cultivated bacteria belong to the order
Myxococcales and showed between 89–99% homology to strains of myxobacteria. Therefore, some of
these cultures represent new undescribed but cultivable species, genera, and perhaps even families
(Figure 13).
Although numerous (cultivation-independent) studies about bacterial diversity of hot
springs/geothermal sources are published, the NCBI search for sequences of uncultured thermophilic
myxobacteria or myxobacteria from hot springs revealed only very few matches. Hot springs are
probably not the most suitable habitat for the mainly mesophilic myxobacteria. But, based on the
cultivation success mentioned by Iizuka et al. [116], it is certainly worth investigating these habitats
more precisely to isolate new myxobacteria.
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Figure 13. Neighbour joining tree of some myxobacterial type strains (16S rRNA-genes) and cultures
(in bold) from hot springs (AB246767-AB246770, AB246772) [117] and alkaline hot spring, all from
Japan. Suborders of the order Myxococcales, origin of samples, and accession numbers are shown. Bar,
0.1 substitutions per nucleotide position.
Some publications deal with myxobacteria from cold environments like Arctic soils. However,
in the study of Brockman who tried to isolate myxobacteria from Alaskan and Canadian Arctic soils,
myxobacterial growth was only observed when soil plates were incubated at 24 ◦C–26 ◦C, but not at
6 ◦C–8 ◦C [118]. In contrast, Dawid described psychrophilic myxobacteria which grow at 4 ◦C but not
under mesophilic conditions between 18 ◦C and 30 ◦C (after 7–9 month of incubation) on samples of
Antarctic soils [117].
Due to long incubation times of psychrophilic strains, their biotechnological use in large scale
fermentation would be expensive and time consuming and would only be worthwhile if a highly
promising antibiotic was detected in such a psychrophilic strain.
6. Conclusion
In summary, myxobacteria are highly adaptable cosmopolitans. They can grow/survive in various
kind of habitats and areas of different, even extreme climatic conditions. In 1993, only 2 suborders, 4
families, 12 genera, and 38 species were assigned to the order Myxococcales [28], but in 2018, already 3
suborders, 10 families, 29 genera, and 58 species are described. Although the number of species grows
every year, consideration of data from cultivation-independent studies reveals that we only see the tip
of the diversity iceberg.
In 2010, 67 distinct core structures and about 500 derivatives were known from approximately
7500 myxobacterial strains [48]. Only seven years later, Herrmann et al. could refer to five natural
product classes produced by myxobacteria [49]. These new molecules show such promising activity
that several of them may serve as early lead structures for drug development. This shows the enormous
potential of myxobacteria as producers of new, bioactive secondary metabolites. As mentioned by
Müller and Wink, three of the most promising approaches toward finding novel anti-infectives from
microorganisms are the use of biodiversity to find novel producers, the variation of culture conditions
and induction of silent genes, and the exploitation of the genomic potential of producers via “genome
mining” [119]. With focus on novel producers, the biggest challenge for microbiologists is to get access
to the so far uncultivated bacteria.
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Abstract: Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV),
hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health
due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the
recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and
toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is
a need for identifying agents with novel modes of action and improved efficacy. Viral-based
illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV
or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV.
Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative
drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous
structurally and functionally unique bioactive compounds, which have only recently been screened
for antiviral effects. This research has already led to some interesting findings, including the discovery
of several candidate compounds with broad-spectrum antiviral activity. The present review looks at
myxobacteria-derived antiviral secondary metabolites.
Keywords: myxobacteria; antivirals; secondary metabolites; HIV; Ebola; hepatitis viruses
1. Introduction
Antimicrobial resistance (AMR) threatens the effective treatment, control and management of
an increasing range of infections caused by viruses, bacteria, parasites and fungal pathogens [1].
Development of effective therapies to suppress human immunodeficiency virus (HIV) and hepatitis B
virus (HBV) has been achieved with great success [2]. However, the medicines are not curative,
and therefore more efforts in HIV and HBV drug discovery are directed toward longer-acting
therapies or compounds with new mechanisms of action that could potentially lead to a cure or
complete eradication of the viruses [2]. In 2010, an estimated 7–20% of people starting antiretroviral
therapy (ART) globally had drug-resistant HIV [3]. Some countries have recently reported levels
of 15% amongst those starting HIV treatment, and up to 40% among people re-starting therapy [3].
Of great concern are the high levels of viral resistance towards nucleoside reverse transcriptase
inhibitors (NRTIs) as recently found in Kenyan children [4]. In 2015, the World Health Organization
(WHO) recommended that everyone living with HIV should start on antiretroviral treatment.
Hence, increased ART resistance is expected as more people start ART [3]. The United States Food and
Drug Administration (FDA) approved anti-HIV drugs are classified into eight classes according to
modes of action [5]. The common side effects of Abacavir® and other NRTIs are that they can cause
life-threatening side effects, including a serious allergic reaction, a build-up of lactic acid in the blood,
and hepatotoxicity [6,7]. In fact, each drug class of the FDA approved anti-HIV drugs has side effects,
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and some are contra-indicated for co-infected patients with HIV and HBC or HCV [8]. On the other
hand, all influenza A viruses circulating in humans were reported to be resistant to Amantadine® and
Rimantadine®, two essential antivirals for treatment of epidemic and pandemic influenza A. However,
the frequency of resistance to Oseltamivir® another antiviral with different mode of action for treating
influenza A remains low at 1–2% [3]. Treatment failure of antivirals has been suggested to be caused
by the emergence of recombinant viruses, drug resistance, and cell toxicity [9,10]. Compounds with a
different mode of action can play an essential role in overcoming AMR. Viral disease such as influenza
spreads fast and knows no borders, with the vast masses of people travelling all over the globe due to
efficient transport systems. Hence, there is an urgent need for international collaboration to identify
new antiviral agents with new modes of action and better efficacy.
Myxobacteria are well-known to be producers of biologically active secondary metabolites with
novel carbon skeletons and new modes of action [11–13]. Many compounds isolated from myxobacteria
have recently been found to have impressive antiviral activity. More so, some have been found to have
an unusual broad-spectrum antiviral activity [11,12,14].
2. Myxobacteria
Myxobacteria are δ-proteobacteria belonging to the order Myxococcales. They are
rod-shaped, Gram-negative bacteria that exhibit gliding motility and swarm on solid surfaces.
Under nutrient-limiting conditions, they form species-specific fruiting bodies (Figure 1) [15].
Within these fruiting bodies, some vegetative cells convert to myxospores, which are
desiccation-resistant and can survive over decades. Under appropriate conditions the spores
germinate [16]. These soil-dwelling microorganisms have also been isolated from other habitats
such as the bark of trees, oceans, freshwater lakes, and herbivore dung [15,17]. Myxobacteria
have also been isolated from extreme environments such as desert soils [18]. Numerous unique
classes of secondary metabolites have been isolated from myxobacteria, the majority of which are
biogenetically derived from polyketide synthases (PKSs) and non-ribosomal peptide synthetases
(NPRSs) or a hybrid of PKSs and NPRSs [12,15,19,20]. PKSs and NPRSs are enzymatic “assembly
lines” of complex multi-step biosynthetic pathways for making compounds by catalysing the stepwise
condensation of a starter unit with small monomeric building blocks [19]. The ability to produce
unique metabolites is conferred by the creative biosynthetic pathways and the large genome of
9–14 Mb [21], consistent with the strengthening correlation between genome size and the extent
of secondary metabolites produced [21–25]. In fact, the sequenced genomes of myxobacteria are
the largest yet known from any bacterium [20–23,25]. In the last 35 years, over 100 new carbon
skeleton secondary metabolites, with over 600 analogues, have been isolated from over 9000 strains
of myxobacteria [12]. The metabolites exhibited antifungal, antibacterial, antimalarial, antitumor,
and anti-immunomodulatory properties some with novel modes of action and have been reviewed
extensively [12,20,26]. Microorganisms are valuable as producers of bioactive metabolites because
they can be cultivated in bioreactors from as little as below 5 mL to large scales of over 100,000 L,
making the production of natural products independent of season, locality, or climate [15]. Furthermore,
conditions in a bioreactor are controllable to optimise production of the desired outcome. Particularly
important as illustrated by Zeeck et al., 2002 in the ‘OSMAC’ (One Strain-Many Compounds) approach,
which revealed that microorganisms do not exhaust their potential for producing metabolites under
standard laboratory conditions [27].
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Figure 1. Images of myxobacteria. (A–C): Sorangium cellulosum; (A): Fruiting bodies; (B): Swarming
on agar plate; (C): Cells from the liquid medium under the light microscope. (D–E): Images of the
producers ofthiangazole (7), phenalamide A1 (8) and phenoxan (9), from agar plates; (D): Myxococcus
stipitatus; (E): Polyangium species; (F–G): Angiococcus disciformis (strain An d30) producer of myxochelins;
(F): culture under the light microscope from liquid media; (G): culture on agar plate. Images provided
by Joachim Wink (HZI Braunschweig).
3. Secondary Metabolites from Myxobacteria with Antiviral Activity
3.1. Human Immunodeficiency Virus (HIV)
HIV is a lentivirus of the Retroviridae family. HIV targets immune cells, and reverse transcribes
its single-stranded RNA (ssRNA) genome, integrating into the host chromosomal DNA. The virus
uses high antigenic diversity and multiple mechanisms to avert recognition by the human immune
system thus posing a challenge to host defences and treatment [28].
Various assays have been developed and used to identify molecules with anti-HIV activity.
Some of the assays includes structure-based design of a small molecule CD4-antagonist with broad
239
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spectrum anti-HIV-1 activity [29], structure-based identification of small molecule antiviral compounds
targeted to the gp41 core structure of the human immunodeficiency virus type 1 [30], and identification
of HIV inhibitors by high-throughput (HTP) two-step infectivity assay [31]. The HTP assay has been
used on myxobacterial-derived molecules with success due to the ability to screen a large number of
molecules in a short period.
Sulfangolids, the first sulfate esters containing a series of secondary metabolites produced
by several strains of Sorangium cellulosum, were isolated together with the structurally related
macrolide kulkenon (5) [32]. Sulfangolid C (1), soraphen F (2), epothilon D (3), and spirangien B (4),
showed impressive activity, with EC50 values in the nM range with a selectivity index value greater
than 15 (SI > 15) in the high-throughput two-step infectivity assay [31]. Despite the impressive antiviral
activity of 5, the SI is low because of toxicity. A search in the SciFinder database revealed dozens
of analogues of soraphen and epothilone [33]. It may be promising to screen the large number of
analogues in the soraphen and epothilone families to attempt to encounter more potent representatives
with better SI values. The soraphens have been reported as acetyl-CoA carboxylate transferase
inhibitors [34], while the epothilones stabilise microtubuli of macrophages in a similar manner as
Taxol® without showing taxol-like endotoxin activity [35,36]. In fact, the FDA-approved anticancer
drug, Ixabepilone®, is an epothilone B derivative [37]. Metabolites 3 and 4 are reported to decelerate the
phosphorylation and degradation of inhibitor of kappa Bα (IkBα) [36,38]. The compounds identified
as preliminary hits for anti-HIV included 1–5 (Table 1, Figure 2) [31]. Rhizopodin (6), from Myxococcus
stipitatus was identified as interesting in the two step HTP assay, likely because of its mode of action [31].
HIV cell-to-cell transmission is the primary route of HIV infection in naive cells in vivo. Actin filaments
are known to be essential for virological synapse formation, therefore, virus synapses are interfered by 6,
which is a known actin inhibitor. Disorazol, tubulysin and stigmatellin variants were also reported to
have mild anti-HIV activity [31]. Thiangazole (7), phenalamide A1 (8), and phenoxan (9) isolated from
two strains of Polyangium sp. and Myxococcus stipitatus strain Mx s40 were reported to have anti-HIV
activity (Figure 2) [39]. They all revealed high activity by suppressing HIV-1-mediated cell death
in the MT-4 cell assay with EC50 values of 9 and 8 in the nanomolar range, whereas thiangazole (7)
had an impressive EC50 value in the picomolar range, making it a possible lead compound for
anti-HIV therapy (Table 2, Figure 2) [39]. In another assay involving measuring ATP levels as a
parameter of cell viability of TZM-bl cells aetheramide A (10a) and aetheramide B (10b) isolated
from the recently described genus Aetherobacter, inhibited HIV-1 infection with IC50 value of 0.015
and 0.018 μM, respectively [40–42]. Concurrently, the aetheramides were reported to be moderately
antifungal and cytotoxic [41]. The chemical structures of 10a and 10b are rare, containing a polyketide
moiety and two amino acid residues, thus forming a new class of antivirals [40–42]. This discovery of
new antivirals from the recently described myxobacteria genus, Aetherobacter, represents an example
of the enormous biosynthetic capabilities of myxobacteria and their importance to drug discovery
efforts [42]. Ratjadon A (11), an α-pyrone metabolite isolated from Sorangium cellulosum (strain Soce
360), was reported to inhibit HIV infection by blocking the Rev/CRM1-mediated nuclear export
pathway [43,44]. The CRM1-Rev complex is an attractive target for the development of new antiviral
drugs because the nuclear export of unspliced and partially spliced HIV-1 mRNA is mediated by the
recognition of a leucine-rich nuclear export signal (NES) in the HIV Rev protein by the host protein
CRM1/Exportin1 [44]. Despite 11 being reported to exhibit a strong anti-HIV activity, it has a low
selectivity due to toxic effect. The low SI value limits the potential use of 11 as a therapeutic drug. More
studies with derivatives of 11 need to be done. It is important to observe that different assays were used
to screen for anti-HIV compounds. There is a need therefore for a standardised method to be able to
adequately compare the anti-HIV activity of those compounds that have been identified as preliminary
hits. Equally important is an evaluation of the mechanism of action on viruses in comparison to the
mechanism of action on bacteria or fungi. Investigation for synergism between the identified anti-HIV
compounds for possible use at a lower concentration to improve the selectivity index of the metabolites
should be looked into in the future. Even the active metabolites that cannot realistically be further
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developed as drug candidates because they are too toxic, could be used as biochemical tools to attain a
better understanding of the invasion mechanism of HIV, or for development of synthetic analogues
that mimic these compounds without causing toxicity.
 
Figure 2. Myxobacterial-derived compounds with activity against human immunodeficiency virus (HIV).
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Table 1. Preliminary anti-HIV hits from a high-throughput two-step infectivity assay [31].
Compound MW 1 EC50 (μM) CC50 (μM) SI **
Nevirapine * 266 0.07 81.8 >103
sulfangolid C (1) 682 0.41 8.18 20.2
soraphen F (2) 522 0.30 5.02 16.5
epothilon D (3) 491 0.0005 0.012 24.4
spirangien B (4) 717 0.007 0.35 52
kulkenon (5) 734 0.07 0.36 5.3
* Control, 1 Molecular weight, EC50: effective concentration; CC50: cytotoxic concentration; ** Selectivity
Index = CC50/EC50. EC50 is the concentration of a drug or metabolite which induces a response halfway between
the baseline and maximum after a specified exposure time or gives the desired effect to 50% of test subjects. While
SI is a comparison of the amount of a drug or metabolite that causes the desired effect to the amount that causes
death or toxicity. Metabolites with a low EC50 and a high SI values are good drug candidates.
Table 2. Anti-HIV-1 activities of compounds derived from myxobacteria by MT-4 cell assay [40,41].
Compound MW 1 Tx 2 (nM) AE 3 (μM) SI **
AZT * 267 250,000 25 104
thiangazole (7) 539 >4700 0.0047 >106
phenalamide A1 (8) 491 102,000 1.02 105
Phenoxan (9) 379 >6600 6.6 >103
* azidothymidine Control, 1 Molecular weight, 2 Toxicity (Tx) is the lowest toxic concentration (nM) of the compound
in the MT-4 cell assay, 3 Antiviral efficacy (AE) is given as the lowest effective concentration (μM) of the compound
at which 100% prevention of the virus-mediated cytopathogenicity was observed in the MT-4 cell assay, ** Selectivity
Index = Tx (nM)/AE (μM).
3.2. Human Cytomegalovirus (HCMV)
HCMV belongs to the β-herpesvirus family, with a high prevalence, infecting up to 80% of the
general population usually asymptomatic in healthy people [45]. Diseases associated with HCMV
include glandular fever and pneumonia. HCMV is also an important pathogen in organ transplant
patients responsible for significant morbidity and mortality in organ transplant recipients, and a major
cause of disease in patients with HIV infection [46]. HCMV infections in newborns may result in
hearing loss, mental retardation and palsy [47]. The available FDA-approved therapeutic options for
HCMV infection include ganciclovir, foscarnet, cidoforvir, and fomivirsen [48]. These drugs have
different mechanisms of actions or applications, and represent the successes that had been made
against the challenges of HCMV [48–50]. Several anti-HCMV drugs were reported to have low potency,
poor oral bioavailability, and adverse side effects [50]. Moreover, drug resistance strains were reported
to emerge [51]. Hence, there has been a renewed interest in search of new inhibitors of HCVM [50,51].
Of greater concern is the increase in the number of people living with transplanted organs, and the
increase in HIV infected people [52]. Technological advancements have enabled organ transplants to
be more accessible while the increase in HIV-infected individuals is due to new retroviral therapies that
have converted HIV infection to chronic disease as infected people live longer, leading to increased
cases of HCMV infection [52]. In 2011, the first case of HCMV-treated with AIC246, a novel anti-CMV
compound that targets the viral terminase complex and remains active against virus resistant to DNA
polymerase inheritors was reported [53], which represents a good example of the renewed interest
for HCMV inhibitors [53]. Almost 60 patents claiming novel agents for the treatment of HCMV were
launched from January 1996 to 2000, but so far none of these projects has led to the approval of
an anti-HCMV drug [49]. However, the recent FDA approval of letermovir (Figure 3), providing a
long-awaited alternative for preventing cytomegalovirus infection in allogeneic hematopoietic stem
cell transplant recipients [54] is very encouraging.
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Figure 3. PREVYMIS™ (letermovir) a recently (2017) FDA-approved drug for the prevention of Human
cytomegalovirus (HCMV) infection and disease in organ transplant patients.
A class of myxobacterial compounds, myxochelin, belonging to a larger group of natural products,
siderophores, were isolated from several strains of myxobacteria [53,55]. Siderophores are secondary
metabolites produced by some microorganisms under iron-limiting conditions, and enhance the
uptake of iron [56]. Other siderophores isolated from myxobacteria includes nannochelins and
hylachelins. Various studies have revealed myxochelins to be potent antitumour agents [55,57–59].
The antitumour activity was demonstrated to be caused by inhibition of human 5-lipoxygenase
(5-LO) [58]. Surprisingly the inhibition of 5-LO by myxochelins was found not correlating with the iron
affinities [58]. The enzyme 5-LO is responsible for the catalysis of two initial steps in the biosynthesis
of leukotriens, starting from arachidonic acid [58]. Leukotriens are well-known mediators of a variety
of allergic reactions such as inflammatory, rheumatic arthritis, allergic rhinitis and cardiovascular
diseases [58]. Importantly, 5-LO pathways were associated with cancer proliferation, hence explaining
the observed strong anticancer activity of myxochelin [58,60]. Nannochelins are reported to have no
significant antimicrobial activity [24].
Myxochelin A (12a) was initially isolated from the culture broth of Angiococcus disciformis
(strain An d30). Later on, myxochelins B (12b), C (12c), D (12d), E (12e), and F (12f) were isolated and
also synthesised (Figure 4) [60,61]. The corresponding biosynthetic gene clusters have been identified
in Stigmatella aurantiaca (Sga 15), and Sorangium cellulosum (Soce 56) [62]. Additional siderophores
have been isolated from Nannocystis exedens (21a–21c) and Hyalangium minutum (20a–20c) [63,64].
Myxochelin C (12c) inhibited HCMV with an IC50 value of 0.7 μg/mL [46,53]. It could in future
become feasible to test others among the over 500 different siderophores that are known to science [65].
In particular, the known myxobacterial-derived siderophores, such as nannochelins (21a–21c),
hylachelins (20a–20c), and all the other myxochelin analogues (Figure 4) should be screened for various
antiviral activities, especially anti-HCMV, and should be studied for structure activity relationship for
possible discovery of more potent antivirals.
3.3. Ebola Virus Disease (EVD)
Ebola haemorrhagic fever is caused by the Ebola virus (EBOV), a single stranded RNA enveloped
virus belonging to the family Filoviridae. EVD first appeared in 1976 in two simultaneous outbreaks,
one in Nzara, South Sudan, and the other in Yambuku, the Democratic Republic of Congo. The latter
occurred in a village near the Ebola River, from which the disease takes its name [65,66]. EVD case
fatality rate is around 50%, with different cases from 25% to 90% fatality in past outbreaks reported [65].
Furthermore, EBOV is known to persist in immune-privileged sites, such as testicles, inside of the eye,
and central nervous system, and in some people who have recovered from EVD [65]. The effect of the
persistence is yet to be known [66].
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Figure 4. Myxobacterial-derived siderophores.
The re-emergence of Ebola occurred in West African countries causing 11,308 deaths leading to
the WHO on 8 August 2014, declaring the epidemic to be an international public health emergency [66].
An experimental Ebola vaccine called rVSV-ZEBOV has been reported to show high protection against
EVD [67]. No drug or licensed vaccine currently exists; hence there is an urgent need for drugs that
inhibit entry or multiplication of EDV [62,67]. Developing an assay to test compounds for anti-EBOV
poses a significant challenge because of the cost of equipment for the high risk, Biosafety S4 organism,
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involved [66]. However, various metabolites from myxobacteria were screened for EBOV inhibition by
an assay with a surrogate system using Ebola envelope glycoprotein GP-pseudotyped lentiviral vectors
(Figure 5) [67]. GP-pseudotype lentiviral vectors were used as tools to investigate the entry process of
the viruses, enabling studies without the need of using the native Ebola virus reducing the safety level
from the highest level 4 to level 2 [67]. The same analysis was conducted with vesicular stomatisis
virus (VSV)-G-pseudotyped vectors to determine the EBOV-specificity of the inhibitory function of
the compounds. Chondramides (13a–13d) were reported to inhibit EBOV-GP-mediated transduction
with impressive IC50 values of 24–42 nM. The VSV-G-mediated transduction was less efficient, with an
IC50 value of 55–111 nM [66]. Chondramides (13a–13d), a class of compounds known to interfere with
actin, were isolated from a myxobacterium belonging to the genus Chondromyces [68]. Members of
the genus Chondromyces belong to those myxobacteria known to synthesise two or more chemically
unrelated secondary metabolites with different mechanisms of action [69]. Other promising hits were
the noricumazoles, a family of polyketides from Sorangium cellulosum. Noricumazole A (14a) was found
to inhibit EBOV-GP with an IC50 value of 0.33 μM. In fact, 14a was found to be EBOV-GP specific and
showed no significant inhibition against (VSV)-G-pseudotyped vectors [67]. Noricumazoles are known
to be potassium channel blockers with 14a known to be highly toxic while the derivatives, 14b and
14c, are equally active with lower toxicity [67,70]. The screening of myxobacterial natural compounds
library resulted in the identification of inhibitors of EBOV-GP pseudotyped vectors, chondramides and
noricumazole, whose mechanism of action is actin-stabilising and the channel blockers respectively [67].
These metabolites will give insights into the EBOV infection mechanism, rather than being used as
drugs, because the modes of actions are expected to have side effects. However, the lower toxicity
of 14b and 14c, which are derivatives of 14a, is exciting and qualifies 14a to be considered as a lead
structure for the development of EBOV inhibitors.
Figure 5. Structures of myxobacterial-derived compounds with activity against Ebola virus (EBOV).
Chondramides (13a–d) are known to be actin inhibitors, while noricumazols (14a–c) are known
potassium channel inhibitors [70,71].
3.4. Hepatitis C Virus
HCV is an enveloped, single-stranded RNA virus with positive polarity (ss (+) RNA). HCV is
transmitted by blood-to-blood contacts, such as through intravenous injections, blood transfusion,
and various exposures to blood contaminants. It can also be transmitted by contact with bodily fluids
including saliva or semen of an infected person [72]. By 2015, there were 71 million people infected with
HCV globally [73]. HCV and hepatitis B virus (HBV) infection are the major causes of hepatocellular
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carcinoma (HCC), associated with cirrhosis [74]. Currently, no products are available to prevent HCV
infection. There are some drugs available that can cure HCV infection [75]. However, treatment is
complicated by HIV-HCV/HBC co-infections with drug-drug interactions between anti-HIV and
anti-HCV drugs, resulting in serious side effects and can lead to the death of patient [8]. The discovery
of broad-spectrum antivirals may play an essential role in overcoming this challenge.
The recently isolated compounds from Labilithrix luteola, labindoles A (15a), and B (15b) have
been reported to have moderately inhibited HCV (Figure 6) [75]. Interestingly the labindoles were
said to have no cytotoxicity, anti-bacterial or antifungal activities. 3-chloro-9H-carbazole (17) and
4-hydroxymethyl-quinoline (18) also isolated from Labilithrix luteola were reported to have a strong
inhibition of HCV [75]. Soraphens are a family of polyketide-derived macrolactones comprising over
50 metabolites known for strong antifungal activity [76]. However, recent studies have suggested
that soraphen A (16) inhibits HCV replication in HCV cell culture models expressing subgenomic
and full-length replicons as well as a cell culture-adapted virus with an IC50 value of 5 nM [11,77].
The HCV assay involved the development of subgenomic replicons that replicate autonomously in
the human hepatoma cell line Huh-7 to be able to screen for anti-HCV activity. The subgenomic
replicons are genetic materials from HCV, which represent the actual invasion and replication of HCV
on the liver cells [75]. Furthermore, 16 is known to depolymerise the acetyl-CoA carboxylase (ACC)
complexes into less active dimers [77]. The mechanism of action of 16 is a valuable probe to study the
roles of ACC polymerisation and enzymatic activity in viral pathogenesis [77]. Various minor structure
alterations of 16 did not affect the antiviral activity [11]. Owing to the fact that soraphens inhibit both
HIV and HCV, it has been proposed that the broad-spectrum activity of 16 could be due to targeting
commonly used host factors or pathways necessary for viral replication [78]. Another recently isolated
myxobacteria-derived secondary metabolite, lanyamycin (22) from Sorangium cellulosum (strain Soce
481) moderately inhibited HCV with IC50 value of 11.8 μM [78]. The macrolide, 22, is closely related to
the bafilomycins, a class of secondary metabolites from actinobacteria [79]. Interestingly bafilomycin
A was previously shown to possess good activity (IC50 value of 0.1 nM) against influenza A virus,
which is below its cytotoxic levels [80]. Screening of 22 for activity against influenza A virus and other
pathogenic viruses, and studying the mode of action would be interesting.
 
Figure 6. Compounds with activity against Hepatitis C Virus.
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4. Conclusions
The reported antivirals discoveries call for more screening of myxobacterial-derived compounds,
especially against other medically important viruses. Myxobacteria have demonstrated to be creative
producers of molecules that can have valuable applications as possible lead structures for the
development of antiviral drugs. Some broad-spectrum antivirals such as soraphen A could be
of interest for the possibility of treating co-infection cases. Further, the possibility of using these
myxobacteria derived secondary metabolites for treating both opportunistic infections and the HIV
could be explored. The challenge of some compounds being toxic can be approached by structure
modification for possibility of reducing toxicity while maintaining efficacy, as observed with the
analogues of soraphen and noricumazoles. Moreover, some metabolites found to have potent antiviral
activity may not be used as drugs themselves, due to toxicity, but they can serve as excellent tools
to study and understand the viral invasion. This valuable information can be used to select other
metabolites with similar mechanisms of action or structural modification of the compounds, to reduce
their toxicity without substantially altering the activity. This ability of myxobacteria to produce such
a vast number of secondary metabolites is most likely brought about by many years of evolution to
adapt to survival in an ecological condition of competitive existence in the presence of competitors
and invaders such as fungi, bacteriophages, and other bacteria. A recent comprehensive study
involving molecular phylogeny with HPLC-MS profiling has revealed an unparalleled diversity of
metabolites, along with strong correlations of the metabolite production to the phylogenetic position
of the corresponding producer organisms [81]. Therefore, it appears promising to isolate more
myxobacteria that represent novel genera and species from unexplored environments and screen them
systematically for the production of further unique compounds with antiviral activities.
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Abstract: Whole genome sequencing of actinomycetes has uncovered a new immense realm
of microbial chemistry and biology. Most biosynthetic gene clusters present in genomes were
found to remain “silent” under standard cultivation conditions. Some small molecules—chemical
elicitors—can be used to induce the biosynthesis of antibiotics in actinobacteria and to expand the
chemical diversity of secondary metabolites. Here, we outline a brief account of the basic principles
of the search for regulators of this type and their application.
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1. Introduction
Since the discovery of streptomycin by Selman A. Waksman, actinomycetes have become one
of the most fruitful sources of new antibiotics. Most antibiotic classes in current clinical use were
discovered during the “golden era”, 1940–1960s, by phenotypic screening of soil microorganisms.
Moreover, since the 1960s, a significant number of approved drugs has been designed using chemical
modifications of natural scaffolds. Due to an “innovation gap” in this area, society is now facing an
emerging threat of microbial drug resistance. An urgent need for new effective antimicrobials has
become an important social and political issue [1,2].
On the other hand, achievements in genome sequencing of actinomycetes has revealed a difference
between their potential and observed biosynthetic gene expression. Biosynthetic gene clusters (BGCs)
are several generally contiguous genes encoding enzymes responsible for a stepwise assembly of
complex bioactive molecules. According to data from the majority of published genomes, most BGCs
remain “silent” under standard cultivation conditions. These silent, or cryptic, BGCs represent a
potential source of new scaffolds for the discovery of novel antimicrobials [3–5]. Several techniques for
activation of silent BGCs have been developed in recent decades, e.g., direct identification of BGCs and
their expression in heterologous hosts [6–10], and systematic alteration of cultivation parameters (the
“one strain—many compounds” (OSMAC) approach) [11–13]. These strategies are extremely powerful
although still remaining laborious and resource-intensive, especially for large (>40 kb) BGCs. Further
techniques comprise co-cultivation [14,15], ribosome engineering [16–18], and the use of chemical
elicitors—compounds that induce the synthesis of antibiotics in actinomycetes [14,19–21]. The last
approach is accounted and discussed succinctly in this review, covering literature up to December 2017.
Here, we focus on small organic molecules capable in nanomolar to micromolar minimum effective
concentrations to induce biosynthesis of secondary metabolite in actinomycetes.
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2. γ-Butyrolactones (GBL) and Related (auto)Regulators
Historically, A-factor (1, Chart 1) (A for “autoregulation”) was the first compound that
revolutionized our views of the secondary metabolism and development cycle of actinomycetes.
This γ-butyrolactone (GBL) derivative was discovered by Prof. Khokhlov and co-workers in 1967 [22].
Chart 1. GBL and closely related regulators: butenolides (avenolide, S. rochei butenolides or SRB) and
furans (methylenomycin furans or MMF).
A-factor acts as a pleiotropic regulator: it binds to the A-factor receptor protein (ArpA) and causes
dissociation of this suppressor from DNA. This triggers the transcription of the adpA gene encoding the
transcription activator AdpA, which in turn induces morphological differentiation, spore formation,
and biosynthesis of secondary metabolites [23,24].
In further decades, many other closely related autoregulators were discovered, e.g., Streptomyces
virginiae butanolides (VBs A-E, 2a–e) [25–27], Factor I (2f) [28], Factors II and III (3a,b) [29], Gräfe’s
factors (4a–c) from S. bikiniensis and S. cyaneofuscatus [30], IM-2 (5a) [31,32], SCB1 (5b) [33,34],
SCB2,3 (5c,d) [35] and SCB4–8 (5e–i) [36], methylenomycin furans (MMFs, 6) [37], avenolide (7a)
from S. avermitilis [38], related compounds (7b–e) from S. albus [39], and two S. rochei butenolides
(SRBs, 8a,b) [40]. The stereoconfiguration of avenolide analogues 7b–e reported very recently has
not been assigned [39]. All these compounds have a high degree of similarity in their chemical
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nature (butanolides, butenolides, or furans), biosynthesis pathways, and in mechanisms of action on
actinomycetes. The transduction of the chemical signal starts from binding with a specific receptor
protein (like ArpA in the A-factor signaling cascade) belonging to the TetR family of transcriptional
regulators; the binding of compounds probably causes conformational changes, thus inducing the
relocation of the DNA-binding domain and DNA release [23].
TetR transcriptional repressors are well represented and widespread in bacteria [41,42]. The
recent study on the distribution of the GBL (IM-2, VB)-type and butenolide (avenolide)-type signaling
showed these hormones to be common in actinomycetes. Production of regulators was screened using
S. lavendulae FRI-5 (ΔfarX), S. virginiae (ΔbarX), and S. avermitilis (Δaco) strains with disrupted essential
biosynthetic genes for the corresponding hormone-like molecules. Twenty percent of the investigated
strains produced 5a (IM-2), another 20% produced VBs, and 24% of actinomycetes showed avenolide
activity [43].
Thus, the potential for various applications of A-factor-like regulators is quite high: they induce
biosynthesis of antibiotics of different classes, e.g., aminoglycosides (streptomycin), streptogramins
(virginamycin), peptide ionophores (valinomycin) and others, including clinically significant
antibiotics. For more detail see ref. [24].
3. Other Types of (auto)Regulators
However, GBLs and related compounds are not the only type of regulators found in actinomycetes.
Hitherto, a few different types of autoregulators were reported (Chart 2), e.g., the pi-factor from
S. natalensis (9) [44] and L-N-methylphenylalanyl-dehydrobutyrine diketopiperazine (10) from
S. globisporus [45]. These molecules have no structural similarity to GBL-type compounds and their
mechanisms of action remain unclear [46,47].
Chart 2. Other (non-GBL) types of regulators.
Goadsporin (11) [48,49], an active 19-aa peptide found in the culture broth of Streptomyces sp.
TP-A0584, shows extremely broad elicitation activity on actinobacteria. Induction of sporulation and
growth inhibition were observed in about 80% of Streptomyces sp. and Micromonospora sp. isolates
after goadsporin treatment [50]. Possible mechanism of the goadsporin action on susceptible cells
was postulated by Prof. H. Onaka and co-workers. Bioinformatics analysis of godI—self-resistance
gene from the goadsporin BGC—showed a high degree of homology with ffh encoding the Ffh protein.
The Ffh and 4.5S RNA form the signal recognition particles (SRPs) in prokaryotic cells. The SPRs
recognize the signal peptide of membrane or secretory proteins and facilitate their translocation to the
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cytoplasmic membrane. Binding of Ffh protein with goadsporin causes the upregulation of protein
translocation and maturation, growth inhibition, and alternation of secondary metabolism [51].
It was suggested that goadsporin and its analogs [51,52] could be useful in crop protection:
S. scabies, which is known to cause potato scab, is effectively inhibited by the low concentrations
of goadsporin.
Two “atypical” transcriptional regulators were discovered in S. venezuelae: JadR1 activates the
transcription of jadomycin B (12) biosynthetic genes while repressing its own gene. Jadomycin
B binds to the N-terminal receiver domain of JadR1, causing dissociation of JadR1 from target
promoters. High expression of the biosynthetic enzyme genes leads to accumulation of the product in
a concentration sufficient to inhibit the initial activation. Therefore, jadomycin acts as an autoregulator
of its own synthesis. Similarly, the RedZ protein regulating production of undecylprodigiosine (13)
is modulated by the end product. These findings demonstrate that end-product-mediated control of
antibiotic biosynthesis may be widespread in nature, offering seminal basis for interspecies signaling
and interaction [53,54]. Production of another class of antibiotics, uridyl peptides sansanmycins
(sansanmycin A, 14), active against multidrug-resistant Mycobacterium tuberculosis, is also controlled at
the transcriptional level by the end-product-mediated mechanism [55].
Polyether antibiotics at sub-inhibitory concentrations can elicit the synthesis of secondary
metabolites. Promomycin (15, Chart 3) and closely related compounds (salinomycin,
monensin, and nigericin) promoted the synthesis of cryptic isonitrile antibiotic SF2768 (16) by
S. griseorubiginosus [56,57]. This was the first example of isolation of a novel original compound
using the chemical elicitation approach. However, the action of polyether antibiotics has not yet been
studied on the molecular level.
Chart 3. Antibiotic-antibiotic induction; elicitors and products.
Lincomycin (17) at one tenth of its MIC increased the expression of the pathway-specific
regulatory gene actII-ORF4 in the enzyme gene cluster producing the blue-pigmented antibiotic
actinorhodin (18) in S. lividans, thus resulting in actinorhodin overproduction [58]. Chloramphenicol
activated biosynthetic genes at the transcriptional level and increased the amino acid pool 1.5- to
6-fold, enhancing the production of non-ribosomal peptide antibiotics [59]. Other ribosome-targeted
antibiotics, especially thiosteptone and spectinomycin, at sub-inhibitory concentrations were also
capable of altering colony morphology and antibiotics (13 and 18) production in S. coelicolor M145 [60].
The HiTES (High-Throughput Elicitor Screening) approach [61–63] was developed to discover
small molecule elicitors of silent biosynthetic gene clusters and novel secondary metabolites using a
simple fluorescent assay format. Three copies of eGFP (enhanced green fluorescent protein encoding
gene) inserted in the S. albus J1074 genome both at a neutral site (attB) and inside the biosynthetic
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cluster of interest (sur, surugamide BGC). The difference in fluorescence between attB::Psur-eGFPx3
(the Psur promoter region (~260 bp) upstream of surE) and surE::eGFPx3 strains after testing compound
treatment was used as an indicator of BGC’s activation. Screening of a commercially-available natural
products library (ca. 500 compounds) identified 6 potential elicitors, among these ivermectin b1a
(19, Chart 4) and etoposide (20) had the maximum surugamide BGC activation effect and markedly
changed the secondary metabolome profile of S. albus J1074—14 novel small molecules were isolated
and characterized using these two inducers, e.g., surugamide J (21), albucyclone F (22), and surugamide
F2 (23) [63].
Chart 4. Natural products eliciting surugamide biosynthesis in S. albus J1074 (detected by HiTES).
4. Metabolism Remodeling and Epigenetic Control
Fully synthetic chemicals also can be utilized as elicitors. ARC2 (24, ARC from “Antibiotic-
Remodeling-Compound”) and similar diphenyl ethers (ARC3–5, 25–27) (Chart 5) have become the
first inducer examples discovered by systematic screening of 30,569 small molecules [64,65]. Taking
into account the structural similarity of ARC compounds with triclosan (28), a well-known biocide
and inhibitor of fatty acid biosynthesis, the mechanism of ARCs’ action (Chart 5A) has been proposed.
Generally, ARCs act as metabolism remodeling compounds, changing the balance between primary
and secondary metabolic pathways. The mode of action was confirmed by the experimental data:
ARCs changed fatty acid pool by inhibition of key biosynthetic enzymes like FabI. Remarkably,
triclosan also can stimulate polyketide antibiotic synthesis at sub-inhibitory concentrations [59].
Further investigation of the different ARCs’ effects on the streptomycetes biochemistry revealed
the targets for different molecules (even structurally close) as not being the same; however, all of
them influenced fatty acid metabolism [66]. Chlorinated analog Cl-ARC (29) was used to enhance
the expression of cryptic biosynthetic genes, and the observed difference between growth on control
and elicitor-containing media was studied using a metabolomics approach. More than 100 induced
secondary metabolites were detected, including rare antibiotics [67]. Several identified structures
are represented in Chart 6: oxohygrolidin (30), germicidins A–E (31a–e) 9-methylstreptimidone (32),
nactins (33, 34, 35), desferrioxamines B,E (36, 37), and arylomycin A4 (38).
257
Microorganisms 2018, 6, 52
Chart 5. Synthetic diphenyl ethers (ARCs) as elicitors and their mode of action (A).
Chart 6. Cl-ARC-induced biosynthesis: examples of identified antibiotics [67].
Despite the significant difference in structural DNA organization between eukaryotes
and actinomycetes, inhibitors of histone deacetylase (HDAC) like valproic acid (39) and
suberanilohydroxamic acid (SAHA, 40) (Chart 7) showed effect on antibiotic production by several
Streptomyces strains, especially on nutrient-poor media. The finding was explained by the homology
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between several S. coelicolor enzymes (SCO0452, SCO6464, SCO3330) and human HDAC enzymes [68].
Epigenetic modification could be used for the control of antibiotic biosynthesis; the approach, however,
is not well studied for actinobacteria.
Chart 7. Histone deacetylase (HDAC) inhibitors.
5. Conclusions
Activation of antibiotics’ biosynthesis in actinomycetes by using small-molecule elicitors seems to
be a useful technique for drug discovery. The approach allows identification of new metabolite scaffolds
and enhances synthesis of low yield secondary metabolites. Moreover, antibiotic-antibiotic induction
relationships are believed to be the basis of chemical signaling between different actinobacterial strains
and are, therefore, of interest for chemical ecology. Elicitation is an obvious cost-effective approach in
biotechnology for increasing antibiotic yields and reducing fermentation time.
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